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 1 
Summary 
 
The communication of cells with their environment is a vital necessity for all organisms. Often the 
compounds, which are used to transmit a signal through the extracellular space, are not actually 
entering their target cells. Rather they are binding to their surface, from where the primary signal is 
relayed to the cell's interior through specialized receptor molecules located in its membraneous 
envelope. The signal is then transmitted within the cell through a different compound, which is 
called a secondary messenger. The largest family of cell surface receptors are the so-called G-
protein coupled receptors (GPCRs), which relay the signal to the cell's interior through GTP-
binding proteins (G-proteins). The signals to which these receptors respond are of vast diversity 
ranging from light to small organic molecules to large organic molecules, such as peptide 
hormones. Their broad ligand range hints to their paramount roles in the regulation of many 
biological functions ranging from vision to the response to growth hormones. This importance is 
also reflected in the GPCR's pharmacological importance. Roughly 50% of all currently marketed 
drugs are targeting this receptor subclass. 
The advent of structural biology allowed to understand biological processes on an atomic level. 
Membrane embedded proteins such as the GPCRs are notoriously difficult to characterize 
structurally and in spite of their tremendous biological importance only five unique crystal 
structures of GPCRs are available. Nuclear magnetic resonance (NMR) spectroscopy as the second 
major technique capable of delivering macromolecular structures at atomic resolution hasn't been 
successfully applied to the structure determination of GPCRs. Alternative routes to structural and 
functional information on this receptor class is therefore still highly desirable. In my thesis I present 
the application of two such alternative strategies to a subfamily of the GPCRs called the Y-
receptors. These bind to a set of three neuropeptide hormones, which regulate a host of processes 
from anxiolysis to feeding behavior and memory retention. 
We have tried to isolate the structural entities of the receptor, which are responsible for ligand 
binding and study them outside of the context of their receptor surroundings. While this approach is 
obviously only able to deliver limited structural and functional information, it is in our view a valid 
approach, because many proteins – and membrane proteins in particular – are thought of consisting 
of small, autonomously folding domains. Therefore they can be expected to retain their structural 
features even when detached from their natural molecular environment. The first approach is called 
the “segmentation approach” and aims at dissecting the receptor into suitable fragments and 
studying these fragments individually. This approach has been applied to the N-termini of the four 
major members of the Y-receptor family. In order to obtain these four 40-50 residue peptides in 
15
N-labeled form, they had to be expressed recombinantly in bacteria. Because fragments of such 
limited length tend to be degraded by bacteria, we had to express them as fusions with suitable 
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partners conferring stability in the bacterial cell. The N-termini of the Y2- and Y5-receptors (N-Y2 
and N-Y5) were produced as fusions to the soluble protein ubiquitin and could be liberated from the 
fusion partner through treatment with a ubiquitin specific protease. The N-termini of the Y1- and 
Y4-receptors (N-Y1 and N-Y4) showed unspecific fragmentation when expressed as ubiquitin 
fusions. This fragmentation problem could be solved by using the insoluble ketosteroidisomerase 
(KSI) as a fusion partner, from which N-Y1 and N-Y4 could be liberated through a tobacco etch 
virus (TEV) protease cleavage site introduced between the KSI- and the N-Y1/4 sequence. All four 
N-termini were devoid of any defined structure in aqueous solution. Upon addition of membrane 
mimicking micelles N-Y1 and N-Y5 rigidified partially and a defined !-helical segment could be 
observed in N-Y4. For this fragment also a micromolar affinity to the Y4-receptor's natural ligand 
(the pancreatic polypeptide, PP) could be detected. 
The second approach is called the “grafting approach”. Therein we try to transfer the regions of the 
Y-receptors, which are of interest to us onto a scaffold protein which is more amenable to NMR 
spectroscopy then the receptors themselves. An ideal scaffold should be as small as possible to 
simplify NMR spectroscopy, and should present a number of other favorable characteristics, such as 
high-level overexpression in a easily manageable host such as E. coli. Additionally it should present 
the grafted sequences in a geometrical fashion resembling the one observed in the natural receptor. 
We have tested two hypothesized scaffold molecules for their tolerance of accepting the 
extracellular domains of the Y-receptors. The resulting chimera were assayed for the presence of a 
stable tertiary fold and the capability of interacting with the Y-receptors' natural ligands. 
Both selected scaffolds have a structurally conserved eight-stranded "-barrel core and display 
flexible loops emanating from the "-barrel core. The bacterial lipocalin (Blc) seemed as a promising 
soluble scaffold based on structural and sequence information and also based on previous protein 
engineering work. While we could find numerous suitable attachment points for the Y2-receptor's 
N-terminus, the Blc scaffold proofed to be much less tolerant to directed alterations in its loops. All 
changes made to the loops resulted in strongly reduced folding capacity. 
As a second potential acceptor molecule we evaluated a membrane embedded scaffold, namely the 
outer membrane protein A (OmpA) from E. coli. The rigid transmembrane "-barrel of this protein 
proofed highly tolerant to large changes in its solvent-exposed loop sequences. We grafted all three 
extracellular loops of the Y1-receptor onto this "-barrel scaffold in a number or different 
topological arrangements. The resulting chimera could all be expressed and purified with similar 
yields as the wildtype OmpA. Even though the refolding efficiency of the chimera was lower than 
for OmpA, we managed to elaborate refolding procedures giving yields of >50% of folded protein. 
In two out of four evaluated chimera we were able to clearly see an interaction between the 
chimeric protein and the Y-receptors' natural ligands. Our results indicate an interaction of these 
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chimera with the neurohormones, which qualitatively mimics the natural binding profiles of the Y-
receptors. Even though the binding is weak when compared with the affinities of the real receptors, 
interesting conclusions about the qualitative interaction mode between the chimera and the ligand 
could be obtained: the peptide hormone ligands seem to interact exclusively with their C-terminal 
part with the chimeric receptors. This is in agreement with biochemical data available on the 
interaction between the Y-receptors and their ligands. Specificity of the interaction is corroborated 
by a competition binding assay and interaction studies with neurohormone mutants showing a 
decreased affinity towards the natural Y-receptors. Only about half of the resonances from the 
grafted loops are visible in the spectra of our chimeric receptors. No interaction with the 
neurohormones can be detected on these resonances. Increasing the overall mobility of the grafted 
loops by flanking them with flexible linkers also didn't significantly increase the number of visible 
resonances in the spectra of our receptor constructs and slightly decreased the interaction strength 
between the ligand and the receptor construct. 
Overall we think that our easily accessible chimeric receptor system presents interesting 
possibilities for gaining insight into the interaction of the Y-receptors and possibly other GPCRs 
with their ligands. 
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 5 
Zusammenfassung 
 
Kommunikation von Zellen mit der Umwelt ist lebenswichtig für alle Organismen. Die Moleküle, 
welche zur Übertragung eines Signals verwendet werden, dringen meist nicht in ihre Zielzellen ein, 
sondern sie werden an deren Oberfläche von Rezeptoren gebunden, welche den extrazellulären 
Stimulus ins Zellinnere weiterleiten. Das primäre Signal wird so in ein Sekundäres übersetzt. Die 
G-Protein gekoppelten Rezeptoren (GPCRs) sind die grösste Familie von Oberflächenrezeptoren. 
Der Name dieser Familie kommt daher, dass das Signal via so genannter GTP bindender Proteine 
(G-Proteine) ins Zellinnere weitergeleitet wird. Mitglieder dieser Rezeptorfamilie sprechen auf eine 
grosse Palette verschiedener Signale an, welche sich von Licht über kleine organische Moleküle bis 
hin zu grossen Biomolekülen wie z.B. Peptidhormonen erstreckt. Diese breite Auswahl deutet 
schon die überragende Bedeutung dieser Rezeptorfamilie für die Regulation vieler biologischer 
Prozesse an. Diese Wichtigkeit spiegelt sich auch in der pharmakologischen Rolle der GPCRs 
wider: Ca. 50% aller derzeit verkauften Medikamente zielen auf GPCRs ab. 
Das Aufkommen der Strukturbiologie ermöglichte biologische Prozesse auf atomarer Stufe zu 
verstehen. Die strukturelle Charakterisierung von in der Membran eingebetteten Proteinen wie den 
GPCRs ist notorisch schwierig. Und so sind trotz ihrer enormen Wichtigkeit bisher nur fünf 
Kristallstrukturen von GPCRs veröffentlicht. Die Kernspinresonanzspektroskopie (NMR 
Spektroskopie) als die zweite Technik, welche in der Lage ist, Strukturen von atomarer Auflösung 
von biologischen Makromolekülen zu liefern, wurde bisher nicht erfolgreich auf GPCRs 
angewandt. Alternative Wege zu Strukturinformationen von dieser Rezeptorklasse scheinen also 
erwünscht zu sein. In meiner Doktorarbeit präsentiere ich die Anwendung zweier solcher 
alternativen Strategien, angewandt auf eine Unterfamilie der GPCRs, nämlich die Y-Rezeptoren. 
Diese binden eine Gruppe von drei Neuropeptidhormonen, welche eine Anzahl verschiedener 
Prozesse regulieren – von der Angstlösung über die Steuerung des Essverhaltens bis hin zur 
Erinnerung. 
Wir haben versucht die strukturellen Untereinheiten, welche für die Bindung der Liganden 
verantwortlich sind, ausserhalb ihres natürlichen Kontexts zu untersuchen. Diese Herangehensweise 
erlaubt nur beschränkte strukturelle und funktionale Einsichten. Nichtsdestotrotz ist sie unserer 
Meinung nach sinnvoll, weil viele Proteine – und Membranproteine insbesondere – als Gruppen 
von sich autonom faltenden Untereinheiten betrachtet werden können. Darum darf man erwarten, 
dass diese Untereinheiten ihre Struktureigenschaften auch ausserhalb des Kontexts des gesamten 
Proteins behalten. Der erste Ansatz nennt sich "Segmentationsansatz" und zielt darauf ab, den 
Rezeptor in geeignete Fragmente zu zerlegen, und diese Fragmente dann individuell zu 
untersuchen. Diese Technik wurde auf die N-Termini der vier Hauptvertreter der Y-Rezeptoren 
angewandt. Um diese 40-50 Reste umfassenden Peptide in 15N-markierter Form für NMR Studien 
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zur Verfügung zu haben, mussten sie rekombinant in Bakterien hergestellt werden. Weil solch 
kurze Fragmente im Allgemeinen von Bakterien abgebaut werden, mussten wir sie als 
Fusionskonstrukte mit geeigneten Partnern exprimieren, welche ihnen Stabilität in den 
Bakterienzellen verleihen sollen. Die N-Termini der Y2- und Y5-Rezeptoren (N-Y2 und N-Y5) 
wurden als Fusionen mit dem löslichen Protein Ubiquitin hergestellt, und wurden von diesem 
Fusionspartner mittels einer Ubiquitin-spezifischen Protease abgespalten. Die N-Termini der Y1- 
und Y4-Rezeptoren (N-Y1 und N-Y4) zeigten unspezifische Fragmentierung, wenn sie als Fusionen 
mit Ubiquitin exprimiert wurden. Dieses Fragmentationsproblem konnte durch Fusion der N-
Termini an das unlösliche Protein Ketosteroidisomerase (KSI) überwunden werden. Die Spaltung 
von diesem Fusionspartner erfolgte durch eine zwischen KSI und N-Y1/4 eingefügte "Tobacco Etch 
Virus" (TEV) Proteaseschnittstelle. Keiner der vier N-Termini zeigte eine definierte Struktur in 
wässriger Lösung. Nach Zugabe eines Membranmimetikums in Form von Mizellen zeigte sich in 
N-Y1 und N-Y5 eine partielle Rigidisierung und ein klar definiertes !-helicales Segment konnte in 
N-Y4 beobachtet werden. Ebenfalls für N-Y4 konnte eine mikromolare Affinität gegenüber dem 
natürlichen Liganden (dem pankreatischen Polypeptid, PP) des Y4-Rezeptors nachgewiesen 
werden. 
Der zweite alternative Ansatz zu struktureller Information über die Y-Rezeptoren nennt sich 
"Verpflanzungsansatz". Dabei versuchten wir die Domänen der Y-Rezeptoren, welche für die 
Ligandenbindung verantwortlich sind, auf ein für NMR-Studien leicht zugängliches Grundgerüst zu 
übertragen. Ein ideales Grundgerüst für sollte möglichst klein sein, um die NMR Spektroskopie zu 
vereinfachen. Zudem sollte es eine Anzahl anderer Voraussetzungen erfüllen, wie effiziente 
Expression in E. coli und eine günstige Geometrie, welche jener in den natürlichen Rezeptoren 
ähnlich sein soll. Wir haben zwei solcher Grundgerüste in Bezug auf ihre Fähigkeit, extrazelluläre 
Sequenzen der Y-Rezeptoren aufzunehmen, getestet. Die resultierenden Chimären wurden 
hinsichtlich der Ausbildung einer stabilen Tertiärstruktur und ihrer Affinität gegenüber den 
Liganden der Y-Rezeptoren untersucht. Beide gewählten Grundgerüste haben einen strukturell 
konservierten achtsträngigen !-Barrel Kern. Das bakterielle Lipocalin (Blc) schien auf Grund von 
Struktur- und Sequenzinformation und vorhergehender Mutationsstudien ein viel versprechender 
Kandidat eines löslichen Grundgerüsts zu sein. Während wir zahlreiche Befestigungspunkte für den 
N-Terminus des Y2-Rezeptors finden konnten, zeigte sich Blc viel weniger tolerant bezüglich 
gezielter Änderungen in seinen Loops. Alle Änderungen, die darin vorgenommen wurden, haben 
die Faltung in eine stabile Tertiärstruktur massiv beeinträchtigt. 
Als zweiter möglicher Akzeptor haben wir ein in die Membran eingebettetes Grundgerüst evaluiert, 
nämlich das Outer membrane protein A (OmpA) von E. coli. Das rigide transmembranäre !-Barrel 
Grundgerüst dieses Proteins war sehr tolerant auch gegenüber grossen Veränderungen in seinen 
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Loops. Wir haben alle drei extrazellulären Loops des Y1-Rezeptors in jeweils verschiedenen 
Anordnungen auf dieses !-Barrel Gerüst verpflanzt. Die resultierenden Chimären konnten alle 
gleich effizient exprimiert und aufgereinigt werden wie OmpA selbst. Obwohl die 
Rückfaltungseffizienz der chimären Rezeptorkonstrukte niedriger war als für OmpA, konnten wir 
Rückfaltungsprozesse ausarbeiten, welche uns erlaubten mehr als 50% gefaltetes Protein zu 
erhalten. In zwei der vier untersuchten Rezeptorkonstrukte konnten wir zudem eine deutliche 
Interaktion mit den natürlichen Liganden der Y-Rezeptoren beobachten. Unsere Resultate zeigen, 
dass die Rezeptorkonstrukte mit den Neurohormonen in einer Art wechselwirken, welche die 
natürlichen Bindungsprofile an den Y-Rezeptoren nachahmt. Obwohl die Bindung verglichen mit 
den Affinitäten gegenüber der echten Rezeptoren schwach ist, konnten interessante Schlüsse über 
die qualitative Wechselwirkung gezogen werden: Die Peptidhormone interagieren nur mit ihrem C-
terminalen Teil mit den Rezeptorkonstrukten. Dies ist in Übereinstimmung mit veröffentlichten 
biochemischen Daten über die Interaktion zwischen den Y-Rezeptoren und deren Liganden. Die 
Spezifität der von uns beobachteten Interaktion wird bewiesen durch Kompetitionsexperimente und 
Interaktionsstudien mit Mutanten der Neurohormone, welche eine verringerte Affinität gegenüber 
den natürlichen Y-Rezeptoren zeigen. Nur etwa die Hälfte der Resonanzen von Resten der 
verpflanzten Loops sind in den Spektren der Rezeptorkonstrukte sichtbar, und keine Anzeichen 
einer Wechselwirkung mit den Neurohormonen kann in diesen Resonanzen ausgemacht werden. 
Indem wir die verpflanzten Loops mit flexiblen Linkern versehen haben, wurde die Mobilität dieser 
Loops erhöht. Dies hat allerdings auch nicht zum vermehrten Erscheinen von Resonanzen in den 
Spektren geführt, sondern eine etwas abgeschwächte Wechselwirkung dieser Konstrukte mit den 
Neurohormonen wurde beobachtet. 
Wir denken, dass unser leicht zugängliches chimäres Rezeptorsystem interessante Möglichkeiten 
bietet, um unser Verständnis der Interaktion der Y-Rezeptoren und möglicherweise auch anderer 
GPCRs mit ihren Liganden zu vertiefen. 
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Chapter I: Introduction 
 
1. Signal transduction in general and introduction to the topic of 
this thesis 
 
For both unicellular and multicellular organisms signal transduction across the cellular membrane 
constitutes a vital need. The hydrophobic nature of the interior of the cellular membrane, however, 
forms an impenetrable/insurmountable barrier to hydrophilic molecules, precluding passive 
diffusion of such molecules as an effective means of signal transduction. Membrane embedded 
proteins are necessary to achieve this task, which can either be accomplished by i) binding the 
signaling molecule on the extracellular side and, through a conformational change of the membrane 
embedded protein, releasing it on the intracellular side into the cell or ii) by binding the signaling 
molecule on the extracellular side and relaying the signal to the intracellular side without a transport 
of the actual signaling molecule across the membrane. In the second mechanism the signal is then 
propagated inside the cell by so-called "secondary messengers". The membrane embedded protein 
relaying the signal from the outside to the inside of the cell is called a "receptor". An important 
class of such signal receptors is called G protein-coupled receptors (GPCRs), because they relay the 
extracellular signal in the interior of the cell by a so-called G protein (vide infra). There are about 
1000 genes coding for such receptors in the human genome, representing the major family of 
human membrane embedded proteins1. 
GPCRs, as many other membrane proteins as well, are very sensitive molecules with respect to their 
structural and functional integrity, making their study a very challenging task. One sub-class of the 
GPCRs is believed to interact with their cognate ligands mainly through its surface exposed 
extracellular parts. Our work is inspired by the idea, that these extracellular parts could be studied 
separately, i.e. in absence of the hydrophobic transmembrane helices, responsible for most of the 
problems arising in the work with GPCRs. Several approaches to realizing this idea have been 
formulated (vide infra). The two routes we are following can be called "segmentation approach" 
and “grafting approach”. They can be briefly summarized as follows: In the segmentation approach, 
a GPCR is split at suitable positions, mainly at domain boundaries, and the resulting fragments are 
studied. The grafting approach is based on the idea of transferring the external parts of a GPCR to a 
scaffold protein, without disturbing its overall global fold. The scaffold approach relies on the 
assumption that small, preferably soluble proteins exist, which possess a core determining the 
global fold and some surface exposed loops unimportant to that fold. The resulting chimeric protein 
could then be - depending on the size of the scaffold - considered as a “minireceptor”, because it 
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carries all the parts of the receptor hypothesized to be important for ligand binding (hence the term 
“receptor”), but at the same time shows the favorable characteristics of small, soluble proteins 
(hence the term “mini”). The resulting minireceptor should be easier to produce and characterize 
spectroscopically. This idea is exemplified in figure 1. 
Error! Reference source not found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the following chapter I would like to set the both basis for understanding the biological concepts 
most relevant for the study of membrane proteins in general and GPCRs specifically and give an 
introduction to the experimental techniques we applied. 
 
 
2. Biological Membranes 
 
2.1 Chemical composition of biological membranes 
All cells are surrounded by at least one layer of a membrane as a delimiter to the outside world. The 
two main components of a biological membrane are lipids and proteins. Their ratio varies between 
different types of membranes, but typically can be considered 1:1. In the inner mitochondrial 
membrane, which is responsible for maintaining and harvesting the proton-motive force, the protein 
content is especially high, reaching 75%. In the myelin sheets insulating nerve cells, the protein 
content is unusually low and only reaches 25%. The functional roles of the two main components of 
Figure 1: Exemplification of the grafting approach. The 
extracellular N-terminus (red) and the loops (green) connecting 
the transmembrane (TM) helices are colored in a model GPCR 
on the left. The 7TM scaffold and the incracellular loops are 
shown in gray. In the selected !-barrel shown on the right might 
serve as an alternative scaffold for the extracellular domains of a 
GPCR. 
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a biomembrane is considered to be opposite: while lipids form a border against the cell's 
environment, the proteins are responsible to enable (specific) exchange with the cell's surroundings. 
Such a communication between a cell's interior and the outside is not only necessary for nutrient 
uptake, but is essential to allow the coordination between individual cells in a multicellular 
organism (vide infra). Lipids have a characteristic amphiphilicity. They are composed of a 
hydrophobic hydrocarbon tail and a hydrophilic head. The lipids found in biomembranes can be 
classified into different families. The glycerolipids have a glycerol backbone which is esterified at 
two positions with fatty acids of varying length and saturation (vide infra). The third hydroxy group 
is linked to a hydrophilic moiety either through a glycosidic bond to a carbohydrate 
(glyceroglycolipids) or via a phosphodiester (glycerophospholipids) to an alcohol such as choline, 
ethanolamine or glycerol. Sphingolipids are derivatives of sphingosine carrying a hydrophobic acyl 
chain and polar head groups analogous to the glycerolipids. The third major class of biological 
lipids are the isoprene-based sterols. In higher organisms glycerolipids are mainly found in 
intracellular organelles. Sphingolipids are most prominent in the plasma membranes of animal cells. 
Sterols can be found in many different membranes and are absent from bacteria. A structurally and 
functionally peculiar class of lipids known as lipopolysaccharides are found in the outer membranes 
of gram negative bacteria (vide infra). The acyl chains found in membrane lipids have an even 
number of carbon atoms ranging from 14 to 26. Predominant are chains with 16 (palmitic acid) and 
18 (stearic acid) C-atoms. In case of unsaturated fatty acids the double bond nearly always has the 
cis configuration. The degree of unsaturation varies from 0 to 4 double bonds and in glycerolipids 
unsaturated chains are usually esterified to position 2 of the glycerol. Palmitoleic acid, the mono-
unsaturated form of palmitic acid, can be found in amounts of up to 10%, while higher unsaturated 
C16 species are very rare. Oleic acid and linoleic acid, the mono- and di-unsaturated forms of 
stearic acid, make up 10-20% and ~25% of all C18 fatty acid species, respectively. Each membrane 
has its characteristic lipid composition. Phosphatidylcholine (PC) is abundant in animal membranes, 
but absent in bacteria, which have a high content of phosphatidylethanolamine (PE) and 
phosphatidylglycerol (PG). Chloroplasts contain high amounts of glyceroglycolipids and very little 
phospholipids. Plasma membranes usually have the highest cholesterol content (up to 25%) and in 
animals are particularly rich in sphingolipids (around 20%). Reflecting its prokaryotic ancestry, the 
inner mitochondrial membrane is devoid of cholesterol. The two leaflets of a lipid bilayer are 
usually not symmetric with respect to their lipid composition. This lipid asymmetry can be found in 
all membranes, but is most pronounced in the plasma membrane. This lipid asymmetry has to be 
constantly maintained against the tendency of lipids to equilibrate between two leaflets. The 
dedication of energy resources to the maintenance of lipid bilayer asymmetry indicates its 
functional importance, which has been observed for instance in the process of apoptosis2. 
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2.2 Biophysical properties of biological membranes 
All amphiphilic molecules have the tendency to form aggregate structures in solution. In aqueous 
environments the lipids associate in such a way as to minimize the energetically unfavorable 
exposure of their fatty acid chains to the polar water molecules. The aggregates can adopt different 
shapes, depending on the form of the lipids, which is mainly determined by the ratio of the lateral 
cross sections of the head group and hydrophobic chains. Cone- and wedge-shaped lipids (and also 
detergents) form micelles or inverted micelles, respectively (figure 1a). Typical 
glycerophospholipids can be thought of as cylindrical entities with a circular cross-section of ~9 Å 
(yielding a surface area of ~65 Å2)3. In aqueous solution such cylindrical lipids spontaneously 
organize into bilayers, which gradually curve to form closed vesicles (figure 1a). 
The hydrophobicity profile of a bilayer is a smooth transition from the polar extramembrane 
environment to the apolar membrane interior4 (figure 2d). The region between these two extremes is 
generally referred to as the “interface region”5. While in the extramembraneous space polar and 
charged amino acids are predominant and in the hydrophobic core apolar residues prevail, in the 
interface region aromatic amino acids are found particularly often6. In the ~15 Å interface region a 
gradual transition from the bulk aqueous phase to an essentially anhydrous, apolar hydrocarbon 
phase takes place4,7. 
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Figure 2: The biolphysical properties of lipids found in biomembranes. a) Lipids molecules of 
different shapes aggregate in different forms. b) Lipids with voluminous phatty acid chains (wedge 
shaped) have negative spontaneous curvature values, whereas such with sterically less demanding 
chains (cone shaped) have positive spontaneous curvature values. b) The three different modes of 
membrane protein anchoring: Integral (left), peripheral (middle) and lipid anchored (right). d) 
Hydrophobic matching: To a certain extent a membrane can adapt its hydrophobi diameter to the 
specific demands of an embedded protein. d) The hydrophilicity profile through a lipid bilayer is a 
smooth curve with lowest values in the hydrocarbon core and highest values near the polar 
headgroups. 
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2.3 Proteins embedded in biological membranes 
The proteins which are anchored in a membrane can be classified according to different criteria 
(figure 1c). One of the most commonly used classification is based on the anchoring mechanism, by 
which the protein is embedded in the membrane. Peripheral membrane proteins are only inserted 
partially or only interact with the membrane surface, and can usually be detached from the 
membrane under mild conditions, such as increased ionic strength. Integral membrane proteins on 
the other hand have one or more domains, which span the full diameter of the membrane, and can 
usually only be extracted under harsh conditions, e.g. with strong, ionic detergents. Integral 
membrane proteins can be divided into two structural classes: 1) the ones spanning the membrane 
with !-helices or 2) the ones inserting into the membrane in the form of a "-barrel. Therefore the !-
helix and the "-strand are the only two secondary structural elements, which can be found in 
membranes. This makes sense, as they ensure the saturation of all hydrogen-bond donors and 
acceptors in the hydrophobic membrane interior. A minimum of 20 to 30 amino acids in !-helical 
conformation (1.5 Å rise per residue) are required to pass a biological lipid bilayer, which typically 
has a thickness of 30-50 Å. Such TM helices are usually highly hydrophobic sequences. This 
enables their identification of !-helical membrane proteins based on their amino acid sequence. The 
"-strands of "-barrel membrane proteins, in contrast, are not easy to identify as only every second 
side chain of a TM "-strand faces the hydrophobic environment of the membrane, whereas the 
others point into the lumen of the barrel (vide infra). 
A third class of membrane proteins is anchored in the membrane not through membrane spanning 
protein sequences, but through posttranslationally attached lipid moieties. The range of such lipid 
modifications is diverse with the most common being fatty acylation8 and prenylation8,9 of cysteines 
and modifications of C-termini with glycosyl phosphatidyl inositol (GPI)10,11. Whereas the former 
two types of lipid modification is found in the interior of the cell, the latter serves to anchor proteins 
to the outer leaflet of the plasma membrane. 
The diameter of a bilayer is primarily determined by the length and the unsaturation of the fatty acyl 
chains. It is, however, not a fixed value, but can adjust to environmental conditions. The adaptation 
of the lipid molecules to match the hydrophobic thickness of an embedded protein has been 
observed12,13. This adaptation is certainly limited to a certain extent. Beyond this limit also a 
membrane embedded protein can adjust to a given hydrophobic thickness, for instance by tilting its 
!-helices14. 
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3. G protein coupled receptors (GPCRs) 
 
3.1 GPCRs: function 
The earliest development of a theory of soluble molecules binding to complementary partners on 
the cell surface is generally attributed to the german scientist Paul Ehrlich (1854-1915), who in 
1897 in his "Seitenkettentheorie" set the basis for today's selection theory in immune response. For 
this theory he was awarded the nobel price in medicine in 1908. The term "receptor" or "receptive 
substance" was first mentioned by Langley and his student Dale in the first decade of the 20th 
century in their work on adreno- and acetylcholine receptor ligands15,16. While until the middle of 
the 20th century the studied receptors were characterized physiologically and pharmacologically 
(i.e. with smooth or skeletal muscle preparations), in the 1960s and 1970s also biochemical 
characterization became more and more substantial, resulting in the identification of the 
intracellular effector machinery of the studied receptors17-19. One class, which transmitted their 
signal through a guanine nucleotide binding protein, was hence called G-protein coupled receptors 
(GPCRs). For a long time the nicotinic acetylcholine receptor and rhodopsin were the only 
receptors available in pure forms due to their abundance in electric eel and bovine retina rod cells, 
respectively. The purification and enrichment of other, less abundant GPCRs only became feasible 
with the advent of the radioligand binding technique. The purification of the "2-adrenergic receptor 
or "2-adrenoreceptor ("2-AR)20 by this method allowed to sequence small peptide stretches of the 
receptor. From these stretches oligonucleotide probes could be designed that allowed to clone the 
cDNA of the receptor in 198621. Much to the surprise of everyone the "2-AR showed sequence 
homology to the visual pigment rhodopsin21, which was already sequenced in 198222,23. Both 
receptors were predicted to have a 7 transmembrane topology because of 7 highly hydrophobic 
stretches present in their sequence. Based on this homology it was quickly suggested that many or 
all GPCRs might share this structural feature21 (figure 3a). From then onward many receptor genes 
were cloned based on homology to the "2-AR or rhodopsin. For these clones often no function was 
known, and they were hence termed "orphan receptors". Even now, a majority of all cloned GPCRs 
are still "orphan"24. In light of the fact that close to 50% of all currently marketed drugs target 
GPCRs25, de-orphanization initiatives are believed to yield attractive new drug targets26. After the 
complete sequencing of the human genome27 the number of GPCRs in the human genome was 
estimated to be around 10001. 
The chemical diversity of signals activating GPCRs is exceptional. It includes molecules as diverse 
as biogenic amines (dopamine, adrenaline, histamine, acetylcholine, serotonin), peptides (many 
peptide hormones, some of which are modified [N-formylated, C-amidated], opioids), 
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glycoproteins, lipids (anandamides, cannabinoids, lysophosphatidic acid), nucleotides (adenosine, 
cAMP, ADP, ATP) and amino acids (glutamate, GABA). However, GPCRs can not only be 
activated by chemical signals but also by physical stimuli such as light or mechanical stresses. 
All GPCRs act as guanine nucleotide exchange factors (GEFs)28. In their activated form GPCRs 
catalyze the exchange of GDP for GTP on their first downstream effector, the G! subunit of the so-
called heterotrimeric G-proteins. This nucleotide exchange leads to the dissociation of the 
heterotrimeric G-protein into activated G! :GTP monomer and a G"# heterodimer. Both these 
molecules can have effector activities. Among other mechanisms (vide infra) the duration of the 
signal is determined by the intrinsic GTP hydrolysis activity of the G! subunit. GTP hydrolysis of 
the G! subunit leads to a termination of the signaling by drastically lowering the G! activity and by 
reassociation with the G"# subunit
29 (figure 3b). 
Heterotrimeric G-proteins are composed of three different subunits named as G! , G" and G#. In the 
human genome there are 16 genes that encode G! -subunits, five genes that encode G"-subunits and 
14 genes that encode G#-subunits
30. The G! -family is further subdivided into four groups based on 
sequence homology: Gs,!, Gi/o,!, Gq/11,! and G12/13,!
31. The first two subfamilies are named according 
to their effect on adenylyl cyclases. The “s” subscript in Gs,! stands for G! -subunits "stimulating" 
and the “i” in Gi/o,! inhibiting the adenylyl cyclase. Members of the Gq/11,! subfamily stimulate 
phospholipase C" (PLC-") and activation of G12/13,! is followed by stimulation of the G-protein 
Rho32. All these "downstream effectors" regulate the activity of further components of the signaling 
cascade (figure 3b). The large number of effectors involved in a signaling cascade allows the cell to 
modify (e.g. to amplify or damp) the cellular response at various points. The G! subunit 
nomenclature is commonly also used to classify GPCRs: hence, GPCRs are referred to as Gs-, Gi- or 
Gq-coupled. 
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Within G! , the C-terminal tail is believed to be the primary site for receptor recognition
33-35, but 
also six other regions, including the N-terminal domain and several helical regions, within the G! 
subunit have been shown to be important for interactions with GPCRs31,36. 
One GPCR might have more than one ligand binding specifically to it, each leading to a different 
Figure 3: a) Schematic representation of the structural characteristics of a GPCR. Depicted are the 
seven transmembrane helices (numbered I to VII) and the extra- and intracellular loops connecting 
them. Furthermore the extra- and the intracellular N- and C-terminal domains are shown. The C-
terminal domain is usually anchored to the lipid membrane through palmitoylation of a cystein 
residue. b) A possible intracellular signal transduction cascade actviated after the binding of a 
ligand/signal to a GPCR. Exchange of GDP with GTP on the G" subunit leads to a dissociation of 
the heterotrimeric G-protein. The subunits can then activate effectors such as the phospholipase-! 
(PLC-!) which generates so called "secondary messengers" (e.g. inositol-1,4,5-triphosphate in the 
case of PLC-!) which in turn lead to cellular responses (e.g. the release of Ca2+ from internal 
stores). 
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cellular response. While for instance lipoxin is known to bind selectively to a receptor for 
formylated peptides37, leading to an increase in adhesion of cells to laminin, a screening study 
identified a different class of selective agonists for that receptor, which leads in a different tissue to 
a transient calcium accumulation in the cytoplasm38. This proves the hypothesis that one GPCR can 
elicit multiple physiological responses. 
 
3.2 GPCRs: structure 
Despite the tremendous importance of GPCRs for the (mal)functioning of all higher organisms, 
fundamental information about their molecular details (e.g. location of ligand binding sites, 
conformational changes upon activation or the specific interactions with downstream regulatory 
proteins) is still scarce. 
Particularly limiting to biophysical characterization are the naturally low expression levels and high 
instability of such proteins. For most biophysical characterization techniques, including NMR 
spectroscopy and X-ray crystallography, large quantities (usually tens of milligrams) of pure protein 
are required. Because most natural sources have too low expression levels to allow for the 
extraction of sufficient amounts, recombinant technology is usually applied to increase yields, but 
also to facilitate the often tedious purification protocols for membrane proteins. However, the 
heterologous expression systems commonly used (vide infra) often lead to heterogenous receptors 
due to non-homogenous post-translational modifications or misfolding of the receptors in the 
heterologous hosts. 
In the following paragraphs I would like to give a brief overview about the methods used for 
obtaining membrane proteins in general and specifically GPCRs for biophysical studies. Different 
units for the quantification of expression levels are in use. The most commonly used are picomoles 
of the target protein per milligram of total membrane protein (pmol/mg), expressed copies per cell, 
percent of total membrane protein and percent of total cellular protein. The interconversion between 
these units for a 45 kDa protein (the typical size of a GPCR) in different host systems is 
summarized in the following table (all numbers from Schertler, 199239: 
 
 
 
pmol/mg copies per cell % of membrane protein % of total protein
E. coli 10 2000 0.5 0.05
yeast 10 50000 0.25 0.05
insect cells 10 1000000 0.25 0.05
mammalian cells 10 1000000 0.25 0.05
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3.2.1 GPCR extraction from naturally (over)producing cells 
Rhodopsin is the receptor located in the retina of the eye responsible for the detection of light (it is a 
photoreceptor). Even though it is a special GPCR in many respects, it is still considered the 
"prototypical" GPCR, just because it is the best studied thus far (vide infra). One peculiarity of 
rhodopsin is the nature of its stimulus: While most GPCR stimuli are chemical entities (i.e. 
molecules) it is a physical entity, namely a photon, which leads to the activation of rhodopsin. 
The expression of rhodopsin in retinal cells is driven by a strong rod photoreceptor-specific 
promoter40. In human retina, nearly 108 opsin molecules are produced per day41. In one rod cell 
there are typically around 107 rhodopsin molecules, primarily in the stacked discs but also in the 
plasma membrane. Activation of 1 to 104 photoreceptors can generate a response to low intensity 
light. The opsins located in the cones (the other major photo-receptive cells of the retina) are 
responsible for color discrimination. Their overall structure is supposed to be very similar to 
rhodopsin. 
With a chemical homogeneity of 98% the rhodopsin molecules in the rod outer segments (ROS) are 
uniquely homogenous as compared to other GPCRs41. In several studies it was found that the retinal 
cells' biochemical machinery is also capable of expressing and folding of other GPCRs42-44. 
Rhodopsin carries a characteristic sequence of eight amino acids at its C-terminus. These are 
necessary for transport of the mature protein to the ROS45. This characteristic C-terminal motif has 
been fused to GPCRs other than rhodopsin in recombinant expression studies of foreign GPCRs in 
retinal cells (vide infra). 
 
 
3.2.2 Recombinant (over)production 
As to now, no universal expression system for the recombinant production of GPCRs has been 
found or established despite numerous efforts46,47. 
E. coli is by far the most popular host for the expression of recombinant proteins, mostly because of 
its simplicity of use and the availability of various expression plasmids and strains which have been 
reported to allow high-level protein production. In E. coli there are two strategies for the expression 
of GPCRs in particular and recombinant proteins in general: (a) expression of functional 
membrane-inserted receptors or (b) expression of the protein into incorrectly folded, insoluble 
aggregates, so called "inclusion bodies". The latter approach necessitates the development of a 
protocol for functional refolding of the receptor after purification under denaturing conditions. 
Both approaches depend on the optimization of many parameters. The first strategy was applied to 
the rat neurotensin receptor NTS1 for example48. It has been found that transcription and translation 
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efficiency were not critical for the overproduction of certain GPCRs, but that receptor insertion into 
the cytoplasmic membrane seemed to be the rate-limiting step and could be enhanced by expressing 
the receptor with suitable fusion partners49-52. In the example of NTS1 an N-terminal fusion of the 
E. coli periplasmic protein maltose-binding protein (MBP) provided efficient translocation of the 
MBP by means of its signal peptide, thereby positioning the N-terminus of the fusion construct in 
the periplasm. At the C-terminus the nature of the affinity tag was found to have a substantial effect 
on the expression level of the MBP-NTS1 fusion protein. In addition to choosing suitable fusion 
partners for the protein to be expressed and processed correctly by the translocation machinery 
“gentle” expression conditions were also required in the case of NTS1 in order not to overload the 
translocation complex48. Such "gentle" conditions can generally be achieved by using low-copy 
number plasmids with weak promotors and a low growth temperature53. The expression levels for 
such systems are often low, resulting in the production of around 1000 receptor fusion molecules 
per cell. Subsequent purification requires the careful optimization of buffer composition and 
detergents used during purification to keep the protein in its native form 53,54. This includes the 
design of purification protocols with the least possible number of steps in the shortest possible time 
to achieve a maximum yield of pure functional receptor. 
The approach of expressing a GPCR into insoluble inclusion bodies necessitates the development of 
a protocol for functional refolding of the receptor55, a task which sometimes can't be achieved and 
always requires the screening of a large number of different conditions. This strategy was 
successfully applied to the human leukotriene B4 receptor56. In this study the receptor was purified 
and refolded in one step by nickel-affinity chromatography under denaturing conditions. After the 
receptor had bound to the column the denaturing buffer was replaced by a detergent containing 
buffer, free of denaturant. Refolding efficiency depended, among other factors, on the nature of the 
detergent, the position of the His-tag, and the column loading56. Expression levels for constructs 
accumulated in inclusion bodies can be very high, reaching >10% of total cell protein. 
It should be kept in mind that the overexpression of all eukaryotic proteins in most prokaryotic 
hosts is limited by the lack of posttranslational modifications and often results in the accumulation 
of misfolded proteins in inclusion bodies, whether this is desired or not57. 
Additionally the different lipid composition of prokaryotes compared to that of eukaryotes possibly 
alters GPCR properties58 and the lack of eukaryote-specific chaperones may prevent proper 
folding59,60. 
Some prokaryotes, however, do have the capability of performing posttranslational protein 
modifications. The most notable case is the N-linked glycosylation machinery found in the 
bacterium Campylobacter jejuni. It is encoded by 12 genes organized into a protein glycosylation 
locus, pgl, and can be functionally transferred to E. coli thereby enabling E. coli to perform N-
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linked glycosylation61. In contrast to eukaryotic glycosylation, bacterial N-glycosylation can 
function on folded proteins and is independent of the translocation process62. The principal 
components of the C. jejuni glycosylation system (namely the oligosaccharyltranferase PglB and 
the lipid-linked oligosaccharide) can be purified and reconstituted to form an efficient in vitro 
protein glycosylation system. Such an in vitro system has been used to determine the structure of 
both the protein and the oligosaccharyl part of the small glycosylated protein AcrA (~100 amino 
acids) from C. jejuni63. 
Yeast provide a eurkaryotic environment which is genetically extremely well characterized and easy 
to handle even for standard biophysical laboratories. Therefore it combines the ease of genetic 
manipulation and culturing with the possibility of post-translationally modifying a protein. 
However, as yeast, representing a “lower” eukaryote, show significantly different glycosylation 
patterns as compared to “higher” eukaryotes, also in this host misfolding and concomitant 
malfunctioning of recombinantly expressed proteins of higher eukaryotes has been a problem64. 
Various yeast species have been used for the expression of GPCRs including the baker's yeast 
Saccharomyces cerevisiae and the methylotroph Pichia pastoris. In yeast expression systems the 
foreign gene is either located on an episomal plasmid which replicates independently from the 
chromosomes, or it lies on a plasmid which integrates into the chromosomes after transfection. 
Yeasts perform a variety of posttranslational modifications of proteins, they are genetically very 
well characterized, their growth is usually easy and cheap and large numbers of mutants can be 
quickly produced and screened. This makes them an interesting production host for recombinant 
(membrane) protein production. Several GPCRs have been overexpressed to various degrees in S. 
cerevisiae
46,65. The methylotrophic yeast P. pastoris is a particularly interesting expression system 
because of the high cell densities and the concomitant high expression levels that can be reached 
with this organism66. The expression levels which could commonly be reached for GPCR 
overexpression in yeast varies widely, but levels of up to >100 pmol/mg have been reported46,67. As 
is the case for bacteria, cultures of simple eukaryotes such as yeast can be grown in media 
containing up to 100% D2O. Tuning the the H2O/D2O ratio of such cultures allows to achieve 
almost any desired deuteration level of the target protein68-70. Of the lower eukaryotes, especially P. 
pastoris is an attractive host for protein deuteration due to its good tolerance of D2O and 
concomitant high cell densities, which thus can be achieved71. 
Even though yeasts are capable of posttranslationally modifying proteins, it should be noted that 
these modifications can differ from the ones that are found in higher eukaryotes. This is particularly 
true for N-linked glycosylation. Efforts are undertaken, however, to design yeast strains with a 
"humanized" glycosylation pattern72. 
The low maintenance requirements and the ability of insect cells to perform posttranslational 
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modifications has established insect cell cultures as a popular expression system for recombinant 
eukaryotic proteins more than 25 years ago73. Insect cell lines from Spodoptera fruigperda (Sf) 
ovarian tissue are the most commonly used insect cell lines74. These insect cells are capable of 
carrying out all posttranslational modifications commonly found in mammalian cells (e.g. 
phosphorylation, glycosylation, fatty acid acylation). It should be mentioned, however, that the N-
glycosylation pattern is more simple than in mammals and usually of the "high-mannose" type75. To 
enhance recombinant protein expression76,77 and obtain a mammalian-like posttranslational 
modification pattern insect cell lines from different species, Trichoplusia ni and Estigmena acrea, 
were developed78,79. Overexpression of the target protein is induced by the infection of the cells 
with a genetically modified baculovirus, carrying the coding region of the protein to be expressed 
under a strong viral promotor, usually the polyhedrin promotor79. The virus of choice is usually the 
Autographa californica virus, which is a double-stranded DNA virus, surrounded by a lipid 
membrane80. The viral cycle is lytic and causes cell death 4-5 days after infection. Sometimes it can 
be desirable to express the foreign protein under the control of a weaker early viral promotor. These 
early promotors, however, show considerably lower expression efficiency. 
Baculovirus-infected insect cells have proven efficient for the production of several GPCRs, 
allowing the overexpression of the "1- and "2-AR and the A2A adenosine receptor, which finally 
resulted in the solution of their crystal structures (vide infra). Some of these could be purified to 
homogeneity in mg quantities (expression levels of 10-100 pmol/mg) including the 5-HT3 serotonin 
receptor81, the human histamine H1 receptor82, the human thromboxane A2 receptor83, the human 
A2A adenosine receptor
84,85, the human cannabinoid CB1 and CB2 receptors86, and the human "1- 
and "2-adrenergic receptors87. Generally 10-100 pmol of receptor per mg of total membrane protein 
could be obtained, corresponding to ~106 receptors per cell, which is as much as 500 times as high 
as the expression levels found in the naturally producing mammalian cells46. 
The photoreceptor cells (PRCs) of the Drosophila melanogaster eye have been used for the 
recombinant overexpression of GPCRs88. These cells contain a protein synthesis machinery which 
allows to synthesize rhodopsin in large quantities (vide supra). It is possible to genetically engineer 
D. melanogaster to allow for the tissue- and developmental stage specific overexpression of 
recombinant proteins. The combination of these two factors makes the Drosophila PRCs a 
potentially interesting system for the recombinant production of large quantities of recombinant 
proteins in general. The system has been used for the overexpression, purification and functional 
reconstitution of the D. melanogaster metabotropic glutamate receptor (DM-GluRA). However, as 
was also found in this study not all GPCRs could be overexpressed successfully. In the case of the 
DM-GluRA, however, the system proved to be highly efficient, giving 3-fold higher yields than the 
commonly used Sf9 insect cells88. The system offers other advantages such as the intrinsically low 
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protease activity in photoreceptor cells and the high ratio of target disc membranes to other cellular 
membranes leading to smaller amounts of misfolded receptor due to transport of the receptor to the 
incorrect location. 
Similarly the strategy of expressing GPCRs recombinantly in photoreceptor cells could also be 
applied to the human serotonin receptor and the endothelial differentiation gene receptor family in 
Xenopus laevis tadpoles89. While no data on the glycosylation homogeneity in the D. melaongaster 
expression system is given, Zhang et al. report homogenous glycosylation in the X. laevis system89. 
This is in contrast to other higher eukaryotic expression systems, for which often heterogenous 
glycosylation patterns are found. They attribute the lack of un- or mis-glycosylated protein to the 
fact that the rod photoreceptor cells will only transport properly folded and homogeneously 
glycosylated proteins to the rod outer segment (ROS). Thereby the rods themselves "purify" the 
proteins within the ROS41. 
As the main interest is in human GPCRs, expression systems mimicking human cells as closely as 
possible are generally the most preferred. GPCRs have been recombinantly overexpressed in a 
number of mammalian cells including human embryonic kidney (HEK) cells, which have been used 
successfully to overexpress dopamine receptors90, !- and "-adrenergic receptors91,92, rhodopsin93 
and yeast pheromone receptor Ste2p94. Other popular mammalian cells for recombinant protein 
production are chinese hamster ovary (CHO) or COS (stemming from monkey kidney) cells. Two 
fundamentally different approaches have been used to transfer heterologous genetic material into 
mammalian cells: transient and stable transfection. In transient expression genetic material is 
injected into the host cells either by transfecting them with a plasmid or by delivery of the genetic 
material using a recombinant virus. Both techniques use non-selective conditions (i.e. no selection 
markers) and are therefore usually preferred for short-term protein expression. This is in contrast to 
stable cell lines where the target gene is co-transfected together with a selectable marker, and 
application of selective pressure allows to propagate cells having taken up the genetic material over 
many generations. The transient expression strategy is ideal for functional studies and 
characterization of a target membrane protein by ligand binding assays or patch-clamp techniques. 
Usually only a fraction of the cells are transfected and those only survive for a few days. Many 
membrane proteins have been expressed transiently by transfection of mammalian cells with 
plasmid DNA and robust overexpression in the 100 pmol/mg range could be observed95-97. An 
alternative method for transiently expressing foreign genes in mammalian cells is provided by 
recombinant viruses. Compared to the direct transfection with plasmid DNA, the viral systems offer 
the advantage of high infection efficiency and the presence of strong viral promotors is responsible 
for high transgene expression levels. The drawbacks of viral vectors lies in their potential bio safety 
risk and the high cell lethality. The two most commonly used viruses for transfection of mammalian 
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cells are the vaccinia and the Semliki Forest virus (SFV). These viruses are capable of infecting a 
large number of mammalian (and other higher eukaryotic) cell lines98. This has allowed the 
production of recombinant GPCRs in mammalian cells in suspension cultures in many cases. Often 
the expression levels were up to 100-fold higher than achieved with other systems, lying above 100 
pmol/mg99,100. Glycosylation of GPCRs produced in SFV-based expression systems is not always 
homogenous99 and should therefore be checked carefully. 
If a large quantity of a membrane protein is required over a long period of time, it is generally 
worth the work of establishing a stable cell line. Stable cell lines can be achieved using constructs 
that integrate into the host genome or replicate and segregate episomally. Integrating constructs are 
often put under selective pressure to select for clones having incorporated multiple copies of the 
target gene. For the "2-adrenergic receptor expression levels of 200 pmol/mg could be achieved 
with this strategy101. 
As deuteration of large proteins is often a necessity to obtain NMR spectra of high quality, it should 
be kept in mind, that cells of higher eukaryotic species will not grow in media containing more than 
30-50% D2O. The fractional deuteration resulting from this low H2O/D2O ratio is often insufficient 
for NMR studies. This problem can be circumvented by supplementing the growth medium with 
2H-labeled amino acids from algal extracts, analogous to the strategies for obtaining 15N- and 13C-
labeled proteins in these systems70,102. Proteins with a high deuteration levels at all carbon atoms 
except C! can thus be produced also in higher eukaryotes. 
 
3.2.3 Cell-free protein expression 
Overexpression of (heterologous) protein often faces difficulties ranging from impaired cell-growth 
due to toxicity of the overexpressed protein to instability of the target protein due to intracellular 
protein degradation mechanisms. Such issues can be circumvented by so-called cell-free (CF) 
expression103, which is an in vitro translation system, consisting exclusively of the components 
required for ribosomal protein synthesis (tRNAs, ribosomes, free amino acids, aminoacyl-tRNA 
synthetases, nucleoside triphosphates, initiation-, elongation-, and termination factors, ...). 
Furthermore, CF systems are "open", allowing direct access/manipulation during translation. An 
additional benefit from an NMR point of view is the absence of cellular metabolic pathways 
responsible for isotope scrambling104,105. In basic translation mixes no membrane compartments are 
present and the expression of membrane proteins results in the accumulation of insoluble 
aggregates, which however can often be solubilized by mild detergents106,107. The addition of 
detergents or lipids to the translation mix allows to insert an expressed membrane protein directly 
from the ribosome into micelles108,109 or liposomes110-112. 
Extracts of E. coli and wheat germs are the most widely used systems. The cell extracts can be 
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prepared in a normal molecular biology lab113,114, but are also available commercially115,116. 
Protocols for the preparation of E. coli117-119 and wheat germ120,121 extracts are well documented. 
Because of their pharmacological importance and the difficulties in heterologous expression, 
GPCRs are particularly interesting candidates for CF expression systems108,122,123.  
The protein yields that can be achieved with the CF system can be very high, typically giving mg of 
protein from 1 ml of the translation reaction. For both soluble113,117 and membrane proteins112,124,125 
yields in the mg/ml range have been reported. Together with the short reaction times this makes CF 
expression also an interesting technique for high-throughput proteomics126,127. 
 
 
3.2.4 Structural characterization of GPCRs 
Circular dichroism is able to report on the secondary structure of proteins. In 1978 studies using this 
technique provided the first experimental evidence for an extensive !-helical content in rhodopsin, 
which was consistent with 7-9 transmembrane (TM) helical segments128. In 1983 when the primary 
sequence of rhodopsin was published a hydropathy plot indicated clearly the presence of seven 
hydrophobic transmembrane sequences22. The next major breakthrough in GPCR structural studies 
came 10 years later when two dimensional crystals of rhodopsin in phospholipid bilayers could be 
grown and analyzed by cryo-electron microscopy yielding a projection density map at a resolution 
of about 9 Å. These studies for the first time visualized unequivocally the bundle of seven 
transmembrane helices129. In 2000 the first high-quality three dimensional crystals of bovine 
rhodopsin in mixed micelles were obtained130, allowing Palczewski et al. the determination of the 
first high-resolution structure of a GPCR at a 2.8 Å resolution131 (figure 4a). 
 26 
 
 
Figure 4: a) Ribbon representations of three different GPCRs and the crystallizzation strategy 
which was applied. Rhodopsin was extracted from a native source, whereas the !-ARs were 
produced recombinantly in insect cells. Mutations introduced into !1-AR in order to obtain stable 
crystals and fusion (T4L) or interaction (Fab) partners for the crystallization of !2-AR are colored 
red. b) Snake plot representation of the !1-Ar with the ionic lock colored green, the rotamer toggle 
switch colored blue and the NPXXY motif colored red. These three motifs are also colored in the 
same manner in the crystal structure of !1-AR on the right. c) Overlay of the rhodopsin (gray) and 
opsin (orange) crystal structures. The main differences are in the i3 loop region and at the bottom 
of TM5 and 6. They are highlighted in red. 
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The obtained structure essentially confirmed the predicted topology of GPCRs as consisting of an 
N-terminal extracellular domain, a cytoplasmic C-terminal domain and seven transmembrane 
helical segments (TM1-7) interconnected by three intracellular loops (ICL1-3) and three 
extracellular loops (ECL1-3), but also revealed the presence of a non-anticipated short antiparallel 
"-sheet in ECL2. 
The crystal structures of four other GPCRs, namely the human "2-adrenergic receptor132-136 ("2-
AR), the avian "1-adrenergic receptor137 ("1-AR), the human A2A adenosine receptor
138, and bovine 
opsin139, followed in 2007 and 2008. Except for opsin all of these structure represent "ligand 
bound" states: rhodopsin is covalently bound to retinal131, the "1-adrenergic receptor is bound to the 
antagonist cyanopindolol137, "2-adrenergic receptor to the inverse agonist carazolol132-134 and 
timolol135,136, and the A2A adenosine receptor is in complex with the antagonist ZM241385
138. 
Of these GPCRs rhodopsin is the only one which has not been expressed recombinantly, but could 
be extracted in sufficient amounts from natural sources (vide supra). A second major challenge in 
the handling of GPCRs is their low thermal stability140. Of the structures determined thus far, only 
rhodopsin didn't require any stabilization strategies to allow crystallization. The main strategies 
followed to allow successful crystallization of the above mentioned GPCRs shall be outlined briefly 
in the following paragraph. As was already mentioned rhodopsin could be extracted from a natural 
source in sufficient amount. Additionally, rhodopsin thus far has been the only GPCR with 
reasonable thermal stability. Therefore the crystallization of rhodopsin didn't require any 
recombinant expression strategies and/or mutagenesis screenings (figure 4a). This is much in 
contrast to the other GPCRs, for which crystal structures have been published. The "2-adrenergic 
receptor was truncated near the C-terminus and N-linked glycosylation was removed to increase the 
thermal stability. Additionally it carried an affinity tag for efficient purification. The low solvent 
exposed surface area necessitated the application of different strategies to increase the number of 
crystal lattice-forming contacts. In one determined structure "2-AR was co-crystallized with an 
antibody Fab fragment stabilizing the TM5/TM6 regions132 (figure 4a). In the other determined 
structure the TM5/TM6 region was stabilized through the insertion of the T4 lysozyme sequence 
into the third intracellular loop (ICL3)133,134 (figure 4a). Comparison of the structures of the two 
different constructs showed minimal deviations, indicating that the fusion of the T4 lysozyme 
sequence had little effect on the overall structure of "2-AR. The same strategy (truncation, removal 
of glycosylation, affinity tag and insertion of the T4 lysozyme sequence into ICL3) was chosen for 
obtaining high quality crystals of the human A2A adenosine receptor
138. The "-AR1 was truncated in 
the flexible ICL3 and N- and C-termini. Additionally the palmitoylation site was removed and an 
affinity tag introduced. A number of point mutations (7 in total; all in the TM helices) was 
introduced to increase the thermal stability of the receptor137 (figure 4a). Except for the ICL2, which 
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comprises a short helical segment, the overall structure is very similar to the "2-AR. Furthermore, 
all GPCRs structures determined thus far, with the exception of opsin, were bound to a ligand, 
which stabilized their structure. 
The sequence comparison of many GPCRs141 and the recently published crystal structures (vide 
supra) have led to the postulation of key residues/motifs important for the structure and function of 
GPCRs. A number of highly conserved proline residues in the TM helices in TM4, TM5, TM6 and 
TM7 have been identified, which are thought to introduce kinks in the helices and thereby forming 
the ligand binding pocket142. Other conserved residues in the TM region of GPCRs have also been 
identified141. It could be shown experimentally, that several conserved residues have a strong 
influence on the active/inactive equilibrium of the receptors. One of them is a tryptophan residue in 
TM6, commonly embedded in a CWxP motif and named "rotamer toggle switch" (figure 4b) as the 
side chain rotameric conformation of the Trp plays a role in receptor activation. The residues which 
comprise this switch are coupled and modulate the bend angle of TM6 around the highly conserved 
proline in its center143. Another important motif is the (D/E)RY motif near the cytoplasmic end of 
TM3 (figure 4b). The strictly conserved arginine (residue 3.50 according to the Ballesteros-
Weinstein numbering scheme [vide infra]) forms an ionic interaction with a conserved glutamate 
(6.30) on TM6, termed the "ionic lock". This "lock" has long been thought to keep the receptor in 
the inactive state144-146. Recent crystallographic data on the ionic lock, however, are not conclusive 
as to whether this is really the task of this motif147,148. The interaction pattern of an asparagine 
(7.49) and a tyrosine (7.53) both located in TM7 as part of a NPxxY motif (figure 4b) is also 
thought to play an important role in receptor activation149. A current model for the activation of 
GPCRs states, that as long as it is unliganded, the inactive state of a GPCR is stabilized by 
noncovalent interactions among different motifs such as the ones mentioned above. Structurally 
distinct ligands then lead to the breakage or retention of different combinations of these motifs150. 
These ligand-dependent response profiles are useful in the explanation of the different activation 
profiles, which can be observed within one family of ligands for a certain GPCR. 
The solution of the "2-AR structure bound to the inverse agonist timolol135,136 revealed the presence 
of a specific cholesterol binding site (cholesterol consensus motif, CCM) located between TM2, 
TM3 and TM4. Based on sequence similarities among multiple GPCRs in the CCM region, 
cholesterol binding might be a general feature of these receptors 135. 
Presently eighteen rhodopsin and opsin crystal structures have been published (for a compilation of 
all GPCR crystal structures published so far see appendix E in chapter 4). Several of these, 
including the original publication131, are of rhodopsin in the inactive ground state. But also for 
isorhodpsin (containing the non-native chromophore 9-cis-retinylidene)151, two light activated 
intermediates populated early in the activation chain152, a photoactivated receptor in the meta-I 
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state153,154 as well as the opsin apo-protein139 crystal structures have been published. Opsin is the 
retinal-free form of rhodopsin (the apo-protein), which is generated after photoactivation through 
the hydrolysis of the Schiff base. 
All the rhodopsin structures discussed so far were determined on bovine rhodopsin. Additionally 
also the crystal structures of squid rhodopsin has been solved155,156. There are three main 
characteristics of light-activated rhodopsin: first, it shows an isomerization of the retinal 
chromophore from the 11-cis to the all-trans form, second, it manifests a spectral shift of its 
absorbance maximum from 500 nm to 378 nm, which is caused by the deprotonation of the Schiff 
base linking the chromophore to Lys2967.43 (the numbering scheme used is the three-letter amino 
acid abbreviation followed by the residue number and the Ballesteros-Weinstein numbering of the 
residue in superscript) of the protein157,158, and third, a hydrogen bond between Arg1353.50 of the 
(D/E)RY motif in the third and Glu2476.30 in the sixth transmembrane helix, the so-called “ionic 
lock”, is broken159. The structure of the photoactivated rhodopsin shows all of these 
characteristics154. Comparison between the ground and activated structures reveals the largest 
differences in the third cytoplasmic loop of the receptor (figure 4c). This loop becomes completely 
disordered upon activation, with some residues missing in the electron density map. However, 
already in the ground state this loop is more disordered than other regions in the receptor as is 
evident from its increased temperature factor. The breaking of the ionic lock upon receptor 
activation is seen from an increase in the distance between Arg1353.50 and Glu2476.30 from 2.7 Å to 
4.1 Å in the ground and activated states, respectively. 
In the structures of the "1- and "2-adrenergic receptors, which are both in the inactive state, the 
ionic lock motif is broken. In the case of the "1-AR the inverse agonist cyanopindolol is bound137, 
and it is not clear as to why a compound lowering the basal activity of the receptor should disrupt 
the ionic lock, a feature which is commonly attributed to the activation of the receptor. In the case 
of the "2-AR even less conclusion about the broken ionic lock can be drawn, because an arginine 
residue of the T4 lysozyme fusion, which has been inserted into the third intracellular loop to 
enhance protein crystallization, disrupts the (D/E)RY motif133,134. 
As might be expected, the most significant structural differences between the published receptor 
structures lie in the extracellular loops. For instance the second extracellular loop 2 (ECL2) of 
rhodopsin together with the N-terminus forms a short "-sheet, that shields the covalently bound 
bound retinal from bulk solvent, thereby preventing Schiff base hydrolysis. This shielding is further 
enhanced by the conformation, which is adopted by the glycosylated N-terminus160,161. The ECL2 
of the two adrenoreceptors, on the other hand, contain both a short !-helix which is stabilized by 
intra- and inter-loop disulphide bonds. The N-terminal domain of these two receptors is 
disordered133,134,137. It appears that the extracellular face of the adrenoreceptors has, in contrast to 
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rhodopsin, evolved in such a way as to allow easy access to the ligand binding site. 
The ECL2 of the A2A receptor shows constrained conformations exposing the ligand-binding cavity 
to bulk solvent. The conformational constraints on the loop are mainly imposed by multiple 
disulphide bonds138. The advent of additional high-resolution structures will be needed to judge, 
whether the open binding pocket is a general feature of GPCRs that bind soluble small-molecule 
ligands. 
The binding sites of retinal, cyanopindolol and carazolol are overlapping in superpositions of 
rhodopsin131, "1-AR137 and "2-AR133,134, respectively. The binding orientation of the ligand is 
parallel to the membrane bilayer in all three above mentioned receptors, which is in contrast to the 
perpendicular orientation of ZM241385 bound to the A2A receptor
 138. The aliphatic tail of carazolol 
in the "2-AR structure follows a very similar path to retinal in rhodopsin. In both cases the ligand 
extends from TM7, where it makes polar interactions in the case of carazolol and is covalently 
bound for retinal, to the interface of TM5/TM6. It is only here that the orientations of the two 
ligands start to differ as retinal extends deeper towards the center of the membrane, where it 
interacts with Trp2656.48 of the "toggle switch". 
The most interesting question concerning the activation is probably, how the changes in the 
interactions in the ligand binding pocket can be propagated to the cytoplasmic loops and thereby 
translated into G-protein activation. The structure of opsin highlights the transmembrane helix 
rearrangements which take place during receptor activation139 and the structure of opsin in complex 
with a G-protein peptide can provide clues about the actual conformational state of the TM helices 
and the intracellular loops of a GPCR in the active state162.  
The opsin molecule doesn't correspond to activated rhodopsin, but rather represents a state later in 
the activation chain, and can be considered something like a desensitized or reduced activity form 
of rhodopsin. However, it does show residual activity in activation of transducin which is markedly 
higher as compared to ground state rhodopsin163, for which basal activity is almost zero. Through 
infrared spectroscopy studies it was inferred, that opsin at low pH adopts a conformation that 
resembles the active state of metarhodopsin II164,165. The crystal structure of opsin was determined 
at low pH (5.6)139 and several conformational changes of residues located near the ligand binding-
pocket relative to rhodopsin could be observed. Most importantly the side chain of Trp2656.48, the 
“toggle switch", moves into the space previously occupied by the ionone ring of the retinal. The 
most dramatic structural differences between rhodopsin and opsin are observed at the cytoplasmatic 
surface of the molecule. The cytoplasmatic ends of TM5 and TM6 and the interconnecting ICL3 are 
shifted away from the center of the helix bundle. At the same time the ends of the two helices move 
closer to each other. This movement observed in the crystal structures is consistent with previous 
biophysical data obtained by site directed spin labeling studies166,167. The ionic lock is broken and 
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Arg1353.50 forms a new interaction with Tyr2235.58, while Glu2476.30forms a salt bridge with 
Lys2315.66. Tyr3067.53 from the NPXXY motif on TM7 occupies some space in opsin which has 
been occupied by TM6 in dark-state rhodopsin, thereby probably stabilizing the activated 
conformation characterized by the TM5/TM6 movement. Overall the change from inactive 
rhodopsin to an activated form is thought to create a cavity between TM3, TM5 and TM6 to which 
transducin can bind, a hypothesis which is also corroborated by the crystal structure of opsin in 
complex with a C-terminal peptide of transducin162. The transducin peptide adopts a helical 
conformation and interacts with opsin in an amphipathic manner. No significant structural changes 
are seen upon binding of opsin to the C-terminal transducin peptide. 
All these findings, which highlight the structural changes required for the activation of rhodopsin, 
however, do not answer the question, how the binding event near the extracellular side of the 
receptor is translated into the structural changes observed on the cytoplasmic side. More 
biophysical data, especially such with time resolution, will be required to answer this question. 
 
3.2.5 Ligand binding in class B GPCRs 
With roughly 700 members class A GPCRs represents the largest subfamily of the 7TM receptors. 
Class B receptors with approximately 15 members are distinguished by their large N-terminal 
extracellular domain (ECD) of 100-160 residues which have a prominent role in ligand binding1,168. 
The ligands of class B GPCRs are endogenous peptide hormones such as glucagon, parathyroid 
hormone (PTH), corticotropin-releasing factor (CRF), growth-hormone releasing factor (GRF), 
pituitary adenylate cyclase (PACAP), glucose-dependent insulinotropic polypeptide (GIP), 
glucagon-like peptide 1 (GLP-1) and many more. Even though to date no high-resolution structure 
of a class B GPCR has been reported to date, the principles underlying ligand binding and receptor 
activation are better understood than for the class A GPCRs. This is mainly due to the fact that the 
large ECD1 of various receptors have been expressed recombinantly and could be used to perform 
ligand binding studies in vitro, leading to several high-resolution structures of free ECD and in 
complex with the cognate ligand. These include a subtype of human PACAP receptor169, human 
PTH receptor170, human GIP receptor171, human GLP-1 receptor172, the murine type-2" CRF 
receptor173,174 and  the human type-1 CRF receptor175,176.  
Receptor binding occurs generally through the C-terminal residues with the ligands adopting a 
helical conformation upon receptor binding, thereby generating the conformationally active state. 
Receptor activation is then thought to occur through an interaction of the structured N-terminal part 
with the transmembrane region of the receptor177. This model is consistent with all of the above 
structural studies and also explains why N-terminally truncated peptide ligands generally act as 
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antagonists. 
All these ECDs share a common fold (called "secretin family recognition fold") comprised of an N-
terminal helix, two antiparallel two-stranded "-sheets and three conserved disulfide bonds. Most 
notably the NMR studies on the ECDs of the two CRF receptors showed two unstructured loops 
undergoing dynamics on the millisecond to second timescale leading to line broadening effects. 
One of these loops gets structured upon ligand binding173-175. 
 
3.3 GPRC classification and residue nomenclature 
Contrary to the structural homology common to all GPCRs, these receptors do not show any overall 
sequence homology across all members of the family141,178. However, significant sequence 
homology can be found within the three major subfamilies. Family A, which is the largest 
subfamily, is represented by rhodopsin but also includes the "-adrenergic receptors. Family B 
receptors are related to the glucagon receptor and receptors of family C to the metabotropic 
neurotransmitter receptors. Two additional small subfamilies D and E are made up by the yeast 
pheromone receptors STE2 and STE3, respectively. And in the organism Dictyostelium discoideum 
a sixth subfamily of cAMP receptor constitutes subfamily F178. 
Family A is by far the largest and most studied. It can be subdivided into smaller subgroups. Even 
though the overall homology among all family A receptors is low there are a limited number of 
highly conserved key residues. This high degree of conservation indicates that they have an 
essential role for the structural or the functional properties of the receptor. The only residue which 
is absolutely conserved among all family A GPCRs is the arginine in the E/DRY motif near the 
cytoplasmic side of TM3 (vide supra)141,178. An additional characteristic for family A GPCRs is a 
conserved disulfide bridge between ECL1 and ECL2 and several conserved residues within the TM 
helices. Within the family A GPCRs, however, differences regarding the binding site of the ligand 
exist. It is these differences which serve as the basis for a further division of this family into three 
different subgroups: Subgroups 1 and 2 differ from subgroup 3 by their short N-terminal domains 
(10-50 residues vs ~100 residues, respectively). The distinguishing feature between subgroups 1 
and 2 is the location of the ligand binding pocket on the receptor. Whereas for subgroup 1 the 
ligand binding pocket is buried in the receptor's TM region, the binding pocket for subgroup 2 
members is formed by the extracellular parts (N-terminus and loops) of the receptor. 
Representatives of subgroup 3 are thought to bind their ligands mainly via their N-terminus179 
(figure 5). 
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Family B of GPCRs is made up of approximately 20 different members, which bind a variety of 
peptide hormones. Importantly the (D/E)RY motif is absent in this GPCR subfamily, which has a 
large (~100 residues) extracellular N-terminal domain containing several cysteines, which 
presumably form a disulfide bridge network180, as the most characteristic structural feature. The 
characteristic disulfide bridge connecting ECL1 and ECL2 is absent in family B GPCRs179. 
The N-terminus of family C GPCRs is even longer, ranging from 500 to 600 amino acids and 
sharing sequence similarity with periplasmic binding proteins of bacteria181. The ligand binding site 
is believed to be located exclusively in this large extracellular domain182. 
Because of the large variation in the length of the GPCR polypeptide chain between different 
subfamilies, but also within such subfamilies, a residue numbering system not primarily based on 
the position in the primary sequence is required to allow for the comparison of different GPCRs. 
Different numbering schemes have been devised183-185, with the one from Ballesteros and Weinstein 
being the most commonly used nowadays185. In their scheme each helix is labeled with its number 
(i.e. from 1 to 7). The most conserved residue in each helix is then arbitrarily given the number 50 
(see figure 8 for an example). Residues towards the C-terminus will sequentially be given numbers 
Figure 5: Classification of GPCRs into three main families according to structural characteristics 
as explained in the text. 
 34 
bigger than 50, and residues towards the N-terminus will be labeled with numbers smaller than 50. 
This residue number will be separated from the helix number by a dot and both numbers are in 
superscript, if they are added to the three-letter abbreviation code of an amino acid. As an example 
the most conserved residue in TM5 of rhodopsin is a proline. This proline would therefore be 
labeled as Pro5.50. Its preceding isoleucine would be called Ile5.49 and its succeeding leucine Leu5.51. 
 
3.4 Alternative strategies for the structural characterization of GPCRs 
Even though high resolution crystal structures of a few GPCRs could be obtained in the last years, 
the efforts leading to such a structure are still huge, mainly because crystallization of membrane 
proteins is still a more than challenging task. Since these proteins contain large areas of 
hydrophobic surfaces, they must be isolated in detergents, which "mask" a large proportion of the 
accessible surface area and render it incapable of forming protein-protein contacts, which are 
essential for forming three-dimensional crystals. The second major technique allowing the 
determination of high-resolution protein structures is NMR. While this approach has become very 
successful in the structure determination of soluble proteins, its use to study membrane proteins has 
been much more limited. The reasons for this are manyfold. Obtaining suitable amounts of 
membrane proteins for structural studies is associated with many difficulties. While issues 
concerning the low levels of expression, the tedious purification process, and the often inherently 
low thermal stability of membrane proteins also concern crystallographic studies, an additional 
factor prevents the successful application of NMR methods to the study of many membrane 
proteins. This is the molecular weight (MW) of the proteins under study. As there is no theoretical 
MW limit for the study of a system by X-ray crystallography crystal structures of systems as large 
as the (entire) ribosome186-188 or the fatty acid synthetase189,190 have been determined (both with 
molecular masses of ~2.5 MDa). Major technological improvements of the NMR hardware include 
the increasing magnetic field strengths191, the design of cryogenically cooled probes192 and the 
development of microcoil NMR193. On the methodological side the MW limit for structure 
determination has been pushed from 10 kDa in the early days of NMR194, where only proton-proton 
correlation experiments could be recorded, to ~50 kDa through the introduction of triple resonance 
techniques195, to currently ~100 kDa through the development of elaborate labeling schemes196,197, 
perdeuteration and transverse relaxation optimized NMR spectroscopy198,199. Currently the largest 
molecules whose structures have been solved by NMR completely are around 80 kDa. One example 
is the 82 kDa malate synthase G from E. coli200. While the polypeptide chain of a typical GPCR 
alone is usually in the 50 kDa range, the detergent molecules associated with the polypeptide chain 
make the effective MW much larger.  
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4. NMR spectroscopy with membrane proteins 
 
4.1 Introduction 
Even though membrane proteins make up roughly 50% of the proteome of an organism, structural 
information on this class is much underrepresented compared to soluble proteins. Of the membrane 
proteins of known structure those with large extramembraneous domains are predominant, while 
information on small membrane proteins with a high membrane-embedded portion is scarce. This 
imbalance stems from the requirement of protein-protein contact areas for the growth of three-
dimensional protein crystals201. From an NMR point of view exactly these small membrane proteins 
are ideal candidates for structure determination. It is thus likely that solution NMR will play an 
important role in delivering structural information on this class of proteins. 
 
4.2 The role of detergents in NMR spectroscopy with membrane proteins 
As was already mentioned membrane proteins must be solubilized from their native lipid 
environment through detergents. In order to make a membrane protein amenable to solution NMR 
spectroscopy, the chosen detergent must keep the membrane protein in its native conformation and 
additionally the detergent-solubilized membrane protein must be small enough to allow fast 
isotropic tumbling in solution. Detergent micelles are the most commonly used solubilizing agent 
for solution NMR studies. A series of zwitterionic and anionic detergents is available and have been 
used successfully in NMR spectroscopy202, whereas uncharged detergents are less frequently used 
for NMR studies of membrane proteins. Aside from the charge of their head-groups, detergents are 
characterized by their critical micelle concentration (cmc), monomeric molecular weight and 
aggregation number. From the latter two the molecular weight of a micelle aggregate can be 
calculated. Even though extensive screening studies have been carried out in order to find a 
universal detergent for NMR studies, generally the optimal solubilization conditions, including the 
choice of the detergent, must be worked out for each membrane protein203-205. For enzymes native 
structure can be tested through functional assays as demonstrated for the diacylglycerol kinase 
(DAGK)206-209 or the "-barrel bacterial outer membrane protein PagP210-212. 
Even though detergents such as sodium dodecylsulfate (SDS)213, dodecylphosphocholine (DPC)214 
and lauryldimethylamine N-oxide (LDAO)215, which have the charged head group directly attached 
to the alkyl chain, have been used successfully in structural studies (see references for examples), 
this family of detergents has a propensity to destabilize proteins202. More promising for the 
 36 
preservation of native structure and biological function are detergents, which carry a polar, but 
uncharged spacer between the charged head group and the apolar tail. Two prominent members of 
this family are dihexanoyl phosphatidylcholine (DHPC)216 and the lysophospholipids204 with alkyl 
chain lengths of 14 and 16 C-atoms and different headgroups such as phosphatidylcholine or 
phosphatidylglycerol. 
Micelles are usually depicted as spherical aggregates. In nature, however, they often assume oblate 
or prolate shapes217-219. The molecular weight of a typical micelle is in the range of 50-100 kDa. 
When a membrane protein is solubilized in a detergent micelle, a so called “mixed micelle” is 
formed. In case of large membrane proteins with molecular weights in the range of the micelles the 
molecular weights of micelle and protein are usually not additive. Rather the hydrophobic surface 
area of the protein determines how many detergent molecules can be bound, and hence ultimately 
determines the size of the mixed micelle206. Therefore the size of the protein-micelle complex 
cannot simply be minimized just by choosing a detergent type known to form small micelles. 
Apart from micelles small isotropic bicelles, composed of long-chain lipids forming a planar mini-
bilayer, whose rims are covered by short-chain lipids, have been used successfully in solution 
NMR. Due to their planar surface they represent the most membrane-like environment in which 
solution NMR is still possible. Bicelles have also been used extensively in solid-state NMR studies 
of membrane proteins220-224 and are therefore an ideal system for combined solution/solid-state 
NMR studies. Apart from membrane associated peptides220 also a few membrane proteins studied 
successfully in bicelles by solution NMR. Among them are the "-barrel proteins OmpA225 and 
OmpX13. A further development of the bicelle system are lipid-protein nanoscale bilayers226, which 
may prove useful for solution NMR in the future as indicate promising results with the 
mitochondrial voltage dependent anion channel VDAC-1227. They are reconstituted high density 
lipoprotein particles composed of a planar patch of ~160 lipid molecules, with the rim of the patch 
covered by the lipid binding protein apolipoprotein A-I. 
Two other promising solubilization media for membrane proteins are amphipols228 and reversed 
micelles229. The latter have been used to enclose soluble proteins within their aqueous interiors. 
Dissolving these large complexes in low viscosity alkanes such as pentane or hexane results in more 
rapid overall tumbling than can be observed for the enclosed soluble protein in water230-232. 
Applications of this system for the study of membrane proteins are currently in progress233. 
 
4.3 Isotope labeling strategies in NMR spectroscopy with membrane proteins 
Obtaining chemical shift assignments of membrane proteins requires 2H, 13C, 15N-labeled samples 
in almost all cases. Fortunately for many of the screening processes (refolding efficiency, sample 
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stability, spectra quality) the much cheaper 15N-enrichment alone is sufficient. Generally 15N-1H 
heteronuclear single quantum correlation (HSQC) spectra can be recorded on solely 15N-labeled 
samples of up to 100 kDa in size234. As most NMR experiments rely on the excitation and detection 
of 1H magnetization, deuterated proteins necessitate the introduction of protons for 1H-based 
experiments to work. This is usually done by dissolving the denatured protein in H2O, which leads 
to the exchange of 2H to 1H at all exchangeable sites including the backbone 15N-1H amide group. 
In addition to protonation at the backbone amide sites in an otherwise highly deuterated 
background, its is also possible to selectively protonate methyl groups of Val, Leu and the $1 of Ile 
by supplementing an E. coli minimal medium with precursors of these amino acids, which carry 
only protons at the methyl sites and deuterons in all other sites197. The precursors which allow this 
type of labeling are !-ketoisovalerate and !-ketobutyrate70,235. Provided a complete backbone 
assignment is available the methyl 13C and 1H chemical shifts can be assigned by relaying proton 
magnetization generated on the methyl to the backbone N-H groups by experiments specifically 
designed for highly deuterated proteins carrying selectively labeled methyl groups236,237. Recently 
also the selective methyl protonation of alanines became feasible at reasonable cost238. Ala is, in 
contrast to Val, Ile and Leu, evenly distributed across a protein's sequence and therefore is a very 
attractive residue for the selective labeling. In a highly deuterated protein the lack of protons other 
than the ones in the exchangeable sites hampers the structure determination based on proton-proton 
NOEs. The selectively protonated methyl groups therefore serve as an important source of 
additional NOE based structural restraints239, because generally NH-NH NOEs alone are 
insufficient to determine the global fold of a protein236. An exception are the "-barrel proteins in 
which NH-NH NOEs give many long-range restraints, allowing to accurately define the global 
fold234. 
 
4.4 Alternatives to traditional NOE based structural restraints 
4.4.1 Residual dipolar couplings 
The scarcity of NOE restraints in highly deuterated proteins necessitates the access to other 
structural information, in order to obtain accurate protein structures. Residual dipolar couplings 
induced by partial alignment of the protein in the magnetic field is able to deliver such 
information240,241. Alignment is achieved by special media of significant magnetic anisotropy that 
hence have a preferred orientation in the magnetic field. The non-isotropic orientation of these 
media is then (partially) transferred to the protein under study. Commonly used alignment media 
include large bicelles242, bacteriophages243,244, mechanically strained polyacrylamide gels245,246 and 
DNA nanotubes247,248. Unfortunately the former two are incompatible with the detergents required 
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for the study of membrane proteins249. Strained polyacrylamide gels have been successfully used to 
align membrane proteins250,251, but often decrease the tumbling rate, especially in large systems. 
The DNA nanotubes seem to be a promising system for aligning membrane proteins, but relatively 
little knowledge is available so far, which is also due to their complicated synthesis. 
 
4.4.2 Paramagnetic relaxation enhancement 
Unpaired electrons of paramagnetic molecules can lead to a dramatic increase in relaxation rates of 
nuclear coherences through electron-nuclear spin dipolar interaction, because of the large 
magnetogyric ratio of the electron (#2H/#1H ~ 660)
252. This phenomenon is called paramagnetic 
relaxation enhancement (PRE). Paramagnetic compounds in the solvent, such as dissolved O2, can 
lead to an overall broadening of the resonances of the molecule under study. In case a paramagnetic 
species, such as a metal ion or a nitroxide spin label, is attached to a protein, despite the presence of 
broadened lines in vicinity of the paramagnetic center, useful structural information can be 
obtained. Whereas NOE restraints are limited to ~6 Å, PRE is active over considerably larger 
distances of up to 25-35 Å253,254 and has hence been recognized early as a potentially important 
effect for obtaining long-range distance information255. In proteins where NOE restraints are 
difficult to obtain, PRE restraints can thus be beneficial for defining the global fold. An additional 
advantage of PRE based distance restraints is, that they can be obtained much more easily than 
NOE restraints, especially for large proteins where signal overlap and poor resolution often hamper 
the acquisition of NOE restraints, and they do not necessarily require assignment of sidechain 
resonances. In addition, they can be placed in more flexible regions, which are difficult to assign. 
Only certain metalloproteins naturally possess paramagnetic centers. Therefore this class of 
molecules is the one most extensively studied making use of PRE256-258. Proteins lacking a natural 
paramagnetic center can often be labeled with paramagnetic nitroxide centers through site-directed 
spin labeling (SDSL)259. Application of this technique has been used to tackle lacking long-range 
NOE distance restraints such as unfolded260/disordered261-265 proteins, but also large soluble 
proteins253 and most notably membrane proteins209,266,267. In the case of the integral membrane 
proteins Mistic267 from B. subtilis and diacylglycerolkinase (DAGK)209 from E. coli PREs were 
used in addition other structural restraints. In the case of the E. coli outer membrane protein A266 
PREs from SDSL on 11 single cysteine mutants were used to refine the previously published 
solution structure. However, it could also be shown in that case that the PREs alone yielded a 
structure of reasonable quality. 
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4.5 New experimental frontiers in membrane protein NMR spectroscopy 
As traditional proton based NMR reaches its limits in the study of large systems, alternative 
strategies, such as NMR experiments relying solely on 13C have been developed268,269. 
The larger a protein, is the slower it tumbles in solution, which implicates fast relaxation of 
coherences and concomitantly broad lines in the NMR spectrum. At high magnetic field the dipole-
dipole interaction and the chemical shift anisotropy (CSA) are the dominant relaxation pathways. In 
an scalar coupled I-S spin system with the S spin having a large CSA (as is for instance the case for 
the 1H-15N spin system of the backbone amide) the IS correlation spectrum is composed of four 
components of differing line widths. In the narrowest of these components the dipole-dipole 
interaction and the CSA partially compensate each other. The TROSY (transverse relaxation 
optimized spectroscopy) experiment is designed such that only the component with the narrowest 
line width is retained in the spectrum and all the other components are discarded198. The original 
TROSY experiment has been enhanced270,271 and its principle has been introduced in a variety of 
multidimensional experiments, enabling resonance assignment199,272-274 and structure 
determination275 exploiting the TROSY phenomenon. The introduction of the TROSY principle 
pushed the molecular weight limit for solution NMR to ~100 kDa. Other relaxation interference 
mechanism can also be exploited, giving rise to TROSY phenomena for groups which don't show 
significant CSA such as the methylene and methyl groups276-278. 
 
4.6 GPCRs studied by NMR spectroscopy 
The application of solution NMR to the study of GPCRs can be divided into four main fields: First 
the characterization of GPCR fragments, second the examination of ligands bound to GPCRs279-282, 
third the detection of selectively labeled probes in rhodopsin283-285. In the fourth field, the study of 
full-length GPCRs only few successes could be achieved so far286. 
 
4.6.1 Detection of selectively labeled probes in GPCRs 
Several different NMR observable probes have been incorporated into rhodopsin and could be used 
for its study by solid-state and liquid-state NMR methods. 
The incorporation of a selectively 15N- or 13C-labeled amino acid types into rhodopsin has been one 
of the main strategies to study full length GPCRs by NMR. Such selective labeling is achieved by 
adding appropriately labeled amino acids or their precursors to the growth medium of mammalian 
cells (HEK cells) used for the recombinant production of rhodopsin. In an initial study283 lysine 
carrying a 15N-label at its !-amino group ([!-15N]lysine) was included in the growth medium of the 
HEK cells stably expressing rhodopsin at about 2.5 mg/l of cell culture287. 11 lysine residues are 
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distributed over the rhodopsin sequence, 9 of which are in the cytoplasmic, 1 in the intradiscal 
(extracellular), and 1 in the TM domain (Lys296, to which the retinal chromophore is attached). 
Samples of native rhodopsin (as judged by a A280 to A500 ratio of ~1.6
288) in dodecyl maltoside 
(DM; 4-7%) or octyl glucoside (OG; 1.4%) micelles measured at 4 °C showed only one peak in the 
[15N,1H]-HSQC spectra. Only going to higher temperatures and/or including 5% SDS in the 
samples led to the appearance of additional peaks, however with concomitant denaturation of 
rhodopsin. Based on an HNCO experiment289, a protease digestion assay and antibody binding 
studies the visible peak under native conditions was assigned to the lysine residue located in the C-
terminus of rhodopsin. As the size of the rhodopsin containing micelles was estimated by dynamic 
light scattering (DLS) to be around 100 kDa, the lack of the remaining 10 signals was attributed to 
conformational exchange processes on the micro- to millisecond time scale leading to exchange 
broadening of the respective resonances and not to a total molecular weight of the system outside 
the accessible range of such basic 2-dimensional experiments as the TROSY version of the 
[15N,1H]-HSQC. In a following study conducted by the same group tryptophan carrying a 15N-label 
at its !- and %-nitrogens ([!,%-15N]tryptophan) was included in the growth medium of the same 
HEK cell line used in the previous study287. Four of the five tryptophans of rhodopsin are located in 
the TM region and only one is in the extracellular domain. The [15N,1H]-HSQC spectra of 
rhodopsin showed more than the expected 10 peaks. Whereas the expected 5 from the side chains 
are observed in the characteristic indole region more than 5 peaks are seen in the backbone amide 
region. This led to the conclusion that the backbone showed conformational exchange in the micro- 
to millisecond time scale, whereas the side chains had less conformational freedom. This was 
supported by inspection of the packing density around the Trp side chains in the rhodopsin crystal 
structure. This conclusion is opposite to what is commonly observed in proteins, where more often 
the side chains show conformational flexibility rather than the backbone. The conformational 
exchange processes observed in the backbone in both studies with rhodopsin might be a general 
feature of membrane proteins, as it was also observed in other families such as the "-barrel 
OmpA214,290, bacteriorhodopsin291,292 and diacylglycerol kinase209,293. 
The incorporation of selectively labeled amino acids into an otherwise unlabeled background can 
mostly be achieved in vivo in E. coli294 and also in eukaryotic cells such as Sf9 insect cells295. This 
in vivo approach assures that it occurs under conditions which will not disturb the tertiary structure 
of the protein, which is certainly an advantage of this technique. The disadvantage of this technique 
is that the number of accessible labels is limited to the 20 natural amino acids. Even though in the 
last years significant progress has been made in the design of bacterial strains which allow the 
incorporation of “unnatural” amino acids into proteins296,297, the application of these strategies is 
still not trivial. Furthermore they are not applicable to any desired label. Therefore the in vitro 
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introduction of labels is a widespread strategy. While this approach theoretically allows the 
incorporation of almost any conceivable label, it is limited by the availability of a suitable coupling 
method and on sterical limitations imposed by the protein-label pair. Since any label needs to be 
coupled to a reactive group of the polypeptide chain, often also selectivity issues arise. A 
commonly applied strategy to overcome this problem is the generation of (single-)cysteine mutants 
of a protein and coupling the label of choice via a thiol-reactive group to the mutant protein. A 
particularly interesting label for NMR studies is 19F, due to its high magnetogyric ratio and the 
absence of a 19F background in proteins298. In a series of studies conducted in the Khorana lab285,299, 
19F labels were introduced into rhodopsin through oxidative coupling of [2-tri19F]trifluoroethylthiol 
to the side chains of native and mutated cysteine residues in the rhodopsin sequence. Changes in the 
positions and line-widths of the 19F-resonances of a rhodopsin sample measured in the dark were 
observed after illumination of the sample299. Furthermore NOEs between 19F-pairs allowed 
estimation of inter-residual distances and their comparison with previously published values 
determined from other experiments285. 
 
4.6.2 Examination of ligands bound to GPCRs 
The CC chemokine receptor 5 (CCR5) plays a role in the regulation of immune cell trafficking and 
is activated by a number of endogenous chemokines300. It is also associated with HIV infecting host 
cells301. The structure of the CCR5 has been modeled based on the crystal structure of rhodopsin302 
and the structure of the N-terminal 15 residues has been recently solved in complex with the HIV 
envelope protein gp120 (vide supra)303. Furthermore the binding sites of the CCR5 N-terminus 
have been mapped onto the CCR5 binding chemokine RANTES304. To enable further biophysical 
studies of the interaction of CCR5 with its chemokine interaction partners, an insect cell expression 
system and a purification protocol for CCR5 have been established282. With this system sufficient 
quantities CCR5 could be purified to allow the characterization of its interaction with RANTES by 
isothermal titration calorimetry. The 1H-spectrum of the CCR5 in DPC micelles showed good 
signal dispersion282, encouraging further studies of CCR5 by NMR. In a previous study on the same 
system the interaction of RANTES with receptor fragments comprising the N-terminus and the 
three extracellular loops has been examined. The binding surface of RANTES was found to be 
strongly positively charged and to overlap with sequences which have been known to be important 
for blocking HIV infection304. 
On the cytoplasmic side the interaction partners of GPCRs are the G-proteins. Especially the third 
intracellular loop and the C-terminus of the GPCR are thought to be important for this 
interaction305-308. The precise mechanism by which an activated receptor molecule (R*) binds to the 
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G-protein and catalyzes nucleotide exchange remains unknown. However, several important 
regions for receptor binding within G! and G"# have been identified
309-311. In G! one of the best 
studied interaction sites is the C-terminus, due to its susceptibility to ADP-ribosylation by pertussis 
toxin312. A synthetic undecapeptide from the C-terminus of transducin was shown to be a 
competitive inhibitor of G-protein activation by light activated rhodopsin34. Structural changes in 
this peptide upon association with purified light activated rhodopsin were elucidated by transferred 
nuclear Overhauser effect (TRNOE) spectroscopy313, revealing that the peptide gets structured only 
after light activation of rhodopsin281. When the NMR sample consisted of the peptide and dark 
adapted rhodopsin, no long-range interactions could be detected in the NOESY spectrum, whereas 
after exposure to light a number of long-range interactions could be detected, indicating the 
assumption of a defined structure of the peptide281. 
Another ligand conformation determination was carried out for the pituitary adenylate cyclase 
activating polypeptide (PACAP) bound to its receptor, the PACAP receptor280. In their study 
Inooka et al. have determined the receptor-bound conformation of a truncated variant of the 27 
residue PACAP. This truncated variant was the first 21 residues of the full-length PACAP and was 
therefore called PACAP21. The truncated PACAP21 was chosen, because it has a higher 
dissociation rate and weaker affinity towards the receptor, which puts PACAP21 in the fast 
exchange regime on the NMR chemical shift timescale. In the NOESY spectrum of a sample 
consisting of PACAP21 in presence of the receptor both TRNOE and NOE peaks were observed. 
While the former arise from the receptor-bound form, the latter stem from free PACAP21. 
Displacement of PACAP21 from the receptor was achieved by addition of the higher-affinity 
PACAP, allowing to measure the NOESY spectrum of PACAP21 free in solution. Subtraction of 
the two NOESY spectra yielded a spectrum showing only TRNOE peaks, from which the 
conformation of the receptor-bound PACAP21 could be calculated. Except for the N- and C-
terminus all residues showed defined backbone and side chain conformations. The first 3 residues 
were in a disordered extended conformation and were followed by 5 residues comprising two 
unusual "-turn structures. The structured remainder of the peptide was !-helical. This receptor-
bound conformation was compared with the structure of full-length PACAP bound to DPC 
micelles. Except for the "-turn region the two structures showed striking similarities, suggesting 
that the helical surface of the peptide interacts with the micelles and the receptor in a similar 
manner. 
The muscarinic acetylcholine receptors (mAChRs) belong to the GPCR family. For the related 
nicotinic acetylcholine receptor (nAChR), which does not belong to the GPCR family, the 
conformation of the bound acetylcholine ligand has been determined by NMR in 1988314. In 2002 
the conformations of the two mAChR ligands (S)-metacholine and (2S,4R,5S)-muscarine bound to 
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their receptor were determined by NMR279. First the conformation of the two ligands free in 
solution was determined from the coupling constants determined in one-dimensional 1H-
experiments. The conformation of the ligands bound to the mAChR was then determined from 
transferred NOE peak intensities obtained through subtraction of a NOESY spectrum of the 
respective ligand in complex with the mAChR and a NOESY spectrum of the same sample after 
addition of atropine, a strong mAChR antagonist, displacing the metacholine or muscarine ligands 
from the receptor. Rotations around the bond connecting C1 and C2 of the ligands were observed 
upon binding to the receptor supporting the binding of the ligands in a gauche conformation of the 
N-C1-C2-O dihedral angle. This was in contrast to earlier studies that reported the anti rotamers to 
be the receptor activating conformations315. The discrepancy between the two findings was 
explained by inaccuracies in the definition of the conformations in the earlier studies. 
The ligand of rhodopsin was also derivatized with NMR-observable reporter groups and effects of 
photoactivation were observed on 19F resonances in liquid-state NMR316 and on 13C- and 15N-
resonances by solid state NMR317-325. For these experiments rhodopsin was purified from bovine 
retina according to standard procedures, followed by an exchange of the natural retinal by the 
synthetic derivatives, by treating the purified rhodopsin samples with hydroxylamine (H2NOH) 
under light irradiation. The resulting “apo” form of rhodopsin was purified by centrifugation and 
treated with the synthetic retinal derivative326. Both the liquid and solid state NMR studies sought 
to determine the conformation of the chromophore when bound in the 11-cis form in ground state 
rhodopsin and the all-trans form in light activated metarhodopsin II (MII). 
A number of other ligand conformations when bound to their GPCR receptors has been studied by 
solid state NMR, including the histamine327 and the neurotensin receptors328. 
 
4.6.3 NMR studies of full-length GPCRs 
The complete resonance assignment of a protein gives the spectroscopist the possibility to probe a 
wealth of information with atomic resolution. Whereas the classical information sought in 
biological NMR is internuclear distances (mainly inter proton distances) defining the three-
dimensional structure of the molecule under study, the measurement of other parameters, such as 
the dynamical properties of a nucleus, can yield just as important clues in elucidating biological 
processes. NMR is unique in being able to provide a wealth of structural and dynamics information 
on an atomic resolution. Therefore it is not surprising that the complete resonance assignment of a 
GPCR would be a milestone in the structural biology of this class of receptors. It should be stated 
here, that presently no such complete resonance assignment, let alone a complete NMR structure, of 
a GPCR has been obtained so far. Nevertheless a few promising steps towards achieving this goal 
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have been made. The results coming closest to this goal is were published in 2008 by Gautier et 
al.
286. Even though their system is strictly speaking not a GPCR, it is also a 7 TM protein and can 
therefore be considered a “GPCR analog”. They have reported the near complete backbone 
assignment, secondary structure determination, and analysis of backbone dynamics of sensory 
rhodopsin pSRII from Natronomonas pharaonis. pSRII belongs to the family of microbial 
rhodopsins and acts as a phototaxis receptor329. Both of these functions are driven by the cis-trans 
isomerization of the bound retinal molecule. 
The success of this challenging project was dependent on optimal conditions in many respects. On 
the biological side it was clear that the study of such a large system necessitated a high-level of 
deuteration to meet the required resolution and sensitivity needs. These premises restricted the 
available host systems to E. coli and P. pastoris (vide supra). After purification of native pSRII in 
DM micelles the protein was exchanged into diheptanoylphosphatidylcholine micelles, which, at 50 
°C, allowed the acquisition of high quality NMR spectra. On the NMR experimental side sufficient 
sensitivity and resolution could only be obtained in a reasonable amount of measuring time by the 
application of nonuniform sampling schemes in combination with maximum entropy 
reconstruction330,331. The uniform 13C,15N-labeling scheme in conjunction with >95% deuteration 
allowed the assignment of almost all C! , C" and C' shifts through the use of TROSY
198 versions of 
3D out-and-back HNCA/HN(CO)CA, HN(CA)CB/HN(COCA)CB, and HN(CA)CO/HNCO199,332 
experiments. After assignment the secondary structure was probed by calculating &$C! – &$C", a 
value which indicates !-helical secondary structure if positive and "-sheet structure if negative333. 
The observed pattern for this value was in very good agreement with the crystal structure334. The 
dynamics of the pSRII backbone were determined through measurement of the longitudinal (T1) 
and transverse (T2) relaxation times of the amide 
15N, and the 15N1H-heteronuclear NOE. From the 
measured T1 and T2 values a rotational correlation time of ~20 ns was calculated, corresponding to 
a protein-detergent complex of 50-70 kDa. Some minor conflict with results from a previously 
published solid state NMR study of pSRII335 was explained by the different hydrophobic 
environments used in two studies. 
The solution NMR studies published on full-length GPCRs so far don't come close to the success 
achieved with sensory rhodopsin. In 2005 a publication reported obtaining high quality NMR 
spectra for uniformly labeled human vasopressin V2 receptor (V2R) in lyso-
myristoylphosphatidylcholine (LMPC) micelles336. The initial promising results had to be, at least 
partially, revoked soon after, when it was realized that a majority of the observed peaks were in fact 
from a contaminant and not from the V2R337. After removal of the contaminant the spectra showed 
80 of the total of ~350 expected peaks. Considering the scarcity of NMR data on full-length GPCRs 
this should still be considered a successful application of NMR to the study of GPCRs and a 
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promising starting point for the improvement of the system under study. 
No solution NMR studies of uniformly labeled rhodopsin have been published so far. But a HEK 
cell line stably transfected with the opsin gene was used to label half of the rhodopsin residues338. 
[15N,1H]-HSQC spectra showed only around 20 peaks, which were identified as belonging to the C-
terminus. Comparison with spectra of a peptide consisting of the 19 C-terminal residues of 
rhodopsin led to the conclusion, that the C-terminus of the full-length rhodopsin was unstructured 
under the chosen experimental conditions and hence gave rise to narrow line widths. 
Decreased molecular tumbling rates due to increased molecular size limit the applicability of 
solution NMR. Solid-state NMR (ssNMR) under conditions of magic angle spinning (MAS) 339 
doesn't suffer from these effects and has been shown to be able to characterize molecular structure 
and dynamics340. MAS has allowed to study the topology of various membrane proteins using a 
variety of different nuclei340-342. 
On the subject of GPCRs ssNMR has been most extensively used for the study of 
rhodopsin322,324,343 - and its retinal chromophore344. Recent progress in the heterologous expression 
and reconstitution into lipid membranes of GPCRs has allowed to target other systems. In terms of 
ligand structure this includes most notably the determination of the receptor bound structure of 
human neurotensin fragment 8-13327. Even though not a GPCR, sensory rhodopsin II from 
Natronomonas pharaonis (NpSRII) is a seven-helix membrane protein containing a bound retinal 
chromophore and hence bears similarity in many respects with rhodopsin. The characterization of 
the secondary structure, dynamics, and topology of this system335 points out the feasibility of 
ssNMR structural studies of heterologous 7TM proteins. More recently, other GPCRs such as the 
human Y2-receptor345 or H1-receptor328 could be reconstituted into environments suitable for 
ssNMR studies. Tapaneeyakorn et al. have recently given an excellent review over the solid state 
(and solution) NMR work carried out on the subject of GPCRs346. 
 
4.6.4 Alternative strategies for gaining structural and functional information of GPCRs 
After the summary of NMR approaches to the study of GPCRs it seems clear that no straight 
forward techniques for these class of receptors exists so far. Therefore, alternative approaches to 
GPCR structure are desirable. One such approach is the study of suitable fragments of a receptor. 
By this approach the size of the system under study can be chosen by the experimenter. Evidently 
such a choice should follow a certain rationale. One such rationale is to express fragments 
corresponding to individual domains of a larger molecule. Of course the validity of such an 
approach needs to be questioned concerning its usefulness/value. It seems clear that this strategy is 
only able to allow limited conclusions as compared to the study of full length receptors. 
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Nevertheless there is evidence that peptides often retain their secondary structures when removed 
from their tertiary structure environment of a protein347,348. This finding can be expected to be true 
especially for secondary structural elements which are defined by short-range interactions as is the 
case for !-helices349 and turns350. Additionally the design of so-called split receptors of rhodopsin351 
and the S. cerevisiae !-factor receptor Ste2p352 has shown that receptor fragments can complement 
each other restoring the functionality of the full length receptor. Thus it seems to be a promising 
approach to elucidate the secondary structure of a helical bundle protein by studying fragments 
thereof. Many fragments of GPCRs have been studied with biochemical and biophysical methods. 
The finding that fragments derived from the cytoplasmatic face of rhodopsin were able to 
competitively inhibit the interaction between rhodopsin and its G-protein transducin353 encouraged 
the first structure determination of such a fragment by NMR354. The biophysical characterization of 
such fragments often included structure determination by NMR or sometimes also X-ray 
crystallography. The experimental conditions are chosen such as to mimic the native environment 
encountered in biological membranes. Often organic solvents or mixtures of organic solvents and 
water have resulted in high quality spectra. Even though these solvents are chemically very 
different from lipid membranes, it could be shown that the structure in such solvents can be very 
close to the structure which is adopted under more physiological conditions355. A system which is 
more closely related to biological membranes is the use of small spherical micelles. These micelles 
are composed of lipid molecules and are therefore chemically very close mimics of biomembranes. 
Their small size makes them suitable for NMR studies, however, also it results in the main 
difference with respect to lipid bilayers, which is their high surface curvature. A list of fragments, 
whose structures have been successfully solved by NMR is compiled in the following table: 
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Receptor Fragment Structure Function Medium Length Ref. 
       
Angiotensin II ATA1A Helix 8 amphipathic helix membrane interaction water, TFE/water (1:2) 21 
356
 
 i3 (res. 213-231) amphipathic helix n.d. TFE/water (1:2) 19 
356
 
 i3 (res. 227-242) mainly disordered none found TFE/water (1:2) 16 
356
 
 e1 loop Type 2 !-turn stabilized by membranes membrane interaction water, SDS micelles 15 
357,358
 
       
Parathyroid hormone 
receptor 
i3 loop (linear) N-terminal helix, rest extended membrane interaction SDS micelles 29 
359
 
 i3 loop (cyclic) N-terminal helix, rest in loop conformation membrane interaction DPC and SDS micelles 29 
359,360
 
 e1 loop 
Turn with helical stretches on either side of the 
loop 
membrane interaction DPC micelles 44 
361
 
       
Cannabinoid receptor i3 loop 
Turn with helical stretches on either side of the 
loop 
inhibits interaction with G-
protein 
SDS micelles 44 
362
 
 Helix 8 helical in presence of micelles membrane interaction water and DPC micelles 21 
363
 
 TM1-i1-TM2 n.d. (assignment only) n.d. DMSO 74 
364
 
 N-term-TM1-i1-TM2 n.d. n.d. DMSO 101 
364
 
 TM5-i3 helical TM5 n.d. DMSO 53 
365
 
       
Cholecystokinin-2 receptor e3 loop 
Turn with helical stretches on either side of the 
loop 
ligand and membrane 
interaction 
DPC micelles 27 
366-368
 
       
"-factor receptor (Ste2p) TM1 glycine-kinked helix flexibility in kink region TFE/water (4:1) 33 
369
 
 TM2 bent helix n.d. TFE/water (4:1) 35 
369
 
 TM3 straight helix rigid helix TFE/water (4:1) 35 
369
 
 TM4 bent helix n.d. TFE/water (4:1) 36 
369
 
 TM5 bent helix rigid helix TFE/water (4:1) 36 
369
 
       
"-factor receptor (Ste2p) TM6 proline-kinked helix flexibility in kink region TFE/water (4:1) 31 
369
 
 TM7 proline-kinked helix flexibility in kink region TFE/water (4:1) 30 
369
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Receptor Fragment Structure Function Medium Length Ref. 
       
"-factor receptor (Ste2p) e1 loop (linear) flexible with slight helical tendency n.d. DMSO 33 
370
 
 e1 loop (cyclic) flexible with slight helical tendency n.d. DMSO 33 
370
 
 e3-TM7-C-term helical TM7, some helical tendency in C-term   TFE/water (1:1) 73 
371
 
 e3-TM7-C-term helical TM7, some helical tendency in C-term   
CHCl3/MeOH/water 
(4:4:1) 
73 
371
 
 e3-TM7-C-term helical TM7, unstructured e3 and C-term micelle integration DPC micelles 73 
14
 
 N-tern-TM1-i1-TM2-e1 
N-terminus containing amphipathic helix followed 
by helix(TM1)-loop(i1)-helix(TM2) motif 
micelle integration of TMs and 
micelle interaction of 
amphipathic helix 
LPPG micelles 80 
372
 
       
rhodopsin C-terminus 
second half well defined with short antiparallel !-
sheet 
inhibits interaction with G 
protein 
not mentioned 33 
354
 
 N-term helical with breaks at prolines n.d. DMSO 40 
373
 
 e1 loop 
Turn with helical stretches on either side of the 
loop 
n.d. DMSO 32 
373
 
 e2 loop 
Turn with helical stretches on either side of the 
loop 
n.d. DMSO 34 
373
 
 e3 loop 
Turn with helical stretches on either side of the 
loop 
n.d. DMSO 25 
373
 
 TM1 Helical conformation none found DMSO 16/16 
347
 
 TM4 Helical conformation none found DMSO 17/16 
347
 
 TM5 helical conformation with disordered ends none found DMSO 20/18 
347
 
 TM6 helix bent at internal Pro n.d. DMSO 15 
374
 
 i1 loop well structured !-turn none found water 17 
375
 
       
rhodopsin C-terminus 
second half well defined with short antiparallel !-
sheet 
inhibits interaction with G 
protein 
not mentioned 33 
354
 
 i3 loop turn-helix-turn motif 
inhibits interaction with G 
protein 
water 22 
376
 
 Helix 8 helical in presence of vesicles (CD) none found SUVs, LUVs 12 
377
 
       
CCR5 N-term helical from res. 7 to 15 
interaction with gp120-CD4 
complex 
water 14 
303
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Receptor Fragment Structure Function Medium Length Ref. 
       
Bradykinin B2 receptor i2 loop 
Turn with helical stretches on either side of the 
loop 
membrane interaction DPC 36 
378
 
 C-term fragment Short amphipathic helix (helix 8) membrane interaction DPC 58 
379
 
       
Neurokinin-1 receptor N-term fragment helical structure near beginning of TM1 none found DPC 39 
380
 
 e3 loop helical in presence of micelles membrane interaction DPC 26 
380
 
 e2 loop fragment helical in presence of micelles none found DPC 37 
381,382
 
       
!-adrenergic receptor i3 loop 
helical structure near beginning of TM6 in 
presence of micelles 
membrane interaction TFE, LMPC 12 
383
 
 C-term fragment Helical conformation 
unstructured in water, helical in 
presence of detergents/lipids 
water, LMPC, di-MPC 15 
383
 
 Helix 8 
Helical conformation in DMSO, disordered in 
water 
none found water, DMSO, DPC 34 
384
 
       
"2A adrenergic receptor TM3-i2 helical in presence of micelles membrane interaction DPC 32 
385
 
 TM3-i2-TM4 helical in presence of micelles membrane interaction DPC 35 
385
 
       
Adenosine A2A receptor TM1 Helical conformation (CD) none found vesicles and micelles 23 
386
 
 TM2 Helical conformation (CD) none found vesicles and micelles 23 
386
 
 TM3 Helical conformation (CD) none found vesicles and micelles 26 
386
 
       
Adenosine A2A receptor TM4 Helical conformation (CD) none found vesicles and micelles 24 
386
 
 TM5 Helical conformation (CD) none found vesicles and micelles 26 
386
 
 TM6 Helical conformation (CD) none found vesicles and micelles 27 
386
 
 TM7 Helical conformation (CD) none found vesicles and micelles 28 
386
 
       
V1A vasopressin receptor i2 loop 
Turn with helical stretches on either side of the 
loop 
inhibits interaction with G 
protein 
TFE, SDS, DPC 22 
375,387
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Receptor Fragment Structure Function Medium Length Ref. 
       
Thromboxane A2 receptor e2 loop Loop structure in solution none found water 21 
388
 
 e3 loop Loop structure in solution none found water 19 
389
 
       
Corticotropin releasing 
factor receptor 
N-terminal domain 
Defined 3D structure with partially unstructured 
regions 
Folding of unstructured region 
upon ligand binding 
water 95 
174
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5. The neurohormones of the neuropeptide Y family 
 
5.1 Introduction to the neurohormones of the neuropeptide Y family 
Neuropeptide Y (NPY) and the two gut hormones peptide YY (PYY) and pancreatic 
polypeptide (PP) form the NPY family of neurohormones. Neurohormones are 
defined as hormones which are produced by or act on the nervous system. All three 
peptides are 36 amino acids long and carry an amidated carboxy-terminus, which is 
essential for their functioning (figure 6). 
 
5.2 Pharmacological profiles of the neurohormones from the NPY family 
PP was the first family member to be identified and characterized390. It is almost 
exclusively synthesized in endocrine pancreas and released in response to food intake. 
The known effects of PP are mainly restricted to the gastrointestinal tract and include 
inhibition of pancreatic secretion and regulation of intestinal motion391. Binding sites 
for PP have, however, also been found in several brain regions of rats392, suggesting 
its potential to directly affect the central nervous system. This hypothesis is also 
supported by the finding that intracerebroventricular injection of PP stimulates 
feeding in several different species393,394. 
PYY was first isolated from porcine intestine using a method specifically developed 
for capturing carboxy-terminally amidated peptides395-398. Briefly, crude peptide 
mixtures were treated with a protease and the free amino acids were derivatized with 
dansyl chloride. Amidated amino acids were then distinguished from free 
carboxylates based different solubility in organic solvents395. Because of the N- and 
C-terminal residue being tyrosines (Y), the peptide was named peptide YY. Similar to 
PP also PYY is released in the gastrointestinal tract in response to ingestion and has 
similar physiological effects391. 
NPY was first isolated from pig brain using the same method by which PYY was 
discovered397. It is one of the strongest orexigenic peptides known. Upon 
intracerebroventricular injection it has been found to induce carbohydrate-rich food 
uptake in many species393,399. Centrally administered NPY decreases 
thermogenesis400, has anticonvulsant activity401, inhibits sedation402, mood and 
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memory403 and has general anxiolytic effects404. NPY is co-localized with 
noradrenaline in sympathetic nerves and enhances noradrenaline-mediated 
vasoconstriction405. Centrally administered NPY, however, reduces arterial blood 
pressure and heart tone406. NPY is implicated in several pathological conditions: The 
most obvious are, not surprisingly, based on its orexigenic effect, various eating 
disorders such as anorexia, bulimia neurosa, and diabetes407. Also several 
cardiovascular disorders and some tumor diseases are associated with abnormal 
plasma levels of NPY408. A very interesting finding indicates that NPY plays a role in 
alcohol consumption in rats409,410 and in humans411, a result particularly interesting in 
the context of the general anxiolytic activity of NPY. The neurohormone NPY is itself 
regulated by several neuropeptides and hormones412. One example is the 28 amino 
acid peptide ghrelin that is released in the gut and triggers the release of growth 
hormone via a GPCR413,414. Another example is the adipose hormone leptin which 
acts as a satiety factor possibly by inhibiting NPY release in the hypothalamus415. 
NPY is the most abundant neuropeptide in the mammalian central nervous system416, 
but is also expressed in the peripheral nervous system417. Briefly the actions of the 
three neurohormones of the NPY family can be summarized as NPY having 
neurotransmitter properties418 and PYY and PP acting as hormones419. 
 
5.3 Biosynthetic aspects of the neurohormones of the NPY family 
C-terminal amidation is found with roughly 50% of the bioactive peptide hormones. 
The primary translation products is a precursor containing signals for the appropriate 
biochemical modification420. Amidated peptides are usually synthesized in 
specifically differentiated secretory cells where the precursors are cleaved into the 
final products plus a one residue glycine overhang at the C-terminus 420,421. The 
formation of the amide is then the last step in the synthesis of the bioactive 
compounds420,422. An amidation enzyme (peptidyl-glycine !-amidating 
monooxygenase [PAM])423 and a carboxypeptidase424 responsible for these two 
posttranslational modifications of the peptide hormone precursors have been cloned. 
 
5.4 Structural characteristics of the neurohormones of the NPY family 
The amino acid sequence of NPY is one of the most conserved during evolution with 
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22 positions being constant in all known NPY sequences425. The number of conserved 
residues is decreased to 15 in PYY and 7 in PP425, making the latter one of the least 
conserved peptides known so far426. Seven positions are absolutely conserved among 
all species of NPY, PYY and PP. These are Pro5, Pro8, Gly9, Ala12, Tyr27, Arg33 
and Arg35425 (figure 6). 
The first atomic resolution structure of a member of the NPY family was obtained for 
avian PP (aPP) by X-ray crystallography427 and later for bovine PP (bPP) in solution 
by NMR428. 
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Residues 1 to 8 form a type-II polyproline helix, which is followed by a type-I "-turn 
connecting to residues 15 to 32, which form an !-helix, and the four most carboxy-
terminal residues are in a flexible loop conformation. A surprisingly stable helical 
hairpin is formed by backfolding of the polyproline helix onto the !-helix. This 
structural motif is commonly referred to as the PP-fold (figure 6). The tertiary 
Figure 6: Neurohormones of the NPY family. Top: Sequence comparison of porcine NPY (pNPY) 
and PYY (pPYY) with bovine PP (bPP). Residues which are conserved among all three 
neurohormones throughout all species are colored red. Bottom: Threedimensional structures of 
pNPY, pPYY and bPP in water and in DPC micelles. In the structure of pPYY and bPP in water, the 
interdigitating Pro and Tyr residues are colored  red and blue, respectively. 
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contacts which stabilize this fold are formed by interdigitation of the conserved 
proline residues in position 2, 5, and 8 on the polyproline helix and the tyrosines 20 
and 27 on the !-helix. 
The solution structure of PYY in aqueous solution was shown to be highly similar and 
to also display the characteristic PP-fold429,430. Surprisingly, in the highly homologous 
NPY the backfolding is absent431,432 (figure 6). The NMR data which indicated the 
absence of a stable helical hairpin conformation for human431 and porcine432 NPY 
suggested the presence of NPY dimers which interact via the side chains of their C-
terminal !-helices in an anti-parallel fashion. Based on data obtained from CD-
spectroscopy it was suggested, that at lower concentrations NPY is present in a 
backfolded form433. According to these data dimer formation is only observed at high 
concentrations of NPY, like they are typically used for NMR studies, and goes hand 
in hand with unfolding of the helical hairpin conformation. The assumption of 
backfolded NPY at low concentrations, however, is controversial, as there are also 
data arguing against this hypothesis434. Dimer formation has also been observed in the 
crystal structure of aPP427. The dissociation constants have been calculated as 1.6 µM 
porcine NPY (pNPY)432 and 0.3 µM for aPP435. 
The structures of the neurohormones in aqueous solution in the absence of any 
biological membranes or cognate receptors might deliver only limited information on 
their bioactive conformation. It would therefore be desirable to conduct structural 
studies in the presence of biomembranes, or preferentially, functional receptors. The 
latter approach requires the ability to produce and purify the receptor in mg amounts 
and could only be applied to a very limited set of ligand-GPCR pairs (vide supra). 
Structure determination by NMR in presence of biomembranes is usually not feasible, 
due to the large size of the membrane particles, which are usually present in the form 
of vesicles, whose slow rotational tumbling is prohibitive for NMR studies. The 
formation of phospholipid aggregates is dominated by two opposing forces: the 
electrostatic repulsion between head groups and the attractive van der Waals 
interactions of the hydrophobic tails. In cases where the repulsive forces are 
dominating, micelles are formed, as these have the geometry with a minimal number 
of head groups per surface area. Often such micelles are small enough to allow 
structure determination of bound molecules by NMR. Micelles resemble biological 
membranes with respect to their polarity profile7 and are therefore often referred to as 
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“membrane mimicking agents”. The small size of these spherical particles entails a 
large surface curvature, which is in contrast to commonly found biological 
membranes436. A large variety of micelle forming (synthetic) detergents are available 
and have been shown to be suitable for NMR studies202. 
All three members of the NPY family have been characterized in terms of their 
structure and dynamics in presence of dodecylphosphocholine (DPC) micelles (figure 
6). Whereas in aqueous solution PYY and PP are structurally similar, in the presence 
of micelles PYY430 and NPY437 adopt a similar conformation, with PP taking an 
alternative conformation438. It was found that pNPY and pPYY interact via the 
hydrophobic face of their C-terminal !-helix with the micelle, while the N-terminus 
freely diffuses in solution. bPP also interacts with the micelle via its C-terminal !-
helix, but the N-terminus is also loosely associated with the micelle surface. It has 
been proposed that this association is mediated by Tyr7 in bPP430, which has a 
favorable free energy of transport into the water-membrane interface439, in contrast to 
the Asn7 and Ala7 found in pNPY and pPYY, respectively. In addition also the C-
terminal pentapeptide, which contains particularly important residues for receptor 
binding (vide supra), differs structurally in bPP from the pNPY/pPYY pair430. 
The NMR study of human parathyroid hormone (hPTH) in the presence of DPC 
micelles showed that the membrane environment induced a higher degree of 
conformational order than the one found in purely aqueous buffer440.  
 
5.5 Ligand recognition from the membrane bound state 
In his membrane compartment theory Schwyzer proposed the membrane as a catalyst 
for peptide-receptor interactions441-445. In this theory the membrane is subdivided into 
three electrostatically distinct compartments: the hydrophobic, the fixed-charge and 
the aqueous compartment. The membrane influences receptor selection of regulatory 
peptides by guiding important residues into the appropriate compartment. 
The interaction of the neurohormones of NPY family with micelles might imply a 
model for the binding of the ligand to the receptor, in which in a first step the ligand 
binds to the membrane, thereby increasing the effective hormone concentration in the 
vicinity of the ligand and reducing the search for the receptor from three- to two-
dimensional space. According to the membrane compartment theory binding to the 
membrane probably occurs in a conformation facilitating subsequent receptor binding 
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and hence the membrane bound conformation has been proposed to resemble the 
receptor bound conformation. In the case of NPY and PYY this hypothesis is 
corroborated by the similarities of their pharmacological profiles446 which are 
reflected by their structural resemblance when bound to micelles, but not in free 
aqueous solution430. In the proposed model for the binding mechanism of NPY family 
peptides to their receptors the peptides first bind to the membrane through 
electrostatic interactions. The peptide then reorients such that the hydrophobic 
residues penetrate into the interior of the membrane. In this state the hormone diffuses 
along the membrane. In this conformation the peptide can be recognized by the 
receptor and may or may not undergo further conformational changes to finally adopt 
the bioactive conformation in the ligand binding pocket of the membrane430,446. 
 
 
5.6 Interaction of the neurohormones of the NPY family with their receptors 
In an attempt to identify interacting residues within the ligand Beck-Sickinger et al. 
have conducted a full Ala scan for human NPY at the human Y1-receptor447. Most 
significant reductions in affinity were observed for Arg33 and Arg35. Moreover, 
binding was almost completely abolished when the C-terminal amide was replaced 
with a free C terminus. From these results direct interactions involving hormone 
residues Arg33 and/or Arg35 and an Asp receptor residue (Asp289 in case of the 
hY1-receptor) have been postulated. Nevertheless, Dougherty has also proposed that 
pi-cation interactions involving one of the Arg residues and aromatic receptor 
residues contribute to binding448. 
A turn-inducing dipeptide composed of alanine and amino isobutyric acid (Ala-Aib) 
introduced into positions 31 and 32 of pNPY, yielding [Ala31, Aib32]-pNPY has been 
Figure 7: A model for the recognition of neurohormones from the membrane bound state. An 
equilibrium between free and membrane bound neurohormone (left) preceeds the formation of 
preliminary transient contacts with the receptor (middle) and the final insertion of the 
neurohormone in the receptor's ligand binding pocket. 
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identified as conferring Y5-receptor selectivity449. The same could be observed for the 
[Ala31, Pro32]-pNPY mutant450. The micelle bound structures of these mutants in 
comparison with wild-type pNPY only differ in the C-terminal residues, which are 
more disordered in the mutants than in the wild-type. 
To understand the different pharmacological profiles and solution structures of NPY 
and PP, chimeras of these two peptides were studied. Exchanging the segment 19-23 
in human PP (hPP) with the sequence found in pNPY, yielding the chimera [pNPY19-
23]-hPP, had no effect on the formation of the PP-fold as it is also assumed by hPP. 
The complementary [hPP19-23]-pNPY also displayed the structural features of its 
parent pNPY, which does not assume the PP-fold in solution. When bound to 
detergent micelles the two chimera showed the same overall structures as did their 
parent molecules, exhibiting a structured C-terminal helix and a flexible N-terminal 
tail. The C-terminal part of the helix was identical in the chimeras and the parent 
peptides, but the N-terminal part differed in the starting points of the helix451. 
In a different study the receptor binding properties of hPP was studied by the 
introduction of point mutations, the exchange of fragments 1-7, 1-17 and the above 
mentioned 19-23. A combination of several changes resulted in [cPP1-7, pNPY19-23, 
H34]-hPP which showed specificity for the Y5-receptor452. 
 
 
6. The Y-receptor subfamily of GPCRs 
 
6.1 Introduction to the Y-receptors 
The neuropeptides exert their effects via several receptor subtypes (Y-receptors). Four 
main receptors, named Y1-453-455, Y2-456-459, Y4-460,461 and Y5-462, have been cloned 
so far. Two minor receptors named Y3-463 and y6-464 receptors have been cloned, but 
little information is available for them. In the following I will mainly focus on the 
four main Y-receptors. All identified Y-receptors belong to the superfamily of G 
protein-coupled receptors (GPCRs) and act via G proteins of the Gi family, whose 
activation leads to an inhibition of the adenylate cyclase. They range in size from 375 
to 455 residues and show the prototypical characteristics of GPCRs: They show seven 
hydrophobic amino acid stretches, which are spanning the membrane as !-helices. 
 59 
These transmembrane helices are connected by three intra- and three extracellular 
loops. Typical for the subfamily 1b of GPCRs there is a predicted disulfide bond 
between extracellular loops 1 and 2. Furthermore soluble, extracellular N-terminal 
domain and intracellular C-terminal domains are present. 
 
6.2 Pharmacological profiles of the Y-receptors 
The different receptor subtypes are localized in various tissues, both in the central 
nervous system and in the periphery. 
The table below gives a summary about the most important data concerning the four 
major Y-receptors: 
 
6.3 Evolutionary relationships between the Y-receptors 
Sequence comparisons show, that among these four receptors, the Y1 and Y4 are the 
most closely related (42% sequence homology) while Y2 and Y5 are equally distant 
from each other and from the Y1/Y4 pair (~30% homology to Y1)465,466. These 
relationships are also reflected when the predicted soluble N-termini of the four 
receptors are compared, as is shown in the sequence alignments below. 
 
Receptor Y1 Y2 Y4 Y5
amino acids 384 381 375 455
related action
Ki NPY [nM]  0.81a  0.02a  1.9a  0.19a
Ki PYY [nM]  1.1a  0.01a  1.1a  0.06a
Ki PP [nM]  >100a, b  >1000a, b  0.04a, b  27a, b
major 
occurrence
peripheryc, 
hypothalamusd CNSe, f, g intestine, pancreash hypothalamusi
vasoconstriction, 
anxiolysisc, d, j
memory, epilepsy, 
secretionck, l
gastro-intestinal 
regulationm food intakei
Table 1: Biochemical, biophysical and physiological characteristics of the four major families of 
the Y-receptors. a) McCrea, Regul. Pept., 87, 47-58, 2000; b) Small, Proc. Natl. Acad. Sci. U S A, 
94, 11686-91, 1997; c) Wahlestedt, Med. Biol., 64, 85-8, 1986; d) Wahlestedt, Science, 259, 528-
31, 1993; e) Gehlert, Mol. Pharmacol., 49, 224-8, 1996; f) Gerald, J. Biol. Chem., 270, 26758-61, 
1995; g) Rose, J. Biol. Chem., 270, 22661-4, 1995; h) Lundell, J. Biol. Chem., 270, 29123-8, 1995; 
i) Gerald, Nature, 382, 168-71, 1996; j) Grundemar, Br. J. Pharmacol., 105, 45-50, 1992; k) 
Flood, Peptides, 10, 963-6, 1989; l) Potter, Regul. Pept., 25, 167-77, 1989; m) Schwartz, 
Gastroenterology, 85, 1411-25, 1983 
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NPY1R_HUMAN      MN-STLFSQVENHSVHS-NFSEKNAQLLAFENDDCHLPLAMI 40 
NPY4R_HUMAN      MNTSHLLALLLPKSPQGENRSKPLGTPYNFS-EHCQDSVDVM 41 
                 ** * *:: :  :* :. * *:  .    *. :.*: .: :: 
NPY2R_HUMAN      MGPIG-AEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELID-STKLIEVQ 
50 
NPY5R_HUMAN      MSFYSKQDYNMDLELDEYYNKTLATENNTAATRNSD-FPVWDDYKSSVDDLQ 
51 
                 *.  .  : : :  ::*   :  ..:... .   .*  *   * .:.: ::* 
In several studies the N-termini of Y-receptors have – as is typical for GPCRs of the 
subfamily 1b – been shown to be involved in ligand binding467,468. We therefore 
sought to express the 40 to 50 residue N-terminal fragments of the four Y-receptors 
and characterize them NMR-spectroscopically. 
 
6.4 Ligand binding specificities of the Y-receptors 
NPY and PYY bind equally well to the receptors Y1, Y2, and Y5 (nanomolar to 
subnamomolar dissociation constants). Only PP shows selectivity towards the Y4-
receptor (picomolar dissociation constant). The ability of NPY and PYY to bind to 
three different receptor subtypes is probably related to their conformational flexibility, 
which enables the peptides to adopt more than one energetically favorable 
conformation. 
The Y1-receptor is expressed in blood vessel and parts of the central nervous system. 
Its most important effects are vasoconstriction469,470 and anxiolysis471. Roles in the 
regulation of feeding behavior394 and alcohol consumption409,410 have been reported. 
The Y1-receptor is pharmacologically characterized by high affinity for NPY and 
PYY and the corresponding analogs carrying a proline at position 34 (Pro34 analogs) 
and low affinity for N-terminally truncated analogs and for PP453,454,472. 
The Y2-receptor is expressed in various locations of the peripheral nervous system, 
such as sympathetic and parasympathetic nerve fibers, the intestine and certain blood 
vessels. Its physiological functions are suppression of neurotransmitter release470,472 
and enhancing memory retention473. NPY, PYY and their C-terminal fragments are 
potent activators of the Y2-receptor, while the Pro34 analogs and PP show only weak 
effects458,459,462. 
The Y3-receptor has been mainly localized in the brainstem. It is involved in 
 61 
inhibition of catecholamine release474 and the modulation of arterial blood 
pressure475,476. The Y3-receptor is able to bind NPY and its Pro34 analog, but is 
insensitive to PYY and PP475,476. 
The Y4-receptor is expressed in various tissues such as the heart, intestine, colon and 
pancreas. Upon activation it leads to a decrease in pancreatic secretion and 
contraction of the gall bladder477. PP binds with much higher affinity (picomolar 
dissociation constant) to the Y4-receptor than NPY, PYY and their corresponding 
Pro34 analogs (nanomolar dissociation constants)460,478. 
The Y5-receptor is expressed in the hypothalamus, where it is believed to play a role 
in the regulation of food intake462. Its ligands include NPY, PYY, their Pro34 analogs 
and the large N-terminally truncated analogs like NPY(2-36) and NPY(3-36). The C-
terminal fragments and PP show reduced affinity462,479. 
The role of the y6-receptor is unclear, because it is a pseudogene in several species480. 
The pharmacological effects of this receptor are controversial464,481. 
The ability of the neurohormones to bind to several different receptors complicates 
the determination of structure-affinity and structure-activity relationships. For being 
able to characterize one receptor with respect to the others it would be helpful to have 
selective ligands. The non-selectivity of receptor binding of NPY and PYY is 
believed to be a result of their conformational flexibility. Accordingly the ligands are 
able to fulfill different conformational requirements imposed by the different 
receptors. Therefore imposing conformational restraints on the ligands might be a 
potential route to selective ligands for the receptor subtypes. If one were able to 
synthesize an analog mimicking the active conformation of a ligand on a given 
receptor, it should be selective for that particular receptor subtype (i.e. show no 
affinity for the other receptor subtypes). Such analogs can be obtained in the form of 
non-peptide species or peptides with reduced flexibility, e.g. through cyclization or 
using spacer templates482. Unfortunately efforts to towards selective agonists for 
GPCRs has been less successful than to obtaining selective antagonists483, probably 
because the non-peptidic analogs that were studied were too small and therefore could 
not induce a conformational change of the receptor, due to a lack of contact points 
between ligand and receptor. 
The molecular evolution of the Y-receptors has been difficult to deduce, due to the 
lack of available non-mammalian sequences. Presently it is believed that Y-receptors 
can be sorted into three subfamilies based on their sequence homology. The 
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subfamilies are named after their first member as Y1, Y2 and Y5. Their overall 
sequence identity is low (27-31%) and a bit higher in the TM regions (40-43%). The 
Y1 subfamily also includes the Y4R and y6R and share a sequence identity of 50% 
and 60% overall and in the TM regions, respectively. Structural comparison suggests 
that the Y1R/Y4R pair and the Y2R/Y5R pair form distinct subfamilies within the Y-
receptor family484. 
All currently known Y-receptors show some absolutely conserved residues. 
Particularly interesting in terms of ligand binding might be those conserved sites in 
the extracellular domain, and among those the ones which are Y-receptor specific (i.e. 
which are only conserved in Y-receptors, but not in all other peptide ligand binding 
GPCRs) should be determining the binding modes of the NPY family peptides to their 
receptors.  
The search of such residues resulted in the identification of Asp6.59, located in the 
interface between TM6 and ECL3485. Interestingly it was found that in other peptide 
binding GPCRs, position 6.59, together with the adjacent position 6.58, is frequently 
conserved within a family. The identification of Asp6.59 as a residue which might be 
important in determining the ligand binding mode of Y-receptors was in agreement 
with previous studies confirming the important role of that residue for ligand 
binding467,486,487. The replacement of Asp6.59 with Glu was tolerated in all Y-receptor 
subtypes, whereas replacement with Ala, Asn and Arg led to a loss in affinity and 
potency485. In a complementary mutagenesis approach the residues of NPY 
interacting with Asp6.59 were identified: Whereas in Y2R and Y5R Asp6.59 interacts 
with Arg33 of NPY, in Y1R and Y4R Asp6.59 interacts with Arg35. 
 
6.4.1 The Y1-receptor 
One of the most thorough ways of characterizing the interaction of a peptide ligand 
with its receptor is the systematic single exchange of each residue of the ligand by L-
alanine. Such a study was carried out to characterize the binding of NPY to the Y1-
receptor447. The four natural alanines were substituted by glycines. The most 
important residues for binding of NPY to the Y1-receptor were according to this study 
Pro5, Pro8, Arg19, Tyr20 and the C-terminal positions 27-36 including Tyr27, Arg33 
and Arg35. Whereas for the two C-terminal Arg residues the reduction in binding 
affinity was on the order of 104 to 105-fold, for the other mentioned residues it was 
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around 103-fold. 
The finding that three positively charged arginine residues are critical for binding of 
NPY to the Y1-receptor led to the theory that the receptor-ligand interaction might be 
predominantly electrostatic and therefore mediated through negatively charged 
residues on the receptor. This hypothesis was tested by replacing negatively charged 
residues in the extracellular domain of the Y1-receptor with alanines486. These 
mutants were expressed transiently in HeLa cells (epithelial cells of a cervical 
carcinoma of a patient called Henrietta Lacks) and their ability to bind NPY was 
assayed by a radioligand binding assay using 125I-NPY488. The human Y1-receptor 
(hY1) contains 30 negatively charged residues of which 14 are located in a putative 
extracellular domain: 5 in the N-terminal part, 2 in extracellular loop 1 (ECL1), 6 in 
ECL2 and 1 in ECL3. 
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Figure 8: a) Multiple sequence alignment of the Y1-receptor from eight major mammalian species. 
Above the sequence the predicted TM helices are indicated by gray rods and all other domains by 
gray lines. The most conserved residue in each helix (shaded red) serves as the basis for the 
Ballesteros-Weinstein numbering scheme. b) Snake plot of the predicted topology of the human Y1-
receptor. The most conserved residue in each helix (shaded red) serves as the basis for the 
Ballesteros-Weinstein numbering scheme. 
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None of the mutations introduced in the N-terminus affected NPY binding. In ECL1 
the D104A substitution led to a complete loss of affinity for NPY, whereas the E110A 
mutant didn't show any altered NPY binding. In ECL2 two aspartates, namely Asp194 
and Asp200, were essential for NPY binding and the mutation of Asp205 resulted in a 
significant loss of binding affinity. The other 3 positions proved to be tolerant for 
substitution. The D287A mutation in the ECL3 again resulted in the complete loss of 
affinity for NPY. It is interesting to note that the mutations affecting NPY binding the 
most are all clustered at the top of TM helices 5 and 6. 
 
6.4.2 The Y2-receptor 
The same Ala-scan which was conducted for the interaction of NPY with the Y1-
receptor showed only minor effects on the binding to the Y2-receptor447. In the N-
terminal part only the replacement of Pro5 lead to a significant (~500-fold) decrease 
in receptor affinity. The replacement of Arg33 and Arg35 lead to a decrease in 
affinity of ~103- and 105-fold, respectively. Surprisingly also the substitution of Thr32 
lead to a drop in the affinity of 103-fold. 
A study in which each residue in NPY was exchanged with its D-isomer showed only 
reduced affinity for species carrying the mutation in the 30-35 region489. Overall the 
Ala- and D-amino scan showed that the most important part of NPY for binding to the 
Y2-receptor is the C-terminal fragments. The minimum binding motif necessary for 
interaction was found to be the C-terminal nonapeptide of NPY490. In order to force a 
defined structure upon this peptide lactam bridges connecting residues i and i+4 were 
introduced at different positions. It was shown that peptides carrying the bridge 
between residues 27 and 31 or 28 and 32, respectively, are very potent activators of 
the Y2-receptors491. These cyclic peptides were both studied by NMR and molecular 
dynamics simulations491. Based on these findings it was suggested that the bioactive 
conformation of the NPY ligand when bound to the Y2-receptor may consist of a 
hairpin-like structure in which the N- and C-termini are in close proximity, with the 
C-terminal part being in direct contact with the receptor, and the N-terminal part 
helping in the stabilization and correct orientation of the C-terminus. 
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6.4.3 The Y4-receptor 
The characteristic feature of the Y4-receptor is its high affinity and specificity for PP 
showing a Kd in the picomolar range and a more than 100-fold preference over NPY 
and PP478. However, it should be noted that also NPY and PYY display comparably 
high affinity for the Y4-receptor with dissociation constants in the nanomolar 
range492. The key residues conferring high affinity binding of NPY to the Y4-receptor 
were determined in a complete Ala scan of NPY493. As for the Y1- and Y2-receptors 
the two Arg residues at positions 33 and 35 where found to be critical for binding. Ala 
substitution at these sites led to a Kd >1000 nM. Also the replacement of Tyr27 led to 
an almost 100-fold decrease in the affinity. Binding studies with PP/NPY chimera 
indicated that the ligand requires a stable helix for being able to bind to the 
receptor452. 
 
6.4.4 The Y5-receptor 
A lot of research has been dedicated to elucidating the structure-affinity and structure-
activity relationships of the Y5-receptor after reports indicated its role in the 
regulation of feeding behavior, together with the Y1-receptor494-498. 
The Ala scan of NPY revealed that the N-terminal prolines 2, 5 and 8 are important 
for receptor binding. Their Ala substitution resulted in up to 100-fold losses in 
binding affinity493. The two C-terminal Arg 33 and 35 and Tyr27 were all shown to be 
important for binding to the Y5-receptor as well. Studies with PP/NPY chimera 
indicated the requirement of a stable !-helix for receptor binding, which, however, 
was not sufficient for conferring high affinity452. The introduction of an Ala-Aib 
(Amino isobutyric acid) at positions 31 and 32 of NPY led to a highly selective ligand 
for the Y5-receptor449. It has been speculated that this motif may be responsible for 
selectivity by inducing a well-defined conformation in the C-terminus of NPY. 
 
6.5 Summary 
In summary it can be said that Y1R, Y2R and Y5R preferentially bind NPY and PYY, 
whereas Y4R shows preference for PP456,460,461,466,499. While Y1R and Y4R only can 
bind full-length ligands460,500,501, Y5R tolerates the deletion of the first residue462 and 
Y2R is even capable of binding significantly shortened peptides such as the NPY(13-
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36) variant500. The C-terminal pentapeptide of the ligands has been identified to be 
essential for binding to all Y-receptor subtypes447,502. The binding mode of the 
neuropeptide hormones is different in the Y1/Y4 pair than in the Y2/Y5485, because of 
the different orientation of the ligands towards the essential Asp6.59. 
 
 
7. Introduction to the loop grafting strategy 
 
7.1 General 
Our group has been studying a wide variety of neurohormones of the NPY family 
using high-resolution NMR14,430,437,438,446,450,451 and has – based on these studies – 
proposed a model for the binding of these hormones to their cognate receptors446. 
Structural and mechanistic insight into such binding processes are anticipated to 
provide a basis both for the rational design of novel and the improvement of already 
existing agonists and antagonists to a rapidly growing pool of GPCRs for which 
natural ligands have been identified. Because of the detailed studies that have been 
conducted in our group on the above mentioned neurohormones and the detailed 
biophysical and biochemical characterization in other groups, the receptors for the 
NPY-family neuropeptides are an interesting model system for the investigation of 
ligand binding to GPCRs for our group. 
In many photoaffinity-labeling studies the contact points between receptors and their 
ligands have been assigned to the extracellular face of GPCRs, which is comprised of 
an N-terminal domain and three extracellular loops (ECLs) of variable size381,503,504. 
These findings are in accordance with an established model for ligand binding to their 
GPCRs, which is proposed to consist of an initial membrane-binding event prior to 
recognition and binding of the receptor441,446,505. Structural and dynamical features of 
the extracellular domains of the receptor are therefore inferred to be of critical 
importance in the ligand binding process. Even though rhodopsin has served as a 
starting point for the modeling of many other GPCRs506,507, doubts about the accuracy 
of this approach can be raised508,509. Especially for the extracellular loops two major 
concerns apply: first, the loop regions of rhodopsin itself are structurally not well 
defined in the crystal structure131 and second, the high structural and functional 
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diversity of GPCR ligands points to high structural diversity in the receptor loop 
regions, which is also reflected by a low sequence homology between different 
GPCRs outside the transmembrane regions. 
Even though the production of GPCRs amenable to biophysical studies has made 
considerable progress in the past48, the elucidation of membrane protein structures is 
still a far from trivial task. Their lipidic surrounding prevents crystal growth for x-ray 
diffraction studies in many cases and increases their effective molecular weight to a 
range outside that commonly applicable to NMR studies. Alternative approaches to 
gaining structural information on such difficult targets would therefore be of great 
importance.  
One such strategy, called 'segmentation approach', is the expression of several 
peptides spanning the whole primary sequence of a target GPCR. It emerged after the 
finding that small regions of some proteins exhibit the same secondary structure in 
individual solubilized peptides as observed in the corresponding region of the intact 
protein510-512. Several GPCRs have thus far been characterized in this way349,513. 
We propose here an additional such 'alternative' approach to structural information on 
the extracellular part of GPCRs. The central idea of our approach is the fusion of the 
extracellular loops and N-terminal domain of a GPCR onto a soluble protein scaffold, 
and it will therefore be referred to as 'grafting approach' in the following (see figure 
1). Several advantages as compared to the 'segmentation approach' are noteworthy: 
Binding affinities of ligands for isolated receptor loops often lie in the µM 
range349,513. The binding affinities between ligands and whole receptors, however, 
commonly are considerably higher, mostly in the nM range (see 
http://www.gpcr.org/7tm for a collection of ligand binding data). These higher 
binding affinities can be explained by the cumulative effects of two or more µM 
binding sites present in two separate loops. A system in which several or all loops of 
one receptor can be presented simultaneously would therefore seem desirable; a 
feature provided by the 'grafting approach', at least under the assumption that a 
scaffold with the desired geometry can be found. An additional requirement for a 
suitable scaffold is its solubility, which helps in studying the often partly hydrophobic 
loops.  
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8. The scaffolds 
 
8.1 Lipocalins 
 
8.1.1 Nomenclature, family members and classification of the lipocalins 
The lipocalins have first been identified in a study comparing the sequence of the 
milk protein "-lactoglobulin (BLG) of two aquatic mammals (dolphin and manatee) 
with bovine BLG. In this study the similarity to human serum retinol binding protein 
(RBP) was noted, and conserved sequence and structural motifs were identified514. In 
the subsequent years numerous eukaryotic proteins were assigned to the newly 
discovered protein family. It was only several years later that members of the 
lipocalin family were also identified in prokaryotes515,516. 
For the classification of lipocalins two systems have been proposed. One relies on the 
presence or absence of conserved sequence motifs and divides the members 
accordingly into kernel and outlier lipocalins517. Kernel lipocalins, which through this 
classification system make up the largest subgroup, each share three conserved 
sequence motifs, while members of the family matching not more than two of these 
motifs are falling into the outlier group. The first of these motifs is shared by all 
lipocalins and can therefore also serve as a means of assigning a protein to the 
lipocalin family. 
However, due to the unusually low sequence similarity among different lipocalin-
family members a classification, which is not based on sequence information seems 
desirable. 
Therefore Skerra has proposed a classification based on the knowledge of the three 
dimensional structure of several lipocalin family members. A group of six 
biochemically different proteins, coinciding very much in their three dimensional 
structure are named the “prototypic” lipocalins518. Proteins having a lower root mean 
square deviation (RMSD) than a given threshold to the above mentioned group of 
sequences will accordingly also fall into the class of prototypic lipocalins. 
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8.2 Sequence and structure relationships of the lipocalins 
 
The lipocalin fold is very well conserved and characterized by an eight-stranded 
"#barrel and a C-terminal !-helix519. The eight "-strands of the barrel (commonly 
referred to as strands A to H) are linked by a succession of +1 connections. These 
seven loops (commonly referred to L1 to L7) are all short "-hairpins, except loop L1 
which is a large $-loop folding back to close partially the ligand binding-site found at 
its side of the barrel. Preceding strand A the lipocalins carry a characteristic 310-helix 
(figure 10a and 10b).  
With the exception of bovine odorant binding protein all mammalian lipocalins carry 
between one and three disulfide bridges.  
The lipocalins form together with two other families of ligand-binding proteins, 
namely the fatty acid binding proteins (FABPs) and the avidins, the superfamily of 
calycin proteins520. The avidins are basically very similar to the lipocalins, that is they 
are also eight-stranded "-barrels. The differences between the two families are the 
lacking C-terminal !-helix and the replacement of the $-L1 through a normal "-
hairpin in the avidins. The FABPs are structurally somewhat different. They are ten-
stranded "-barrels also lacking the C-terminal !-helix and carrying a long L1 loop 
with two short !-helices in it. 
The primary sequence, however, shows unusually low levels of sequence 
conservation among different members of the family. Only few characteristic 
signatures could be detected. The most general being a GXW motif near the N-
terminus519,521. 
 
8.3 Biological functions of lipocalins 
 
Lipocalins are typically small (15-20 kDa) secreted proteins which often show the 
ability to bind small hydrophobic molecules (e.g. retinol, as mentioned above). 
The biological functions of the lipocalins goes far beyond transport functions initially 
assigned to them. Until now such diverse tasks as pheromone activity522 cryptic 
coloration523, olfaction524, enzymatic synthesis of prostaglandins525,526, and even 
cellular regulative functions such as regulation of the immune response527,528 and 
mediation of cell homoeostasis529, have been identified as being accomplished or 
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regulated by lipocalins (for a review of lipocalin functions see Flower, 1996517. 
 
 
8.4 Bacterial lipocalins 
 
The first bacterial lipocalin Blc was identified in Escherichia coli515. Blc was 
identified as contributing for the adaptation of cells to starvation and a high-
osmolarity environment. Both of these conditions are known to exert particular stress 
on the cell envelope. 
Blc is translated with a type-2 signal peptide (also referred to as lipoprotein signal 
peptide) that is characteristic for bacterial lipoproteins530. This signal peptide is made 
up of a N-terminal sequence, which carries formyl-methionine and it contains one or 
several basic amino acids (N-region) followed by a hydrophobic segment (H-region). 
These two regions are common in all types of signal peptides. Lipoprotein signal 
peptides are followed by a conserved cleavage site of three amino acids preceding an 
invariant cysteine demarcating the mature N-terminus of the protein. This N-terminal 
cysteine is modified with a N-acyl-S-sn-1,2-diacylglycerylcysteine moiety in E. coli 
mature lipoproteins. Blc lipoprotein is targeted to the outer membrane and thought to 
be exposed to the periplasm531. 
Because of the lack of the second structurally conserved region that is found in all 
'kernel' lipocalins, Blc has been classified as an 'outlier' lipocalin516. 
From a synthetic standpoint it is important to note, that Blc is also different from most 
lipocalins in that it lacks intramolecular disulfide bonds facilitating its handling. 
Blc shows close similarity to the mammalian lipocalin apolipoprotein D515 commonly 
referred to as ApoD and to the insect lipocalin lazarillo of the American grasshopper 
Schistocerca americana
532 (figure 9). 
Blc, ApoD and lazarillo are the only lipocalins known so far to be anchored to lipid 
bilayers. While in Blc and in lazarillo this task is accomplished by the fatty-acylated 
cysteine and a C-terminal glycosylphosphatidylinositol (GPI) anchor respectively, 
ApoD is thought to bind to membranes via its hydrophobic loop inserted between "-
strands 7 and 8533. The sequence alignment of ApoD with Blc shows, that this 
hydrophobic loop is the only significant insertion of amino acids (see figure 9). ApoD 
is thought to interact with high-density lipoprotein (HDL) particles in blood plasma 
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by means of its hydrophobic loop inserted in between "-strands 7 and 8533. Supporting 
this model is a lone cysteine residue found adjacent to this putative hydrophobic 
binding loop which was found to form an intermolecular disulfide bond with the 
HDL-associated apolipoprotein A2534. 
The alignment of lazarillo with Blc and ApoD (see figure 9) shows that the amino 
acids corresponding to the putative hydrophobic binding loop in ApoD are mutated in 
lazarillo to hydrophilic residues, which might reflect its different ligand binding 
requirements. 
The similarity between the three proteins mentioned above is, however, not restricted 
to structural features, but also a close relationship on the functional level can be 
observed:  
While lazarillo is mainly expressed in developing neurons and is thought to control 
axon guidance535, ApoD accumulated in remyelinating peripheral nerve following 
damage536 and Blc is, as mentioned before, expressed upon stress on the cell 
envelope. This suggests a common biological role of these three proteins in the repair, 
remodeling and biogenesis of membranes. 
 
 
Figure 9: Sequence alignment of bacterial lipocalin, human apolipoprotein D and the lazarillo 
protein. Absolutely conserved and conserved residues are indicated by solid and faint red shading, 
respectively. Sequences which are cleaved off in the mature proteins are shaded yellow and 
disulfide forming cysteines are shaded pairwise in purple (disulfide bond 1) and green (disulfide 
bond 2). The hydrophobic stretch anchoring Apo D to the membrane extends from C136 to L140. 
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8.5 Lipocalins as Scaffolds 
The term scaffold designates a (natural) molecular architecture onto which 
structurally unrelated elements can be grafted with the goal of creating novel 
functions. Protein scaffolds are characterized by a stable core region, which is capable 
of folding irrespective the peptide sequence outside this region. In an ideal case the 
region outside the core is completely uncoupled from the folding of the stable core 
and tolerates every conceivable sequence change. A few types of protein folds have 
been identified and evaluated as potential scaffold candidates537. In nature this type of 
modular protein architecture is rare. Prominent examples are the immunoglobulins 
(Igs)538, the TIM barrel enzymes539, and in some respect also the GPCRs (vide supra). 
The identification of new protein scaffolds is driven by the search for artificial 
proteins with tunable, prescribed ligand binding properties. The antibodies of our 
adaptive immune system constitute such library of binding molecules, made up six 
hypervariable loops displayed on a conserved structural framework. An estimated 108 
antibodies are circulating through the human body allowing the tagging of intruding 
structures for degradation/clearance by dedicated host cells. 
Retinol-binding protein (RBP) was the first lipocalin, whose high resolution structure 
was solved540,541. Soon after the structure of the lipocalin bilin-binding protein (BBP) 
was elucidated542,543. It was obvious that despite the low sequence homology, 
structurally these two proteins where closely related. The structures of four additional 
lipocalins corroborated this view544-547. A superposition of 5 lipocalins is shown in 
figure 10c. 
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Based on high structural homology within the "-barrel core and considerable 
structural and sequence divergence within the loop regions, lipocalins have been 
proposed as molecular scaffolds. In a first application of this idea a metal-binding site 
was introduced on the solvent-exposed surface of RBP548. A few years later also the 
loops at the open end of the barrel were changed by a combination of rational protein 
design and combinatorial protein biochemistry to yield a protein capable of binding 
fluorescein549. Several positions in the BBP sequence were randomly mutated to 
generate a large library of different sequences. Individual mutants displaying 
fluorescein binding properties were selected from this pool using phage display 
technology550. In an analogous screening, lipocalin-derived binders to the biologically 
important molecule digoxigenin could be generated551. Lipocalins have, however, also 
been successfully used as a scaffold for generating high affinity binders to human 
proteins, as has been shown for an engineered apolipoprotein D binding to 
hemoglobin552. Such binders were termed "anticalins", because they mimic the 
antibodies of the immune system. 
The physiological role of lipocalins is the binding and sequestration/transport of 
hydrophobic and/or chemically sensitive molecules517,537. In this respect the lipocalins 
seem to be ideal candidates for creating artificial binders to small molecules, an 
Figure 10: a) The characteristic structural features of a lipocalin are eight !-strands (green) 
forming a barrel, an N-terminal 310-helix (red) and a C-terminal "-helix (blue). b) The crystal 
structure of the bacterial lipocalin (pdb code 1QWD) with the characteristic structural elements 
colored as described under a). c) Superposition of 5 lipocalins (bilin binding protein [1BBP]: 
yellow; bacterial lipocalin [1QWD]: red; retinol binding protein [1RBP]: purple; bovine !-
lactoglobulin [1B8E]: blue; apolipoprotein D [2APD]: green). The !-barrel core is structurally 
conserved, while the loops show large structural variations. 
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activity which has proven difficult with many other scaffolds. 
The availability of a high resolution structure is a prerequisite for the use of any given 
protein as a scaffold. Additional practical aspects, such as the presence/absence of 
posttranslational modifications or disulfide bonds, should also be considered, when 
selecting a scaffold. 
 
 
9. Outer membrane protein A of E. Coli 
 
9.1 The outer membrane of gram negative bacteria 
 
Bacteria are commonly classified into two or three categories according to their 
appearance after treatment with the so-called Gram staining procedure553. Gram-
positive bacteria get stained by the Gram staining procedure. They have a thick 
peptidoglycan layer (vide infra) surrounding their plasma membrane. Gram-negative 
bacteria, on the other hand, are not colored by the applied stain. Their plasma 
membrane is also enveloped by a peptidoglycan layer, which itself, however is 
surrounded by an additional lipid bilayer. Gram-negative bacteria are therefore 
characterized by two lipid bilayers, one called the inner membrane (IM) and one 
called the outer membrane (OM). The space between these two membranes is called 
the periplasm and contains peptidoglycan layer. The peptidoglycan layer is composed 
of peptide linked polysaccharides: The polysaccharide is a polymer of a disaccharide 
composed of N-acetyl-muraminic acid and N-acetyl-glucosamine as the repeating 
unit. Polysaccharide strands are interconnected between N-acetyl-muraminic acid 
moieties with peptides built up of D- and L-amino acids554. The peptidoglycan layer 
serves as an extracytoplasmic cytoskeleton which determines the cell's shape and 
protects it from lysis in environments of low osmolarity. 
 
9.1.1 Chemical composition of the bacterial outer membrane 
While the IM is a regular phospholipid bilayer (in E. coli composed of 70-80% 
phosphatidylethanolamine, 15-20% phosphatidylglycerol and <5% cardiolipin)555, the 
OM is a highly asymmetric bilayer consisting of phospholipids (70-80% 
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phosphatidylethanolamine, 20-30% phosphatidylglycerol) on the periplasmic and of 
lipopolysaccharides (LPS) on the extracellular surface556,557.  
LPS are large fatty-acylated oligosaccharides which can be subdivided into three 
structural parts: The highly immunogenic lipid A, the core oligosaccharide, and the 
O-antigen polysaccharide558. While the core oligosaccharide and the O-antigen are 
pure saccharide structures, the lipid A molecule is a "-1',6-linked glucosamine 
disaccharide, which is monophosphorylated on both glucosamine moieties (at 
positions 1 and 4'). Furthermore it is acylated with four "-hydroxyacyl groups, two or 
three of which are themselves acylated at their "-hydroxy group with acyl chains559. 
This structural difference is also reflected in the proteins residing in the two 
membranes: While integral inner membrane proteins have !-helical TM anchors 
(White, J Biol Chem, 276, 32395, 2001), the outer membrane proteins (OMPs) have 
"-barrel TM anchors consisting of antiparallel, amphipathic "-strands560. Apart from 
the integral membrane proteins, the outer IM leaflet and the inner OM leaflet also 
contain lipoproteins, which are anchored to the membrane by an N-terminal N-acyl-
diacylglycerylcysteine (the cysteine being the N-terminal amino acid of the 
protein)561,562. 
 
9.1.2 Bacterial outer membrane proteins 
Interestingly none of the OM components are produced at the OM: Whereas OMPs, 
whether they are integral or lipid-anchored, are produced in the cytoplasm, the OM 
phospholipids and LPS are made at the cytoplasmic side of the IM563-565. All these 
compounds therefore require transport to their final destination. 
The E. coli genome codes for about 100 lipoproteins. The transport of OM 
lipoproteins has been elucidated by biochemical studies. After N-terminal lipid 
modification561 at the periplasmic side of the IM they interact with the ABC 
transporter LolCDE. IM lipoproteins are not bound by this complex, because they 
possess a so-called 'Lol-avoidance signal'. Upon ATP hydrolysis the lipoprotein is 
released to the periplasmic chaperone LolA, which guides the lipoprotein through the 
periplasm to the OM, where it is handed over to the OM lipoprotein LolB, which 
assembles the lipoprotein finally in the OM562. 
The glycerophospholipids exchange freely between the outer leaflet of the IM and the 
inner leaflet of the OM; the mechanism for this reversible transport is not understood 
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yet. Lipopolysaccharides, on the other hand, are exported from the IM to the OM in 
an unidirectional manner566. The LptA/LptB proteins are responsible for the transport 
of LPS across the periplasmic space567. Whether this transport occurs by diffusion of 
the LPS loaded LptA/LptB complex through the periplasm or whether the transport is 
carried out during the formation of transient contact sites, is still under dispute568,569. 
After their synthesis in the cytoplasm a signal sequence targets the OMPs to cross the 
IM. The protein machinery involved in the translocation of bacterial membrane 
proteins is called the “Sec machinery”, as all those components were originally 
identified in screens for deficiencies in protein secretion570. The Sec translocation 
machinery can be divided into two functionally different subsets: The chaperone SecB 
is a soluble cytoplasmic protein and keeps the proteins in a translocation competent 
(i.e. unfolded) state and at the same time prevents aggregation by shielding exposed 
hydrophobic sequences. The SecY, SecE, and SecG are all membrane proteins and 
interact to form a complex (SecYEG). This complex interacts with the peripheral 
membrane protein SecA, and it is this quaternary complex that drives the 
translocation of secretory proteins across the IM. The energy for this translocation is 
provided by the proton-motive force and ATP hydrolysis571-573. The signal sequence 
and the bound SecB chaperone target the protein to the membrane embedded 
SecAYEG complex. After translocation the signal sequence is cleaved in the 
periplasm574. It should be noted at this point that also bacterial IMPs are processed by 
the Sec machinery. The treatment of these proteins differs from the secreted and OM 
proteins in a way that, if a hydrophobic TM segment of an IMP is detected by the Sec 
channel, it will open laterally and release the hydrophobic TM segment into the 
surrounding phospholipid bilayer574 in an analogous fashion as it is proposed for the 
synthesis of eukaryotic transmembrane proteins575,576. Hydrophobic TM segments as 
they are characteristic for !-helical membrane proteins can therefore be considered as 
a targeting signal to the IM, which explains their absence from the OM. 
While periplasmic and secreted proteins can adopt their native conformation after 
translocation through the IM, OMPs are immediately bound by chaperones. The most 
important of these are Skp and SurA568. Skp binds selectively to unfolded OMPs577,578 
already while they are in progress of translocation579. The postulated mode of action 
of Skp was recently confirmed in an NMR study: Trimeric Skp forms soluble 1:1 
complexes with outer membrane protein A (OmpA) from E. coli by burying the 
hydrophobic TM domain within a cavity, while keeping the non-aggregation prone 
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periplasmic domain freely in solution in its folded form580. SurA, in contrast to Skp, 
functions as a folding chaperone for OMPs581,582. Data indicate that SurA acts later in 
the OMP insertion pathway than Skp. A working model therefore postulates that Skp 
initially binds nascent OMPs to prevent their aggregation and then hands them over to 
SurA which assists in their delivery to the OM and concomitant folding and 
membrane insertion583. After this chaperone assisted passage through the periplasm, 
OMPs are inserted into the OM via a machinery called "-barrel assembly machinery 
or Bam complex584,585. 
 
9.2 ?-barrel proteins 
 
9.2.1 Occurrence of ?-barrel membrane proteins 
The exclusive appearance of "-barrel proteins in the OM is most likely due to the fact 
that "-barrels are very efficient pores and would thereby disrupt the proton gradient 
across the IM. Several toxins act indeed by forming "-barrels within energy-
transducing membranes586. 
Whereas roughly 20 amino acids are necessary to transverse the membrane with an !-
helix5, only 8 residues are required to fully span the membrane with "-strand. For 
both !-helix and "-strands the effective number of residues is usually higher due to a 
tilt of the respective structural element relative to the membrane normal. Because the 
side chain of only every second residue faces the hydrophobic lipid environment, "-
barrel TM segments usually don't display an especially pronounced hydrophobicity. 
The structures of about 30 "-barrel membrane proteins have been solved to date. The 
observed numbers of TM strands ranges from 8 to 22. The quaternary structure is 
predominantly monomeric. One class of "-barrel MPs, the porins, is trimeric. In one 
case an oligomer of 8 identical subunits forms one single barrel structure587. All "-
barrel structures solved so far display an even number of "-strands with the N- and C-
termini located on the periplasmic side. To both stated characteristics there is one 
exception: Several autotransporter proteins expose their N-terminus on the 
extracellular face after threading it through "-barrel pore588, thereby seemingly 
“violating” the rule that N- and C-terminus have to lay on the periplasmic side. The 
rule that all barrels are composed of an even number of strands was broken in 2008, 
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when the structure of the mitochondrial OMP VDAC-1 (voltage dependent anion 
channel) was solved by NMR spectroscopy215. The presented structure showed a 19-
stranded "-barrel with the first and last strand being aligned in a parallel fashion. N- 
and C-termini were both lying on the periplasmic face, because the C-terminus was 
threaded through the pore formed by the 19-stranded barrel. 
 
Figure 11: a) Ribbon representation of a selected conformer of a solution NMR structure of OmpA 
(1G90). The !-strands of the barrel are colored cyan and delimit the surface of OmpA being 
inserted in the membrane. b) The characteristic aromatic belt observed in many !-barrel membrane 
proteins is indicated by coloring the backbone bonds of all aromatic residues of OmpA yellow. c) 
View from the extracellular space into the barrel of OmpA. Charged and polar residues are 
represented in red and yellow, respectively. d) Electrostatic surface potential of OmpA. Negatively 
and positively charged residues are colored and blue, respectively. The outer surface of the central, 
membrane embedded region is largely hydrophobic. e) A superposition of OmpA (gray; 2GE4) with 
a loop-shortened OmpA which had been used as a scaffold for the EF-hand loop of calmodulin 
(orange; 2JMM). 
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9.2.2 Electrostatic characterization of ?-barrel membrane proteins 
Electrostatically "-barrel MPs are characterized by a hydrophobic exterior of the 
barrel facing the lipids of the membrane and a usually hydrophilic interior of the 
barrel (i.e. they show an inverted electrostatic profile compared to soluble proteins). 
The loops interconnecting the "-strands of the barrel are hydrophilic and short on the 
periplasmic and long on the extracellular side589. As is the case for !-helices, the 
antiparallel "-sheet structure fulfills the requirement of saturating all hydrogen 
bonding capabilities of the backbone's carbonyl oxygens and amide hydrogens5. 
The TM "-strands of "-barrel membrane proteins are rich in glycines, tryptophans and 
tyrosines. The two aromatic members of this trio are mainly found in the “interface” 
regions of the membrane. 
The lumen of the smaller barrels (i.e. the eight-stranded outer membrane protein A, 
OmpA) is tightly packed with an interaction network of polar residues' sidechains. 
Pockets of ordered and unordered water molecules can also be found within these 
small "-barrels. 
The lumen of larger "-barrels, as for instance the 12-stranded NalP from Neisseria 
meningitidis, is large enough to also accommodate secondary structure elements 
formed in the extracellular loops. The 16- and 18 stranded porins have pores, which 
are completely filled with water, and sometimes entire extracellular loops fold back 
into the pore, thereby modulating substrate specificity. Even larger "-barrels as the 
22-stranded coupled transporter proteins contain entire “plug” or “cork” domains that 
fill most of the lumen. 
 
9.3 Functions of ?-barrel membrane proteins 
 
Functionally the OM proteins of Gram-negative bacteria can be classified into six 
families560: (1) general porins, (2) passive transporters, (3) active transporters, (4) 
enzymes, (5) defensive proteins, and (6) structural proteins. A summary of this 
classification with examples and references is given in the table below. 
Category Member Function Ref 
    
1. general porins OmpC general diffusion pore 
590
 
 OmpF general diffusion pore 
591
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 PhoE general diffusion pore, some specificity 
591
 
    
2. passive transporters LamB maltose transport 
592
 
 ScrY sugar transport 
593
 
 FadL fatty acid transport 
594
 
    
3. active transporters FepA siderophore transport 
595
 
 FecA siderophore transport 
596
 
 FhuA siderophore transport 
597
 
 BtuB vitamin B12 transport 
598
 
    
4. enzymes OMPLA phospholipase 
599
 
 OmpT protease 
600
 
 PagP palmitoyl transferase 
210
 
    
5. defensive proteins OmpX defense 
601,602
 
    
6. structural proteins OmpA structural 
214,603
 
 
9.3.1 General porins 
OmpF, OmpC and PhoE are the three major porins produced by E. coli. They are all 
trimeric, belong to the family of general porins and their crystal structures have been 
solved. In spite of their non-specificity they can be classified according to the charge 
and size of solutes which they are able to transport. While OmpF and OmpC show a 
slight preference for cations, PhoE prefers inorganic phosphate and anions560,604. 
While the expression of OmpF and OmpC is regulated by osmotic pressure, PhoE is 
expressed in response to phosphate starvation. The size limit for solutes passing 
through the porins is considered to be around 600 Da605. The general porins can play 
an important role in the development of antibiotic resistances, as is exemplified by the 
low susceptibility to "-lactams by gram-negative pathogens with a reduced number of 
porins in their OM604,606.  
9.3.2 Passive transporters 
In the case of influx through the general porins it is assumed, that the solute does not 
interact with the porin, resulting in unspecific uptake and high flux rates. In case the 
solute interacts with its transporter, the diffusion rate will be slowed down, but 
specificity will be gained. The equilibrium constant of the interaction between the 
transporter's interior and the solute will have an influence on the flux607. This is the 
case in passive transporters such as the maltoporin LamB608. X-ray diffraction 
analysis of maltose soaked LamB crystals indicated a transport route through the 
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LamB channel, consisting of a row of aromatic amino acids (“greasy slide”) that is 
flanked by polar residues (“ionic track”) along which the maltose substrate is 
transported609,610. 
9.3.3 Active transporters 
The active transporters, which are involved in the uptake of large substrates (e.g. iron 
siderophores or vitamin B12) depend on the electrochemical potential of the 
cytoplasmatic membrane and an energy-transducing protein complex called TonB-
ExbBD. FhuA597 and FepA595 are two such active transporters mediating the uptake of 
iron-siderophore complexes. They both form a 22-stranded "-barrel with the N-
terminus forming a plug to the pore.  
Enzymes 
The first OM "-barrel enzyme to be characterized was the phospholipase OMPLA611. 
OMPLA is activated upon Ca2+-induced dimerization599. Dimerization for instance is 
triggered by the migration of glycerophospholipids to the outer leaflet of the OM 
which frees Ca2+ ions previously involved in the bridging of the phosphates of LPS. 
By its phospholipase activity OMPLA is able to counteract the glycerophospholipid 
inflow and restore the required lipid asymmetry in the OM612. The active site in 
dimeric OMPLA is formed by a Asn-His-Ser catalytic triad located on the exterior of 
the "-barrel. In the monomeric state these residues are associated with a glucosamine 
moiety of lipid A613. 
The OM "-barrel protease OmpT was identified as a nuisance in protein purification 
in E. coli614. It is specific for the cleavage between two basic amino acids615. This 
specificity renders OmpT ideal in for the recognition of cationic antimicrobial 
peptides, in which often diads of basic amino acids can be found. Based on the crystal 
structure of OmpT it is expected that the O-antigen polysaccharide extends far beyond 
the opening cleft of OmpT and thereby shields other OMPs from digestion by 
OmpT616. Only proteins/peptides which penetrate into the O-antigen polysaccharide 
layer are susceptible for encounter with the OmpT active site617. 
The third OM "-barrel enzyme to be discovered is the palmitoyltransferase PagP618. 
PagP transfers a palmitate chain from the sn-1 position of a phospholipid to the 
hydroxy group of a "-hydroxyacyl chain of lipid A. This transfer occurs in the OM. 
PagP is an 8-stranded "-barrel as determined by X-ray crystallography211 and NMR 
spectroscopy210 and is very specific for the transfer of palmitate. This specificity is 
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conferred by a palmitate-recognition pocket, known as the “hydrocarbon ruler”, 
which is located in the barrel's interior at the level of the LPS exposed half of the 
barrel211. 
PagP is a scavenger system to prevent accumulation of glycerophospholipids in the 
LPS leaflet of the OM similar to OMPLA. In contrast to OMPLA, however, PagP also 
functions in the absence of divalent cations and could become the only functioning 
rescue system under conditions of depletion of these ions618,619. Additionally to 
maintaining OM asymmetry through the degradation of glycerophospholipids the 
transfer of palmitoyl to lipid A also might be a strategy to avoid a host's innate 
immune system: after palmitoylation lipid A is less immunogenic and a bacterial 
invader therefore less likely to be attacked by e.g. antimicrobial peptides of the host's 
immune system620. 
9.3.4 Defensive proteins 
The 8-stranded "-barrel OmpX is a representative of the defensive OMPs. It is 
important for survival of a pathogen by neutralizing a host's defense mechanism: e.g. 
the mediation of survival in macrophages and inhibition of the complement system621. 
The structure of OmpX has been solved both by X-ray crystallography601 and NMR 
spectroscopy602. 
Structural proteins 
The main structural OMP is OmpA which occurs in about 100000 copies per cell. It is 
composed of a 170 residue N-terminal TM domain and a 155 residue C-terminal 
periplasmic domain622. The physiological function as a structural protein consists of 
providing a link between the OM and the underlying peptidoglycan layer623. The 
crystal structure of the OmpA TM domain was solved in 1998603, which was 
complemented by the NMR structure published in 2001214. 
 
9.4 Thermodynamic stability of ?-barrel membrane proteins and introduction to 
OmpA 
The outer membrane protein A (OmpA) from E. coli consists of a 171 residue TM 
domain located in the OM and a 154 residue periplasmic domain. The TM domain is 
an 8-stranded "-barrel and the periplasmic domain is globular624,625. The TM domain 
of OmpA could be expressed and purified independently of the periplasmic domain 
and its structure has been solved by X-ray crystallography603,626 and NMR214. 
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The surface exposed loops of OmpA have many functions. They are involved in the 
recognition of nutrients such as iron-siderophore complexes and sugars627,628, toxic 
agents such as bacteriophages or colicins629-631 and probably also in the recognition of 
eukaryotic targets for bacterial pathogens632-634. 
Extensive mutagenesis data showed the robustness of OmpA and its tolerance towards 
amino acid substitutions, especially in the longer extracellular loops, the short 
periplasmic turns and the face of the barrel facing the lipid bilayer635. The TM domain 
of OmpA could be circularly permutated without impairing the assembly and function 
in the OM622. The extracellular loops could be shortened to a minimal length, also 
without impairing the assembly and function in the OM635. OmpA which was 
denatured by chaotropic agents could successfully refolded into detergent micelles636 
and lipid bilayers637 by rapid dilution of the denaturant. The simplicity of OmpA 
refolding led to the development of expression systems, for which OmpA 
accumulates as insoluble inclusion bodies638. The inclusion body expression system 
allows to purify denatured OmpA in large quantities (>100 mg per liter of bacterial 
culture). 
OmpA has long been a popular model system for the study of refolding of membrane 
proteins. Apart from its relative abundance in the E. coli OM the possibility for easily 
monitoring its folding state by gel electrophoresis639 have accounted for its popularity. 
This assay has been used to study the unfolding of urea denatured OmpA in small 
unilamellar vesicles. A gradual shift from the folded to the unfolded state with a 
midpoint at approximately 3 M urea could be observed by SDS-PAGE. Fluorescence 
spectroscopy experiments at pH 7 yielded the free energy of unfolding, !G0u,H2O to be 
4.5 kcal/mol589. Larger "-barrels whose lumina are blocked by “plug” domains, such 
as FhuA, show independent unfolding of the “plug” and the "-barrel. Whereas the 
“plug” domain unfolds a 65 °C the "-barrel is stable up to 74 °C640. 
9.5 Mechanism of in vitro ?-barrel membrane protein folding 
The kinetics of folding of OmpA in dioleoyl-sn-phosphatidylcholine (DOPC) lipid 
bilayers proceeds in three distinct phases. The fastest phase is the association of the 
unfolded protein with the lipid bilayer. It has a time constant of 6 min and is 
independent of temperature. The second phase is the partial, but not yet complete 
insertion of the "-strands into the bilayer. This phase had a time constant of 15 min to 
3 h and was strongly temperature dependent. The third phase marks the termination of 
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the folding process and ends with the complete insertion of the "-strands and 
formation of the tertiary structure. This last phase could only be observed at 
temperatures above 30 °C and occurred with a time constant of about 2 h. At 37 °C 
complete folding could be observed after 6 h641. Placing fluorescence quenchers at 
different depths in the membrane bilayer by covalent attachment to methylene groups 
in the fatty acid chains allows to measure the immersion depth of tryptophan residues 
in a time-resolved manner. This technique was called time-resolved distance 
determination by fluorescence quenching (TDFQ)642. Application of this technique to 
the folding of OmpA showed that all of the four extracellular loops crossed the 
membrane with the same time course643. Therefore OmpA inserts and folds in the 
membrane by a mechanism in which all extracellular loops translocate through the 
bilayer in a concerted manner. This movement of the loops, which are followed by the 
"-strands leads to a continuous insertion of the "-strands and a concomitant formation 
of tertiary structure. This is in contrast to the two-stage folding model suggested for 
!-helical membrane proteins644 in which individual TM helices insert into the 
membrane independently and then in a second stage associate to form the tertiary 
structure. 
The whole OmpA membrane insertion and folding process can be described as the 
hydrophobic collapse of the unfolded state U into an intermediate called IW in 
solution, followed by the binding of IW to the membrane surface, where intermediate 
IM1, which is characterized by disordered Trps, is formed. No secondary structure is 
observed in IM1. Subsequently intermediate IM2 is formed, with all Trps located at a 
distance of about 10 Å from the membrane center. A fraction of the secondary 
structure elements is formed in this intermediate, which is sometimes also referred to 
as a “molten disk”. Next the "-strands start to move towards the membrane center, 
and in intermediate IM3 the Trps located near the extracellular loops are located in the 
membrane center, whereas a Trp located near the periplasmic side remains at a 
distance of 10 Å from the center. This structure is more globular and is therefore also 
referred to as “molten globule”. Secondary structural elements are formed in this 
state, but the correct tertiary fold has not been reached yet. In the last step IM3 
proceeds to form the fully folded native state N, in which the Trps located near the 
extracellular loops are again located at a distance of about 10 Å from the membrane 
center, but this time on the side of the membrane opposite to where they started their 
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journey.  
9.6 In vivo folding of ?-barrel membrane proteins 
In vivo the folding of OMPs is much faster than in vitro645 and it is therefore likely 
that there are proteins assisting the efficient membrane incorporation of OMPs. The 
two main periplasmic chaperones are Skp and SurA (vide supra). Skp seems to be an 
ideal shuttling protein, because it is soluble, but can bind peripherally to phospholipid 
bilayers578. It is able to bind many different nascent OMPs577. However, it has been 
shown, that Skp does not accelerate folding of its substrates. It therefore seems to be a 
shuttle rather than an active folding catalyst. 
SurA is a periplasmic peptidyl-prolyl isomerase that assists the folding of several 
OMPs581. 
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Abstract 
Binding of neurohormones from the NPY family to their receptors, the so-called Y receptors, 
that belong to the superfamily 1b of G-protein coupled receptors, might include transient binding 
to the N-terminal domains of the receptors. Accordingly we have studied structural features of 
the N-terminal domains from the Y1, Y2, Y4, and Y5 receptor subtypes (N-Y1, N-Y2, N-Y4, N-
Y5). We developed efficient strategies for their recombinant expression. N-Y4 and N-Y1 were 
expressed as insoluble fusions to enforce accumulation into inclusion bodies, whereas N-Y2 and 
N-Y5 were expressed as soluble fusion proteins. All N-terminal domains are fully flexible in 
aqueous buffer. In the presence of phospholipid micelles some stretches within the polypeptides 
adopt helical conformations, but these are too unstable to be characterized in detail. Using 
chemical shift mapping techniques interactions of NPY, PYY and PP, the three members of the 
neurohormone family which are the Y receptors’ natural ligands, with N-Y1, N-Y2 and N-Y5 
revealed chemical shift changes in all cases, with the largest values being encountered for PP 
interacting with N-Y1 or N-Y5 both in the presence as well as in the absence of phospholipid 
micelles. The strength of the interactions, however, is generally weak, and the data also point to 
non-specific contacts. Previously, in case of the interaction of N-Y4 with PP the contacts were 
shown to be electrostatic in nature. This work indicates that association of the peptides with the 
N-terminal domains may generally be part of their binding trajectory.  
Keywords: GPCR, Y receptors, membrane proteins, structural biology, SPR 
 
1 Introduction 
G-protein coupled receptors (GPCRs) present the pharmacologically most important class of 
receptors and the most important target for pharmaceutical drugs1. Recently, significant progress 
has been made in structural studies of GPCRs. For example, the structures of bovine rhodopsin, 
the data on the !1 and !2 -adrenergic receptors and on squid rhodopsin2,34,5 have improved our 
understanding of this biologically important class of proteins. 
Generally the structure of GPCRs can be described as an extracellular N-terminal domain 
(ranging in size from ten to several thousand residues), which is anchored in the 
plasmamembrane by 7 transmembrane helices (7TM segment). The latter are interconnected by 
three intra- and three extracellular loops. The 7TM segment is followed by a cytoplasmic C-
terminal domain. While the extracellular N-terminal domain of bovine rhodopsin was 
surprisingly well-structured and revealed the non-anticipated presence of a short anti-parallel !-
 115 
sheet, the corresponding segment of the !-adrenergic receptor could not be traced in the electron 
maps presumably because of its inherent flexibility.  
Previously, we have in detail investigated structural properties of a 41 amino acid fragment 
corresponding to the N-terminal domain of the human Y4 receptor (N-Y4)6. This receptor 
belongs to a class of GPCRs targeted by neurohormones of the neuropeptide Y family7,8. The Y 
receptors are comprised of four subtypes called Y1, Y2, Y4, and Y5 with Y4 showing high 
affinity and specificity for the pancreatic polypeptide (PP). While unstructured in solution a short 
"-helical stretch comprising residues 5 to 10 was observed in the presence of phospholipid 
micelles for N-Y4. 
In this work we now report on our recent studies on structural properties of all other human N-
terminal domains from the human Y receptors (for sequences see Figure 1). 
 
Synthetic routes for recombinant production of the polypeptides in isotopically labeled form are 
described and compared to each other. The N-terminal domains from all Y receptors are fully 
unstructured in aqueous solution. In contrast, in the presence of phospholipid micelles all N 
termini except of N-Y2 form helical segments with variable degree of stability. 
In our previous work we demonstrated that N-Y4 interacts with PP. Surface plasmon resonance 
(SPR) measurements indicated weak (Kd 50 µM) binding, and subsequent mutagenesis 
experiments revealed that electrostatic interactions from anionic ligand and cationic N-Y4 
residues contributed to that interaction. In this work we also tested binding of the principal 
members of the NPY family (the neuropeptide Y (NPY), the pancreatic polypeptide (PP) and the 
peptide YY (PYY)) to all other N-terminal domains from this class of GPCRs. 
Figure 1: Sequence alignment of the principal members of the NPY family and of the N-
terminal domains from the various Y receptor subtypes.  
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2 Materials and Methods 
 
15NH4Cl was from Spectra Isotopes (Columbia, USA),d13-MES, d38-DPC- (99%-d), and D2O was 
from Cambridge Isotope Laboratories (Andover, Massachusetts, USA). 5-doxylstearic acid was 
from Aldrich (Buchs, Switzerland). Oligonucleotide primers were synthesized by Microsynth 
GmbH (Balgach, Switzerland). 
 
2.1 Expression and purification of N-terminal domains from the human Y receptors 
Depending on their stability against proteolysis the N-terminal domains were either expressed as 
fusions to ubiquitin (N-Y2 and N-Y5) or to ketosteroidisomerase (N-Y1 and N-Y4).  
In case of N-Y2 and N-Y5 the amino acid sequence was reverse translated into a DNA sequence 
taking into account the preferred E.coli codon usage including a terminal stop codon and a SalI 
restriction site. The resulting fragments were purified by electrophoresis and gel extraction and 
digested with SalI, resulting in fragments that were blunt-ended on one side and contained SalI-
cohesive end on the other end. These fragments were ligated into the pUBK19 vector (gift from 
T. Kohno, Mitsubishi Kasei Institute of Life Science, Tokyo, Japan), which had been digested 
with NsiI and SalI and purified before. The resulting plasmids were sequenced and transformed 
into C41 cells9. For production of 15N-labeled peptides M9 minimal media containing 15N-
ammoniumchloride as the sole nitrogen source was used, otherwise expression was done on LB 
medium. In each case 1 liter of medium containing 50 µg/ml kanamycin was inoculated with 10 
ml of an overnight LB culture. Cultures were induced at OD600 around 0.5 with 0.4 mM IPTG. 
LB- and minimal medium cultures were grown under induction for 4 h and 11 h, respectively. 
Cells were harvested by centrifugation on a Sorvall GSA rotor at 4 °C and stored at -20 °C. The 
cell pellets were thawed on ice for 1 h and resuspended in 25 ml denaturing basic buffer (50 mM 
Tris pH 8, 6 M GdnHCl, 100 mM NaCl, 1 mM !#mercaptoethanol). The suspension was lysed 
by sonication on ice.  
The ubiquitin fusion proteins were purified by Ni-NTA chromatography. Refolding was 
achieved by applying a linear gradient to exchange the denaturing basic buffer to native binding 
buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM !-mercaptoethanol, 20 mM imidazole), and the 
protein was eluted with binding buffer containing 200 mM imidazole. The eluates were diluted 
10-fold with basic buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM !-mercaptoethanol) and a 1 
mg/ml YUH-solution (for expression and purification of YUH see appendix G) was added in a 
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20-fold dilution. The cleavage reactions were allowed to proceed for 3 hours at 37 °C. 
In case of N-Y1 and N-Y4 the DNA sequences were subcloned from wt cDNA of the 
corresponding Y receptor (University of Missouri-Rolla (UMR) cDNA Resource Center) by 
PCR. During PCR, a GSGSGS linker followed by TEV cleavage sequence was introduced at the 
N terminus of the target sequence. After digestion with XhoI and EspI, the fragments were 
ligated with T4 DNA ligase into the pET31b vector, which had been digested with XhoI and 
EspI. The correctness of the constructs was verified by DNA sequencing (Synergene Biotech, 
Switzerland). The resulting plasmids were transformed into BL21(DE3) for expression. For 
production of 15N-labeled peptides M9 minimal media containing 15N-ammoniumchloride as the 
sole nitrogen source was used, otherwise expression was done in LB medium. In each case 1 liter 
of medium containing 50 µg/ml kanamycin was inoculated with 10 ml of an overnight LB 
culture. Cultures were induced at OD600 of 0.7 with 1 mM IPTG, harvested after 5 hours by 
centrifugation on a Sorvall GSA rotor at 4 °C and the pellets were stored at -20 °C.  
The fusion proteins were purified from inclusion bodies by Ni-NTA chromatography in presence 
of 6 M GdnHCl. After removal of GdnHCl by dialysis the precipitated fusion protein was 
solubilized in 50 mM Tris pH 8.0 in the presence of 2% N-lauryl sarcosine upon sonication to a 
final concentration of 2 mg/ml. The resulting solution was dialyzed against a 20-fold excess of 
50 mM Tris, pH 8.0 for 4-6 times. The solution was diluted 10 times with 50 mM Tris pH 8.0 
and EDTA and DTT were added to a final concentration of 0.5 mM and 1 mM, respectively. 
TEV protease (for expression and purification of TEV protease see appendix H) was added to a 
final concentration of 100 mM and the cleavage mixture was incubated at 4°C over night. 
All target peptides were finally purified by C18-RP-HPLC (Vydac, USA) by using a 
water/acetonitrile/0.1% TFA gradient. Yields ranged from 3 mg to 20 mg peptide from 1 liter of 
culture. The mass of all peptides was confirmed by MALDI-TOF MS or ESI MS: N-Y1: 4532.9 
Da (theoretical value: 4533.0 Da); 15N-N-Y1: 4587.0 Da (theoretical value: 4587.0 Da); N-Y2: 
5509.3 Da (theoretical value: 5510.0 Da); 15N-N-Y2: 5568.0 Da (theoretical value: 5570.0 Da); 
N-Y4: 4554.0 Da (theoretical value: 4556.1 Da); 15N-N-Y4: 4614.0 Da (theoretical value: 4611.1 
Da); N-Y5: 6053.7 (theoretical value: 6053.4); 15N-N-Y5: 6119.5 Da (theoretical value: 6118.4 
Da). 
 
2.2 NMR and CD spectroscopy 
For studies of structure or backbone dynamics 1 mM solution of the peptides at pH 5.6, 20 mM 
d13-MES, 300 mM d38-DPC were used. All spectra were recorded on an AV-700 Bruker NMR 
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spectrometer at 310 K. Chemical shifts were calibrated to the water line at 4.63 ppm and nitrogen 
shifts were referenced indirectly to liquid NH3. The spectra were processed using the Bruker 
Topspin2.0 software and transferred into the XEASY10 and Cara11 programs for further analysis.  
For chemical shift assignments 3D 15N-resolved TOCSY and NOESY12 were used. In case of 
N-Y5 we decided to use 13C,15N labeling in combination with experiments that directly correlate 
sequential amide moieties13. Upper-distance limits for structure calculations of N-Y1 were 
derived from a 70 ms NOESY spectrum14. Structures were calculated in the program CYANA 
using its standard simulated annealing protocol15.  
A proton-detected version of the steady-state 15N{1H}-heteronuclear Overhauser effect 
sequence was used for measurement of the heteronuclear NOE16. Therein, the buildup of the 
NOE was achieved through a pulse train of 120 degree proton pulses separated by 5 ms over a 
period of 3 seconds. 
For measurements of interactions by chemical shift mapping methodology 0.1 mM solutions of 
the 15N-labeled neurohormones were mixed with the corresponding peptides from the N-terminal 
domains at pH 5.6, 20 mM d13-MES, 300 mM d38-DPC, and the deviations of peak positions 
were extracted from the [15N,1H]-HSQC spectra and computed according to 
$%=SQRT($(1H)2+0.2*$(15N)2). Particular care was taken to ensure that no shifts in pH occurred 
when adding the N-Y peptides. In case of addition of various equivalents of pNPY to 15N-labeled 
N-Y2 in the presence of DPC micelles the sample was prepared in 20 mM d13-MES, 300 mM d38-
DPC at pH 5.6 and pNPY was added as a solid. 
For CD analysis, a certain amount of peptides was dissolved in 300 mM DPC buffered with 20 
mM MES (pH 5.6), such that the far UV absorption was around 1. CD spectra were recorded at 
37°C on Jasco model J-810 using a quartz cuvette with path length of 1 mm to minimize 
absorption by the detergent. All spectra were averaged from 3 consecutive measurements in the 
range between 190 and 250 nm with a slit width of 1 nm and a scanning rate of 5 nm/min. The 
blank sample was recorded under identical conditions and subtracted from the sample spectra. 
The final CD intensity is expressed as mean residue ellipticity (deg cm2 dmol-1). 
3 Results 
3.1 Expression of N-terminal domains in isotopically labeled form 
Isotope labeling of the investigated peptides was required for the study of backbone dynamics 
using 15N relaxation and for chemical shift mapping experiments for the study of macromolecular 
interactions.  Such labeling precludes the usage of peptides produced from solid phase 
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synthesis17,18 and necessitates recombinant production. For reasons of simplicity we generally 
prefer E.coli as the expression host19. To avoid rapid degradation in E.coli, the peptides need to 
be linked to a (more) stable fusion partner20. Specific cleavage from the fusion partner can be 
accomplished for systems for which a specific hydrolase (e.g. a ubiquitin hydrolase) is available 
or by introducing a unique cleavage site, either a protease-sensitive site or a site prone to 
chemical cleavage such as CNBr21 or hyroxylamine22 (see Fig. 2). 
 
Figure 2: Scheme showing the two strategies used to produce peptides corresponding to the N-
terminal domains of the Y receptors and examples from N-Y5 and N-Y4 for the corresponding 
scheme, respectively. 
CNBr cleavage in our case was incompatible with the presence of Met residues, and poor 
efficiency was observed with hydroxylamine, and therefore enzymatic cleavage had to be used. 
However the latter methods require that the fusion protein can be solubilized under conditions 
that are compatible with enzymatic activity. 
Since the four Y receptor N-terminal fragments studied herein are all reasonably water-soluble 
and contain Met residues we initially decided to express them in 
15
N-labeled form as C-terminal 
fusions to N-terminally decahistidine-tagged yeast ubiquitin23. After purification of the fusion 
construct by Ni-affinity chromatography the desired peptide was liberated through treatment 
with yeast ubiquitin hydrolase (YUH). This system allowed the recovery of about 6 mg of 
15
N-
labeled N-Y2 and N-Y5 from 1 L of culture. Unfortunately, attempts to express N-Y1 and N-Y4 
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using this method resulted in unspecific C-terminal degradation. To circumvent intracellular 
proteolysis, N-Y1 and N-Y4 were expressed as a fusion to the highly water-insoluble protein 
ketosteroidisomerase (KSI), which resulted in accumulation of the fusion protein in inclusion 
bodies. A TEV protease cleavage site was introduced between KSI and the target peptide24,25. 
The sequence recognized by the TEV protease is ENLYFQ with Q as the P1’ residue. To achieve 
the natural peptide sequence after cleavage, the P1’ residue was replaced with the first residue 
from the target sequence (here it is Met)24, and an additional GSGSGS linker was inserted 
between KSI and the TEV cleavage site to prevent steric hindrance during cleavage.  
A problem of the chosen strategy was that the water-insoluble fusion protein must be solubilized 
in detergent that is compatible with activity of the TEV protease26. After extensive detergent 
screening, we observed that the ionic detergent sarcosyl solubilizes the fusion protein while 
preserving TEV protease activity to a satisfactory extent. Cleavage efficiency for this system is 
around 40% allowing recovery of about 2 mg of 
15
N-labeled N-Y1 and N-Y4 from 1 L of 
bacterial culture. 
 
3.2 Assignment of chemical shifts 
Sequence-specific resonance assignments were done using the strategy developed by Wüthrich 
and coworkers27. Due to extensive resonance overlap of the poorly folded peptides 15N-resolved 
three-dimensional TOCSY or NOESY data had to be utilized for this task. Representative 
[15N,1H]-HSQC spectra of all four peptides are depicted in Fig. 3. 
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Figure 3: [15N,1H]-HSQC spectra of all Y receptor N-terminal domains, recorded at 310 K in the 
presence of DPC micelles. Top left: N-Y1, top right: N-Y2, bottom left: N-Y4, bottom right: N-Y5. 
In case of N-Y5 a 13C,15N-labeled sample, allowing the acquisition of triple resonance spectra, 
was required. For N-Y1, a set of experiments was first recorded in aqueous buffer. After 
completed analysis in water the assignments were adjusted to the spectra recorded in the 
presence of dodecylphosphocholine (DPC) micelles with the help of NOESY spectra. Chemical 
shifts have been deposited in the BMRB database under accession codes 80.8933262 (N-Y1), 
80.6873033 (N-Y2) and 80.74817093 (N-5).  
 
3.3 Screening structural properties using 
15
N relaxation and CD spectroscopy 
CD spectroscopy is a convenient tool to estimate the type and content of secondary structure in 
peptides and proteins. The CD spectra of all N-terminal domains in the presence of DPC micelles 
are depicted in Fig 4. The spectrum of N-Y2 displays its minimum around 197 nm, the typical 
absorption band of unstructured peptides. For all other peptides the minimum is red-shifted and 
indicates population of helical substructures. The intensities of the absorptions, however, also 
clearly show that the helical content is very low in all cases, and the typical double minimum at 
208 and 222 nm is not visible. For N-Y4, for which we previously observed an "-helix involving 
residues 5 to 10, the absorption is stronger than for the other peptides. 
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Figure 4: CD spectra of peptides from all N-terminal domains, recorded at 37 °C in 300 mM 
DPC, 20 mM MES pH 5.6 solution. Data are shown for N-Y1 (solid line), N-Y2 (dotted line), N-
Y4 (dash-dotted line) and N-Y5 (dashed line). Data are converted to mean residue ellipticities. 
The dispersion of the NMR signals in the region of the amide protons is traditionally used to 
estimate to which extent a peptide or protein is folded28. In case of the N-terminal domains from 
the Y receptors signal dispersion of all peptides was small, indicating that they were largely 
unfolded. To better assess whether these peptides still contained folded segments we recorded 
the 15N{1H}-NOEs (H-NOEs). These values range from 0.6 and 0.8 for well-folded elements of 
secondary structures, and progressively decrease for more flexible amide moieties resulting in 
negative values for fully flexible segments29. The H-NOE data for all N-terminal peptides reveal 
that all peptides are essentially unstructured in aqueous buffer (data not shown). 
Since in the naturally occurring GPCR the N termini are attached to a membrane-protein the 
backbone dynamics were additionally probed in the presence of a commonly used membrane-
mimicking detergent, DPC30 (see Fig. 5). Again the peptides are not rigidly structured. In the 
case of N-Y4 we could previously show that a rather stable hydrophobic "-helix is formed 
between residues 5 and 10, present both in zwitterionic (DPC) as well as in anionic (SDS) 
micelles6, reflected by H-NOEs exceeding values of 0.6. In contrast, the N termini from all other 
Y receptors are less well ordered. The N-Y2 is fully flexible most likely due to the complete lack 
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of interactions with phospholipid surfaces. The absence of such contacts is supported by the fact 
that essentially no chemical shift changes occur between N-Y2 in aqueous buffer and in DPC 
micelles. In contrast, both N-Y1 and N-Y5 reveal short stretches of the polypeptide chain that 
become rigidified in the presence of the micelles.  
 
Figure 5: Values of the 15N-{1H}NOE, recorded at 700 MHz proton frequency along the 
sequence for Y1 (top left), Y2 (top right), Y4 (bottom left) and Y5 (bottom right). The area 
containing values larger than 0.6, indicating rather well-folded segments, has been s 
 
3.4 The structures of the N-terminal domains in the presence of phospholipid micelles 
The H-NOE data of N-Y4 revealed the presence of a hydrophobic helix in the segment 
comprising residues 5 to 10. In addition, a nascent helix was observed in the region including 
residues 26 to 35. Inspection of the H-NOE data depicted in Fig. 5 clearly indicates that N-Y2 is 
devoid on any structured segments. Moreover, the H-NOE of N-Y5 is generally below 0.6 and 
mostly values are even smaller than 0.4. In our experience secondary structure cannot reliably be 
determined in these cases. We speculate that the molecule, similarly to N-Y4, is segregated into a 
N-terminal helical region, and a much more destabilized shorter C-terminal helical region 
separated by a longer non-ordered segment, but the peptide is not ordered sufficiently well to 
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allow for structural characterization by NMR in detail. 
In case of N-Y1, however, elevated values of the H-NOE are observed indicating that this 
polypeptide may be amenable to more detailed structural studies. Accordingly, we have assigned 
all proton and nitrogen resonances of N-Y1. During assignment a larger number of contacts 
involving sequential amide protons were observed, indicating that the &,' space of helical 
backbone conformations was significantly populated. Such stretches were for example observed 
for residues 4 to 9 and residues 24 to 32. An expansion of the spectral region of the [1H,1H]-
NOESY that displays the sequential amide proton NOEs in the segment from 24 to 32 is shown 
in appendix E. However, except for two ",N (i,i+3) NOEs observed in the segment 4-9 no 
medium-range contacts were found. The relative strength of intra-residual and sequential "(,NH 
contacts changes between extended and helical conformations31, with the intra-residual distance 
in helices stronger than the sequential one, whereas in extended or unfolded segments the 
sequential distance is much shorter. A comparison of peak intensities revealed that the sequential 
NOEs were generally stronger, and in the light of sequential contacts of amide protons, indicate 
conformational averaging between helical and extended conformations to some extent. 
Considering this observation it was not really surprising that persistent violations remained in the 
structure calculations, and helical conformations were only seen involving residues 4 to 9, a 
region, in which the H-NOE is larger than 0.6. The 3J(HN,H") couplings were larger than 6.5 Hz 
throughout the sequence (data not shown), reflecting the remaining conformational instability of 
N-Y1. To our surprise we have not been able to detect any medium-range contacts in the 
segment 15 to 28, which according to the dynamics data should also be better ordered. We 
suspect this region to be transiently helical considering the occurrence of sequential amide 
proton contacts throughout this segment.  
To summarize, the spectroscopic data indicate that N-Y4 and N-Y5 are similar in that both 
contain two helical regions separated by a flexible central segment, with only the N-terminal 
helix in N-Y4 being well ordered. N-Y1 is largely helical between residues 4 and 28, but the 
remaining conformational flexibility precludes its detailed structural analysis. N-Y2 is fully 
flexible and devoid of any detectable residual structure.  
 
3.5 Interaction studies with neuropeptides from the NPY family 
We have recently proposed that the peptides of the NPY family may transiently bind to the N-
terminal domains of Y receptors in order to become transferred from the membrane-bound state 
into the genuine binding pocket of the receptor6,32. While in that work surface plasmon resonance 
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was used to establish the strength of the bPP-NY4 (b: bovine) interaction, preliminary 
experiments using bPP or pPYY (p: porcine) and the N-terminal domains from the other 
receptors have indicated that the interaction between the peptides and the other N-terminal 
domains are too weak to be detected by SPR. We have also extensively tried to apply isothermal 
titration calorimetry but reproducibility of the data recorded in presence of micelles was very 
unsatisfying, most likely related to the fact that this technique in detergent becomes very 
challenging when the dissociation constant is more than 10 µM. Therefore we utilized chemical 
shift mapping experiments both in the presence and absence of DPC micelles in order to derive 
preliminary data on binding of the peptides from the NPY family to N-Y1, N-Y2 and N-Y5. It 
should be mentioned, however, that changes in chemical shift To briefly summarize these 
experiments, we note that in case of pPYY changes are similar (but small) for all N-terminal 
domains, whereas in case of bPP NY1 or NY5 behave differently compared to  N-Y433-35. To 
investigate whether pNPY really associates with N-Y2 we have performed a titration experiment, 
in which up to 10 equivalents of pNPY were added to 15N-labeled N-Y2 (see Fig. 6). The data 
clearly show concentration-dependent changes of positions of resonances from the N-Y2. 
Resonances in the segments comprising N-Y2 residues 16-21 and 33-50 are mostly affected. We 
noticed that acidic residues Glu and Asp are particularly numerous among the residues showing 
large chemical shift changes when pNPY is added in large excess. This might point to rather 
non-specific electrostatic contributions to the weak interaction between N-Y2 and pNPY, a fact 
that has been also observed for the interaction of N-Y4 with bPP. To summarize the interaction 
studies we can say that significant and reliable effects were only detected in the presence of DPC 
micelles, and that the interaction of bPP with N-Y4 is much stronger than for the other peptides.  
 
Figure 6: Chemical shift deviation of N-Y2 after addition of 1 and 10 equivalents of pNPY (from 
left to right). For additional data points at 0.5, 2 and 4 equivalents see appendix I. 
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4 Discussion 
We have postulated, that binding of ligands to Y receptors is preceded by association of the 
ligands with the plasma membrane. Thereby, the apparent concentration of the ligand is 
increased and the search for the receptor reduced from three to two dimensions36-38. We now 
studied whether parts of the receptor that protrude into the extracellular compartment may help 
in transferring ligands, which have accumulated in vicinity of the membrane, into the binding 
pocket. Such portions of receptors that point into the extracellular space are the N-terminal 
domains. Herein, we have developed strategies to produce these polypeptides recombinantly in 
isotopically enriched form for use in high-resolution NMR studies. 
The work has demonstrated that these peptides can all be expressed as soluble fusions to 
ubiquitin. However, N-Y4 and N-Y1 are degraded in the intracellular milieu, and hence much 
better yields were obtained using insoluble fusions. Cleavage of the target sequence from the 
insoluble fusion partner could be achieved by solubilizing the fusion protein in the mild 
detergent sarcosyl, which proved to be compatible with enzymatic activity of the TEV protease 
used to cleave the peptide from the fusion protein. 
Studies on the structure and dynamics of the peptides using NMR revealed that they are all 
completely disordered in aqueous buffer. In the presence of phospholipid micelles, segments of 
most receptor N termini became conformationally stabilized, with the exception of N-Y2, which 
remained unstructured. Otherwise, more (N-Y4) or less stable (N-Y1 or N-Y5) helical segments 
occurred within the sequences. For all N-terminal peptides chemical shift changes occurred 
between spectra recorded in presence and absence of DPC micelles, except for N-Y2. This 
implies that all other peptides associate with the micelle to some extent. Previously, we have 
made extensive use of the thermodynamic data of Wimley and White for partitioning of single 
amino acids into the water-membrane interface or the membrane interior39 to rationalize how 
peptides interact with phospholipids micelles. A common observation was that the occurrence of 
the aromatic residues Trp and Tyr help in anchoring peptides in the interface40. The partitioning 
values of the four sequences of the N-terminal domains from the Y receptor subtypes are shown 
in appendix F. In N-Y4 a stretch comprising residues 5 to 11 is predicted to show partitioning 
into the micelle interior. This corresponds exactly to the region that becomes helically structured 
in the presence of micelles. In case of N-Y2 many negatively charges residues occur throughout 
the sequence, while they are clustered in the central (unstructured) segment in N-Y4. Even more 
importantly, many Pro residues are present in N-Y2 that might prevent formation of secondary 
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structure. The sequence of N-Y5 in comparison to N-Y2 is much more amphiphilic in nature, 
and therefore more likely to favorably interact with the micelles. Again, the regions that become 
better structured in the presence of DPC micelles correspond to stretches rich in 
hydrophobic/aromatic residues and hence are predicted to partition into the micelles. The fact 
that the N-termini of the Y receptors are largely unstructured is compatible with present 
structural knowledge derived from crystal structures of family 1 GPCRs2-5,41,42. In these the N-
termini are rather flexible. However, a short two-stranded antiparallel !-sheet complementing the 
!-sheet formed by residues of the long e2 loop is encountered in bovine rhodopsin2, whereas a 
very short helix is present in squid rhodopsin5. In both !-adrenergic receptors, the N-terminal 
portions are not defined in the crystal structures4,42. 
Our interaction studies using chemical shift mapping indicated that bPP strongly interacts with 
all N-terminal domains, but differences in the sensitivity of certain positions are observed. In 
contrast, for pPYY or NPY the changes are smaller, and tertiary structure is lost when pPYY 
associates with the membrane surface. Transient binding of PYY to any of the N-terminal 
domains is expected to alter the equilibrium between membrane-associated peptide, which is 
devoid of tertiary structure, and the membrane-detached peptide, that could possibly re-adopt its 
PP fold. In our BiaCore measurements we could detect strongest binding (Kd approx. 50 µM) for 
the bPP-NY4 interaction, and chemical shift mapping also revealed the largest changes for bPP 
upon addition of N-Y4. The fact that the interaction between bPP and N-Y4 is much stronger 
(Kd 50 µM) than for any other combination of neurohormone and N-terminal domain could 
indicate that this contact additionally contributes to binding in the pocket, and may help to 
explain why binding of PP to the Y4 receptor is much tighter than binding of PP to the other 
subtypes, or stronger than binding of NPY or PYY to all Y receptors. Otherwise we generally see 
a rather weak non-specific electrostatic interaction. Whether these interactions are strong enough 
to really help promoting the membrane-bound peptides into the receptor-binding pocket is 
unclear based on these data. It however is unlikely, that they really significantly contribute to 
binding in the genuine binding pocket. Very recently, Beck-Sickinger et al. investigated mutants 
of the Y receptor, in which the N-termini were truncated43. Their data indicate little loss of 
binding affinity and signal transduction in the truncated mutants except for the Y2 receptor. 
Whether these observations indicate that diffusion of the ligand from the membrane-bond state 
into the receptor-binding pocket may proceed via different, alternative pathways will need to be 
subject to further studies. 
To summarize this work has described synthetic methods to produce all N-terminal domains in 
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isotopically labeled form in quantities sufficient for the analysis by various biophysical methods. 
Structural studies revealed them to be fairly flexible. However, although N-Y2 is fully unfolded, 
residual helical structures were detected in N-Y1 and N-Y5. For the case of N-Y4 we could 
previously detect a short rather rigid "-helical stretch in the presence of DPC micelles. In 
contrast to N-Y4, the nascent helical regions of N-Y1 and N-Y5 contain too much residual 
motion, so that structure calculations did not fully converge towards "-helical structures. All 
peptides interact with the N-terminal domains of N-Y1, N-Y2 and N-Y5, but the interactions are 
weaker than those previously described for bPP binding to N-Y4. 
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6 Appendix 
 
In tables A-D chemical shifts were referenced to the water line taken at 4.63 ppm at 310K. The 
15
N scale was derived indirectly by multiplying the frequency of 0 ppm for protons (the Bruker 
parameter SF) by 0.101329118. Chemical shifts have been deposited in the BMRB data base 
under deposition codes 80.8933262 (N-Y1), 80.6873033 (N-Y2) and 80.74817093 (N-5). 
 
A - Chemical Shifts of N-Y1 in the presence of DPC micelles 
 
 H
N
 H'" H! others 
Met 1 - - -, - )CH2 -, -; *CH3 - 
Asn 2 - - -, - %NH2 -, - 
Ser 3 8.52 4.42 -, - )OH - 
Thr 4 8.32 4.28 4.01 )CH3 1.17; )OH - 
Leu 5 8.23 4.03 1.86, 1.86 )H 1.17; %CH3 0.79, 0.72 
Phe 6 7.97 4.46 2.96, 3.18 %H 7.19; *H -, - ; +H - 
Ser 7 8.02 4.31 3.86, 3.86 )OH - 
Gln 8 8.25 4.28 2.04, 2.04 )CH2 2.33; *NH2 7.44 
Val 9 7.90 3.94 2.05 )CH3 0.88 
Glu 10 8.26 4.09 1.85, 1.88 )CH2 2.33; *H - 
Asn 11 8.29 4.51 2.69, 2.69 %NH2 7.58, 6.86 
His 12 8.32 4.57 3.05, 3.19 %1NH -; %2H 7.09; *1H -; *2NH - 
Ser 13 8.18 4.40 3.79, 3.79 )OH - 
Val 14 8.15 4.00 2.01 )CH3 0.81 
His 15 8.30 4.61 3.09, 3.09 %1NH -; %2H 7.05; *1H -; *2NH - 
Ser 16 8.22 4.62 3.77, 3.80 )OH - 
Asn 17 8.17 4.19 2.63, 2.63 %NH2 7.50, 6.81 
Phe 18 8.22 4.50 2.99, 3.10 %H 7.17; *H 7.25; +H - 
Ser 19 8.17 4.29 3.79, 3.79 )OH - 
Glu 20 8.38 4.14 1.96, 1.96 )CH2 2.22; *H - 
Lys 21 8.15 4.18 1.71, 1.71 )CH2 1.37; %CH2 1.94, 2.02; *CH2 2.74; +NH3
+ - 
Asn 22 8.13 4.57 2.68, 2.68 %NH2 7.49, 6.81 
Ala 23 8.13 4.11 1.36  
Gln 24 8.13 4.15 2.02, 2.02 )CH2 2.31; *NH2 7.49 
Leu 25 8.01 4.16 1.64, 1.64 )H 1.54; %CH3 0.88, 0.81 
Leu 26 7.83 4.17 1.57, 1.57 )H 1.46; %CH3 0.83, 0.79 
Ala 27 7.74 4.19 1.23  
Phe 28 7.97 4.55 3.13, 3.13 %H 7.20; *H 7.04 ; +H - 
Glu 29 8.33 4.20 1.87, 1.87 )CH2 2.18; *H - 
Asn 30 8.30 4.62 2.78, 2.78 %NH2 7.58, 6.86 
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Asp 31 8.19 4.50 2.58, 2.58 %H - 
Asp 32 8.07 4.29 2.78, 2.78 %H - 
Cys 33 8.29 4.75 2.59, 2.65 )SH - 
His 34 8.36 4.66 3.09, 3.09 %1NH -; %2H 7.13; *1H -; *2NH - 
Leu 35 8.32 4.51 1.62, 1.62 )H 1.44; %CH3 0.86 
Pro 36  4.44 1.91, 1.96 )CH2 2.19,2.22 ; %CH2 3.78, 3.83 
Leu 37 8.05 4.18 1.57, 1.57 )H -; %CH3 0.87, 0.81 
Ala 38 8.18 4.27 1.32  
Met 39 8.22 4.38  2.06 )CH2 2.55, 2.66; *CH3 1.96 
Ile 40 7.38 4.01 1.79 )CH2 1.09, 1.37;  %CH3 0.82 
 
B - Amide proton and 
15
N chemical shifts of N-Y1 
 N H
N
   N H
N
 
Met 1      Lys 21 120.03 8.16
Asn 2      Asn 22 118.11 8.13
Ser 3 116.26 8.52 Ala 23 123.09 8.16
Thr 4 116.44 8.36 Gln 24 117.35 8.13
Leu 5 122.70 8.27 Leu 25 120.96 8.03
Phe 6 115.80 7.99 Leu 26 118.60 7.84
Ser 7 114.84 8.04 Ala 27 122.05 7.74
Gln 8 120.60 8.25 Phe 28 117.83 7.98
Val 9 118.80 7.90 Glu 29 120.35 8.34
Glu 10 122.35 8.27 Asn 30 118.61 8.31
Asn 11 118.23 8.29 Asp 31 120.03 8.31
His 12 119.81 8.26 Asp 32 118.07 8.08
Ser 13 115.76 8.24 Cys 33 120.08 8.47
Val 14 120.68 8.18 His 34 119.74 8.39
His 15 120.62 8.38 Leu 35 122.68 8.39
Ser 16 116.22 8.20 Pro 36     
Asn 17 119.23 8.20 Leu 37 120.63 8.05
Phe 18      Ala 38 122.21 8.20
Ser 19 115.90 8.21 Met 39 118.15 8.23
Glu 20 122.30 8.41 Ile 40 122.86 7.38
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C – Amide proton and 
15
N chemical shifts of N-Y2 
 
 N H
N
       N H
N
 
Met 1    Thr 26 114.7 8.08 
Gly 2 112.1 8.59  Thr 27 118.5 8.09 
Pro 3    Pro 28   
Ile 4 120.1 8.16  Arg 29 121.0 8.33 
Gly 5 112.9 8.42  Gly 30 109.4 8.28 
Ala 6 123.6 8.07  Glu 31 119.9 8.15 
Glu 7 119.4 8.39  Leu 32 122.8 8.19 
Ala 8 123.9 8.14  Val 33 122.6 8.04 
Asp 9 119.1 8.12  Pro 34   
Glu 10 120.9 8.30  Asp 35 121.3 8.23 
Asn 11 118.7 8.37  Pro 36   
Gln 12 120.3 8.15  Glu 37 121.8 8.30 
Thr 13 115.7 8.15  Pro 38   
Val 14 122.2 8.09  Glu 39 120.1 8.37 
Glu 15 123.8 8.33  Leu 40 123.3 8.18 
Glu 16 121.5 8.26  Ile 41 121.2 7.98 
Met 17 121.1 8.22  Asp 42 123.9 8.26 
Lys 18 122.8 8.18  Ser 43 117.8 8.36 
Val 19 121.0 8.02  Thr 44 114.9 8.21 
Glu 20 123.9 8.37  Lys 45 122.2 7.83 
Gln 21 120.6 8.15  Leu 46 122.2 7.92 
Tyr 22 120.4 8.12  Ile 47 120.2 7.83 
Gly 23 109.8 8.06  Glu 48 124.4 8.26 
Pro 24    Val 49 121.4 8.06 
Gln 25 119.8 8.49  Gln 50 128.5 7.89 
 
 
D – Amide proton and 
15
N chemical shifts of N-Y5 
 
 N H
N
   N H
N
 
Met 1    Asn 27 120.23 8.43 
Ser 2    Asn 28 119.29 8.35 
Phe 3 118.81 7.84  Thr 29 114.05 8.05 
Tyr 4 118.03 7.63  Ala 30 125.61 8.17 
Ser 5 115.85 8.10  Ala 31 122.26 8.07 
Lys 6 122.27 8.25  Thr 32 112.43 7.92 
Gln 7 119.04 8.18  Arg 33 122.34 8.32 
Asp 8 119.37 8.03  Asn 34 119.25 8.36 
Tyr 9 120.84 8.43  Ser 35 115.51 8.17 
Asn 10 119.60 8.25  Asp 36 121.69 8.26 
Met 11 120.23 8.22  Phe 37 120.00 8.11 
Asp 12 120.96 8.38  Pro 38   
Leu 13 121.09 7.90  Val 39 117.15 8.04 
Glu 14 120.56 8.39  Trp 40 122.72 8.12 
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Leu 15 121.51 8.39  Asp 41 118.58 8.12 
Asp 16 118.01 8.47  Asp 42 118.49 7.95 
Glu 17 118.35 8.04  Tyr 43 119.01 7.82 
Tyr 18 117.72 7.86  Lys 44 121.02 7.75 
Tyr 19 118.50 8.10  Ser 45 115.33 8.12 
Asn 20 117.52 8.21  Ser 46 117.18 8.06 
Lys 21 118.77 7.90  Val 47 118.82 7.84 
Thr 22 113.27 7.80  Asp 48 122.02 8.04 
Leu 23 121.69 7.83  Asp 49 119.12 8.03 
Ala 24 122.63 7.76  Leu 50 121.18 7.90 
Thr 25 112.49 7.92  Gln 51 124.45 7.67 
Glu 26 122.74 8.19  
   
 
 
E - Expansion of the 70 ms NOESY of N-Y1, displaying the assignment of residues 24 to 31: 
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F - Free energies for partitioning residues of the Y receptor N-terminals (top left: N-Y1, top 
right: N-Y2, bottom left: N-Y4 and bottom right: N-Y5) domains into the water-membrane 
interface (circles) or into the membrane interior (diamonds) (data taken from Wimley, Nat 
Struct Biol, 3, 842-848, 1996). Regions of favorable values are shaded in gray.  
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G - Expression and purification of YUH: 
Yeast ubiquitin hydrolase (YUH) was expressed with a C-terminal hexahistidine tag and 
purified on a Ni-NTA column. The plasmid coding for the YUH-construct pYUHK20b was a 
generous gift from Toshiyuki Kohno (Mitsubishi Kasei Institute of Life Science, Tokyo, 
Japan). 
5 ml of LB-broth containing 50 µg/ml kanamycin were inoculated with a colony of BL21 
DE3 pYUHK20b cells, streaked onto plate from a glycerol stock, and incubated for 12 h at 
37 ˚C and 220 rpm. 0.5 liter of LB-broth containing 50 µg/ml kanamycin were inoculated 
with the 5 ml overnight culture and incubated at 37 ˚C and 240 rpm in a 2 l Erlenmeyer flask. 
The culture was induced with 0.4 mM IPTG at an OD600 of 0.6-0.7 and grown for another 5 h 
to a final OD600 of around 5. The culture was harvested by centrifugation at 5000 rpm and 4 
˚C for 20 min. 7 g of wet biomass were obtained from 1 l of culture. The cell pellet was 
frozen at -20 ˚C. 
The cell pellet was thawed on ice and resuspended in 40 ml resuspension buffer (50 mM 
Tris pH 8, 100 mM NaCl, 1 mM !-mercaptoethanol). 9 mg of lysozyme were added and the 
mixture incubated on ice for 15 min. The resuspension mixture was sonicated on ice with a 
Branson Digital Sonifier.  
The lysate was centrifuged twice at 190000 rpm and 4 ˚C for 45 min and loaded onto a 10 
ml column volume (CV) Ni-NTA-agarose column previously equilibrated with running 
buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM !-mercaptoethanol, 10 mM imidazole). 
Bound protein was eluted with elution buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM !-
mercaptoethanol, 100 mM imidazole). The eluate was confirmed to contain the target protein 
by SDS-PAGE. To 10 ml of eluate 1.1 ml of glycerol were added to yield a final glycerol 
concentration of 10%. The YUH-concentration of this mixture was determined by a Bradford 
assay to be 7 mg/ml. This solution was stored at -20 °C in 1 ml aliquots. 
H - Expression and purification of TEV protease: 
The plasmid pTH241 was transformed to Rosetta(DE3) pLys cells. 0.5 ml of an overnight LB 
culture containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol were used to 
inoculate 1 liter of TB also containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol. 
The culture was incubated at 37 °C. When it reached an OD600 of 0.6 it was induced with 0.1 
mM IPTG and the temperature was lowered to 20 °C. After 20 hours the cells were harvested 
by centrifugation and the cell pellet was stored at –20 °C. 
The cell pellet from 1 liter culture was resuspended in 40 ml washing buffer (50 mM 
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sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 7). The resuspension mixture was 
sonicated on ice with a Branson Digital Sonifier. After centrifugation at 4 °C at 30000 g for 
30 min the supernatant was loaded onto a Ni-NTA column. Unbound protein was eluted with 
washing buffer and bound protein was eluted with elution buffer (washing buffer with 200 
mM imidazole). EDTA and DTT were added to a final concentration of 2 and 10 mM, 
respectively. 10 ml eluate were dialyzed over night against 1 liter dialysis buffer (25 mM 
sodium phosphate, 200 mM NaCl, 2 mM EDTA, 2 mM DTT, pH 8) at 4 °C. 10% glycerol 
were added and the protease solution was stored at –20 °C. 
1) Susanne van den Berg, Per-Ake Lofdahl, Torleif Hard, Helena Berglund, Improved 
solubility of TEV protease by directed evolution,  2006, J. Biotechnol., 121, 291-298. 
 
 
I - Titration of N-Y2 with 0.5 (yellow), 1 (orange), 2 (red), 4 (purple), and 10 (blue) equiv. of 
pNPY. 
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K - Chemical shift-mapping data for all neurohormones with N-Y1 (orange), N-Y2 (blue), 
and N-Y5 (green). 
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L - HPLC traces and MALDI-MS analyses of N-Y1, N-Y2, and N-Y5. The HPLC peaks 
corresponding to the peptides of interest are shaded in red. 
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Chapter III: Grafting of extracellular loops of Y-receptors onto 
a soluble !-barrel scaffold 
 
 
Abstract 
 
In this chapter I present the attempt at creating a small, soluble model system that is capable of 
mimicking ligand-binding functions of large, membrane-embedded receptors. These receptors function 
in a modular way, in which a certain part of the molecule is responsible for a specific task. In our case 
one part is responsible for ligand binding, whereas other parts are involved in the signal transduction 
process or allosteric regulation, for instance. The full receptors are large and difficult to characterize 
structurally, but one can resort to studying confirmed or hypothesized modules thereof. I am trying to 
develop such an approach for studying one of the most important classes of cell surface receptors, the 
so-called G-protein coupled receptors (GPCRs). Cell surface receptors commonly are thought of 
consisting of three distinct modules or “domains”: an extracellular, a transmembrane and an 
intracellular domain. We intend to study the extracellular part of a GPCR, which is responsible for 
binding the receptor's cognate ligand, by grafting it onto a stable supporting molecule, a so-called 
“scaffold”. The resulting minireceptor should be easier to produce and characterize spectroscopically. 
GPCRs are of enormous clinical importance1 and the availability of a suitable model for such receptors 
will be a valuable tool for the assessment of novel potential GPCR binding molecules. 
 
 
 
1. Introduction 
 
1.1 A new approach to structural information on membrane proteins 
 
G-protein coupled receptors (GPCRs) are a class of membrane embedded proteins, spanning the 
hydrophobic membrane interior with seven transmembrane (TM) helices, connected by both three 
intracellular and extracellular loops2. GPCRs are of enormous clinical importance1, and as long as no 
straight forward approaches to the three-dimensional structures of these molecules exist, the 
availability of models for such receptors will continue to be a valuable tool for the investigations of 
many different GPCRs. One sub-class of the GPCRs is believed to interact with their cognate ligands 
mainly through its surface exposed extracellular parts. Our work is inspired by the idea, that these 
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extracellular parts could be studied separately, i.e. in absence of the hydrophobic transmembrane 
helices, responsible for most of the problems arising in the work with GPCRs. Several approaches to 
realizing this idea have been formulated. The route we are following can be called “grafting approach” 
and can be briefly summarized as follows: If a small, soluble protein exists, which possesses a core 
determining its global fold and some surface exposed loops unimportant to that fold (i.e. a so-called 
“scaffold” protein), the external parts of a GPCR could be transferred to that stable core domain, 
without disturbing the overall global fold of the scaffold. The resulting chimeric protein could then be 
considered as a “minireceptor”, because it carries all the parts of the receptor hypothesized to be 
important for ligand binding (hence the term “receptor”), but at the same time shows the favorable 
characteristics of small, soluble proteins (hence the term “mini”). This idea is exemplified in figure 1. 
 
 
 
 
Figure 1: Left: Structure of the prototypical GPCR bovine rhodopsin with extracellular loops and 
N-terminus color-coded in red and green, respectively. Right: Structure of a bacterial soluble !-
barrel protein, which is suggested to be a suitable scaffold protein, with similar color-coding of 
loops and N-terminus. 
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1.2 Scaffold molecules in nature and their use in synthetic protein chemistry 
 
The advent of elaborate nucleotide synthesis and PCR schemes and highly efficient cloning techniques 
made it theoretically possible to produce large numbers of randomized derivatives of any given starting 
sequence. The theoretical number of different sequences of length n that can be composed of the 20 
natural, proteinogenic amino acids rises with n in a factorial way. Therefore, already for relatively short 
sequences a manual expression and purification of each subsequence is practically not feasible. 
Through the invention of the “phage display” technology it became possible to screen large libraries for 
desired properties, thereby preventing the necessity to manually express, purify and test each potential 
candidate protein. The central idea of this technique is to create an as large as possible protein 
“library”, where each protein and the genetic information that codes for it are physically linked. 
Provided an efficient selection strategy is present, one target protein along with its DNA-sequence can 
thus be pulled out of a mixture of billions of different proteins. Most commonly such a selection 
strategy consists of the surface immobilization of a source-protein and screening for target-proteins 
showing affinity to the source. With this technique the size of a “library” is no longer dictated by the 
number of sequences, which can be manually expressed and purified, but by other factors such as the 
transformation efficiency. 
Such libraries of randomized sequences are very useful, and binders to a wide variety of different 
molecules can commonly be selected from one such given library. The mammalian immune system can 
be considered an elaborate in vivo protein library. The concept of generating libraries with structurally 
and functionally related compounds has, however, not evolved in mammals, but evolutionary much 
earlier in the class of the arachnids3. 
In vitro such libraries are generated by the application of randomizing PCR techniques. The bottle-neck 
for the generation of an as large as possible number of randomized sequences is the achievable 
transformation efficiency, i.e. how many colonies one can get from a given amount of randomized 
DNA. Still this renders the randomization of the complete sequence of a typical small protein not 
feasible. However this is also not desired. Instead, it is often more desirable to randomize only short 
surface-exposed sequences. The advantages of this approach are twofold: first, the number of 
theoretically possible variants is much smaller, and second the unchanged sequence can, in some 
instances, be considered to not undergo any structural changes. If the second criterion is fulfilled by a 
protein one speaks of it as a “scaffold”. Such a scaffold is for instance formed in the immune system by 
the constant regions within the immunoglobulins or in the above mentioned arachnid peptide toxins by 
unchanged cysteine residues, which by forming intramolecular disulfide bond patterns, determine the 
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global fold of the peptides3. 
From the above-mentioned one can define certain characteristic features that a protein, which could 
possibly act as a scaffold, should present. First and foremost such a candidate scaffold should show 
high sequence diversity in conjunction with a conserved tertiary fold. In other words it should have 
been evolved by nature to be tolerant to changes in its amino acid sequence without losing its overall 
folding pattern. Additionally the protein family to which the potential scaffold belongs should possess a 
well-defined and structurally conserved hydrophobic core and a solvent accessible binding pocket, 
which is spatially and structurally well separated from the scaffold core. Ideally a potential scaffold 
candidate should already show diverse biochemical function among its family members. In other words 
nature should already have proven, that it can recognize ligands of great diversity. 
 
 
1.3 Lipocalins as a scaffold 
 
One protein family, which meets these requirements are the lipocalins. Lipocalins are a class of soluble 
!-barrel proteins, first described in 19854. They are typically small (15-20 kDa), secreted proteins 
which often show the ability to bind small hydrophobic molecules5-7. The lipocalin fold is very well 
conserved and characterized by a short N-terminal 310-helix followed by an eight-stranded !-barrel and 
a C-terminal "-helix. The eight !-strands of the barrel (commonly referred to as strands A to H) are 
linked by short !-hairpin loops, except for the first loop (L1), which forms a large #-loop7. 
The lipocalin family possesses a well-conserved (hydrophobic) core, while the loop regions show more 
structural diversity8,9. Furthermore, many members of the lipocalin family possess a solvent-accessible 
site for the recognition of their ligand10, which is spatially well separated from the core. Finally, the 
ligands recognized by lipocalins are of remarkable diversity5. Hence, they meet all of the above-
mentioned requirements to be of use as scaffold molecules. Indeed lipocalins have been used 
successfully as scaffolds in numerous cases8,11-13 and concomitantly robust expression and purification 
strategies for these proteins have been established. Under these premises we have selected the bacterial 
lipocalin Blc as our scaffold for the following reasons: 
• the crystal structure of that protein has recently been solved10, which enables rational 
replacements of its loops with the desired GPCR extracellular loops 
• it carries three loops located on one and four on the other face of the barrel and thereby allows 
to introduce all three GPCR extracellular loops simultaneously; additionally the N-terminus of 
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Blc is mainly in an extended conformation and spans across both faces of the barrel, which 
allows the incorporation of the receptor N-terminus on either face of the barrel by attaching it 
an a suitable position within the extended Blc N-terminal sequence 
• its sequence has been modified in order to allow for the expression as a monomeric, soluble 
protein in E. coli, yielding a protein in the molecular weight range amenable to high-resolution 
NMR without requiring expensive deuterium-labeling  
• both periplasmic and cytoplasmic expression systems have been devised, so that disulfide bonds 
linking the loops or potential attachment points for reporter groups, such as spin labels, may be 
introduced 
• it uses the Strep-tag II14 technology for protein purification, which enables efficient purification 
and offers the possibility of immobilizing the protein on a streptavidin-coated surface for 
binding studies using SPR technology 
 
It is commonly believed that the architecture of the helical bundle from different GPCRs is similar15, 
and hence we extracted distances and relative orientations of the anchoring points (i.e. those points in 
the sequence, where the loops are anchored to the 7TM or the !-barrel scaffold) of all known GPCR 
structures and compared them to our designated scaffold Blc as shown in figure 2. Therein, !2-
adrenergic receptor anchoring points are depicted in blue and are represented by the C" atom closest to 
the extracellular membrane surface. The extracellular loops are schematically depicted as the arrows 
connecting two such anchoring points. Likewise the Blc anchoring points are represented in yellow. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Drawing displaying the relative orientations of loop-anchoring C" 
atoms in the human !2-adrenergic receptor (!2-AR; left) and Blc (right). 
Each anchoring point is labeled with the number of the transmembrane "-
helix (!2-AR) or !-strand (Blc) to which it corresponds (roman numbers). 
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From the comparison of the distances between the hypothesized anchoring points of the Y-receptors 
and the confirmed anchoring points for the Blc scaffold, it is obvious that they do not match exactly. 
Therefore, it is to be expected that any grafted loops will probably require the simultaneous co-transfer 
of some flexible linker residues in order to relieve structural constraints, which would be imposed on 
the loops from the scaffold otherwise. Glycine- and serine-glycine-rich repeats have been found to be 
suitable linkers in studies having encountered similar such problems previously. However, the figure 
also reveals, that the relative orientation of the loop anchor points corresponds rather well between the 
model GPCR rhodopsin and our target scaffold Blc. Considering that it is unclear, whether loops of the 
Y-receptors are well-structured at all, and taken into account that i) Boivin et al.16 could detect 
interactions described by Kds as low as 1.4•10
-6M between immobilized biotinylated peptides 
corresponding to the second extracellular loop (ECL2) of the urotensin receptor and its natural ligands 
and ii) the fact that we could demonstrate binding of the peptides to the free N-terminal domain, and 
iii) the possibility to from a disulfide bond between the 1st and 2nd loop to further restrain the system in 
a correct manner indicates, that a system capable of tight binding to the neurohormones may be 
successfully designed. 
 
 
1.4 Structural characterization of the lipocalins 
 
Lipocalins have a very conserved characteristic fold. Its core is an eight-stranded !-barrel. N-terminally 
the barrel is preceded by a short 310-helix and C-terminally it is followed by a regular "-helix
6,17. The 
secondary structure and its characteristic packing are depicted schematically in figure 3. 
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The bacterial lipocalin for which the crystal 
structure was determined10 also shows the 
above depicted core secondary structure. 
Additionally it carries a short two-stranded !-
sheet at its N-terminus. The residues of the 
N-terminal !-strand, however, are an artifact 
from the chosen cloning strategy. The 
relevance to the overall structure of Blc of 
this !-sheet is thus disputable. The secondary 
structural elements mapped onto the amino 
acid sequence of the construct used in the 
crystallographic study are shown in figure 4. 
Additionally this figure shows a sequence 
comparison between the construct used in the 
crystallographic study, the wt-Blc and the 
sequence of our construct. Our construct 
lacks the first 19 residues of the construct 
used in the crystal structure study and carries 
an additional 9 residues at the C-terminus, 
which serve as an affinity tag, but is almost 
identical otherwise. Most notably the single cysteine residue present at position 131 in the crystal 
structure is replaced by a serine (figure 4). 
 
Figure 3: The extended secondary structure elements 
of a typical lipocalin are shown in an extended 
representation in the upper picture, while their 
schematic packing against each other is shown in the 
lower picture. Green arrows represent the !-strands, 
while the yellow ellipsoid and the yellow rectangle 
represent the N-terminal 310-helix and the C-terminal 
"-helix, respectively. 
 148
 
Figure 4: I) Crystal structure of Blc (1QWD.pdb) with !-strands of the barrel colored in green, N-
terminal 310- and C-terminal "-helix colored yellow and short antiparallel !-sheet in the N-terminus 
colored red. II) The extended secondary structure elements of Blc according to the crystal structure. 
Color-coding as in I). III) Shows a sequence alignment produced with CLUSTALW of the wildtype Blc 
sequence as deposited in the SwissProt database (P0A901 BLC_ECOLI), the sequence of the X-ray 
crystal construct (BLC_X-RAY) and the Blc construct used by us (BLC_pBlc3). 
 
1.5 The receptors of the NPY-family neuropeptides: The Y-receptors 
Our group has studied a wide variety of neurohormones of the neuropeptide Y (NPY) family using 
high-resolution NMR18-21 and has proposed a model for the binding of these hormones to their cognate 
receptors that includes membrane-association as an initial step20. Structural and mechanistic insight 
into such binding processes is anticipated to provide a basis both for the rational design of novel, and 
the improvement of already existing receptor-agonists and antagonists. Because of the detailed studies 
that have been conducted in our group on the above mentioned neurohormones and the detailed 
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biophysical and biochemical characterization in other groups22-25, the receptors for the NPY-family 
neuropeptides are called Y-receptors and have been chosen as a model system for the investigation of 
ligand binding to GPCRs. 
The neuropeptides exert their effects via several receptor subtypes called Y-receptors. Four main 
receptors, named Y1-26-28, Y2-29, Y4-30,31 and Y5-32, have been cloned so far. All identified Y-receptors 
act via pertussis toxin-sensitive G proteins of the Gi family. They range in size from 375 to 455 
residues and show the prototypical characteristics of GPCRs of subfamily 1b. The different receptor 
subtypes are localized in various tissues, both in the central nervous system and in the periphery. NPY 
and peptide YY (PYY) bind equally well to the receptors Y1, Y2, and Y5 (nanomolar to sub-
nanomolar dissociation constants). Only the pancreatic polypeptide (PP) shows selectivity towards the 
Y4-receptor (picomolar dissociation constant). The ability of NPY and PYY to bind to three different 
receptor subtypes may be related to their conformational flexibility, which enables the peptides to 
adopt more than one energetically favorable conformation. 
The table below gives a summary about the most important data concerning the four major Y-
receptors: 
Sequence comparison shows, that among these four receptors, the Y1 and Y4 are the most closely 
related (42% sequence homology) while Y2 and Y5 are equally distant from each other and from the 
Y1/Y4 pair33,34. These relationships are also reflected when the predicted soluble N-termini of the four 
receptors are compared, as is shown in the sequence alignments below. 
Receptor Y1 Y2 Y4 Y5
amino acids 384 381 375 455
related action
Ki NPY [nM]  0.81a  0.02a  1.9a  0.19a
Ki PYY [nM]  1.1a  0.01a  1.1a  0.06a
Ki PP [nM]  >100a, b  >1000a, b  0.04a, b  27a, b
major 
occurrence
peripheryc, 
hypothalamusd CNSe, f, g intestine, pancreash hypothalamusi
vasoconstriction, 
anxiolysisc, d, j
memory, epilepsy, 
secretionck, l
gastro-intestinal 
regulationm food intakei
Table 1: Biochemical, biophysical and physiological characteristics of the four major families of the Y-
receptors. a) McCrea, Regul. Pept., 87, 47-58, 2000; b) Small, Proc. Natl. Acad. Sci. U S A, 94, 11686-
91, 1997; c) Wahlestedt, Med. Biol., 64, 85-8, 1986; d) Wahlestedt, Science, 259, 528-31, 1993; e) 
Gehlert, Mol. Pharmacol., 49, 224-8, 1996; f) Gerald, J. Biol. Chem., 270, 26758-61, 1995; g) Rose, J. 
Biol. Chem., 270, 22661-4, 1995; h) Lundell, J. Biol. Chem., 270, 29123-8, 1995; i) Gerald, Nature, 
382, 168-71, 1996; j) Grundemar, Br. J. Pharmacol., 105, 45-50, 1992; k) Flood, Peptides, 10, 963-6, 
1989; l) Potter, Regul. Pept., 25, 167-77, 1989; m) Schwartz, Gastroenterology, 85, 1411-25, 1983 
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NPY1R_HUMAN      MN-STLFSQVENHSVHS-NFSEKNAQLLAFENDDCHLPLAMI 40 
NPY4R_HUMAN      MNTSHLLALLLPKSPQGENRSKPLGTPYNFS-EHCQDSVDVM 41 
                 ** * *:: :  :* :. * *:  .   *. :.*: .: :: 
NPY2R_HUMAN      MGPIG-AEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELID-STKLIEVQ 50 
NPY5R_HUMAN      MSFYSKQDYNMDLELDEYYNKTLATENNTAATRNSD-FPVWDDYKSSVDDLQ 51 
                 *.  .  : : :  ::*   :  ..:... .  .*  *  * .:.: ::* 
In several studies the N-termini of Y-receptors have – as typical for GPCRs of the subfamily 1b - been 
shown to be involved in ligand binding35,36. We therefore sought to express the 40 to 50 residue N-
terminal fragments of the four Y-receptors and characterize them by NMR. 
Their ligands, the members of the NPY family, are C-terminally amidated polypeptides comprised of 
36 amino acids. Their postulated role in the regulation of food-uptake37,38 has stirred vigorous research 
in many pharmaceutical companies. Seven positions are absolutely conserved among all species of 
NPY, PYY and PP. These are Pro5, Pro8, Gly9, Ala12, Tyr27, Arg33 and Arg3539 (figure 5). The first 
atomic resolution structure of a member of the NPY family was obtained for avian PP (aPP) by X-ray 
crystallography40 and later for bovine PP (bPP) in solution by NMR41. Residues 1 to 8 form a type-II 
polyproline helix, which is followed by a type-I !-turn connecting to residues 15 to 32, which form an 
"-helix, and the four most carboxy-terminal residues are in a flexible loop conformation (figure 5). A 
surprisingly stable helical hairpin is formed by backfolding of the polyproline helix onto the "-helix. 
This structural motif is commonly referred to as the PP-fold. The tertiary contacts, which stabilize this 
fold are formed by interdigitation of the conserved proline residues in position 2, 5, and 8 on the 
polyproline helix and the tyrosines 20 and 27 on the "-helix42. The solution structure of PYY in 
aqueous solution was shown to be highly similar21,43. Surprisingly, in the highly homologous NPY the 
backfolding is absent44 (figure 5). All three members of the NPY family have also been characterized 
in presence of dodecylphosphocholine (DPC) micelles mimicking a biological membrane (figure 5). 
Whereas in aqueous solution PYY and PP are structurally similar, in the presence of micelles PYY21 
and NPY45 adopt a similar conformation, with PP taking an alternative conformation19. It was found 
that pNPY and pPYY interact via the hydrophobic face of their C-terminal "-helix with the micelle, 
while the N-terminus freely diffuses in solution. bPP also interacts with the micelle via its C-terminal 
"-helix, but the N-terminus is also loosely associated with the micelle surface. It has been proposed, 
that this association is mediated by Tyr7 in bPP21, which has a favorable free energy of transport into 
the water-membrane interface46, in contrast to the Asn7 and Ala7 found in pNPY and pPYY, 
respectively. In addition also the C-terminal pentapeptide, which contains particularly important 
residues for receptor binding23, differs structurally in bPP from the pNPY/pPYY pair21. 
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Little is known about the structure of any of the Y-receptor subtypes, nor have high-resolution 
experimental data on the complex formed between these and the neurohormones been published. 
Nevertheless, in many photoaffinity-labeling studies the contact points between receptors and their 
ligands have been assigned to the extacellular face of the GPCR. In case of human NPY at the human 
Y1-receptor Walker et al. have postulated a prominent role for Asp residues of the Y1-receptor in the 
ligand binding process25. In particular, an Asp residue at the interface between the 6th TM domain and 
the third extracellular loop is conserved in all known Y-receptor sequences. Other potential sites of 
interaction were postulated to reside within the N-terminal domain and the first extracellular loop24. 
Figure 5: Neurohormones of the NPY family. Top: Sequence comparison of porcine NPY (pNPY) 
and PYY (pPYY) with bovine PP (bPP). Residues, which are conserved among all three 
neurohormones throughout all species, are colored red. Bottom: Threedimensional structures of 
pNPY, pPYY, and bPP in water and in DPC micelles. In the structures of pPYY and bPP in water, 
the interdigitating Pro and Tyr residues are colored red and blue, respectively. 
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2. Results 
 
2.1 Expression of N-terminal domains in isotopically labeled form 
 
2.1.1 Expression and purification of NY2R 
We first sought to find out, if some structural entities in the Y-receptors exist, which show some basic 
affinity towards the neuropeptides, even when removed from their natural context of the 7TM Y-
receptor. To this end we produced the N-terminal fragment of the Y2-receptor (NY2R) both in 
unlabeled and in 15N-labeled form. 
Isotope labeling of the investigated peptides was required for the study of backbone dynamics using 
15N relaxation and for chemical shift mapping experiments for the study of macromolecular 
interactions. Such labeling precludes the usage of peptides produced from solid phase synthesis and 
necessitates recombinant production. For reasons of simplicity E. coli is generally the preferred 
expression host. To avoid rapid degradation in E. coli, the peptide needs to be linked to a (more) stable 
fusion partner. Specific cleavage from the fusion partner can be accomplished for systems for which a 
specific hydrolase (e.g. a ubiquitin hydrolase, TEV hydrolase) is available or by introducing a unique 
cleavage site, either a protease-sensitive site or a site prone to chemical cleavage, for example by 
CNBr47 or hydroxylamine48. In our case CNBr cleavage was incompatible with the presence of Met 
residues in the NY2R sequence, and poor efficiency was observed with hydroxylamine. Therefore 
enzymatic cleavage had to be used. 
Since the Y2-receptor N-terminal fragment should be reasonably water-soluble, we initially decided to 
express it as a C-terminal fusion to N-terminally decahistidine-tagged yeast ubiquitin. After 
purification of the fusion construct by Ni-affinity chromatography, the desired peptide was liberated 
through treatment with yeast ubiquitin hydrolase (YUH). This system allowed the recovery of about 6 
mg of 15N-labeled NY2R from 1 L of culture. In figure 6 the purification procedure from 
overexpression of the fusion construct in E. coli to the final, purified NY2R is shown. 
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The N-termini of the other three Y-receptors were produced by other members in our group as reported 
in Zou et al.49 and in chapter 1 of this thesis. A comparison between the N-terminal sequences of the 
four Y-receptors is shown in figure 7. It can be seen that the NY1R and the NY4R and the NY2R and 
NY5R share pair wise similarity among each other. 
 
2.1.2 Structural characterization of NY2R by NMR and interaction studies with neurohormones 
From preliminary shift mapping experiments it was clear that the neuropeptides and the NY2R 
interacted in a specific manner with each other. This was mainly evident for NPY from two 
Figure 6: Left: Schematic representation of the ubiquitin fusion system for the recombinant 
production of NY2R. Right: SDS-PAGE of the expression, purification and cleavage of the 
ubiquitin-NY2R fusion construct. Lane 1: molecular weight marker; lane 2: cells expressing 
ubiquitin-NY2R before induction; lane 3: cells expressing ubiquitin-NY2R after induction; lane 4: 
ubiquitin-NY2R after purification by Ni-NTA chromatography; lane 5: cleavage reaction mix at the 
beginning of the reaction; lane 6: cleavage reaction mix at the end of the reaction. 
Figure 7: Sequence alignments of the human Y-receptor N-terminal domains. 
 154
complementary sets of titration experiments: 
The changes in the 15N-labeled neuropeptide NPY proton-nitrogen correlation spectra ([15N,1H]-
HSQC) upon addition of unlabeled NY2R (U-NY2R) could be attributed to specific residues within the 
sequence of the neuropeptides, because for these the complete sequential assignment was known from 
previous work. A comparison of spectra of all three members of the NPY family before and after 
addition of 2 equivalents of NY2R is shown in figure 8. The observed changes are much more 
prominent in NPY than in PYY and PP. For NPY the most pronounced changes can be observed for 
residues A14, E15, Y21 and H25. 
 
Figure 8: The upper row shows [
15
N,
1
H]-HSQC spectra of 0.2 mM 
15
N-labeled neuropeptides in 20 
mM d13-MES pH 6, 300 mM d38-dodecylphosphocholine (DPC) at 37 °C without (red) and with 2 
equivalents of unlabeled NY2R (U-NY2R) added. The lower row shows the chemical shift changes al 
along the sequence of the respective neuropeptide. 
 
In order to be able to perform the complementary type of analysis for the NY2R upon titration with the 
unlabeled neuropeptides, it was first necessary to assign the resonances of NY2R peptide. Sequence-
specific resonance assignments were obtained using the strategy developed by Wüthrich and 
coworkers50. Due to extensive resonance overlap of the poorly folded peptide 15N-resolved three-
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dimensional TOCSY and NOESY data had to be utilized for this task. Below some resolved spin 
systems from the TOCSY and some inter-residual connectivities from the NOESY are shown. 
 
A table with all the amide proton chemical shifts of NY2R is given in Appendix D. 
This resulted in a complete assignment of the 50 residue peptide. In figure 10 a [15N,1H]-HSQC 
spectrum is shown with the peaks labeled with the corresponding amino acid one letter code and 
number. A table with all the amide proton chemical shifts of NY2R is given in Appendix D. In order to 
test for interaction between NY2R and NPY a titration experiment was carried out. A sample 
containing 0.1 mM 15N-NY2R, 300 mM d38-DPC, 20 mM d13-MES pH 5.5 was prepared. [
15N,1H]-
HSQC spectra of this sample were measured at 37 °C after the addition of 0, 1, 2, 4 and 10 equivalents 
Figure 9: TOCSY strips and NOESY of 0.9 mM NY2R, 300 mM d38-DPC, 20 mM d13-MES pH 5.5, 
10% D2O at 37 °C. On the left five the amide region TOCSY strips of some selected, well resolved 
spin systems are shown. On the left the H
N
-H
"
 region of the NOESY spectrum is shown. The 
connectivity between seven spin systems is highlighted. 
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of unlabeled NPY. A graphical representation of the observed chemical shifts is given in figure 10. The 
most pronounced chemical shift changes are observed for a central and a C-terminal fragment of NY2R 
both rich in negatively charged amino acids. 
Interactions of two peptides in solution should, in principle, not only be evident from chemical shift 
changes, but also through changes in the local dynamics in the two interacting molecules. A way of 
estimating peptide dynamics is the measurement of the heteronuclear 15N{1H}-NOE. This kind of 
Figure 10: Top left: [
15
N,
1
H]-HSQC spectrum of 0.9 mM N-NY2R, 300 mM d38-DPC, 20 mM d13-
MES pH 5.5, 10% D2O at 37 °C. Each peak is assigned as shown by the one letter amino acid code 
and its number in the sequence. Top right: Overlaid [
15
N,
1
H]-HSQC spectra of 0.1 mM 
15
N-NY2R, 
300 mM d38-DPC, 20 mM d13-MES pH 5.5 after the addition of 0 (red), 0.5 (orange), 1 (yellow), 2 
(green), 4 (cyan) and 10 (purple) equivalents of unlabeled NPY. Bottom: Chemical shift changes in 
the spectra of 
15
N-NY2R after the addition of 0.5, 1, 2, 4 and 10 equivalents of unlabeled NPY. 
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measurement was carried out for 15N-NY2R in the absence and in presence of unlabeled NPY. The 
observed values are depicted in figure 11. As mentioned the most prominent chemical shift changes 
were observed for a central (residues 14-22) and a C-terminal (residues 33-50) fragment. This is more 
or less in accordance with the changes observed in the heteronuclear NOE of NY2R upon addition of 
NPY. Even though the changes are small, they are centered roughly around the same two regions. 
 
 
Figure 11: Top: 
15
N{
1
H}-NOE of 0.9 mM N-NY2R in 20 mM d13-MES, 300 mM d38-DPC at 27 °C 
without (blue circles) and with 2 equivalents of unlabeled NPY (red triangles) added. Bottom: 
Difference of the 
15
N{
1
H}-NOE between the sample with and without 2 equivalents of unlabeled 
NPY. 
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As both the chemical shift changes and the heteronuclear NOE changes upon addition of NPY show a 
similar behavior, with two distinctly influenced regions around Met17 and Thr44, the N-terminus of the 
Y2-receptor might be considered a good candidate for the transfer onto our !-barrel scaffold as some 
interaction with the neurohormones seems to be present also outside the context of its natural 7TM 
receptor. The fact, that segments rich in negatively charged residues are displaying the largest 
interactions, and the weakness of the interaction indicates that the N termini display weak electrostatic 
interactions to the neurohormones, a feature that has been investigated in more detail for the PP-NY4 
interaction by Zou et al.51. 
 
 
2.2 Characterization of the soluble scaffold 
2.2.1 Expression and Purification of Blc 
For later grafting experiments it would be beneficial to have the scaffold thoroughly characterized 
spectroscopically possible. Ideally a complete sequential assignment of at least the backbone should be 
present to be able to easily distinguish resonances from grafted sequences from scaffold resonances in 
later experiments. Also, the knowledge about the dynamics of the scaffold molecule might be 
beneficial to choosing good points in the sequence to attach or insert the foreign Y-receptor protein 
sequences. 
We selected the bacterial lipocalin (Blc) as a possible soluble scaffold. This gene has been cloned into 
the pASK-IBA5 and pASK-IBA3 vectors in the group of Prof. Skerra giving us the possibility to 
express the Blc both in the cytoplasm (pBlc5) and in the periplasm (pBlc3). The insert is composed of 
501 bp coding for the 167 residues of Blc plus, in the case of pBlc3 a sequence coding for a bacterial 
leader peptide, which directs the mature protein into the periplasm and is cleaved off after membrane 
translocation by the E. coli signal peptidase I. In our case the leader peptide is the OmpA signal 
peptide52. The periplasmic expression of proteins offers several advantages: (i) the recombinant protein 
can form disulfide bonds (if present) in the oxidative periplasmic space, (ii) it is separated from the 
mostly cytosolic host cell proteases, (iii) the outer membrane of gram-negative bacteria such as E. coli 
can be selectively disrupted under mild conditions without disrupting the cell’s inner membrane, 
avoiding “contamination” of the recombinant protein with cytosolic proteins and (iv) the periplasmic 
space is open for diffusion of solutes up to 600 Da, allowing the addition of folding enhancing 
substances to the culture medium53,54. A disadvantage of periplasmic expression of recombinant 
proteins, however, is that it is often accompanied by aggregate formation. Advantageous to the 
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cytosolic expression of recombinant proteins is the fact that it often results in higher yields. For strong 
overexpression, however, also in the cytosol the formation of insoluble aggregates, so-called “inclusion 
bodies”, is often observed. The yield of correctly folded, soluble protein can in both cases be increased 
by lowering the growth temperature55. This however, comes at the cost of a slower growth rate. 
The pASK-IBA vectors, which are commercially available from IBA (http://www.iba-go.com), are 
derived from the plasmid pASK7556. Their expression cassette is under transcriptional control of the 
tightly regulated tetA promoter/operator and is flanked by XbaI and HindIII restriction sites. The tet 
repressor is encoded on the same vector and is under constitutive expression of the !-lactamase 
promoter. This ensures a tight repression in the absence of inducer14,57,58 and a stoichiometric 
relationship between cellular repressor molecules and the plasmid copy number. The strength of the 
tetA promoter is comparable to the conventionally used lacUV5 promoter. It can be induced by the 
addition of anhydrotetracyclin at a concentration, which is not antibiotically effective. 
Just downstream of the XbaI restriction site the pASK-IBA3 vector contains the OmpA signal 
sequence, which mediates secretion of the target protein into the periplasmic space. In the pASK-IBA5 
vector this sequence is missing, resulting in cytoplasmic accumulation of the target protein. Both parent 
vectors contain just upstream of the HindIII restriction site a sequence coding for the Strep-tag II104. 
This tag is derived from the Strep-tag59, which is itself derived from the biotin binding epitope of 
streptavidin. Both these tags contain a HPQ motif 60, which is characteristic for streptavidin binding 
peptides and has the property of binding to streptavidin competitively with biotin, which is 
streptavidin’s natural ligand. This allows for the use of very gentle conditions for the elution of bound 
Strep-tag fusion proteins from streptavidin affinity columns with dilute biotin solutions59. The Strep-tag 
II is composed of the sequence Asn-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (NWSHPQFEK) and was 
developed from the Strep-tag mainly as a variant more suitable for all N-terminal, C-terminal and also 
internal fusion to target proteins61. Targeted random mutagenesis of a flexible loop in streptavidin, 
mutants could be selected with enhanced affinity both for the Strep-tag and for the Strep-tag II62. One 
such mutant showed markedly improved performance in the purification of Strep-tag II fusion proteins, 
when coupled to a chromatographic support62. This mutant was later named StrepTactin and is 
commercially available coupled to different resins for chromatography from IBA. 
Good expression yields for Blc have been obtained in the bacterial strain JM83. However, as this is a 
proline-auxotrophic strain it is not ideally suited for the growth on minimal media, which are 
commonly employed in bio-NMR to obtain isotopically labeled proteins at reasonable costs. We 
therefore decided to evaluate the standard BL21 (DE3) and C41 (DE3) 63, strains for their efficiency in 
expressing the two different Blc constructs. Cell pellets from LB-cultures were analyzed by SDS-
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PAGE for expression efficiency after induction. Figure 12 shows the induction profiles of BL21 (DE3) 
and C41 (DE3) harboring the plasmids pBlc3 and pBlc5, respectively. 
Based on the expression profile shown in the above gel, BL21 (DE3) seemed to be slightly more 
effective for the expression of the periplasmic Blc construct, than the C41 (DE3) strain. The 
cytoplasmic expression failed in both strains under the chosen conditions. We therefore selected the 
periplasmic expression system in BL21 (DE3) cells for the further production of the Blc. 
 
2.2.2 NMR spectroscopic characterization of Blc 
To assess the expression and purification efficiency a 1 liter culture of BL21 (DE3) pBlc3 in unlabeled 
minimal medium was grown. Blc was purified according to the procedure described in the materials 
and methods part to yield approximately 2 ml of a 1 mM unlabeled Blc (U-Blc) solution. A 1D 1H-
spectrum was recorded at 37 °C. Good signal dispersion in the amide proton and in the aliphatic 
regions indicated a correctly folded protein. However, after 15 min at 37 °C substantial precipitation 
with a concomitant deterioration of the NMR spectrum was observed (data not shown). 
Clearly, the sample conditions had to be improved, in order to enable long measuring times at 37 °C. 
Ideally, the sample should show no signs of deterioration even after several days at 37 °C. To improve 
sample stability, a solution of 1 mM U-Blc was dialyzed into several different buffers and the stability 
determined by incubation at a series of temperatures for 2 h. The obtained results are summarized in the 
following table. 
 
Figure 12: Test expressions of the periplasmic and cytoplasmic Blc constructs in LB-broth. Two 
cell strains, BL21 (DE3) and C41 (DE3), were tested. Samples of the uninduced cultures and after 
2, 6, and 18 hours after induction are shown. The periplasmic induction seems to work equally well 
for both cell strains, while the cytoplasmic expression failed in both strains under the chosen 
conditions. 
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The incubation time at 37 °C was prolonged after the initial 2 h until 10 h. It is evident from the above 
table that the stability is significantly improved in the more acidic buffers as compared to neutral or 
basic conditions. The addition of NaCl to the sample showed a weak stabilizing effect at neutral pH and 
a weak destabilizing effect at acidic pH. We chose the acetate buffer at pH 4.5 to be our sample buffer 
for any following experiments, if not stated otherwise. 
Being able to produce Blc in a reasonable amount and having found the conditions ensuring optimum 
sample stability, we expressed Blc in 15N-labeled form. Figure 13a illustrates the purification procedure 
by means of 15% SGS-PAGE. The gel shows that 15N-Blc is > 95% pure. It can also be seen, that the 
spheroblast pellet still contains a lot of the target protein, i.e. that the osmotic shock lysis is only ~50% 
effective. An additional faint band with a molecular weight slightly higher than the target protein could 
not be assigned unambiguously, but probably results from periplasmic Blc, which has its periplasmic 
signal sequence still attached64. The [15N,1H]-HSQC spectrum of 15N-Blc shows good signal dispersion 
and between 140 and 150 out of an expected 156 peaks (167 residues minus 10 proline residues and the 
N-terminal residue) (figure 13b). 
In order to be able to select the suitable spots in the scaffold protein for grafting of loops and N-
terminal segments, the complete resonance assignment of the scaffold molecule would be beneficiary. 
We therefore, decided to express the Blc protein in a 13C/15N double-labeled form to enable a sequence 
specific resonance assignment of the peptide backbone by triple-resonance experiments. Standard 
CBCA(CO)NH65 and HNCA66 triple-resonance experiments were recorded as basis for the assignment 
procedure (figure 13c). 
25 °C 30  °C 37  °C 25 °C 30  °C 37  °C
100 mM Tris pH 8, 1 mM EDTA + - - 20 mM HEPES pH 7.5 + ~ -
100 mM Tris pH 8, 1 mM EDTA, 50 mM NaCl + ~ - 20 mM HEPES pH 7.5, 50 mM NaCl + + -
100 mM Tris pH 8, 1 mM EDTA, 150 mM NaCl + + - 20 mM HEPES pH 7.5, 150 mM NaCl + + -
25 °C 30  °C 37  °C 25 °C 30  °C 37  °C
20 mM PO4 pH 6.5 + + ~ 20 mM MES pH 5.5 + + +
20 mM PO4 pH 6.5, 50 mM NaCl + + ~ 20 mM MES pH 5.5, 50 mM NaCl + + +
20 mM PO4 pH 6.5, 150 mM NaCl + + + 20 mM MES pH 5.5, 150 mM NaCl + + +
25 °C 30  °C 37  °C 25 °C 30  °C 37  °C
20 mM acetate pH 4.5 + + + 20 mM glycine pH 3.5 + + +
20 mM acetate pH 4.5, 50 mM NaCl + + + 20 mM glycine pH 3.5, 50 mM NaCl + + +
20 mM acetate pH 4.5, 150 mM NaCl + + - 20 mM glycine pH 3.5, 150 mM NaCl + + -
Table 2: Stability of 1 mM Blc in various buffers at different temperatures. Incubation times were 2 
h at 25 and 30 °C, and 10 h at 37 °C. Stability was assessed in terms of blurring/precipitation of the 
sample visible by eye. A “+” sign indicates that the sample was stable, a “~” indicates slight 
blurring, while a “-“ indicates strong precipitation.  
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Figure 13: a) 15% SDS-PAGE of the purification process of 
15
N-Blc. The lanes contain the 
following products: 1. pre-stained protein ladder, 2. spheroblast pellet after osmotic lysis, 3. 
supernatant after osmotic lysis, i.e. crude sample, 4. flow-through of StrepTactin column loading, 5. 
to 9. eluate fractions 1to 5 b) [
15
N,
1
H]-HSQC spectrum with assigned peaks of  a ~1 mM 
15
N-Blc 
sample in 20 mM d4-acetate pH 4.5, 10% D2O, 0.5 mM TMSP recorded at 37 °C. c) Strips from 
G22 to A28 from the CBCA(CO)NH spectrum of 
13
C,
15
N-labeled Blc (same sample conditions as for 
the [
15
N,
1
H]-HSQC) exemplifying the assignment strategy. d) Secondary structural elements 
observed in the crystal structure of Blc mapped onto the amino acid sequence. Red arrows indicate 
the strands of the short antiparallel !-sheet lying outside the !-barrel core region. The small yellow 
rectangle represents the short 310-helix immediately preceding the !-barrel. !-barrel strands are 
highlighted with green arrows and the C-terminal "-helix by the large yellow rectangle. 
Unassigned residues are shaded in red. e) Unassigned regions are colored red in the ribbon 
representation of the crystal structure of Blc.  
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About 80% of the backbone resonances of Blc have been assigned and a table with all assigned 
chemical shifts can be found in Appendix E. It is interesting to note, that the unassigned residues 
almost exclusively are located in the odd numbered loops of Blc or in !-strands in the immediate 
vicinity to these loops. These residues could not be assigned due to very weak signals in the triple-
resonance spectra. This is a behavior is often observed in presence of exchange processes, which take 
place on the microsecond to millisecond timescale. 
Chemical exchange processes are temperature dependent and their effect on the NMR resonances 
additionally depends on the magnetic field strength. Recording spectra at different field strengths and 
varying temperatures can thus provide clues about the presence of such exchange phenomena. 
However, [15N,1H]-HSQC spectra recorded from 4 °C to 47 °C at 500 MHz and 700 MHz didn't reveal 
any such effects (data not shown). Unfortunately higher magnetic field strengths were not accessible 
for us. 
 
 
2.3 Design aspects for the soluble scaffold 
 
The N-terminal region of our Blc construct differed from the one for which the crystal structure has 
been published10 (figure 4). While our construct – after cleavage of the periplasmic export signal – 
matches the wildtype Blc almost perfectly, the sequence in the crystal structure carries an additional 19 
N-terminal residues, which are a remainder of the chosen cloning strategy. In order to being able to 
start our grafting trials with a scaffold matching as closely as possible the sequence, for which the 
threedimensional structure has been published, we decided to appended the amino acid sequence 
LESTSLYKK to the N-terminus of our Blc construct, as encoded on the plasmid pBlc3 (see also figure 
4 above). This construct then served as the starting point for our N-terminal grafting studies. The 
decision to only append 9 instead of the full 19 residues was supported by the fact that the first 10 
residues in the crystal structure are not visible in the crystal structure and are hence supposed to be 
unstructured and not important for the overall structure of the protein. 
 
 
2.4 Grafting studies with N-termini of the Y-receptors 
 
Based on the initial success in expression and assignment of both Blc and NY2R, we decided to 
proceed with our project by grafting the NY2R fragment N-terminally onto the Blc scaffold. Two 
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attachment points were selected taking into account the lipocalin general architecture (figures 3 and 4). 
Briefly, the two designed scaffold constructs consisted of (i) exclusively the !-barrel core and the C-
terminal "-helix (construct Blc-N2L40 [NY2R grafted before L40 of Blc; Blc numbering refers to the 
construct used for the crystallographic studies, as deposited under 1QWD.pdb]) and (ii) a longer 
scaffold containing also the antiparallel !-sheet and the 310-helix (construct Blc-N2L11).  
Blc-N2L40 and Blc-N2L11 could be expressed with yields of 4 and 7 mg/l, respectively. However, 
during dialysis of Blc-N2L40 a substantial amount of precipitate was observed. In the subsequent 1D 
1H-NMR and [15N,1H]-HSQC spectra a low signal intensity in combination with a limited signal 
dispersion was observed, indicating the presence of denatured protein. Blc-N2L11 however, behaved 
similar during the purification process than Blc, and NMR samples of ~1 mM concentration showing 
good signal dispersion could be obtained. Based on the very different outcome from the two grafting 
attempts we created a series of 6 more attachment point constructs spanning the region between L11 
and L40. The additionally chosen sites were T14, S20, T23, P25, N32 and F34. The location of all 8 
tested attachment points in the context of the secondary structural elements of the Blc N-terminus are 
shown in figure 14. They were all evaluated regarding the quality of the resulting NMR spectra (figure 
14). The constructs L11 and T14 included all secondary structural elements visible in the crystal 
structure of Blc and gave rise to satisfactory NMR spectra. Constructs S20, T23 and P25 had the 
attachment point of NY2R in between the two !-strands forming the short antiparallel !-sheet and thus 
didn't allow the formation of this secondary structural element. All three constructs showed well-
dispersed spectra. It can therefore be concluded that the formation of the short antiparallel !-sheet is 
not necessary for the formation of the !-barrel, and that this sheet is probably a pure artifact caused by 
the chosen cloning strategy for the X-ray crystallographic study. Constructs N32 and F34 had the 
NY2R sequence immediately before the 310-helix and gave spectra of very poor quality, indicating an 
interference of the NY2R with the correct formation of the !-barrel. Even worse spectra were observed 
for the L40 construct, in which the NY2R was cloned immediately before the first !-strand of the 
barrel. It can thus be concluded that the presence of the short 310-helix plus a spacer of a few residues is 
necessary for the formation of the !-barrel core structure of Blc. 
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In Chapter 1 of this thesis I have described in detail the characterization of all four Y-receptor N-
terminal loops. Especially the N-terminus of the Y4-receptor (NY4R) has proofed difficult to produce 
(Zou, ChemBioChem; 9: 2276-2284, 2008), due to fragmentation of the expressed fusion constructs. It 
was therefore interesting to find out, if Blc could serve as a scaffold for NY4R and retain stability in 
solution. NY4R was fused to Blc at the most promising site (S20) identified in the attachment site 
screening with NY2R. The resulting Blc-N4S20 construct, however, showed fragmentation already 
Figure 14: Top: Secondary structural elements observed in the crystal structure of Blc mapped 
onto the amino acid sequence. Red arrows indicate the strands of the short antiparallel !-sheet 
lying outside the !-barrel core region. The small yellow rectangle represents the short 310-helix 
immediately preceding the !-barrel. !-barrel strands are highlighted with green arrows and the C-
terminal "-helix with a large yellow rectangle. Attachment points of the NY2R are marked with 
green (tolerant) and red (non-tolerant) shaded areas along with the residue number according to 
the crystal structure of Blc. Bottom: Crystal structure of Blc with the N-terminus preceding the !-
barrel colored in yellow. Attachment points of the NY2R are marked with green (tolerant) and red 
(non-tolerant) spheres along with the residue number. [
15
N,
1
H]-HSQC spectra of Blc as a reference 
and all described constructs are shown to illustrate, whether an attachment point tolerates the 
grafting of NY2R or not. All spectra are from ~0.5 mM samples in 20 mM d4-acetate, pH 4 and 
were recorded at 27 °C. The spectra range from 99 to 133 ppm and from 6.0 to 10.6 ppm in the 
15
N 
and 
1
H dimensions, respectively. 
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while in its host cell. The fusion construct could be purified, but NMR spectra were of low quality and 
mass spectrometry proofed heterogeneity due to fragmentation and aggregation (figure 15). 
 
 
2.5 Loop grafting studies 
 
In the studies, that used lipocalins as a scaffold, mutations were introduced at the more open side of the 
!-barrel covering the odd numbered loops 1, 3, 5 and 7. According to the crystal structure of Blc, the 
residues S20, T23 and P25 are in proximity to these loops. These sites thus represent the attachment 
points of choice, if the odd numbered loops of Blc should be replaced with Y-receptor extracellular 
loops. In case one would like to target the even numbered loops 2, 4 and 6 residues L11 and T14 seem 
to be good candidates for allowing proximity of the grafted N-terminus to the loops. 
Figure 15: a) SDS-PAGE of Blc-N4S20 purification. Lane 1 shows a molecular size marker. Lane 2 
shows the cells overexpressing Blc-N4S20 after harvesting. Lane 3 is the spheroblast pellet after 
osmotic lysis of the cells and in lane 4 the final protein preparation after affinity chromatography is 
shown. The fragmented pattern is retained throughout the expression and purification procedure. b) 
[
15
N,
1
H]-HSQC of 0.5 mM Blc-N4S20 in 20 mM d4-acetate pH 4.5 recorded at 27 °C. The only 
strong signals are in the center of the spectrum, which corresponds to the random coil region. c) 
MALDI-TOF MS of the NMR sample indicates the presence of a broad range of molecular weight 
species besides the one expected at 23.8 kDa for monomeric Blc-N4S20. 
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Residue D6.59 of the Y1-receptor was identified as one of the most important for high-affinity ligand 
binding67. It is located in the third extracellular loop of the Y1-receptor. To assess the tolerance of each 
Blc-loop for being replaced with a Y-receptor loop we generated 7 mutants. In each one native Blc loop 
was replaced with the extracellular loop 3 of the Y1-receptor (Cys294 was replaced with a serine 
residue in these constructs). The Y1e3-loop has a length of 14 residues. The length of the Blc loops 
ranges from 2 to 9 residues. A comparison of all Blc loops with the Y1e3-loop is shown in figure 16. 
The changes are substantial. However, in previous studies it was found that lipocalins can tolerate large 
changes to their loop sequences 9. 
 
Because it is very easy to screen for correctly processed periplasmic proteins, all these mutations have 
initially been applied to the periplasmic Blc construct. Osmotic shock treatment and analysis of the 
supernatant didn't show any overexpressed protein. Except for the Blc-d5Y1e3 all the overexpressed 
protein remained in the spheroblast pellet, which indicated a cytoplasmic location of our constructs. 
Subsequent lysis of the spheroblasts by sonication also didn't yield any target protein in the 
supernatant, indicating that our constructs in fact accumulated in the form of insoluble inclusion bodies 
in cytoplasm (data not shown). Tests with the cytoplasmic expression system led to the same results 
(data not shown). The inclusion bodies from one construct (Blc-d1Y1e3) were purified and analyzed by 
SDS-PAGE and MS. Both indicated the presence of two species of slightly different molecular weight. 
Interestingly the two species corresponded to the Blc-d1Y1e3 mutant with and without the periplasmic 
export signal, which indicates aggregation and deposit into inclusion bodies after transport to the 
Figure 16: Comparison of the Blc loop sequences with the Y1e3-loop sequence. The respective Blc 
loop is colored red in the ribbon representation of the !-barrel core of Blc (1QWD.pdb). In the 
table dx denotes the loop being replaced with x representing the loop number. #N corresponds to 
the change in loop length, #pI to the change in isoelectric point of the loop sequences and #+/- to 
the change of positively and negatively charged amino acids in the loop. 
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plasmamembrane and interaction with the signal peptidase. 
As mentioned, loop 5 of Blc seemed to be the only one, which is able to tolerate exchange with the 
foreign Y1e3 loop. It could be shown that this tolerance is generic by also replacing the loop with the 
extracellular loops 1 and 2 of the Y1-receptor (Y1e1 and Y1e2, with Cys197 mutated to serine). 
However, precipitate formation during the purification of these three constructs indicated a decreased 
stability compared to wt-Blc. This was corroborated by NMR spectra, which showed very weak signals 
and rapid sample deterioration (data not shown). Other loop positions were almost completely 
intolerant to changes in their sequences. This was especially striking, when we tried to exchange those 
loops with sections from the Y1-receptor extracellular loops, which were of equal length as the Blc 
loop sequences or equal-length sequences composed solely of glycines and serines. 
Several strategies were tested, to obtain the Blc mutants described above in stable folded forms. 
Growing the cultures under more "gentle" conditions didn't give rise to any folded target protein. 
Likewise he inclusion of osmolytes, such as betaine and benzylic alcohol, in the growth medium didn't 
show any beneficial effects. Several different refolding strategies, including rapid dilution, slow 
dilution by dialysis and on-column methods each carried out under various different conditions, didn't 
yield any stably folded protein. We therefore concluded that the unstructured nature of our constructs 
was not due to incorrect processing in the cell, but rather due to an inherent incapacity of the given 
amino acid sequences to adopt a stable fold. 
 
 
 
3. Discussion 
 
Structural information for G-protein coupled receptors (GPCRs) is hard to obtain and therefore still 
scarce. Difficulties associated with their study partly are inherent to all membrane proteins and partly 
are particular to the GPCRs. New methods besides the established X-ray crystallographic methods 
might thus yield valuable insight into the structure and function of these receptors of tremendous 
biological importance. Two such methods, namely the characterization of fragments of the receptor and 
the grafting of functionally important epitopes onto a soluble scaffold molecule, have been applied to 
the neuropeptide Y receptors (Y-receptors), a subfamily of the GPCRs. We were able to produce the N-
terminus of the Y2-receptor (NY2R) both in unlabeled and in 15N-labeled form as a soluble fusion to 
ubiquitin. After specific cleavage with the yeast ubiquitin hydrolase NY2R could be characterized by 
NMR spectroscopy. The 50 residue peptide didn't show any defined tertiary or secondary structural 
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elements, both in aqueous buffer and in DPC micelles. This is in contrast to other Y-receptor N-
termini49,51. Chemical shift mapping data indicate a weak interaction of NY2R with the natural ligands 
of the Y-receptors (NPY, PYY and PP). Such weak interactions with their ligands could be observed 
for all four Y-receptor N-termini. Whereas with two such N-termini stability problems have been 
encountered during expression49,51, this was not the case for NY2R. The NY2R seemed therefore a 
good candidate for grafting onto a soluble scaffold protein, such as the bacterial lipocalin (Blc). Blc has 
been cloned and purified in other laboratories and its structure has been solved by X-ray 
crystallography 10. However, no NMR data have been published on Blc. Our efforts to produce Blc in 
15N- and 15N,13C-labeled forms have enabled the acquisition of high-quality heteronuclear NMR 
spectra. In the [15N,1H]-NMR spectrum of Blc out of the 156 expected peaks (167 residues minus N-
terminal residue and 10 prolines), 140-150 peaks can be observed. Out of these ~125 backbone amide 
correlations could be assigned. The remaining 15-25 peaks showed very weak signals in the triple-
resonance spectra recorded for assignment purposes. This is often observed, if resonances are 
broadened by exchange processes on the millisecond to microsecond time scale. As the resonances that 
could not be assigned, are almost exclusively located on one side of Blc's !-barrel core, it can be 
assumed that these residues show some flexibility and are neither in highly restricted conformations, 
nor are they highly dynamic. 
In the crystal structure of Blc 10 a short antiparallel !-sheet and a short 310-helix are found in the N-
terminus domain preceding the !-barrel core. The NY2R sequence was appended to the N-terminus of 
the !-barrel core at various attachment points distributed throughout the Blc N-terminus. It was found, 
that some attachment points were well tolerated by the scaffold, whereas other interfered with proper 
folding of the !-barrel core. Generally it can be said, that the further away from the !-barrel core, the 
better the attachment of the foreign NY2R sequence was tolerated. Attachment immediately prior to the 
!-barrel core, eliminating both the short !-sheet and the 310-helix, was not tolerated, suggesting the 
importance of either the helix, the sheet or both for the overall structure of the protein. Disrupting the 
!-sheet, but leaving the 310-helix in place, was tolerated by the scaffold, suggesting the insignificance 
of the !-sheet for the overall structure of the protein. This is in accordance with the fact that the 310-
helix is a conserved structural feature found in many lipocalins6,17 whereas the short antiparallel !-sheet 
is not. As the N-terminal strand of the !-sheet is made up of residues artificially introduced into the 
construct through the chosen cloning strategy 10, its dispensability is also not unanticipated. 
Whereas the attachment of the NY2R sequence to the N-terminus of Blc could be achieved without 
impairing the formation of the !-barrel core, the loops connecting the strands of the barrel were much 
less tolerant to being replaced with foreign sequences. This was surprising considering the fact that the 
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loops in the lipocalins show little sequence conservation among different members of the lipocalin 
family9. Furthermore these loops have been subject to extensive mutagenesis in the production of so-
called anticalins11,68. However, the anticalins were generated using phage display techniques, in which 
randomized proteins in the loops were generated. Binders for a certain target molecule were then 
enriched in several panning rounds, as is common practice in phage display techniques. This setting 
most likely not only allows enriching a population of specific binders for the target molecule. As such 
binding is probably only possible in cases, where the canonical structure of the protein core is retained, 
the technique at the same time also selects for mutations, which don't interfere with this fold. Our 
approach, namely the introduction of a particular amino acid sequence, was fundamentally different 
from the random mutagenesis approach used in the phage display strategy. We conclude that even 
though the lipocalins can be used as molecular scaffolds, their usefulness in this respect is likely linked 
to phage display techniques. 
The failure to generate a soluble minireceptor prompted us for trying out a membrane protein, which 
had been used successfully as a scaffold previously. The results resulting from this project will be 
summarized in Chapter 4 of this thesis. 
 
 
 
4. Materials and Methods 
 
 
4.1 Cloning and expression of NY2R 
 
See Materials and Methods in chapter II. 
 
 
4.2 Expression of neurohormones 
 
See Materials and Methods in chapter II. 
 
 
4.3 Plasmids for the overexpression of Blc 
 
Plasmids for the periplasmic (pBlc3) as well as the cytoplasmic (pBlc5) expression of Blc were 
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available to us. They were derived from the pASK-IBA2 plasmid. Maps of the expressed region of the 
two plasmids can be found in Appendix F. 
 
 
4.4 Conditions for the growth of cells expressing Blc and its derivatives 
 
All cultures were grown at 22 °C and 180 rpm and were induced with anhydrotetracyclin to a final 
concentration of 0.2 µg/ml from a 2 mg/ml anhydrotetracyclin stock in N,N-dimethylformamide once 
the OD550 had reached 0.5. Cells were harvested once the cultures reached stationary phase by 
centrifugation at 4 °C and stored at -20 °C until further processing. 
 
 
4.5 Expression of unlabeled Blc 
 
To assess efficiency of BL21 DE3 and C41 DE3 for the cytoplasmic and periplasmic expression of Blc, 
50 ml of LB containing 100 µg/ml ampicillin were inoculated in a 1:100 dilution with an overnight LB-
culture of BL21 DE3 pBlc3, BL21 DE3 pBlc5, C41 DE3 pBlc3 and C41 DE3 pBlc5. The cultures were 
incubated in 300 ml Erlenmeyer flasks. After 24 h the cultures had reached the stationary phase at an 
OD550 of 2.3 and were harvested. For each one of the cultures a yield of cell wet biomass of 
approximately 6 g/l was obtained. 
 
 
4.6 Expression of 15N-labeled Blc 
 
1 liter of minimal medium (composition see Appendix A) was inoculated in a 1:200 dilution with a 
saturated LB overnight pre-culture and distributed to three 2 l Erlenmeyer flasks. After 11 h the 
cultures were induced. After 25 h the cultures had reached an OD550 of 2.3 and were harvested to yield 
a wet biomass of 3.2 g from 1 liter of culture.  
 
 
4.7 Expression of 13C/15N-labeled Blc 
 
10 ml of LB-broth containing 100 µg/ml ampicillin were inoculated with a colony of freshly 
transformed BL21 DE3 pBlc3 and incubated at 37 °C and 240 rpm until the OD550 was ~0.8. This pre-
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culture was centrifuged at room temperature for 10 min at ~1000 g. The resulting approx. 50 µl pellet 
was resuspended in 50 ml 13C/15N-labeled minimal medium (composition see Appendix B) containing 
3 g 13C-Glucose per liter and incubated at 22 °C and 180 rpm until blurring of the culture was visible 
by eye (OD550 ~0.25). This 50 ml pre-culture was used to inoculate the remaining 950 ml of 
13C/15N-
labeled minimal medium, which was then distributed to three 2 l Erlenmeyer flasks and incubated at 22 
°C and 180 rpm. After 6 h the cultures were induced. After 21 h the cultures reached an OD550 of 2.5 
and were harvested to yield a wet biomass of 4.6 g from 1 liter of culture. 
 
 
4.8 Purification of Blc and its derivatives 
 
Cell pellets were thawed for 1 h on ice before 3.3 ml of chilled buffer P (0.5 M sucrose, 100 mM Tris 
pH 8, 1 mM EDTA) supplemented with 100 µg/ml lysozyme was added per 1 g of wet biomass. The 
viscous solution was incubated on ice for 30-60 min and centrifuged for 30 min at 38700 g at 4 °C. The 
supernatant was centrifuged a second time for 30 min at 38700 g at 4 °C to yield a clear, viscous, 
slightly green colored solution. All subsequent purification steps were carried out at 4 °C. The 
supernatant was loaded onto a StrepTactin column (1 ml of StrepTactin resin per g of cell pellet), 
previously equilibrated with 5 column volumes (CV) of buffer W (100 mM Tris pH 8, 1 mM EDTA), 
by means of a peristaltic pump at a flow-rate of approximately 0.3 ml/min. Bound Blc was washed with 
5 CV of buffer W, before it was eluted with 5 CV of buffer E (100 mM Tris pH 8, 1 mM EDTA, 2.5 
mM desthiobiotin). Fractions were collected and analyzed for content of the target protein by 15% 
SDS-PAGE. 
The column was regenerated by washing away bound desthiobiotin with 10 CV of buffer R (100 mM 
Tris pH 8, 1 mM EDTA, 5 mM 2-(4-Hydroxyphenylazo)benzoic acid [HABA]) and equilibrating it 
with 10 CV of buffer W. 
The Blc-containing eluate fractions were pooled and the concentration estimated from the UV-
absorption at 280 nm using a theoretical absorption coefficient e280 of 40910 M
-1cm-1. The Blc solution 
in the elution buffer was transferred into a 3.5 kDa MW cutoff dialysis bag previously soaked in 20 
mM acetate buffer pH 4.5 at 4 °C. The solution was dialyzed twice against typically a 100-200 fold 
excess of 20 mM acetate buffer pH 4.5 at 4 °C during 12 h. The dialyzed protein solution was 
centrifuged for 10 min at 2500 g at 4 °C to remove any residual precipitate that had formed during the 
dialysis before being concentrated to a volume suitable for NMR (0.25-0.6 ml) in a Amicon Ultra-4 
centricon tube (10 kDa MWCO) at 4 °C. The dialysis buffer was exchanged for the desired NMR 
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buffer (20 mM 2H-acetate buffer pH 4.5, 10% 2H2O, 0.5 mM TSP) in the same centricon tube in three 
1:1 dilution steps. The resulting solution was carefully removed from the centricon tube and 
centrifuged in an Eppendorf tube at 12000 rpm at room temperature for 2 min before being transferred 
to a clean NMR tube. 
 
 
4.9 Grafting of Y-receptor N-termini 
 
The plasmids coding for the constructs Blc-N2L11, -N2T14, -N2S20, -N2N32, -N2F34 and -N2L40 
carrying the N-terminus of the Y2-receptor at various sites were generated from pBlc3 (see Appendix F 
for a plasmid map) as the starting plasmid. They were all generated by an overlapping PCR strategy 
consisting of three rounds for each construct. In summary the Y-receptor N-terminal fragment had to be 
inserted in between the OmpA periplasmic signal sequence at the N-terminus and the Blc !-barrel core 
at the C-terminus. This was achieved by generating by PCR three constructs comprising (i) the XbaI 
restriction for cloning site and the OmpA signal sequence, (ii) the Y-receptor N-terminus and (iii) the 
Blc core plus a HindIII restriction site for cloning. All the fragments were designed to show overlap on 
both sides with the preceding and following fragment as illustrated in the following figure. 
A table with the primers used to generate the three respective fragments of all 6 constructs is shown 
below (all primers are depicted as going from the 5' to the 3' end). 
N2L11 Fragment 1 Fragment 2 Fragment 3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
ctggaatctactagcctgtacaaaa
aaagttctcctacgccgccg 
rv gatcggacccatggcggcctgcg
ctacggt 
ttttttgtacaggctagtagattccag
ctgaacttcgatcagttt 
tcacttcacaggtcaagctta 
N2T14 Fragment1 Fragment2 Fragment3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
actagcctgtacaaaaaaagttctc
ctacgccgccg 
rv gatcggacccatggcggcctgcg
ctacggt 
ttttttgtacaggctagtctgaacttc
gatcagttt 
tcacttcacaggtcaagctta 
N2S20 Fragment1 Fragment2 Fragment3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
atcgaagttcagagttctcctacg 
rv gatcggacccatggcggcctgcg
ctacggt 
cgtaggagaactctgaacttcgat tcacttcacaggtcaagctta 
N2N32 Fragment1 Fragment2 Fragment3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
atcgaagttcagaataatttcgac 
rv gatcggacccatggcggcctgcg
ctacggt 
gtcgaaattattctgaacttcgat tcacttcacaggtcaagctta 
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N2F34 Fragment1 Fragment2 Fragment3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
atcgaagttcagttcgacgccaac 
rv gatcggacccatggcggcctgcg
ctacggt 
gttggcgtcgaactgaacttcgat tcacttcacaggtcaagctta 
N2L40 Fragment1 Fragment2 Fragment3 
fw cgacaaaaatctagataacgaggg gcgcaggccgccatgggtccgat
cggcgcg 
cttggtacctggtatgagattgcc 
rv gatcggacccatggcggcctgcg
ctacggt 
ggcaatctcataccaggtaccaag
ctgaacttcgatcagttt 
tcacttcacaggtcaagctta 
 
The fragments were generated by standard PCR procedures using Vent polymerase PCR products were 
analyzed and purified by 1.5% agarose gel electrophoresis containing ethidium bromide for DNA 
staining. A QiaGen gel purification kit was used for all PCR purifications following the manual of the 
manufacturer. 
200 to 500 ng of the final constructs were digested with XbaI (5 U) and HindIII (10 U) in Tango buffer 
at 37 °C for 2 h, purified on a 1.5% agarose gel and ligated into the pBlc3 vector, digested with XbaI 
and HindIII and purified previously. The ligation reaction was transformed to DH5" cells. Plasmid was 
extracted from positive clones using the QiaGen miniprep kit following the manufacturers instructions, 
and the sequence of the insert was verified by dideoxy-sequencing (Sanger, PNAS, 74, 5463, 1977). 
The constructs Blc-N2T23, -N2P25 and -N4S20 were constructed with following the QuickChange 
mutagenesis strategy. For the two constructs carrying the N-terminus of the Y2-receptor (NY2R) 
pBlc3-N2S20 was used as the starting construct from which 3 and 5 residues between the NY2R 
sequence and the Blc sequence were deleted to generate pBlc3-N2T23 and pBlc3-N2P25, respectively. 
The primers used for the generation of pBlc3-N2T23 were 5'-ctgatcgaagttcagacgccgccgcgtggcg-3'for 
the forward and 5'-cgccacgcggcggcgtctgaacttcgatcag-3' for the reverse, and for the generation of pBlc3-
N2P25 5'-ccaaactgatcgaagttcagccgcgtggcgtgacc-3' for the forward and 5'-
ggtcacgccacgcggctgaacttcgatcagtttgg-3' for the reverse primer. 
pBlc3-N4S20 was generated from pBlc3 as the starting plasmid. QuickChange primers for this 
construct were generated from two short primers (forward primer: 5'-
gctaccgtagcgcaggccgccATGAACACCTCTCACC-3'; reverse primer: 5'-
ccacgcggcggcgtaggagaactCATCACGTCCACGGAATCC-3'; lowercase letters denote stretches from 
the Blc sequence, uppercase letters stretches from the NY4R) amplifying the N-terminus of the Y4-
receptor (NY4R) with overhangs upstream and downstream of the S20 site on both sides. ds-DNA 
fragments were generated by standard PCR methods using Vent polymerase and the fragments were 
purified using a QiaGen gel purification kit following the manual of the manufacturer. QuickChange 
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PCR reactions were carried out following the recommendations from Stratagene (for more detailed 
description of the protocols followed vide infra). Nucleotide sequences of the inserts were verified 
using dideoxy-sequencing69. 
 
 
4.10 Grafting of Y-receptor extracellular loops 
 
All designed constructs were derived from the pBlc3 or pBlc5 plasmid and all mutants were created 
using the QuickChange methodology as described in the QuickChange site directed-mutagenesis kit 
manual from Stratagene (catalog no. 200518). Primer design principles suggested in this manual were 
followed. All components of the kit were bought individually. The dNTP were from Fermentas (cat. 
no. #R0241) and were stored as aliquots at -20 °C. PfuTurbo polymerase was from Stratagene (cat. no. 
600250-52) and DpnI nuclease was from Fermentas (cat. no. #ER1701). All QuickChange reactions 
were carried out in 10 µl total volume containing 1x PfuTurbo buffer (cat. no. 600153-82), 0.5 U 
PfuTurbo polymerase, 0.2 mM dNTPs, ~100 ng of plasmid DNA and 0.2 µM of each mutagenic 
primer. The thermocycling procedure was designed as recommended by Stratagene and can be found in 
appendix B. 5 U of DpnI were added to the reaction and the mixture was incubated at 37 °C for 3 
hours. 1-2 µl of this mixture were transformed to 25-50 µl of self-prepared RbCl2-competent cells by 
heat shock. Plasmid was extracted from the obtained colonies and sequenced by the dideoxy 
sequencing method (Sanger, PNAS, 74, 5463, 1977). 
All primers were purchased from Microsynth (Balgach, Switzerland). Primers for deletion, single 
amino acid change and point mutation reactions were purchased as desalted ~36-mers. Primers for the 
insertion constructs were self-made by PCR using two short (~12 nucleotides) desalted primers 
flanking the insertion region. PCR products were purified with a Sigma PCR clean-up kit (NA1020-
1KT) and used in subsequent QuickChange mutagenesis reaction. Since long primers are expensive and 
require additional expensive purification, this strategy allowed us substantial cost savings. The inserted 
Y-receptor gene sequences were optimized for preferred E. coli codon usage. A table with all the 
deletion and insertion primers is shown in Appendix G. 
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4.11 NMR spectroscopy 
 
4.11.1 NMR spectroscopy - general 
All spectra were recorded on a Bruker AV-600 or AV-700 spectrometer, both equipped with 
cryoprobes.  
Proton chemical shifts were calibrated to the water signal and nitrogen shifts were referenced indirectly 
to liquid NH3 (Live, 1984). Raw data was processed using the Bruker Topspin software version 2.0 and 
2.1 and transferred to XEASY70 or CARA71 for further analysis. 
All 2D experiments utilized TPPI-States72,73 for quadrature detection in indirect proton and carbon 
dimensions, and gradient-selected coherence selection (echo-antiecho) (Kay, JACS, 114, 10663, 1992) 
in combination with sensitivity enhancement schemes74,75 in experiments including detection of amide 
protons. 
 
4.11.2 Assignment of NY2R 
See Materials and Methods in chapter II. 
 
4.11.3 Assignment of Blc 
All spectra for the assignment of Blc were recorded on the AV-600 spectrometer on a 1.1 mM sample 
of uniformly 15N- and 13C-labeled Blc in 20 mM d4-acetate at pH 4.5 containing 10% D2O and at a 
temperature of 308 K. 
A [15N,1H]-HSQC76 with 1024(1H)*150(15N) complex data points was recorded. Spectral widths were 
16 ppm and 40 ppm for the 1H and 15N dimension, respectively. The carrier positions were placed at 
4.75 ppm (1H) and 115.0 ppm (15N). 
A CBCA(CO)NH77,78 with 1024(1H)*32(15N)*75(13C) complex data points was recorded. Spectral 
widths were 14 ppm, 35 ppm and 75 ppm for the 1H, 15N and 13C dimension, respectively. The carrier 
positions were placed at 4.71 ppm (1H), 117.4 ppm (15N), 39.0 ppm (13C"/!) and 54.0 ppm (
13C"). 
A HNCACB 78,79 with 1024(1H)*32(15N)*64(13C) complex data points was recorded. Spectral widths 
were 14 ppm, 35 ppm and 75 ppm for the 1H, 15N and 13C dimension, respectively. The carrier 
positions were placed at 4.71 ppm (1H), 117.4 ppm (15N) and 39.0 ppm (13C). 
A (H)CC(CO)NH80-83 with 1024(1H)*20(15N)*64(13C) complex data points was recorded. Spectral 
widths were 16 ppm, 35 ppm and 75 ppm for the 1H, 15N and 13C dimension, respectively. The carrier 
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positions were placed at 4.71 ppm (1H), 117.4 ppm (15N), 39.0 ppm (13C) and 54.0 ppm (13C"). 
A (H)N(CA)NH84 with 1024(1H)*24(15N)*55(15N) complex data points was recorded. Spectral widths 
were 16 ppm, 36 ppm for the 1H and the two 15N dimensions, respectively. The carrier positions were 
placed at 4.76 ppm (1H), 117.5 ppm (15N). 
 
4.11.4 NMR spectroscopy with Blc derivatives carrying a Y-receptor N-terminus or loop 
All protein samples were studied by measuring [15N,1H]-HSQCs with 1024(1H)*150(15N) complex data 
points was recorded. Spectral widths were 16 ppm and 40 ppm for the 1H and 15N dimension, 
respectively. The carrier positions were placed at 4.75 ppm (1H) and 115.0 ppm (15N). 
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6. Appendix 
 
 
A - 1 liter 15N-labeled minimal medium: 
4 g  KH2PO4 
4 g  K2HPO4 
3.5 g  Na2HPO4 * 2 H2O 
1 g  NaCl 
1 g 15NH4Cl (or 
14NH4Cl if no labeling was required) 
fill up to 960 ml with de-ionized water and autoclave 
To these 960 ml the following were added: 
10 ml MgSO4 1 M (autoclaved) 
25 ml Glucose 20% (sterile filtered) 
2 ml trace metal stock solution (autoclaved) (for composition see Appendix C) 
1 ml thiamineHCl 150 mM (sterile filtered) 
1 ml kanamycin 50 mg/ml or ampicillin 100 mg/ml 
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B - 1 liter 13C/15N-labeled minimal medium: 
4 g  KH2PO4 
4 g  K2HPO4 
3.5 g  Na2HPO4 * 2 H2O 
1 g  NaCl 
1 g 15NH4Cl 
fill up to 960 ml with de-ionized water and autoclave 
To these 960 ml the following were added: 
10 ml MgSO4 1 M (autoclaved) 
15 ml 13C-Glucose 20% (sterile filtered) 
2 ml trace metal stock solution (autoclaved) (for composition see Appendix C) 
1 ml thiamineHCl 150 mM (sterile filtered) 
1 ml ampicillin 100 mg/ml 
 
 
 
C - trace metal stock solution (500X): 
FeSO4 * 7 H2O  4 g/l 
CaCl2 * 2 H2O  4 g/l 
AlCl3 * 6 H2O   1 g/l 
MnSO4 * n H2O  1 g/l 
CoCl2 * 6 H2O  0.4 g/l 
ZnSO4 * 7 H2O  0.2 g/l 
CuCl2 * 2 H2O  0.1 g/l 
H3BO3    0.1 g/l 
 
 
 
 
 
 
 
 
 183 
 
 
D - Chemical shift table of NY2R 
Amide proton and 15N chemical shifts of N-Y2
Residue N /ppm H
N
 /ppm 
Met 1   
Gly 2 112.1 8.59 
Pro 3   
Ile 4 120.1 8.16 
Gly 5 112.9 8.42 
Ala 6 123.6 8.07 
Glu 7 119.4 8.39 
Ala 8 123.9 8.14 
Asp 9 119.1 8.12 
Glu 10 120.9 8.30 
Asn 11 118.7 8.37 
Gln 12 120.3 8.15 
Thr 13 115.7 8.15 
Val 14 122.2 8.09 
Glu 15 123.8 8.33 
Glu 16 121.5 8.26 
Met 17 121.1 8.22 
Lys 18 122.8 8.18 
Val 19 121.0 8.02 
Glu 20 123.9 8.37 
Gln 21 120.6 8.15 
Tyr 22 120.4 8.12 
Gly 23 109.8 8.06 
Pro 24   
Gln 25 119.8 8.49 
Thr 26 114.7 8.08 
Thr 27 118.5 8.09 
Pro 28   
Arg 29 121.0 8.33 
Gly 30 109.4 8.28 
Glu 31 119.9 8.15 
Leu 32 122.8 8.19 
Val 33 122.6 8.04 
Pro 34   
Asp 35 121.3 8.23 
Pro 36   
Glu 37 121.8 8.30 
Pro 38   
Glu 39 120.1 8.37 
Leu 40 123.3 8.18 
Ile 41 121.2 7.98 
Residue N /ppm H
N
 /ppm 
Asp 42 123.9 8.26 
Ser 43 117.8 8.36 
Thr 44 114.9 8.21 
Lys 45 122.2 7.83 
Leu 46 122.2 7.92 
Ile 47 120.2 7.83 
Glu 48 124.4 8.26 
Val 49 121.4 8.06 
Gln 50 128.5 7.89 
E - chemical shift table of Blc 
 
 
 
 
 
 
 
 
 
 
 
Table A1: Assigned chemical shifts of Blc. Spectra were recorded on a 1 mM 
13
C,
15
N-Blc sample in 20 
mM d4-acetate, pH 4.5, 10% D2O, 0.5 mM TMSP at 37 °C. 
F - Plasmid maps of the expressed region of pBlc3 and pBlc5 
pBlc3: 
XbaI restriction site (t'ctaga) 
OmpA signal sequence (underlined) 
Blc (bold) 
StrepII tag (bold underlined)  
HindIII restriction site (a'agctt) 
 
ccatcgaatggccagatgattaattcctaatttttgttgacactctatcattgatagagt 
 P  S  N  G  Q  M  I  N  S  -  F  L  L  T  L  Y  H  -  -  S  
tattttaccactccctatcagtgatagagaaaagtgaaatgaatagttcgacaaaaatct 
 Y  F  T  T  P  Y  Q  -  -  R  K  V  K  -  I  V  R  Q  K  S  
agataacgagggcaaaaaatgaaaaagacagctatcgcgattgcagtggcactggctggt 
 R  -  R  G  Q  K  M  K  K  T  A  I  A  I  A  V  A  L  A  G  
ttcgctaccgtagcgcaggccgccagttctcctacgccgccgcgtggcgtgaccgtagta 
 F  A  T  V  A  Q  A  A  S  S  P  T  P  P  R  G  V  T  V  V  
aataatttcgacgccaaccattatcttggtacctggtatgagattgcccgttttgatcac 
 N  N  F  D  A  N  H  Y  L  G  T  W  Y  E  I  A  R  F  D  H  
cgctttgaacgtggactggaaaaagtcaccgcaacatacagcctgcgtgatgacggcggc 
 R  F  E  R  G  L  E  K  V  T  A  T  Y  S  L  R  D  D  G  G  
ctgaatgtcattaataaaggctataaccctgacagaggaatgtggcagcagagtgaaggg 
 L  N  V  I  N  K  G  Y  N  P  D  R  G  M  W  Q  Q  S  E  G  
aaagcgtactttaccggcgcaccaactcgcgctgcgctgaaagtgtcattctttggtcct 
 K  A  Y  F  T  G  A  P  T  R  A  A  L  K  V  S  F  F  G  P  
ttctatggcggttataacgttattgcactcgatcgggaataccgccatgcgctggttagc 
 F  Y  G  G  Y  N  V  I  A  L  D  R  E  Y  R  H  A  L  V  S  
gggccggaccgcgactacctgtggatactctcccgcacgccaaccatttctgtggaagtg 
 G  P  D  R  D  Y  L  W  I  L  S  R  T  P  T  I  S  V  E  V  
aaacaggagatgctggcagtcgcgacccgggaagggtttgatgtcagtaaatttatttgg 
 K  Q  E  M  L  A  V  A  T  R  E  G  F  D  V  S  K  F  I  W  
gtacagcagcctggtagcgcttggtctcacccgcagttcgaaaaataataagcttgacct 
 V  Q  Q  P  G  S  A  W  S  H  P  Q  F  E  K  -  -  A  -  P  
  
 
pBlc5: 
XbaI restriction site (t’ctaga) 
Blc (bold) 
StrepII tag (bold underlined) 
HindIII restriction site (a’agctt) 
 
 
ccatcgaatggccagatgattaattcctaatttttgttgacactctatcattgatagagt 
 P  S  N  G  Q  M  I  N  S  -  F  L  L  T  L  Y  H  -  -  S  
tattttaccactccctatcagtgatagagaaaagtgaaatgaatagttcgacaaaaatct 
 Y  F  T  T  P  Y  Q  -  -  R  K  V  K  -  I  V  R  Q  K  S  
agataacgagggcaaaaaatgagttctcctacgccgccgcgtggcgtgaccgtagtaaat 
 R  -  R  G  Q  K  M  S  S  P  T  P  P  R  G  V  T  V  V  N  
aatttcgacgccaaccattatcttggtacctggtatgagattgcccgttttgatcaccgc 
 N  F  D  A  N  H  Y  L  G  T  W  Y  E  I  A  R  F  D  H  R  
tttgaacgtggactggaaaaagtcaccgcaacatacagcctgcgtgatgacggcggcctg 
 F  E  R  G  L  E  K  V  T  A  T  Y  S  L  R  D  D  G  G  L  
aatgtcattaataaaggctataaccctgacagaggaatgtggcagcagagtgaagggaaa 
 N  V  I  N  K  G  Y  N  P  D  R  G  M  W  Q  Q  S  E  G  K  
gcgtactttaccggcgcaccaactcgcgctgcgctgaaagtgtcattctttggtcctttc 
 A  Y  F  T  G  A  P  T  R  A  A  L  K  V  S  F  F  G  P  F  
tatggcggttataacgttattgcactcgatcgggaataccgccatgcgctggttagcggg 
 Y  G  G  Y  N  V  I  A  L  D  R  E  Y  R  H  A  L  V  S  G  
ccggaccgcgactacctgtggatactctcccgcacgccaaccatttctgtggaagtgaaa 
 P  D  R  D  Y  L  W  I  L  S  R  T  P  T  I  S  V  E  V  K  
caggagatgctggcagtcgcgacccgggaagggtttgatgtcagtaaatttatttgggta 
 Q  E  M  L  A  V  A  T  R  E  G  F  D  V  S  K  F  I  W  V  
cagcagcctggtagcgcttggtctcacccgcagttcgaaaaataataagcttgacctgtg 
 Q  Q  P  G  S  A  W  S  H  P  Q  F  E  K  -  -  A  -  P  V  
G - Deletion and insertion primers for the generation of the Blc derivatives carrying Y1-receptor 
loop sequences 
Deletion Forward 5'->3' 
d1(dI) cctggtatgagattgcccgtgaaaaagtcaccgcaac 
d2(D1) ccgcaacatacagcctgctgaatgtcattaataaaggc 
d3(dII) cattaataaaggctataacatgtggcagcagagtgaaggg 
d4(D2) gggaaagcgtactttgcgctgaaagtgtcattc 
d5(dIII) gcgctgaaagtgtcattctttttctatggcggttataacg 
d6(D3) ggttataacgttattgcactccatgcgctggttagcggg 
d7(dIV) ccgccatgcgctggttagcctgtggatactctcccgc 
Insertion Forward 5'->3' 
d1Y1e3C294S ctggtatgagattgcccgtttcgactggaaccaccagatcatcgcgacctctaaccacaacgaaaaagtcaccgcaac 
d2Y1e3C294S ccgcaacatacagcctgttcgactggaaccaccagatcatcgcgacctctaaccacaacctgaatgtcattaataaaggc 
d3Y1e3C294S cattaataaaggctataacttcgactggaaccaccagatcatcgcgacctctaaccacaacatgtggcagcagagtgaaggg 
d4Y1e3C294S gggaaagcgtactttttcgactggaaccaccagatcatcgcgacctctaaccacaacgcgctgaaagtgtcattc 
d5Y1e3C294S gcgctgaaagtgtcattctttttcgactggaaccaccagatcatcgcgacctctaaccacaacttctatggcggttataacg 
d6Y1e3C294S ggttataacgttattgcactcttcgactggaaccaccagatcatcgcgacctctaaccacaaccatgcgctggttagcgggccg 
d7Y1e3C294S gccatgcgctggttagcttcgactggaaccaccagatcatcgcgacctctaaccacaacctgtggatactctcccg 
D71Y1e3C294S tacagcctgcgtgatttcgactggaaccaccagatcatcgcgacctctaaccacaacgacggcggcctgaatgtc 
A101Y1e3C294S gcgtactttaccggcgcattcgactggaaccaccagatcatcgcgacctctaaccacaacccaactcgcgctgcgctg 
R126Y1e3C294S gttattgcactcgatcggttcgactggaaccaccagatcatcgcgacctctaaccacaacgaataccgccatgcgctg 
d1Y1e3m7GL ctggtatgagattgcccgtttcgactggaaccaccagatcggactggaaaaagtcaccgcaac 
d1Y1e3m5 ctggtatgagattgcccgtttcgactggaaccaccagatcatcgcggaaaaagtcaccgcaac 
P133Y1e3C294S gctggttagcgggccgttcgactggaaccaccagatcatcgcgacctctaaccacaacgaccgcgactacctgt 
F53Y1e3C294S ttttgatcaccgctttttcgactggaaccaccagatcatcgcgacctctaaccacaacgaacgtggactggaaa 
d1Y1e1 ctggtatgagattgcccgttacaccctgatggaccactgggttttcggtgaagcgatggaaaaagtcaccgcaac 
d3Y1e1 cattaataaaggctataactacaccctgatggaccactgggttttcggtgaagcgatgatgtggcagcagagtgaaggg 
d5Y1e1 gcgctgaaagtgtcattcttttacaccctgatggaccactgggttttcggtgaagcgatgttctatggcggttataacg 
d7Y1e1 gccatgcgctggttagctacaccctgatggaccactgggttttcggtgaagcgatgctgtggatactctcccg 
d1Y1e2C197S 
ctggtatgagattgcccgtcaggttatgaccgacgaaccgttccagaacgttaccctggatgcgtacaaagacaaatacgtttc
ttttgatcagttcccgtccgattctcaccgtctgtctgaaaaagtcaccgcaac 
d3Y1e2C197S 
cattaataaaggctataaccaggttatgaccgacgaaccgttccagaacgttaccctggatgcgtacaaagacaaatacgtttc
ttttgatcagttcccgtccgattctcaccgtctgtctatgtggcagcagagtgaaggg 
d5Y1e2C197S 
gcgctgaaagtgtcattctttcaggttatgaccgacgaaccgttccagaacgttaccctggatgcgtacaaagacaaatacgttt
cttttgatcagttcccgtccgattctcaccgtctgtctttctatggcggttataacg 
d7Y1e2C197S 
gccatgcgctggttagccaggttatgaccgacgaaccgttccagaacgttaccctggatgcgtacaaagacaaatacgtttctt
ttgatcagttcccgtccgattctcaccgtctgtctctgtggatactctcccg 
Table A2: Forward primers for generating the deletions and insertions in the Blc construct. 
Reverse primers are the complement sequences of the primers shown here. Underlined sequences 
are from Blc, non-underlined from the human Y1-receptor gene. 
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Chapter IV: Grafting of extracellular loops of Y-receptors 
onto a membrane-embedded !-barrel scaffold 
 
 
Abstract 
In this chapter I present the attempt at creating a membrane-embedded model system, that is 
capable of mimicking ligand-binding functions of a subfamily of the G-protein coupled receptors 
(GPCRs). These receptors function in a modular way, in which a certain part of the molecule is 
responsible for a specific task. In our case one part is responsible for ligand-binding, whereas other 
parts are involved in the signal transduction process or allosteric regulation, for instance. The full 
receptors are large and difficult to characterize structurally, but one can resort to studying 
confirmed or hypothesized modules thereof. Cell surface receptors commonly are thought of 
consisting of three distinct modules or “domains”: an extracellular, a transmembrane and an 
intracellular domain. We intend to study the extracellular part of a GPCR, which is responsible for 
binding the receptor's cognate ligand(s), by grafting it onto a stable supporting molecule, a so-called 
“scaffold”. The resulting chimeric protein should be easier to produce and characterize 
spectroscopically than the receptor. As a potential scaffold molecule we have chosen the outer 
membrane protein A (OmpA) from E. coli, which is functionally and structurally one of the best-
characterized membrane proteins. 
GPCRs are of enormous clinical importance, and the availability of a suitable model for such 
receptors will be a valuable tool for the assessment of novel potential GPCR binding molecules. 
 
 
1. Introduction 
 
1.1 A new approach to structural and functional information on G-protein coupled receptors 
G-protein coupled receptors (GPCRs) are a class of membrane embedded proteins, spanning the 
hydrophobic membrane interior with seven transmembrane (TM) helices, connected by three 
intracellular and three extracellular loops1. GPCRs are of enormous clinical importance2, and as 
long as no straightforward approaches to the three-dimensional structures of these molecules exist, 
the availability of models for such receptors will continue to be a valuable tool for the 
investigations of many different GPCRs. One sub-class of the GPCRs is believed to interact with 
their cognate ligands mainly through its surface exposed extracellular parts. Our work is inspired by 
the idea, that these extracellular parts could be studied separately, i.e. in absence of the hydrophobic 
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transmembrane helices, which are responsible for most of the problems arising in the work with 
GPCRs. Several approaches to realizing this idea have been formulated. The route we are following 
can be called “grafting approach” and can be briefly summarized as follows: If a protein exists, 
which possesses a core determining its global fold and some surface exposed loops unimportant to 
that fold (i.e. a so-called “scaffold” protein), the external parts of a GPCR could be transferred to 
that stable core domain, without disturbing the overall global fold of the scaffold. The resulting 
chimeric protein could then be considered a “chimeric receptor”, because it carries all the parts of 
the receptor hypothesized to be important for ligand binding (hence the term “receptor”), but at the 
same time the geometries of the grafted loops relative to each other are determined by the stable 
core of the scaffold molecule. This idea is exemplified in figure 1. 
 
 
 
In this work we describe the attempt at grafting the extracellular loops of a GPCR onto the 
membrane-embedded !-barrel of a derivative of the outer membrane protein A (OmpA) from E. 
coli. By NMR spectroscopic methods we are going to evaluate the ability of the obtained chimera to 
assume a stable tertiary fold, and investigate, whether these interact with the GPCR's natural 
ligands. 
 
 
Figure 1: Left: Structure of the prototypical GPCR bovine rhodopsin with extracellular loops and 
N-terminus color-coded in red and green, respectively. Right: Structure of the E. coli outer 
membrane protein A, with the extracellular loops colored green. 
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1.2 Scaffold molecules in nature and their use in synthetic protein chemistry 
The advent of elaborate nucleotide synthesis and PCR schemes and highly efficient cloning 
techniques made it theoretically possible to produce large numbers of randomized derivatives of 
any given starting sequence. The theoretical number of different sequences of length n that can be 
composed of the 20 natural, proteinogenic amino acids rises with n in a factorial way. Therefore, 
already for relatively short sequences a manual expression and purification of each subsequence is 
practically not feasible. Through the invention of the “phage display” technology it became possible 
to screen large libraries for desired properties, thereby preventing the necessity to manually express, 
purify and test each potential candidate protein. The central idea of this technique is to create an as 
large as possible protein “library”, where each protein and the genetic information that codes for it 
are physically linked. Provided an efficient selection strategy is present, one target protein along 
with its DNA-sequence can thus be pulled out of a mixture of billions of different proteins. Most 
commonly such a selection strategy consists of the surface immobilization of a source-protein and 
screening for target-proteins showing affinity to the source. With this technique the size of a 
“library” is no longer dictated by the number of sequences, which can be manually expressed and 
purified, but by other factors such as the transformation efficiency. 
Such libraries of randomized sequences are very useful, and binders to a wide variety of different 
molecules can commonly be selected from one such given library. The mammalian immune system 
can be considered an elaborate in vivo protein library. The concept of generating libraries with 
structurally and functionally related compounds has, however, not evolved in mammals, but 
evolutionarily much earlier in the class of the arachnids3. 
In vitro such libraries are generated by the application of randomizing PCR techniques. The 
bottleneck for the generation of large numbers of randomized sequences is generally the achievable 
transformation efficiency, i.e. how many transformants one can get from a given amount of 
randomized DNA. This renders the randomization of the complete sequence of a typical small 
protein not feasible. However this is often not desired. Instead, it can be more desirable to 
randomize only short surface-exposed sequences. The advantages of this approach are twofold: 
first, the number of theoretically possible variants is much smaller, and second the unchanged 
sequence can, in some instances, be considered to not undergo any structural changes. If the second 
criterion is fulfilled by a protein one speaks of it as a “scaffold”. Such a scaffold is for instance 
formed in the immune system by the constant regions within the immunoglobulins, or in the above 
mentioned arachnid peptide toxins by unchanged cysteine residues, which – by forming 
intramolecular disulfide bond patterns – determine the global fold of the peptides3. 
One can thus define certain characteristic features that a protein, which could possibly act as a 
scaffold, should present. First and foremost such a candidate scaffold should show high sequence 
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diversity in conjunction with a conserved tertiary fold. In other words it should have been evolved 
by nature to be tolerant to changes in its amino acid sequence without losing its overall folding 
pattern. Additionally the protein family to which the potential scaffold belongs should possess a 
well defined and structurally conserved (hydrophobic) core and a solvent accessible region, which 
is spatially and structurally well separated from the (hydrophobic) core. Ideally a potential scaffold 
candidate should already show diverse biochemical function among its family members. In other 
words nature should already have proven, that it is capable of recognizing ligands of great diversity. 
 
1.3 The outer membrane protein A of Escherichia coli 
The outer membrane protein A (OmpA) from E. coli is the most abundant protein component of the 
bacterial outer membrane4 (OM) and consists of a 171 residue transmembrane and a 154 residue 
periplasmic domain5. The TM domain is an 8-stranded !-barrel and the periplasmic domain is 
globular. Both the N- and the C-terminus are located on the periplasmic side of the membrane5. The 
TM domain of OmpA could be expressed and purified independently of the periplasmic domain, 
and its structure has been solved by X-ray crystallography6,7 and NMR spectroscopy8,9 (figure 2a). 
The !-barrel membrane anchor is the characteristic architecture of bacterial and mitochondrial outer 
membrane proteins (OMPs)4. The number of !-strands forming the barrel varies from 8 to 22 and 
the quaternary structure of OMPs is predominantly monomeric10. With one exception11,12, all !-
barrel structures solved so far display an even number of !-strands with the N- and C-termini 
located on the periplasmic side10. 
Electrostatically OmpA - like most !-barrel membrane proteins - is characterized by a hydrophobic 
barrel exterior facing the lipids of the membrane and a hydrophilic barrel interior (figure 2c). I.e. 
this membrane protein family shows an inverted electrostatic profile compared to soluble proteins. 
The loops interconnecting the !-strands of the barrel are hydrophilic and short on the periplasmic 
and long on the extracellular side13 (figure 2a). As is the case for "-helices, the antiparallel !-sheet 
structure fulfills the requirement of saturating all hydrogen bonding capabilities of the backbone's 
carbonyl oxygens and amide hydrogens within the low-dielectric environment of the membrane14. 
The TM !-strands of !-barrel membrane proteins are rich in glycines, tryptophanes and tyrosines. 
The two aromatic members of this trio are mainly found in the interface regions of the membrane 
(figure 2b). The lumen of the smaller barrels (i.e. the eight-stranded OmpA) is tightly packed with 
an interaction network of polar residues' sidechains (figure 2c), whereas the membrane exposed 
surface of the barrel is hydrophobic (figure 2d). 
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Figure 2: a) Ribbon representation of a selected conformer of a solution NMR structure of OmpA 
(1G90.pdb). The !-strands of the barrel are colored cyan and delimit the surface of OmpA being 
inserted in the membrane. b) The characteristic aromatic belt observed in many !-barrel membrane 
proteins is indicated by coloring the backbone bonds of all aromatic residues of OmpA in yellow. c) 
View from the extracellular space into the barrel of OmpA. Charged and polar residues are 
represented in red and yellow, respectively. d) Electrostatic surface potential of OmpA. Negatively 
and positively charged residues are colored and blue, respectively. The outer surface of the central, 
membrane embedded region is largely hydrophobic. e) Superposition of the backbone of OmpA 
(gray; pdb code 2GE4) and a minimal length OmpA carrying the calmodulin EF-hand loop 
(orange; 2JMM). 
 
The surface exposed loops of OmpA have many functions. They are involved in the recognition of 
nutrients such as iron-siderophore complexes and sugars15,16, toxic agents such as bacteriophages or 
colicins17-19 and probably also in the recognition of eukaryotic targets for bacterial pathogens20-22. 
Denatured OmpA can be successfully refolded into detergent micelles23 and lipid bilayers24 by rapid 
dilution of the denaturant. The simplicity of OmpA refolding led to the development of expression 
systems, for which OmpA accumulates as insoluble inclusion bodies25. The inclusion body 
expression system allows purifying denatured OmpA in large quantities (>100 mg per liter of 
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bacterial culture). OmpA has long been a popular model system for the study of membrane protein 
(re)folding. Apart from its relative abundance in the E. coli OM the possibility for easily monitoring 
its folding state by gel electrophoresis26 has mainly accounted for its popularity. 
Extensive mutagenesis data showed the robustness of OmpA and its tolerance towards amino acid 
substitutions, especially in the longer extracellular loops, the short periplasmic turns and the outer 
face of the barrel (Koebnik, J Mol Biol, 285, 1801, 1999). The TM domain of OmpA could be 
circularly permutated without impairing the assembly and function in the OM (Koebnik, J Mol 
Biol, 250, 617, 1995). The extracellular loops could be shortened to a minimal length also without 
impairing the assembly and function in the OM27. This minimal-length OmpA has thereupon been 
proposed as a scaffold molecule and has been named !-barrel platform (BBP), for its potential of 
displaying foreign epitopes on a molecular surface of defined geometry. The grafting of a 12 
residue Ca2+-binding EF-hand sequence of calmodulin from Xenopus laevis in the position of the 
third extracellular loop (L3) of OmpA onto the BBP was a first successful exploitation of this 
minimal-length OmpA as a scaffold28. The BBP carrying the EF-hand sequence could be refolded 
in DHPC micelles and its structure was solved by NMR spectroscopy (figure 2e). 
 
1.4 The receptors of the NPY family neurohormones: the Y-receptors 
Our group has studied a wide variety of neurohormones of the neuropeptide Y (NPY) family using 
high-resolution NMR29-32 and has proposed a model for the binding of these hormones to their 
cognate receptors, that includes membrane-association as an initial step33. Structural and 
mechanistic insight into such binding processes is anticipated to provide a basis both for the rational 
design of novel, and the improvement of already existing receptor-agonists and antagonists. 
Because of the detailed studies that have been conducted in our group on the above mentioned 
neurohormones and the detailed biophysical and biochemical characterization in other groups34-37, 
the receptors for the NPY-family neuropeptides (Y-receptors) have been chosen as a model system 
for the investigation of ligand binding to GPCRs. 
The members of the NPY family are C-terminally amidated polypeptides comprised of 36 amino 
acids and include, besides NPY, the peptide YY (PYY) and the pancreatic polypeptide (PP). Their 
postulated role in the regulation of food-uptake38,39 has stirred vigorous research in many 
pharmaceutical companies. Seven positions are absolutely conserved among all species of NPY, 
PYY and PP. These are Pro5, Pro8, Gly9, Ala12, Tyr27, Arg33 and Arg3540 (figure 3). The first 
atomic resolution structure of a member of the NPY family was obtained for avian PP (aPP) by X-
ray crystallography41 and later for bovine PP (bPP) by solution NMR42. In these structures residues 
1 to 8 form a type-II polyproline helix, which is followed by a type-I !-turn connecting to residues 
15 to 32, which form a "-helix, and the four most carboxy-terminal residues are flexible (figure 3). 
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A surprisingly stable helical hairpin is formed by backfolding of the polyproline helix onto the "-
helix. This structural motif is commonly referred to as the PP-fold. The tertiary contacts, which 
stabilize this fold, are formed by interdigitation of the conserved proline residues in position 2, 5, 
and 8 on the polyproline helix and the tyrosines 20 and 27 on the "-helix43. The solution structure of 
PYY in aqueous solution was shown to be highly similar and to also display the characteristic PP-
fold32,44. Surprisingly, in the highly homologous NPY the backfolding is absent45,46 (figure 3). All 
three members of the NPY family have also been characterized in terms of their structure and 
dynamics in presence of dodecylphosphocholine (DPC) micelles mimicking a biological membrane 
(figure 3). Whereas in aqueous solution PYY and PP are structurally similar, in the presence of 
micelles PYY32 and NPY47 adopt a conformation similar to NPY, with PP taking an alternative 
conformation30. It was found that porcine NPY (pNPY) and PYY (pPYY) interact via the 
hydrophobic face of their C-terminal "-helix with the micelle, while the N-terminus freely diffuses 
in solution. bPP also interacts with the micelle via its C-terminal "-helix, but the N-terminus is also 
loosely associated with the micelle surface. It has been proposed, that Tyr7 mediates this 
association in bPP32, which has a favorable free energy of transport into the water-membrane 
interface48, in contrast to the Asn7 and Ala7 found in pNPY and pPYY, respectively. In addition 
also the C-terminal pentapeptide, which contains particularly important residues for receptor 
binding35, differs structurally in bPP from the pNPY/pPYY pair32. 
The neuropeptides exert their effects via several receptor subtypes called Y-receptors. Four main 
receptors, named Y1-49-51, Y2-52-54, Y4-55,56 and Y5-57, have been cloned so far. All identified Y-
receptors act via pertussis toxin-sensitive G-proteins of the Gi family. They range in size from 375 
to 455 residues and show the prototypical characteristics of GPCRs of subfamily 1b, which are 
ligand binding primarily in the extracellular domain, and a conserved disulfide bridge between 
extracellular loops e1 and e2. The different receptor subtypes are localized in various tissues, both 
in the central nervous system and in the periphery. NPY and PYY bind equally well to the receptors 
Y1, Y2, Y4 and Y5 (nanomolar to sub-nanomolar dissociation constants). Only PP shows 
selectivity towards the Y4-receptor (picomolar dissociation constant). The ability of NPY and PYY 
to bind to four different receptor subtypes may be related to their conformational flexibility, which 
enables the peptides to adopt more than one energetically favorable conformation58, or to the fact 
that they both adopt a conformation that is compatible at all subtypes. 
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Figure 3: Neurohormones of the NPY family. Top: Sequence comparison of porcine NPY (pNPY) 
and PYY (pPYY) with bovine PP (bPP). Residues, which are conserved among all three 
neurohormones throughout all species, are colored red. Bottom: Three-dimensional structures of 
pNPY, pPYY and bPP in water and in DPC micelles. In the structure of pPYY and bPP in water, the 
interdigitating Pro and Tyr residues are colored red and blue, respectively. 
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The table below gives a summary about the most important data concerning the four major Y-
receptors: 
 
Sequence comparison shows, that among these four receptors, the Y1 and Y4 are the most closely 
related (42% sequence homology) while Y2 and Y5 are equally distant from each other and from 
the Y1/Y4 pair40,59,60. 
Little is known about the structure of any of the Y-receptor subtypes, nor have high-resolution 
experimental data on the complex formed between these and the neurohormones been published. 
Nevertheless, in many photoaffinity-labeling studies the contact points between receptors and their 
ligands have been assigned to the extacellular face of the GPCR. In case of human NPY at the 
human Y1-receptor Walker et al. have postulated a prominent role for Asp residues of the Y1-
receptor for binding37. In particular, an Asp residue at the interface between the 6th TM domain and 
the third extracellular loop is conserved in all known Y-receptor sequences (Asp6.59 according to the 
Ballesteros-Weinstein numbering scheme61). Other potential sites of interaction were postulated to 
reside within the N-terminal domain and the first extracellular loop36, such as the converved Asp2.59. 
In appendix F multiple sequence alignments for the four Y-receptors from some major mammalian 
species are shown. 
 
 
 
 
Receptor Y1 Y2 Y4 Y5
amino acids 384 381 375 455
related action
Ki NPY [nM]  0.81a  0.02a  1.9a  0.19a
Ki PYY [nM]  1.1a  0.01a  1.1a  0.06a
Ki PP [nM]  >100a, b  >1000a, b  0.04a, b  27a, b
major 
occurrence
peripheryc, 
hypothalamusd CNSe, f, g intestine, pancreash hypothalamusi
vasoconstriction, 
anxiolysisc, d, j
memory, epilepsy, 
secretionck, l
gastro-intestinal 
regulationm food intakei
Table 1: Biochemical, biophysical and physiological characteristics of the four major families of 
the Y-receptors. a) McCrea, Regul. Pept., 87, 47-58, 2000; b) Small, Proc. Natl. Acad. Sci. U S A, 
94, 11686-91, 1997; c) Wahlestedt, Med. Biol., 64, 85-8, 1986; d) Wahlestedt, Science, 259, 528-
31, 1993; e) Gehlert, Mol. Pharmacol., 49, 224-8, 1996; f) Gerald, J. Biol. Chem., 270, 26758-61, 
1995; g) Rose, J. Biol. Chem., 270, 22661-4, 1995; h) Lundell, J. Biol. Chem., 270, 29123-8, 1995; 
i) Gerald, Nature, 382, 168-71, 1996; j) Grundemar, Br. J. Pharmacol., 105, 45-50, 1992; k) 
Flood, Peptides, 10, 963-6, 1989; l) Potter, Regul. Pept., 25, 167-77, 1989; m) Schwartz, 
Gastroenterology, 85, 1411-25, 1983 
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1.4.1 The Y1-receptor 
The Y1-receptor has a large number of conserved residues (figure 4a). It is therefore not 
straightforward to identify residues that are critical for its function. 
One of the most thorough ways of characterizing the interaction of a peptide ligand with its receptor 
is the systematic single exchange of each residue of the ligand by L-alanine. Such a study was 
carried out to characterize the binding of NPY to the Y1-receptor35. The four natural alanines in 
NPY were substituted by glycine. The most important residues for binding of NPY to the Y1-
receptor were according to this study Pro5, Pro8, Arg19, Tyr20 and the C-terminal positions 27-36 
including Tyr27, Arg33 and Arg35. Whereas for the two C-terminal Arg residues the reduction in 
binding affinity was on the order of 104 to 105-fold, for the other mentioned residues it was around 
103-fold. In constrast to the Y2-receptor N-terminally truncated versions display strongly affinity in 
their interaction with the Y1-receptor. 
The finding that three positively charged arginine residues are critical for binding of NPY to the 
Y1-receptor led to the theory, that the receptor-ligand interaction might be predominantly 
electrostatic and therefore mediated through negatively charged residues on the receptor. This 
hypothesis was tested by replacing negatively charged residues in the extracellular domain of the 
Y1-receptor with alanines37. These mutants were expressed transiently in HeLa cells (epithelial 
cells of a cervical carcinoma of a patient called Henrietta Lacks) and their ability to bind NPY was 
assayed by a radioligand binding assay using 125I-NPY62. The human Y1-receptor (hY1) contains 
30 negatively charged residues of which 14 are located in a putative extracellular domain: 5 in the 
N-terminal part, 2 in extracellular loop 1 (e1), 6 in e2 and 1 in e3.  
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Figure 4: a) Multiple sequence alignment of the Y1-receptor from eight major mammalian species. 
The intensity of the blue coloring indicates the conservation levels of different residues. Above the 
sequence gray rods indicate the predicted TM helices. Gray lines mark the intracellular loops and 
N- and C-termini. Red lines represent extracellular loops. Negatively charged residues in the 
extracellular loops found to be essential for ligand binding are marked with a red asterisk. b) Snake 
plot of the predicted topology of the human Y1-receptor. Solid orange circles indicate sequences, 
which have been grafted onto the scaffold. Solid yellow circles highlight negatively charged 
residues in the extracellular loops found to be essential for ligand binding. Solid green circles mark 
cysteine residues mutated to serine in the grafting constructs. The orange chessboard-patterned 
circles indicate residues, which have been added in a second round of grafting. The blue 
chessboard-patterned circles indicate residues, which are not part of the e1-loop in all predictions 
and have been disregarded for the grafting. 
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None of the mutations introduced in the N-terminus affected NPY binding. In e1 the D104A 
substitution led to a complete loss of affinity for NPY, whereas the E110A mutant didn't show any 
altered NPY binding. In e2 two aspartates, namely Asp194 and Asp200, were essential for NPY 
binding and the mutation of Asp205 resulted in a significant loss of binding affinity (figure 4). The 
other 3 positions proved to be tolerant for substitution. The D287A mutation in the e3 again resulted 
in the complete loss of affinity for NPY. It is interesting to note, that the mutations affecting NPY 
binding the most are all clustered at the top of TM helices 5 and 6. 
 
 
2. Results 
 
2.1 Design aspects 
 
2.1.1 Anchor point geometries of the extracellular loops in GPCRs 
So far atomic structural details at atomic resolution are available for four major different GPCRs. 
These are rhodopsin, the !1- and !2-adrenergic receptors and the A2A adenosine receptor. As of 
December 2009 there have been 24 GPCR structures at atomic resolution deposited in the Protein 
Data Bank (www.rcsb.org). 18 of these are structures on various isoforms of rhodopsin and 4 are of 
the !2-adrenergic receptor. A compilation of the deposited data sets can be found in Appendix E. 
Generally the crystallographic data show high B-factors in the cytoplasmic and in the extracellular 
loops (figure 5a), indicating flexibility in the loop regions, while the TM helices are more rigid. 
This is in accordance with experiences gained during the crystallization process of the GPCRs63 and 
NMR data on the 7TM protein sensory rhodopsin pSRII64. 
We define here the term "anchor points" for the loops of the GPCRs as the C" atoms of those TM 
residues lying at the border between TM helices and loops, i.e. the C" atoms of the terminal residues 
in the TM helices. Two such anchor points form the attachment site for one cytoplasmic or 
extracellular loop. For the three extracellular loops of a GPCR the extracellular anchor points of 
helices II/III, IV/V and VI/VII form the attachment sites for extracellular loops 1 (e1), 2 (e2) and 3 
(e3), respectively. The orientation of these attachment sites relative to each other defines the overall 
topology of the domain formed by the extracellular loops. A comparison of the distances between 
those anchor points on the extracellular side for a selected subset of GPCRs of known structure is 
presented in figure 5b. The spacing between the attachment sites for the three extracellular loops is 
at an average of 13 Å for e1 and e2 and 14 Å for e3 and shows a narrow distribution of roughly +/- 
3 Å. The distances between the loops themselves, say between the C-terminal anchor point of the e1 
and the N-terminal anchor point of the e2 loop, are less well conserved. This indicates that the 
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relative positions of two helices anchoring an extracellular loop are more conserved than the 
relative positions between helices not directly connected by an extracellular loop. The average over 
the distances observed for the analyzed GPCRs served as an estimate for the distances, which can 
be expected in the Y-receptors. 
 
 
The Y-receptor sequences to be grafted were selected based on the predicted topology of the 
individual members of this family, derived from biochemical experiments and bioinformatics tools. 
The extracellular loops are about 15 residues long for e1 and e3 and 30 residues for e2. The 
predicted topology of the Y-receptors and the loops sequences chosen to be grafted are shown in 
figure 4b. 
Figure 5: a) Ribbon representation of 5 selected GPCRs. The ribbons are color coded according to 
the B-factor of the underlying backbone atoms. Blue stands for a low B-factor and red for a high B-
factor. b) Distance statistics for the anchor points observed in a set of 10 selected GPCRs. The 
ribbon representation of the !1-AR has the extracellular loops colored (e1 yellow; e2 red; e3 blue). 
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2.1.2 Anchor point geometries of the extracellular loops in OmpA and minimal-length OmpA 
The importance of the extracellular loops of OmpA for folding has been studied by shortening those 
loops. A minimal-length OmpA, which had all four extracellular loops radically truncated, was 
found to still retain full folding capacity27. The sequence of this minimal-length OmpA compared to 
the wildtype sequence is shown in figure 6a. The ~10 residue extracellular loops of OmpA have 
been replaced with one or two amino acids allowing for the formation of a short !-turn. 
The structure of the !-barrel TM domain of OmpA has been solved both by X-ray crystallography6,7 
and NMR spectroscopy based on NOE restraints8 and refined using residual dipolar couplings in 
addition to the NOE restraints9. A study using the minimal-length OmpA described above as a 
scaffold for the Ca2+-binding EF-hand loop from X. laevis has yielded a high resolution NMR 
structure as well28 (figure 2e). Not surprisingly all five of these structures show higher flexibility of 
the extracellular loops as compared to the !-strands of the barrel and the short periplasmic turns. 
This flexibility is reflected in increased B-factors for the crystal structures and higher rmsd values 
for the NMR structures. This is illustrated in figure 6b, in which the structural elements are color-
coded according to their B-factors or backbone rmsd values. Both crystal structures show a 
pronounced asymmetry of the !-barrel with the strands 4, 5 and 6 being much longer than the other 
five strands. This type of barrel-asymmetry is less distinct in the NMR structures (figure 6a). 
Additionally both crystal structures are lacking defined electron density for a substantial number of 
residues (37 for 1QJP and 22 for 1BXW), all located in the region of the extracellular loops. We 
therefore relied only on the NMR structures for the analysis of the distances and geometries of the 
extracellular loops and their anchor points. We use the term "anchor points" here in analogy to the 
way it was used for the GPCRs, i.e. the C" atoms of the terminal residues in the !-strands of the 
barrel. In figure 6c a statistical analysis of the distances observed in the ten lowest energy 
conformers of the three NMR structures is presented. 
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Figure 6: a) Sequence of the OmpA construct whose structure has been solved by NMR 
spectroscopy (2GE4). The !-strands are indicated by gray rectangles, and the extracellular 
loops are colored red. Cyan letters are mutations compared to our sequence: phenylalanines 
are replaced with tryptophans and the aspartate with a glutamate in our construct. b) 
Ribbon representations of the two crystal structures (1BXW and 1QJP), the two NMR 
structures (1G90 and 2GE4) of OmpA and the minimal-length OmpA carrying the EF-hand 
loop in position of loop 3 (2JMM). The ribbons are color coded according to the B-factor of 
the underlying backbone atoms. Blue stands for a low B-factor and red for a high B-factor. 
c) Distance statistics for the anchor points of the OmpA !-barrel observed in the 3 NMR 
structures (1G90, 2GE4, 2JMM). The top four histograms represent the distances between 
the anchor points connected by the extracellular loops 1 to 4. The average distances 
observed between the anchor points of the extracellular loops of the GPCRs are indicated 
with yellow (e1), red (e2) and blue (e3). The lower 24 histograms represent the distances 
between all other anchor points not directly connected by an extracellular loop. 
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2.1.3 Comparison of anchor points in GPCRs and the scaffold 
The analysis of the distance between anchor points in GPCRs and OmpA shows, that these 
distances are more broadly distributed for OmpA than for the ten selected GPCRs (figures 6c and 
5b). The fact that the distance distribution observed in the GPCRs falls within the distribution found 
in the OmpA structures, suggests that the !-barrel of OmpA might indeed be a good molecular 
scaffold for the extracellular domain of GPCRs. 
It should be noted here, that GPCRs possess 3 and OmpA 4 extracellular loops. Therefore 
depending on the number of Y-receptor loops to be grafted, at least one "acceptor" site in the 
scaffold will remain unoccupied. In order to minimize the possibility of the natural loop residues 
from that site interfering with any potential ligand binding, an acceptor site, not filled with a GPCR 
loop, can be replaced by the minimal, turn-inducing motif found in the study of Koebnik27, allowing 
the formation of a !-turn between the two strands of the barrel. 
 
2.1.4 Construct design 
The frequencies of usage of a given codon are very different in E. coli and eukaryotic cells65,66. As 
the Y-receptor gene sequences were from human, we optimized the loop sequences to be grafted, in 
order to match with the preferred E. coli codon usage. 
In order to determine the compatibility of the Y1-receptor loops with our scaffold, we exchanged 
each of the four extracellular loops of OmpA with each of the three Y1-receptor extracellular loops. 
The resulting 12 constructs were called "one-loop exchange constructs", since only one OmpA-loop 
was exchanged by a Y1-receptor loop and the other three OmpA extracellular loops were left in 
place in these constructs. This is in contrast to the "one-loop graft constructs", where a Y1-receptor 
loop was grafted into one OmpA acceptor site and the other three sites were filled with a minimal 
turn-inducing motif of 1-2 residues, i.e. one Y1-receptor loop was grafted onto the minimal-length 
OmpA. 
Residue D6.59 of the Y1-receptor was identified as one of the most important for high-affinity ligand 
binding67. It is located in the third extracellular loop of the Y1-receptor (Y1e3) (figure 4). We 
therefore grafted the Y1e3 loop (Cys294 was replaced with a serine residue in these constructs) 
onto all four acceptor sites of the OmpA scaffold, replacing the other three loops of OmpA with a 
minimal turn-inducing motif. These four constructs were named "one-loop graft constructs". 
The ultimate goal of this study was to transfer all three extracellular loops of a Y-receptor 
simultaneously onto the minimal-length OmpA scaffold. Theoretically there are 24 different ways 
of arranging three donor loop sequences on the four acceptor sites of the scaffold. However, not all 
of these topologies are expedient. In order to rule out unpromising constructs, we calculated a 
"mismatch score" for each of the 24 possible arrangements. Distance mismatches between all the 
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relevant anchor points (i.e. those six which were attached to a donor loop sequence, but not those 
two which were connected to a minimal turn-inducing sequence) of the scaffold and those of an 
average GPCR were calculated and summed (figure 7). Those constructs giving the lowest 
mismatch scores were considered the most promising candidates. Among the group of candidates 
with low mismatch score, only those with a correct sequential arrangement of the loops (i.e. the C-
terminus of e1 should be followed by the N-terminus of e2) were considered. From these we have 
selected four topological arrangements for the grafting of all three Y1-receptor extracellular loops 
onto the minimal-length OmpA scaffold simultaneously and named these constructs "three-loop 
graft constructs". These four constructs were given the names Y1L1, Y1L2, Y1L3 and Y1L4 (figure 
7). 
 
 
Figure 7: The mismatch scores of the 24 different topologies with which the three extracellular 
loops of the Y1-receptor can be arranged on the four acceptor sites of the minimal length OmpA 
scaffold. Topologies with a correct sequential arrangement of the donor loops are colored orange 
and green, with the latter highlighting the four expressed. The tables at the bottom compare the Y1-
receptor loops and the minimal linker sequences with the native OmpA loops, which they are 
replacing in terms of loop length (!N), isoelectric point (!pI), number of negatively and positively 
charged residues in the loops ("- and "+). 
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2.2 Synthetic aspects 
 
2.2.1 Expression, purification and refolding of wt-OmpA 
OmpA, which has been denatured by chaotropic agents, can be successfully refolded into detergent 
micelles23 and lipid bilayers24 by rapid dilution of the denaturant. The deletion of the DNA 
sequence coding for the periplasmic export signal results in the accumulation of OmpA in the 
cytoplasm in the form of insoluble inclusion bodies. This led to the development of expression 
systems which allow to purify denatured OmpA in large quantities (>100 mg per liter of bacterial 
culture)25. We have overexpressed unlabeled and 15N-labeled OmpA in that way and purified it 
according to established protocols24,68. 15N-labeled OmpA and all derived constructs were expressed 
in M9 minimal medium containing 15NH4Cl as the sole nitrogen source. OmpA was purified in 
denatured form in 8 M urea, with yields of ~200 and ~100 mg per liter of unlabeled LB- and 15N-
labeled M9-culture, respectively. 
The folding state of many bacterial OMPs, including OmpA, can be conveniently monitored by 
non-denaturing SDS-PAGE26. The refolding behavior of OmpA was studied by diluting an urea-
denatured OmpA solution into acetate (pH 4), HEPES (pH 7) or borate (pH 10) buffers containing 
!-dodecyldimaltoside (DDM)69, !-octylglucoside (!-OG)69, tetraethyleneglycol monooctylether 
(C8E4)
69,70, N-lauryldimethyl amineoxide (LDAO)69, dodecylphosphocholine (DPC)69,71 or 
dihexanoylphosphatidylcholine (DHPC)72,73 at concentrations well above their critical micellar 
concentration (cmc) values and at a detergent/protein ratio >500. The table below shows the 
relevant biophyscial constants of these detergents, along with the concentrations that were used and 
the resulting detergent:protein and micelle:protein ratios. 
 
Detergent Charge 
Molecular 
Weight 
[g/mol] 
Critical 
micelle 
conc. 
[mM] 
Aggregation 
number 
used 
conc. 
[mM] 
detergent: 
protein 
ratio 
micelle:protein 
ratio 
DDM Nonionic 511 0.2 110-140 13 524 >3.6 
!-OG Nonionic 292 19-25 90 100 4014 >33 
C8E4 Nonionic 306 8 82 25 1013 8.3 
LDAO Zwitterionic 229 2 69-73 14 560 >6.6 
DPC Zwitterionic 352 1.5 50-60 14 568 >8.3 
DHPC Zwitterionic 454 15 19-35 66 2643 58 
Table 2: Biophysical constants of the detergents used in our refolding screen. All values were taken 
from Sanders, 2006
74
. DDM:  !-dodecyldimaltoside, !-OG:  !-octylglucoside, C8E4:  
tetraethyleneglycol monooctylether, LDAO: N-lauryldimethyl amineoxide, DPC:  
dodecylphosphocholine, DHPC:  dihexanoylphosphatidylcholine 
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The refolding efficiency was monitored by SDS-PAGE. It increased with increasing pH (figure 8a). 
Incubation of the refolding reaction for 5 h at 30 °C in 10 mM borate, 1 mM EDTA, pH 10 resulted 
in near complete folding for the nonionic detergents DDM and  !-OG and the zwitterionic DHPC 
and DPC. The nonionic detergent C8E4 and the zwitterionic LDAO resulted in only partial folding 
at pH 10 (figure 8a). 
15N-labeled OmpA was refolded at pH 10 into !-OG. Not surprisingly the resulting NMR spectrum 
showed less than the expected 168 peaks due to fast amide hydrogen exchange of solvent exposed 
loop residues at pH 10. Lowering the pH to <7 resulted in partial precipitation and a deterioration of 
the NMR spectrum. OmpA was finally refolded into DHPC micelles according to a refolding 
protocol published for the closely related OmpX75, which yielded spectra of good quality at pH 6.5, 
as can be seen in figure 8b. 
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2.2.2 Expression, purification and refolding of the one-loop exchange and one-loop graft 
constructs 
All 12 possible one-loop exchange constructs were expressed and purified in unlabeled form and a 
selected subset in 15N-labeled form with yields similar to the ones obtained for wt-OmpA. 
Concerning the refolding efficiency, the one-loop exchange constructs showed a similar pH 
dependence than observed for wt-OmpA, i.e. increasing efficiency with increasing pH (data not 
shown). In figure 9a the refolding behavior of all 12 constructs in a selected detergent (LDAO) is 
depicted along with a more detailed screening for a few of the constructs (figures 9b and 9c). 
 
Figure 8: a) Refolding of OmpA in four different detergents (for abbreviations and concentrations 
of the detergents see table 2) at pH 7 and pH 10. The denatured form of OmpA corresponds to a 
heat-denatured sample in presence of SDS. b) [
15
N,
1
H]-HSQC spectra of OmpA in "-OG at pH 10 
(left spectrum) and in DHPC at pH 6.5 (right spectrum). 
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These results demonstrate the compatibility of the Y1-receptor loop sequences with the expression 
and folding of the OmpA !-barrel core. Note that the clear separation of folded and bands for wt-
OmpA and the constructs carrying the Y1e1 and Y1e3 loops is absent in the constructs carrying the 
Y1e2 loop. To test that this absence is not due to the inability of the Y1e2 constructs to adopt a 
stable tertiary structure, we conducted NMR experiments, which indicated through their chemical 
shift dispersion, that folded constructs were indeed present. 
Figure 9: Refolding behavior of all 12 one-loop exchange constructs studied by SDS-PAGE. The 
term "unfold" always refers to the heat-denatured of the respective species. a) Y1e3 loop exchange 
constructs: OmpA loop positions are numbered d1 to d4. I.e. d1Y1e3 designates, that the Y1e3 loop 
replaces the extracellular loop 1 of OmpA. Left column: All four constructs carrying the Y1e3 loop 
were refolded in two different detergents (DPC and DHPC) at four different pH values (4, 7 and 
10). Right lane: Their refolding behavior in a set of detergents at the most favorable pH is 
illustrated. b) Y1e1 loop exchange constructs: Left: The construct carrying the Y1e1 loop in the d1 
position was refolded in two different detergents (DPC and DHPC) at four different pH values (4, 7 
and 10). Right: The refolding behavior of all four Y1e1 loop exchange constructs at pH 10 in LDAO 
is compared to the behavior of wt-OmpA. c) Analogous to b), but for the Y1e2 loop exchange 
constructs. 
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The four one-loop graft constructs could be expressed and purified in the same manner as the wt-
OmpA and the one-loop exchange constructs with similar yields. Refolding trials with these 
constructs in DDM, !-OG, LDAO and C8E4 micelles showed less pH dependence compared to wt-
OmpA, as maximum refolding yields could be achieved both at pH 7 and 10. However, these 
maximum yields were at most 50% (in !-OG and C8E4), which is significantly lower than the 
almost complete refolding achieved for wt-OmpA (in DDM and !-OG) (figure 8a). 
A priori, a different migration behavior in SDS-PAGE of the constructs in micellar solution from 
heat- or chemically denatured forms of the same construct is not a proof of the assumption of a 
defined tertiary fold. However, the signal dispersion in the proton dimension of a protein is a good 
indication for the presence or absence of a defined tertiary fold. The dispersion found in the [15N, 
1H]-HSQC spectra (figure 10) clearly indicates such a fold. It should be noted here, that the 
refolding of these one-loop graft constructs showed only ~50% efficiency. No attempt was made at 
Figure 10: Refolding efficiency of four one-loop graft constructs. The Y1e3 sequence was grafted 
onto the minimal length OmpA (miniOmpA) in all four acceptor positions (denoted as d1 to d4). 
The SDS-PAGE shows a decreased refolding efficiency compared to wt-OmpA, which can be 
refolded completely at pH 10. For each of the four constructs the refolding at two different pH 
values and four different detergents is shown. "Unfold" refers to the heat-denatured form of the 
respective construct. The NMR spectra were all acquired with 0.5 mM protein concentration in 10 
mM borate buffer at pH 10 and in the presence of 14 mM LDAO at 47 °C. 
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increasing the yields of the refolding reaction or at separating the folded from the unfolded 
component, as these one-loop graft constructs were only intermediates on the way to constructs 
carrying all three extracellular loops of the Y1-receptor (three-loop graft constructs). 
 
2.2.3 Expression, purification and refolding of the three-loop graft constructs 
The four three-loop graft constructs Y1L1, Y1L2, Y1L3 and Y1L4 could be expressed and purified 
with similar yields than wt-OmpA. 
As the removal of the natural extracellular loops of OmpA and their replacement with the Y1-
receptor loops or minimal turn-inducing motifs represents a substantial change of the overall 
sequence of OmpA, the ability of the constructs to assume a defined three-dimensional structure 
had to be assayed first. This was done in the same way as described for the one-loop exchange and 
one-loop graft constructs. A large set of refolding conditions were screened by SDS-PAGE in order 
to find the conditions giving the best yields of folded constructs. The SDS-PAGE assay allowed the 
assessment of a relatively large number of conditions in parallel and required only small amounts of 
sample (micrograms of protein) and lipids (milligrams). The most promising conditions were 
refolded on a larger scale (milligrams of protein and hundreds of milligrams of lipids) and subjected 
to NMR spectroscopic analysis. Figures 11 and 12 show the elcetrophoretic migration behavior of a 
selected subset of refolding conditions of the four constructs on SDS polyacrylamide gels and 
[15N,1H]-HSQC spectra acquired under the most promising conditions. Note that the migration 
behavior of the folded compared to the unfolded species is reversed in the four constructs when 
compared to the other species studied so far: While folded OmpA (figure 8), the one-loop exchange 
constructs (figure 9) and the one-loop graft constructs (figure 10) migrate slower than the respective 
unfolded speices, the three-loop graft constructs all migrate faster in the folded state than in the 
unfolded sate. 
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A refolding screen was conducted, spanning the pH range from 4 to 10 and a variety of 6 different 
detergents (DDM, !-OG, LDAO and C8E4, DPC and DHPC) at concentrations well above their cmc 
values and at a detergent/protein ratio >500 (table 2). Additionally a group of additives commonly 
known to influence protein refolding, such as L-arginine, glycerol and guanidinium hydrochloride 
(all at various concentrations), were included in the refolding screen, but had no beneficial effect on 
refolding yields (data not shown). A number of different ionic milieus were also tested through the 
addition of ammonium acetate or potassium chloride, but also failed to increase the refolding 
efficiency (data not shown). 
While the screen yielded acceptable refolding efficiencies for Y1L1 and Y1L2, Y1L3 and Y1L4  
could only be refolded to very minor extents under the screened conditions. We therefore tried to 
use the most promising conditions as a starting point for further improvements. Because we had 
already tested a large number of different refolding buffer conditions our efforts were directed at 
improving refolding yields of promising starting conditions by using different refolding techniques 
for a given buffer composition. Initially our refolding screens were conducted by rapidly diluting 
the denatured protein in 8 M urea into the refolding buffer. We first wanted to know, whether urea 
as a denaturant might be responsible for the low refolding efficiency. To test this hypothesis the 
Y1L3 and Y1L4 constructs were re-expressed and purified this time in guanidinium hydrochloride 
(GdnHCl) and not urea as denaturant. It was found, that refolding from the GdnHCl state didn't 
have any influence on the refolding efficiency (data not shown). 
Figure 11: SDS-PAGE analysis of the refolding behavior of the four three-loop graft constructs 
Y1L1, Y1L2, Y1L3 and Y1L4. Refolding efficiencies at three different pH values and in six different 
detergents are shown. "Unfold" refers to the heat-denatured form of the respective construct. 
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As a next parameter the mixing speed of the denatured proteins with the detergent buffer was 
varied. Refolding was carried out by mixing the urea or GdnHCl denatured samples as slowly as 
possible by means of a peristaltic pump with the refolding buffer. This strategy resulted in 
significantly increased refolding yields for the Y1L3 and Y1L4 constructs (figure 12), suggesting 
that the presence of high amounts of unfolded proteins at the same time might interfere with their 
correct folding. Additionally lowering the temperature of the refolding reaction to 4 °C showed 
some beneficial effects.  
 
After this optimization Y1L3 and Y1L4 could be refolded to ~50%, which was enough to obtain 
samples of satisfactory quality for initial NMR studies. In the case of Y1L1 and Y1L2 these new 
refolding conditions didn't result in better refolding results, but rather gave less refolded product. 
Figure 13 depicts [15N,1H]-HSQC spectra of all four constructs: Y1L3 and Y1L4 were refolded 
unter the new improved conditions, while Y1L1 and Y1L2 were refolded according to the old 
protocol by simple rapid dilution into detergent containing buffer. 
It should be noted here, that all four three-loop graft constructs showed a higher electrophoretic 
mobility in the folded state than in the unfolded state. This is opposite to what is observed for wt-
OmpA, the one-loop exchange and the three-loop graft constructs. The presence of a larger number 
of sharp peaks in the random coil region in the NMR spectra of either the three- (figure 13) or one-
loop graft constructs (figure 10) compared to wt-OmpA (figure 8) indicates that the wt-OmpA 
extracellular loops are less flexible than the Y1-loops present in the constructs. 
Figure 12: Refolding optimization for the Y1L3 and Y1L4 constructs. "Unfold" refers to the heat-
denatured form of the respective construct. a) Initial refolding trials for the two constructs at pH 10 
in a number of different detergents. In DHPC (arrows) and "-OG (asterisk) a faint band of folded 
protein can be observed. b) Increased refolding yields after optimization of the refolding conditions 
and procedures in DHPC micelles. c) Refolding screen of Y1L3 in the presence of different DHPC 
concentrations. 
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Figure 13: [
15
N,
1
H]-HSQC spectra of the four three-loop graft constructs. Protein 
concentration was ~0.5 mM in 3% DHPC, 20 mM sodium phosphate, 100 mM NaCl at pH 6.5 
and 47 °C. 
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The high flexibility of the grafted loops results in a number of peaks in the NMR spectra, which are 
much sharper than expected for a protein-micelle complex of ca. 100 kDa. A similar behavior of the 
extracellular loops is also observed in wt-OmpA8, however less pronounced than in the three-loop 
graft constructs (see figures 8 [OmpA] and 13 [three-loop graft constructs]). Assuming a sharp 
transition from a rigid !-barrel core, yielding broad resonance lines, to a much more flexible loop 
region, giving rise to sharp lines, one would expect ~100 broad signals from the !-barrel core and 
~60 sharp signals from the loops for the three-loops graft constructs. The actual number of observed 
sharp peaks is ~40 and for the broad ones ~100 in the case of Y1L3. The non-observable resonances 
are probably rendered invisible by dynamics on the milli- to microsecond timescale, broadening 
their lines beyond detection limits. 
Analysis of the refolding behavior by SDS-PAGE indicate an alteration in the folding efficiency 
upon exchanging native OmpA loops with the loops of the Y1-receptor. The folding mechanism of 
OmpA has been studied in great detail and the extracellular loops are thought to play a significant 
role in this folding process25,76,77. It is therefore not surprising that changes in those loops have an 
influence on the folding behavior. Preliminary NMR studies corroborate these findings. Spectra of 
the OmpA mutants are generally of lower quality than the ones of wildtype OmpA. 
 
2.3 Interaction studies 
 
The prime goals of our grafting attempts were: i) being able to obtain a stably folded chimeric 
receptor molecule displaying all three extracellular loops of a Y-receptor and ii) obtaining a system 
in which ligand binding affinity of the grafted loops can be observed, even when outside their 
natural 7 TM context. The accomplishment of the first aim could be demonstrated for the four 
three-loop graft constructs based on the analysis of the electrophoretic mobility and the signal 
dispersion in NMR experiments. In order to test whether our constructs exhibited ligand binding 
capability we chose to carry out chemical shift mapping experiments. For that purpose for at least 
one of either the ligand or the receptor constructs resonance assignments should be available.  
2.3.1 Assignment of the neurohormones bound to DHPC micelles 
For performing preliminary interaction studies, we decided to assign the backbone amide 
resonances of the peptide ligands of the Y-receptors in the presence of DHPC micelles, because 
these 36 amino acid peptides can be assigned relatively easily. Assignments of the neurohormones 
bound to DPC micelles are available, but only for very few resonances could this assignment be 
transferred to the spectra recorded in the presence of DHPC micelles. Briefly, spin system types 
were identified using a 15N-resolved TOCSY experiment. Based on a NOE-relayed HSQC 
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experiment, these spin systems were linked into fragments, which in turn could be unambiguously 
assigned once they consisted of two or more spin systems. Complete assignment of the backbone 
amide resonances could be obtained for pNPY, two mutants of pNPY (pNPY-R33L and pNPY-
R35L), pPYY and bPP bound to DHPC micelles. A table of all the assigned the chemical shifts of 
the neurohormones can be found in appendix H. 
 
2.3.2 Chemical shift mapping studies with 15N-labeled neurohormones and unlabeled three-loop 
graft constructs 
With the assignment of the peptide ligands in hand we conducted preliminary interaction studies 
between the ligands and our receptor constructs. To this end we titrated 15N-labeled neurohormones 
with unlabeled receptor constructs and observed the changes in the [15N,1H]-HSQC spectrum of the 
ligand. In figure 14 the changes in the spectra of NPY upon addition of 2 and 20 equivalents of the 
receptor constructs are shown. Whereas for the addition of Y1L1 and Y1L2 the spectra of NPY 
show no changes, Y1L3 and Y1L4, when added in excess, induce profound alterations to the 
spectra of NPY.  
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Figure 14: [
15
N,
1
H]-HSQC spectra of NPY and of NPY in the presence of 10 equivalents of the four 
three-loop graft constructs. A clear difference in the spectra is seen after addition of Y1L3 and 
Y1L4. Below the spectra the peak volumes of the NPY resonances in presence of 10 equivalents 
relative to NPY without the receptor constructs are plotted. Whereas Y1L1 and Y1L2 show only 
small changes, the volumes of the C-terminal residues of Y1L3 and Y1L4 are reduced to below 20% 
of their initial values. 
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In our case no shift in peak position but a decreased in peak intensity was observed, which is only 
consistent with a slow exchange process: A ligand that is in equilibrium between a bound and free 
state is expected to show different chemical shifts in the two states. If the exchange rate between the 
bound and free form is much smaller than the difference in chemical shift between the two states, 
two separate resonances per individual spin are expected: one arising from the free and one from the 
bound state (slow exchange). If, however, the exchange rate is much bigger than the difference in 
chemical shift between the two states, only one resonance can be observed (fast exchange regime). 
The position of that resonance will be shifted depending on the equilibrium constant for the 
exchange process. In intermediate cases, where the rate constant of the exchange process is in the 
range of the chemical shift difference between the two states, a pronounced increase in the line 
widths of the resonances can be observed. This "exchange broadening" can broaden a peak beyond 
detection. The excessive broadening of a resonance leading to its disappearance from the spectrum 
could be explained either through such an unfavorable exchange or a dramatic increase in apparent 
molecular weight of the ligand, when it is in complex with a receptor construct. 
Because of the fact that no shift in peak position occurs and because the remaining peak is not 
particularly broadened, we propose that the remaining peak intensity is due to the unbound ligand. 
The signal due to the bound ligand is shifted, as expected in slow exchange, but broadened due to 
intermediate exchange beyond detection. In the alternative case of fast exchange a shift in position 
must occur. 
Fundamentally the line width of an NMR signal is dependent on the tumbling rate (quantified as the 
correlation time, !c) of the molecule from which it arises. In a solvent with a given viscosity the 
tumbling rate in turn is primarily determined by the size of the molecule. In principle, complex 
formation may increase the size of the mixed micelle so much that additional, strong line-
broadening could occur. However, the fact that resonances of the protein are observable argues 
against this, and only leaves the possibility that complex formation leads to recruitment of more 
than one loop-grafted protein to the complex, which is highly unlikely. Instead, the disappearance 
of the C-terminal peaks is more likely due to an exchange process that may be due to small 
conformational exchange processes in the receptor-bound state. 
Integration of the peaks in the [15N,1H]-HSQC allows to quantify the changes in the ligand's signals 
upon addition of receptor construct. In figure 14 the volume changes of the NPY signals upon 
addition of an excess of receptor constructs are shown. The plots show clearly that the C-terminal 
residues are much more affected than the N-terminal ones. This implies a binding of the C-terminal 
"-helix of NPY to the receptor construct, while the N-terminus is moving freely in solution. This is 
in agreement with the identification of the C-terminal residues of NPY being more important for 
receptor binding than the N-terminal ones35,58. Titration of the other two members of the NPY 
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family of neurohormones, PP and PYY, gave similar results (figure 15). Whereas NPY shows a 
very clear difference in the effects of the Y1L3 and Y1L4 receptor constructs on the N- and C-
terminus, this behavior is less pronounced with PYY and particularly with PP. Considering that the 
binding profile of PP to the Y receptor subtype is different than from NPY and PYY, this may in 
general indicate a slightly different binding mode. 
 
Figure 15: Interaction profiles of pNPY (blue), pPYY (orange) and bPP (green) with a 10-fold 
excess of Y1L3. 
218  
In our eyes the specificity of the interaction between the Y1L3/Y1L4 receptor construct pair and the 
neurohormones of the NPY family is corroborated by the fact, that both Y1L1 and Y1L2 don't show 
a significant interaction with the neurohormones, and can therefore by considered as negative 
controls. Also the wt-OmpA and the minimal length OmpA did not have any influence on the 
spectra of the neurohormones (data not shown). To gain additional support for this view we 
conducted a competition experiment, in which unlabeled NPY competes for the binding to 
unlabeled receptor construct with 15N-labeled NPY (figure 16). To a sample of 15N-NPY in the 
presence of 10 equivalents of unlabeled Y1L3 an excess of 50 equivalents of unlabeled NPY was 
added. The re-appearing of all the NPY resonances in the [15N,1H]-HSQC shows that the unlabeled 
NPY competes with 15N-NPY for the binding to the Y1L3 receptor construct. As negative controls 
the effect of Y1L3 on the spectra of ubiquitin and two NPY mutants (NPY-R33L and NPY-R35L) 
with reduced binding affinity to the Y-receptor in vivo35 were investigated. The spectra of ubiquitin 
showed no change upon addition of several equivalents of Y1L3 (data not shown). The two binding 
deficient NPY mutants showed a markedly decreased affinity for Y1L3 (figure 16). In summary 
these findings confirm our view of a specific interaction of the neurohormones of the NPY family 
with the receptor constructs Y1L3 and Y1L4. 
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Because the refolding efficiency of the four constructs is less than 100% it is not a priori clear that 
it is the folded component of the mixture, which is interacting with the neurohormones. Given the 
lack of a method to separate the folded from the unfolded construct and the failing attempts at 
trying to achieve 100% refolding, we chose to "refold" Y1L3 under unfavorable conditions 
(resulting in almost 100% unfolded Y1L3 as judged by SDS-PAGE) and testing the effect of this 
unfolded form of the receptor construct on the spectra of NPY. We can proudly say that from the 
Figure 16: Specificity of the interaction of NPY with Y1L3. a) Unlabeled NPY is able to compete 
with 
15
N-labeled NPY for the binding to Y1L3. Addition of 50 eq. of unlabeled NPY (right spectrum) 
to a sample of 
15
N-NPY (left spectrum) treated with 10 eq. of unlabeled Y1L3 (middle spectrum) 
leads to reappearance of the resonances from 
15
N-NPY. b) A mutant of NPY (NPY-R35L) with a 
known decreased binding affinity to the Y1-receptor in vivo shows weaker interaction with Y1L3 
than does wt-NPY. 
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screening of refolding conditions we had a large number of such unfavorable conditions at hand. 
The most appealing seemed to carry out the refolding in the same detergent that yielded good 
refolding results, but instead of the favorable pH 10 at the unfavorable pH 4. However, at pH 4 the 
receptor constructs mainly precipitated from the detergent solution, leaving no micelle 
integrated/associated misfolded protein present in solution. We therefore chose to carry out the 
"refolding" at the favorable pH 10, but using an unfavorable detergent. In the zwitterionic detergent 
DPC the refolding efficiency of Y1L3 was essentially zero also at pH 10, without showing any 
protein aggregates precipitating out of the solution. NPY was titrated with Y1L3 refolded in DPC at 
pH 10 and addition of 15 equivalents of unfolded Y1L3 to NPY had much less effect than the 
addition of 10 equivalents of the partially folded Y1L3 (figure 17). This lead us to believe that it 
should be indeed the folded fraction of the receptor constructs, which is responsible for the 
interaction with the neurohormones. 
 
Figure 17: Comparison of the interaction profile of NPY with a mixture of folded and unfolded 
Y1L3 (in DHPC; left) and completely unfolded Y1L3 (in DPC; right). 
221  
2.3.3 Chemical shift mapping studies with 15N-labeled three-loop graft constructs and unlabeled 
neurohormones 
To obtain complementary information about the interaction we sought to titrate the 15N-labeled 
receptor constructs with unlabeled neurohormones and observe, what changes are induced in the 
spectra of the receptor. To this end we have expressed all four receptor constructs in 15N-labeled 
form. They were refolded into DHPC detergent micelles and titrated with unlabeled neurohormones 
(figure 18). Surprisingly the [15N,1H]-HSQC spectra of the receptor constructs do not show any 
changes in the peak patterns upon addition of NPY. A possible explanation for this unexpected 
behavior is, that the residues of the receptor constructs, which are responsible for the interaction 
with the neurohormones, are not visible in the spectra. That this might be indeed the case is 
corroborated by the observation that the actual number of observed sharp (and thus most likely 
originating from the flexible loops) peaks in the receptor construct is ~40 out of an expected 59. 
The non-observable peaks are probably absent due to dynamics on the milli- to microsecond 
timescale, broadening their lines beyond detection limits. 
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2.3.4 Backbone assignment of Y1L3 
In order to get to know, which residues are not involved in the binding of the neurohormones, we 
set out to obtain resonance assignments for as many signals in the Y1L3 receptor construct as 
possible. The commonly used assignment strategies for membrane proteins of this size are based on 
triple resonance experiments and require a high level of deuteration. To this end, we expressed 
Y1L3 in triple labeled minimal medium containing 15NH4Cl and deuterated glucose (
2H7,
13C6-D-
Glucose) as the sole nitrogen and carbon source, respectively. 99% D2O served as the solvent. With 
this expression strategy a high level of deuteration can be achieved. In order to allow proton NMR 
experiments 1H has to be re-introduced at the exchangeable amide nitrogens. In our case this is 
achieved by purifying the protein under denaturing conditions in H2O-based solvents. The high 
level of deuteration is absolutely necessary for triple resonance experiments with membrane 
Figure 18: Interaction studies of 
15
N-labeled receptor constructs with unlabeled NPY. HSQC 
spectra covering the full amide proton chemical shift range (upper row) and zoomed in the random 
coil region of the amide proton chemical shift range (lower row) are depicted in the absence 
(black) and in the presence (red spectra) of 10 equivalents of unlabeled NPY. 
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proteins of this size. The comparison between a fully protonated and a highly deuterated sample 
shown in figure 19b illustrates the dramatic improvement in signal-to-noise ratio brought about by 
high levels of deuteration. 
Backbone assignment was carried out with help of a HN(CO)CACB and a HNCACB experiment. 
Out of the 32 expected backbone amide resonances of the long e2-loop (34 amino acids, 2 of which 
are prolines) 31 could be assigned. Of the shorter e1- and e3-loops (13 and 14 expected resonances, 
respectively) only 3 backbone amide resonances from each loop could be assigned. This shows that 
the exchange broadening is exclusively a problem for these two loop sequences. We think we can 
exclude the possibility, that the absence of those loop resonances is a molecular weight effect, 
because we can see many of the peaks of the "-barrel in our spectra. 
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Figure 19: Assignment of Y1L3. a) Assignments of grafted Y1-receptor loops are highlighted in 
yellow (e1-loop), red (e2-loop) and blue (e3-loop). b) The effect of deuteration on the signal-to-
noise ratio illustrated by a slice through the [
15
N,
1
H]-HTROSY spectrum at a 
15
N chemical shift of 
112.5 ppm of a protonated (blue) and deuterated (red) sample. c) Assignment strategy based on 
triple resonance spectra illustrated on a series of matching HNCACB strips. 
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2.3.5 The effect of increasing the flexibility of the grafted loops 
We tried to increase the flexibility of the grafted loops - primarily of the e1- and e3-loop sequences 
- by inserting flexible glycine-serine linkers of different length in between the anchor sites on the 
scaffold and the Y1-receptor's extracellular loops. Derived from the construct Y1L3 we generated 4 
derivatives: one in which each Y1-receptor loop was flanked at both ends by a Ser-Gly dipeptide 
and one in which it was flanked by a Ser-Gly-Ser-Gly tetrapeptide (Y1L3-GS and Y1L3-GSGS). 
Furthermore two analogous constructs, in which only the e1- and e3-loops were flanked, but not the 
e2-loop, were created (Y1L3-gs and Y1L3-gsgs). We observed a significantly different refolding 
behavior of the different linker-flanked constructs. Only the two constructs carrying the flanking 
linker sequences at all three loops were able to fold equally well as the parent Y1L3 construct. 
Whereas the refolding efficiency of these constructs was similar to Y1L3 (~80% efficiency) the two 
constructs carrying the linker sequences only on the e1- and e3-loop only folded with an efficiency 
of only ~50%. For the sake of completeness we also expressed constructs carrying the di- or 
tetrapeptide linker sequences only at the e2-loop (Y1L3-e2gs and Y1L3-e2gsgs). These showed the 
same folding deficiency that was observed for Y1L3-gs and Y1L3-gsgs (figure 20). 
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The [15N,1H]-HSQC spectra of Y1L3-GS and Y1L3-GSGS show additional peaks relative to Y1L3. 
Most new peaks, however, are in the region of the spectrum, which is characteristic for the glycine 
and serine resonances, and the peaks thus most likely arise from the glycine-serine linkers 
themselves, rather than from the intervening loop sequences. Overlays of the spectra from Y1L3 
Figure 20: Comparison of the central region of [
15
N,
1
H]-HSQCs of Y1L3 (black) and Y1L3-GS 
(red, left side) and Y1L3-GSGS (red, right side). A comparison of the refolding behavior and the 
interaction profiles of the four constructs Y1L3-gs, Y1L3-gsgs, Y1L3-GS and Y1L3-GSGS with that 
of Y1L3 is shown below the NMR spectra. 
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and both Y1L3-GS and -GSGS are shown in figure 20. Not surprisingly the glycine-serine linker 
flanked constructs showed a decreased affinity towards the neurohormones (figure 20). 
 
2.3.6 Ion exchange purification of 100% folded three-loop graft constructs and chemical shift 
mapping studies with neurohormones 
We would like to repeat here, that all the interaction studies carried out between the neurohormones 
and the receptor constructs have been performed with a mixture of folded and unfolded receptor 
constructs. Even though we had indications, that it is indeed the folded fraction of the construct 
which is responsible for the interaction with the neurohormones, a definitive proof would only be 
the repetition of the experiments with 100% folded receptor constructs. It is possible to resolve the 
unfolded from the folded species on an analytical scale by means of non-denaturing SDS-PAGE. It 
should be possible therefore to achieve the same thing, on a preparative scale, by means of size 
exclusion chromatography. The application of this technique, however, requires large column 
volumes. Especially if the effective size difference that should be resolved, is small. This seems to 
be the case for the receptor constructs, as a resolution of the two folding states by SDS-PAGE was 
only possible after careful optimization of the conditions, under which the SDS-PAGE was 
performed. Since we are working here with a membrane protein, the presence of a detergent above 
its critical micellar concentration at all times is critical to the stability of the folded protein. The 
high cost of DHPC, in which the receptor constructs showed the highest fraction of folded protein, 
precludes the use of this detergent in size exclusion chromatography. 
Ion exchange chromatography is a method for separation of molecules based on their charge. This 
seems to exclude this technique for the separation of two isoforms of the same protein, as both have 
exactly the same primary sequence, and hence have identical numbers of charged residues. 
However, differently folded protein species are expected to display on their surface different 
numbers of charged groups, which are moreover in different orientation relative to each other, 
resulting in distinct interaction strengths with the charged groups of an ion-exchange resin. The 
small column volumes used in ion exchange chromatography makes this technique also appealing 
to detergent containing buffers. With isoelectric points at pH 5.5 and 4.7 for wt-OmpA and the 
receptor constructs, respectively, these molecules are charged negatively in all our refolding and 
further processing steps. To make use of ion exchange chromatography for the separation of 
negatively charged molecules anion exchange chromatography is the method of choice. Our 
refolding has always been carried out in borate buffer at pH 10. As borate is charged highly 
negatively at this pH it is not a good buffer salt for anion-exchange chromatography. We therefore 
switched the refolding buffer to piperazine or glycine, both also at pH 10. 
Initial trials were carried out with wt-OmpA and the cheap detergent LDAO in which wt-OmpA 
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folds to about 50% at pH 10 (figure 8). This mixture was loaded onto a monoQ anion exchange 
column with a column volume of 1 ml, and bound molecules were eluted with a NaCl gradient. The 
chromatogram of wt-OmpA in LDAO does not show two clearly resolved peaks. Analysis of the 
collected fractions, however, showed that folded wt-OmpA could – at least partially – be separated 
from unfolded wt-OmpA (data not shown). With this result we set out to try our luck with the 
receptor construct Y1L3. The refolding efficiency of this construct in LDAO micelles is only 
around 10% as judged by the relative band intensities on polyacrylamide gels. However, this should 
be sufficient for the assessment of the usability of ion exchange chromatography in separating 
folded from unfolded Y1L3. The chromatogram of this purification is shown in figure 21a along 
with the SDS-PAGE analysis of the collected fractions. In the chromatogram at around 125 mM 
NaCl a sharp peak is seen in the UV absorption. SDS-PAGE revealed this peak to correspond to the 
folded Y1L3, while a broader peak at 400-500 mM NaCl represents the unfolded form(s) of the 
receptor construct. 
 
Figure 21: a) Anion exchange chromatogram of Y1L3 in LDAO micelles. The sharp peak at ~125 
mM NaCl corresponds to the folded form. b) Anion exchange chromatogram of Y1L3 in DHPC 
micelles. The sharp peak at ~115 mM NaCl corresponds to the folded form. c) Comparison of the 
spectra of the folded form of Y1L3 (blue) with a mixture of folded and unfolded (orange) and the 
unfolded form of Y1L3 (green). d) Same comparison as in c), but on the 1D projections of the 
spectra from c). The projection of the crude mixture is shown to be approximately the sum of the 
projections of the folded and unfolded forms. 
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The resolution of the anion-exchange purification is thus much better for the Y1L3 construct than 
for the wt-OmpA. The same behavior was observed also for Y1L4 (data not shown). A plausible 
explanation for this different behavior between wt-OmpA and Y1L3/Y1L4 might be, that the 
receptor constructs display 5 negatively charged groups more and 1 positively charged group less in 
their extracellular loops than does the wt-OmpA. Encouraged by this promising results observed 
with the LDAO detergent, we attempted the same separation with DHPC as the detergent and 
obtained similar results (figure 21b). We where thus finally able to obtain the receptor constructs in 
100% folded form. That the fractions eluting at ~125 mM NaCl contain indeed properly folded 
protein, is corroborated by comparing the chemical shift dispersion observed in these fractions 
compared to the unfolded fractions eluting at 400-500 mM NaCl. Figures 21c and 21d show 
[15N,1H]-HSQC spectra and 1D-projections of the folded and unfolded fractions in comparison with 
spectra from the crude mixture of folded and unfolded protein as is present before the 
chromatography. The spectrum of the crude mixture corresponds about to the sum of the spectra 
from the folded and unfolded forms. 
The titrations of the neurohormones with this folded form, however, didn't show any sign of 
interaction (figure 22). Likewise, no interaction between the unfolded fractions and the 
neurohormones could be observed. Only when all fractions from the purification were mixed, the 
characteristic decrease in the peak volumes of the C-terminal residues of the neurohormones could 
be observed. 
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Figure 22: Comparison of the interaction profiles of NPY with all the fractions collected during an 
ion-exchange purification run. Top left: An anion-exchange chromatogram of the purification of 
Y1L3 in DHPC. Bound protein was eluted with a gradient from 0 to 1 M NaCl and fractions were 
collected for all intervals as indicated by the vertical gray lines. Top right: Interaction profile of 
NPY with a crude mixture of folded and unfolded Y1L3. Bottom: Interaction profiles for each of the 
collected fractions indicated in the chromatogram, the flow-through and a mixture of all fractions. 
As can be seen none of the individual fractions (gray profiles) is capable of eliciting an interaction 
profile as observed with the crude mixture. Only when all fractions are reunited (orange profile), 
the interaction profile of the crude mixture can be reproduced. 
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3. Discussion 
 
3.1 Design of chimeric receptor constructs 
In this work we describe the attempt at grafting the extracellular loops of a GPCR onto the TM !-
barrel scaffold of a minimal length OmpA to generate a chimeric receptor. The transfer of a given 
functionality from one protein to another is a challenging task. It is most likely only promising 
under the assumption, i) that all the essential residues responsible for that functionality are 
transferred and, ii) that these residues retain a suitable relative orientation. In order to obtain a 
chimeric receptor, displaying (natural) ligand binding ability, the distances between loop anchor 
points and between individual loops found in the receptor should be matched by the scaffold as 
closely as possible. The GPCRs of our interest are the receptors of the NPY family of 
neurohormones, the so-called Y-receptors78. Unfortunately to date only little structural information 
on GPCRs is available and none of the Y-receptors is among those GPCRs for which a crystal 
structure could be obtained. In our study we thus relied on the assumption of structural homology 
between the known GPCR structures and the Y-receptors. This hypothesis is common in the field of 
molecular biology and has formed the basis for many homology modeling studies of GPCRs79. 
In a selected set of GPCR structures, the spacing between the anchor points for the three 
extracellular loops is at an average of 13 Å for e1 and e2 and 14 Å for e3 and shows a narrow 
distribution of roughly +/- 3 Å. The distances between the anchor points not directly connected by 
an extracellular loop are less well conserved. This indicates, that the relative positions of two 
helices anchoring an extracellular loop are more conserved than the relative positions between 
helices not directly connected by an extracellular loop. The observed average values over the 
distances for the analyzed GPCRs served as an estimate for the distances which can be expected in 
the Y-receptors, for which up till today no high resolution structural data is available. 
The !-barrel TM domain of OmpA has been solved both by X-ray crystallography6,7 and NMR 
spectroscopy based on NOE restraints8 and refined using residual dipolar couplings in addition to 
NOE restraints9. A study using the !-barrel core of OmpA as a scaffold for the Ca2+-binding EF-
hand loop from X. laevis has yielded a high resolution NMR structure as well28. Not surprisingly all 
five of these structures show higher flexibility of the extracellular loop as compared to the !-strands 
of the barrel and the short periplasmic loops. It is not clear, whether this high mobility is also 
observed in nature or is - at least partly - an effect of the detergents used in the crystallographic 
(C8E4) and NMR (DPC or DHPC) studies, which are chemically very different from the 
lipopolysaccharide environment, which the extracellular loops are facing in vivo6. 
It seems clear, that any scaffold molecule will never perfectly match the loop geometries found in 
GPCRs. However, the a statistical analysis of the distances between the anchor points of the 
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extracellular loops in the NMR structures published on OmpA (pdb codes 1G90, 2GE4 and 2JMM) 
shows, that these distances are definitely within the same range as the ones also observed in the 
GPCRs. The relatively broad distibution of distances between the anchor point whithin one set of 
conformers of an NMR structure of OmpA indicates, that the anchor points of the !-barrel possess 
significant ability for structural adaptation. This indicates that the !-barrel of OmpA might indeed 
be a good scaffold for the extracellular loops of GPCRs. The possibility of inserting flexible linker 
residues between the scaffold's anchor points and the grafted loop residues of the Y-receptors 
presents an additional means of overcoming distance mismatches between the anchor points of the 
GPCRs and the ones of the scaffold. 
Inspection of the crystal structures which have been published on GPCRs so far63,80-85 shows, that 
the extracellular loops are quite flexible. They can hence be assumed to sample a large 
conformational space. The distance distribution between the anchor points of our selected scaffold 
seem to allow for such a flexibility as well. 
We have chosen the Y1-receptor as the "donor" for the extracellular loops over the other Y-
receptors, because the most biochemical data is published on that receptor subtype. As no crystal 
structure of the Y-receptors is available the identification of the alleged loop residues is based on 
structure prediction, GPCR sequence homologies and biochemical data. Based on these data the 
Y1-receptor loop sequences to be grafted were selected. Since OmpA contains 4 extracellular loops 
and GPCRs only 3, one acceptor position in the three-loop graft constructs had to remain empty. In 
this position a very short !-turn inducting sequence of 1-2 residues was inserted, in order to 
minimize the possibility of interference with the GPCR loops. A comparison of all peptide binding 
GPCRs shows, that Asp6.59 is the only residue which is only conserved in the extracellular loops in 
all subtypes of the Y-receptors (Y1 to Y5) and throughout all species (see 
GPCRs_all_peptide_ligand.alig). Interestingly in other peptide ligand GPCRs the positions 6.59 and 
6.58 are often found to be also conserved within one family67. Position 6.59 lies at the top of TM6 
and the beginning of ECL3. Studies on rhodopsin and other GPCRs showed that the top region of 
TM6 and the adjacent ECL are important in ligand binding86-89. 
The lenghts of the grafted loops were 15 residues for the e1 and e3 loops and 30 residues for the e2 
loop. The lenght of the OmpA extracellular loops are also in this range (around 14-18 residues). It 
has been known that the formation of the !-barrel is compatible with very short sequences of only 
1-2 residues27 and with eukaryotic sequences of about equal length than the original OmpA 
extracellular loops28. It could therefore be expected that the scaffold would tolerate at least the e1 
and e3 loop, which even though they are of eukaryotic origin, they have about equal length than the 
native OmpA loops. This is not the case for the much longer e2 loop. To test the compatibility of 
the extracellular looop sequences of the Y1-receptor with the !-barrel core of OmpA, we created 
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mutants in which each extracellular loop of OmpA was replaced with each of the Y1-receptor's 
loops. All 12 variants of these "one-loop exchange construct" could be expressed and refolded as 
the wt-OmpA, indicating the compatibility of the Y1-receptor loop sequences with our scaffold. In 
a second set of constructs one OmpA loop was replaced with a GPCR loop and the other three 
OmpA loops were replaced by a minimal !-turn inducing sequence. Also these "one-loop graft 
constructs" could be expressed and refolded, albeit with a lower efficiency than for the wt-OmpA 
and the one-loop exchange constructs. The partial loss of folding capacity thus seems to be an effect 
of the shortening of the loops and not an effect of the GPCR loops. 
The arrangement of three donor looop sequences on the four acceptor sites of the scaffold is 
possible in 24 different ways. In order to rule out constructs with relative loop orientations 
deviating strongly from the average GPCR topology, we calculated a "mismatch score" for each of 
the 24 possible arrangements. Finally four of these "three-loop graft constructs", named Y1L1, 
Y1L2, Y1L3 and Y1L4, were assembled and expressed. Also they showed a reduced folding 
proficiency  compared to OmpA. In addition, both the one- and three-loop graft constructs showed a 
different electrophoretic mobility behavior then the wt-OmpA or the one-loop exchange constructs. 
While for the latter two the folded species migrates slower compared to the unfolded species, this 
behavior is reversed in the former. 
 
3.2 Folding studies of the receptor constructs 
The presence of a larger number of sharp peaks in the random coil region in the NMR spectra of the 
graft constructs compared to wt-OmpA, indicates that the wt-OmpA extracellular loops are less 
flexible than the Y1-loops present in the chimeric constructs. The increased electrophoretic mobility 
of the three-loop graft constructs compared to the wt-OmpA might thus be explained by the higher 
flexibility of the Y1-receptor loops, imposing less sterical hindrance during the migration through a 
polyacrylamide gel. Based on the results of the refolding studies with the one-loop exchange 
contructs, this increased mobility is mainly mediated by the long Y1e2 loop, as this loop alone is 
capable of removing the the mobility difference between folded and unfolded forms (figure 9c). 
Other possible factors, such as differences in the overall length or charge of the grafted loops 
compared to the wildtype loops, cannot consistently explain the observed electrophoretic behavior. 
Refolding screens were carried out for the three-loop graft constructs with a six different detergents, 
three different pH values and a variety of additivies, commonly known to influence folding 
efficiency. While none of the additives had great influence, the pH and the detergent was critical for 
successful refolding. This behavior is somewhat similar to what is observed for wt-OmpA, where 
also additives didn't show any effect and pH was critical. Also the detergent showed some influence 
on the folding of wt-OmpA, though less severe. A decreased refolding efficiency was also reported 
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in a previous study, which has used the !-barrel of OmpA as a scaffold28. These findings are in 
accordance with the proposed folding model of the OmpA !-barrel, according to which the protein 
first binds to the membrane surface in an unfolded, collapsed form and then assumes its tertiary 
structure through a synchroneous passage of the !-strands and the extracellular loops through the 
hydrophobic membrane interior76. It can be suspected that the inclusion of additives to the refolding 
buffer should only have a minor effect on the membrane, and are therefore not able to greatly 
influence the folding process. The nature of the grafted loops and their protonation state, however, 
can be expected to make a large impact on the folding process as seen from the pH-dependence of 
refolding. Our results indicate that the high flexibility of the grafted loop sequences at least partially 
impede the formation of the !-barrel. 
 
3.3 Ligand interaction studies 
The primary goals of our grafting attempts were: i) being able to obtain a stably folded chimeric 
receptor molecule displaying all three extracellular loops of a Y-receptor and ii) obtaining a system 
in which ligand binding affinity of the grafted loops can be observed, even when outside their 
natural 7 TM context. The accomplishment of the first aim could be demonstrated for the four 
three-loop graft constructs based on the analysis of the electrophoretic mobility in SDS-PAGE and 
the signal dispersion in NMR experiments. In order to test whether our constructs exhibited ligand 
binding capability, we conducted chemical shift mapping experiments. To this end we assigned all 
three members of the neurohormones of the NPY family in the presence of DHPC micelles. The 
titration of 15N-labeled neurohormones with unlabeled receptor construct allowed then the 
observation of changes in the spectra of the neurohormones, which were interpreted as an 
interaction taking place between the peptide ligand and the receptor construct. Whereas Y1L1 and 
Y1L2 had no effect on the spectra of the neurohormones, Y1L3 and Y1L4 induced substantial 
changes. A quantitative estimation of the interaction strength between the neurohormones and the 
two receptor constructs is difficult to obtain, as the receptor construct is not conformationally 
homogenous. I.e. it is not present in purely folded form. The folded fraction could only be estimated 
from comparison of band intensities in SDS-PAGE. Based on the used concentrations in the 
experiments and the fact that slow exchange occurs in the NMR experiments the dissociation 
constant can be estimated to be in the medium-to-low micromolar range. The observed changes 
were the selective disappearance of the C-terminal resonances. The interaction of the 
neurohormones with DPC micelles has been shown to occur through the C-terminal "-helix, 
whereas the N-terminal residues are unstructured and pointing away from the micelle surface into 
the bulk solution30,32,47. The C-terminal residues – especially the conserved positively charged 
arginines at positions 33 and 35 (figure 3) – have been shown to be of particular importance to the 
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interaction of NPY with the Y1-receptor58,90,91. We have therefore produced the two peptides NPY-
R33L and NPY-R35L in 15N-labeled form, assigned their spectra in DHPC micelles, and conducted 
the titration experiments with unlabeled Y1L3. Even though some interaction seems to be retained 
with these two NPY mutants this interaction is clearly strongly reduced in strength. The specificity 
of the interaction between the neurohormones and the Y1L3 and Y1L4 receptor constructs is further 
corroborated by the ability of unlabeled NPY to compete for the binding with 15N-labeled NPY 
(figure 16) and by the fact that there is no detectable interaction with the Y1L1 and Y1L2 constructs 
(figure 14). 
The complementary experiments, namely the titration of 15N-labeled receptor constructs with 
unlabeled neurohormones, failed to lead to a detectable effect. This finding is in conflict with the 
profound changes that the unlabeled Y1L3 and Y1L4 receptor constructs inflicts upon the spectra of 
the neurohormones. However, careful inspection of the spectra of the receptor constructs reveals 
that the number of observed sharp resonances, as they are observed from the flexible, grafted loops, 
is lower than expected. It is therefore possible that the residues responsible for the interaction with 
the neurohormones are not seen in the spectrum. This can be the case, if they are involved in 
dynamic processes on the microsecond to millisecond timescale. Such processes are not uncommon 
for residues at an interface between highly motionally restricted segments as the !-strands of the 
barrel and highly flexible stretches such as the extracellular loops. While all of the 30 residues of 
the long e2 loop gave signals in the spectra which could be assigned, in the shorter e1 and e3 loops 
only 3 out of 15 expected resonances could be observed. 
 
3.4 The influence of loop flexibility on the receptor constructs 
Ligand binding of a receptor is always thought as being a balance between favorable enthalpic 
terms and entropically unfavorable terms, due to the loss of conformational freedom, both of the 
binding pocket of the receptor and the ligand also. Part of this entropic cost is paid by the pre-
arrangement of the interacting residues of the binding pocket. It can be assumed, that if this pre-
arrangement is loosened, the interaction strength between the ligand and the receptor decreases. 
From an NMR point of view, however, the concomitant gain in flexibility could lead to more 
observable resonances due to the decrease of the exchange broadening phenomenon. We therefore 
tried to increase the flexibility of the grafted loops - primarily of the e1- and e3-loop sequences - by 
inserting flexible glycine-serine linkers of different length in between the anchor sites on the 
scaffold and the Y1-receptor's extracellular loops. Derived from the construct Y1L3 we generated 
derivatives, carrying glycine-serine linkers of different lenght and flanking different loops: One 
constructs in which each Y1-receptor loop was flanked at both ends by a Ser-Gly dipeptide and one 
in which it was flanked by a Ser-Gly-Ser-Gly tetrapeptide (Y1L3-GS and Y1L3-GSGS). 
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Furthermore two analogous constructs in which only the e1- and e3-loops were flanked, but not the 
e2-loop, were created (Y1L3-gs and Y1L3-gsgs), and two constructs having only the e2-loop 
flanked with either the di- or tetrapeptide linker (Y1L3-e2gs and Y1L3-e2gsgs). We observed a 
significantly different refolding behavior in the different linker-flanked constructs. Only the two 
constructs carrying the flanking linker sequences at all three loops were able to fold equally well as 
the parent Y1L3 construct. Whereas the refolding efficiency of these constructs was similar to 
Y1L3 (~80% efficiency) the two constructs carrying the linker sequences only on the e1- and e3-
loop only folded with an efficiency of only ~50%. Constructs carrying the linker sequences only at 
the e2-loop. These showed the same folding deficiency that was observed for Y1L3-gs and Y1L3-
gsgs (figure 20). It seems therefore that the lenghts and maybe also the flexibilties of the loops 
relative to each other play a role in the folding process of the three-loop graft constructs. However, 
further experiments would be required to back up this hypothesis. 
The [15N,1H]-HSQC spectra of Y1L3-GS and Y1L3-GSGS show additional peaks relative to Y1L3. 
Most of these, however, stem for the glycine and serine resonances of the linkers themselves, rather 
than from the intervening loop sequences (figure 20). 
Not surprisingly, the interaction of the linker-bearing constructs was slightly weakend compared to 
Y1L3(figure 20). 
 
3.5 Ion exchange purification of purely folded receptor constructs 
We would like to repeat here, that all the interaction studies carried out between the neurohormones 
and the receptor constructs have been performed with a mixture of folded and unfolded receptor 
constructs. Even though we had indications, that it is indeed the folded fraction of the construct 
which is responsible for the interaction with the neurohormones, a definitive proof would only be 
the repetition of the experiments with 100% folded receptor constructs. 
Ion exchange chromatography is a method for separation of molecules based on their charge. 
Although the charge of the two isoforms of the same protein seems to be identical, differently 
folded protein species differ in how they display their surface charged groups, which are moreover 
in different orientation relative to each other, resulting in distinct interaction strengths with the 
charged groups of an ion-exchange resin. The small column volumes used in ion exchange 
chromatography makes this technique also appealing to detergent containing buffers. 
Even though this technique is applicable to the separation of folded and unfolded wt-OmpA, its 
efficiency is limited. Both folded and unfolded OmpA elute at very similar salt concentrations, thus 
giving a bad resolution. The Y1L3 and Y1L4 receptor constructs, in contrast, showed a very clear 
separation between the unfolded and folded forms. This different behavior can be explained by the 
increased net number of negatively charged residues (+5) in the grafted loops compared to the 
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extracellular loops found in the wt-OmpA sequence (figure 7). The signal dispersions encountered 
in the collected fractions confirms, that they indeed correspond to the folded and unfolded forms of 
the receptor constructs. The spectrum of the crude mixture can be deconvoluted into spectra from 
the folded and unfolded forms (figure 21). 
The titrations of the neurohormones with this folded form, however, didn't show any sign of 
interaction (figure 22). Likewise, no interaction between the unfolded fractions and the 
neurohormones could be observed. Only when all fractions from the purification were mixed, the 
characteristic decrease in the peak volumes of the C-terminal residues of the neurohormones could 
be observed. This indicates that for the interaction to occur, both the folded and the unfolded form 
of the construct have to be present. 
 
 
 
4. Materials and methods 
 
4.1 Synthesis and purification of neurohormones 
Synthesis of unlabeled neurohormones was carried out using standard Fmoc-based solid-phase 
peptide synthesis92 using a robot system (ABI433A, Applied Biosystems). Rink Amide MBHA 
resin resin was used to assemble the peptides using standard Fmoc chemistry (20% piperidine in 
DMF for Fmoc deprotection, 4 eq. of HOBt/HBTU for activation, diisopropylthylamine as base, 
and N-methylpyrrolidone as solvent). Peptides were cleaved from the resin and deprotected with 
TFA/water/triisopropylsilane/1,2-ethanedithiol/thioanisole in a ratio of 75/4/1/10/10. Cleaved 
peptide was precipitated and washed twice with ice-cold diethylether. The precipitate was dissolved 
in water/acetonitrile 8/2, lyophilized and purified by C18 reversed phase HPLC. Peptide masses 
were confirmed by ESI-MS. 
Synthesis of 15N-labeled neurohormones was carried out recombinantly in bacteria as fusions to 
ubiquitin93 (for PP) or to ketosteroidisomerase94 (for NPY, NPY-R33L, NPY-R35L, and PYY). The 
expression and purification of neurohormones using theses two systems has been described in detail 
elsewhere30,47. 
 
 
4.2 Plasmids of OmpA and its derivatives 
The starting plasmid for the transmembrane domain (TMD) of OmpA from E. coli was as described 
in Ramakrishnan et al.95. Briefly, this plasmid called pTMD-OmpA holds the sequence coding for 
amino acids 22 to 197 of OmpA as deposited in the UniProtKB/Swiss-Prot database under the 
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accession number P0A910 (OMPA_ECOLI). A methionine residue replaces the 21 residues 
periplasmic export signal present in the wild-type sequence. The removal of this signal results in 
accumulation of TMD-OmpA in the cytoplasm in the form of insoluble inclusion bodies. The 
coding sequence was cloned into the pET22b plasmid between the XhoI and NdeI sites. A plasmid 
map covering the region of the expressed TMD-OmpA sequence can be found in appendix A. All 
designed constructs were derived from this plasmid and all mutants were created using the 
QuickChange methodology as described in the QuickChange site directed-mutagenesis kit manual 
from Stratagene (catalog no. 200518) following a deletion-insertion approach, in which first the 
original OmpA loop sequence was deleted before the foreign Y1-receptor loop sequence was 
inserted. All components of the kit were bought individually. The dNTP were from Fermentas (cat. 
no. #R0241) and were stored as aliquots at -20 °C. PfuTurbo polymerase was from Stratagene (cat. 
no. 600250-52) and DpnI nuclease was from Fermentas (cat. no. #ER1701). All QuickChange 
reactions were carried out in 10 µl total volume containing 1x PfuTurbo buffer from Stratagene 
(cat. no. 600153-82), 0.5 U PfuTurbo polymerase, 0.2 mM dNTPs, ~100 ng of plasmid DNA and 
0.2 µM of each mutagenic primer. The thermocycling procedure was designed as recommended by 
Stratagene and can be found in appendix B. 5 U of DpnI were added to the reaction and the mixture 
was incubated at 37 °C for 3 hours. 1-2 µl of this mixture were transformed to 25-50 µl of self-
prepared RbCl2-competent cells by heat shock. Plasmid was extracted from the obtained colonies 
and sequenced by the dideoxy sequencing method 96. 
All primers were purchased from Microsynth (Balgach, Switzerland). Primers for deletion, single 
amino acid change and point mutation reactions were purchased as desalted ~36-mers. Primers for 
the insertion constructs were self-made by PCR using two short (~12 nucleotides), desalted primers. 
PCR products were purified with a Sigma PCR clean-up kit (NA1020-1KT) and used in subsequent 
QuickChange mutagenesis reactions. Since long primers are expensive and require additional 
expensive purification, this strategy allowed substantial cost savings. The inserted Y-receptor gene 
sequences were optimized for preferred E. coli codon usage. 
We followed a strategy in which in a first round all four extracellular loops of the wt-OmpA were 
removed. The sequences to be deleted were selected based on the construct OmpA#1234 studied in 
by Koebnik27 and that has served as a scaffold in a previous grafting study28. Briefly, in our TMD-
OmpA construct95 residues H19-H31, P62-Y72, K107-G118, and I147-P157 are called OmpA 
extracellular loops 1, 2, 3, and 4, respectively. In a second round the desired topological 
arrangement of the Y-receptor loops on the scaffold was generated in four rounds of mutagenesis, 
filling three positions with Y-receptor loops and the fourth with a minimal turn-inducing sequence 
as used in the two publications mentioned above. Because of a lack of a high-resolution structure 
for any of the Y-receptors, for the human Y-receptors (accession number P25929) the extracellular 
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loops were assumed as annotated in the GPCRDB (http://www.gpcr.org/7tm/), e.g. Y100-M112, 
Q177-S210, and F286-N299 for the Y1-receptor extracellular loops 1, 2, and 3, respectively. Any 
occurring cysteines in these sequences were replaced by serines. The corresponding DNA 
sequences were designed using preferred E. coli codon usage. 
A table with all the primers used to generate the deletions and the insertions can be found in 
appendix I. 
 
4.3 Expression of OmpA and its derivatives 
OmpA and its derivatives were always expressed in unlabeled and in 15N-labeled form. Unlabeled 
and 15N-labeled proteins were expressed in LB and M9 minimal medium, respectively. The minimal 
medium contained 15NH4Cl as the sole nitrogen source and its exact composition can be found in 
appendix C. 
A LB preculture containing 100 µg/ml ampicillin was inoculated with a colony of BL21 (DE3) cells 
carrying the desired plasmid and grown over night at 37 °C and 235 rpm. This preculture was used 
to inoculate the main culture in a 1:100 dilution. 500 ml of the main culture were grown in 2 l 
Erlenmeyer flasks at 37 °C and 230 rpm. Cultures were induced with 1 mM IPTG when the OD600 
reached 0.8. LB cultures were grown for another 2.5-3 h and minimal medium cultures for 4-5 h 
before harvesting. Cells were harvested by centrifugation at 4 °C for 20 min at 3300 g in a Sorvall 
GSA rotor. Cell pellets were stored at -20 °C until further processing. 
 
4.4 Expression of 2H,13C,15N-labeled Y1L3 
3 ml of D2O-LB containing 100 µg/ml ampicillin were inoculated with a freshly transformed colony 
of BL21 (DE3) pY1L3. This preculture was grown at 37 °C and 235 rpm overnight and was used to 
inoculate 250 ml D2O-M9 medium containing 0.25 g 
15NH4Cl and 1 g 
2H,13C-D-glucose. 15 h after 
inoculation the OD600 was 0.9 and the culture was induced with 1 mM IPTG. The culture was 
grown for another 7 h before it was harvested by centrifugation as described above. 
 
4.5 Purification of OmpA and its derivatives 
The purification procedure followed essentially the protocol described in Pautsch et al.68. 
The cell pellet was thawed on ice for one hour and resuspended in the 10-fold volume (w/v) cold 
buffer P (20 mM Tris pH 8.5) by vortexing until no cell clumps were visible any more to yield a 
milky white solution. 
The suspension was sonicated on ice with a Branson digital sonifier for 10 min total sonication time 
(35% power, 2 s pulse on, 4 s pulse off). The milky white solution was centrifuged at for 90 min at 
4300 g on a Sorvall ss-34 rotor at 4 °C. 
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The bright white pellet was resuspended in 2% Triton X-100 in buffer P by vortexing and with help 
of a spatula. The solution was centrifuged for 90 min at 4300 g on a Sorvall ss-34 rotor at 4 °C. 
The bright white pellet was resuspended in a few milliliters of 8 M urea, 10 mM Tris pH 8, 1 mM 
EDTA or in 6 M GdnHCl, 10 mM Tris pH 8, 1 mM EDTA as far as possible by vortexing and with 
help of a spatula (usually for the inclusion bodies from 1 g cell pellet 2 ml of urea solution were 
used). In case the purified construct contained cysteines 10 mM DTT were added to the urea 
solution. This solution was incubated at 37 °C and 200 rpm for 2 h. This solution was centrifuged 
for 20 min at 47800 g at 4 °C on a Sorvall ss-34 rotor. The supernatant was decanted and stored at -
20 °C until further use. This procedure typically yielded 5-10 ml solution with a final protein 
concentration of ~20 mg/ml from 1 liter of bacterial culture. 
 
4.6 Small scale refolding trials with OmpA and its derivatives 
Reaction volumes for screening refolding conditions were generally 50 µl unless noted otherwise. 
The buffers for the refolding screens were 10 mM acetate pH 4, 10 mM HEPES pH 7, 10 mM Tris 
pH 8.8 and 10 mM borate pH 10 and always contained 1 mM EDTA. In case the refolding 
constructs contained cysteines an additional 10 mM DTT was added to the refolding solution. The 
detergent concentration was always chosen to guarantee at least a 500-fold excess of detergent over 
protein or a concentration double that of the critical micellar concentration (cmc) of the respective 
detergent. 1.25 µl of a 20 mg/ml protein solution in 8 M urea, 10 mM Tris pH 8, 1 mM EDTA (+ 10 
mM DTT if applicable) were added. The solution was mixed by vortexing, briefly spun down and 
incubated at 30 °C for 5 h. Refolding efficiency was assessed by 18% SDS-PAGE (for exact 
composition of the gels see appendix D). 
 
4.7 Large scale refolding of OmpA and its derivatives 
1 volume of a 20 mg/ml protein solution in 8 M urea, 10 mM Tris pH 8, 1 mM EDTA were diluted 
at a flow-rate of 1 ml/h with a peristaltic pump into 6 volumes of 3% DHPC, 10 mM borate or 
piperazine, 1 mM EDTA, pH 10 at 4 °C. The solution was incubated at room temperature for 15 h 
and dialyzed against a 200-fold excess of cold 50 mM Tris, 5 mM EDTA, pH 8.5 at 4 °C. The 
solution was then concentrated in an Amicon Ultra-4 centrifugal concentrator (10 kDa MWCO; cat. 
no. UFC801024) to 250-500 µl and diluted with the 2-fold volume of NMR buffer (3% DHPC, 20 
mM sodium phosphate, 100 mM NaCl, 10% D2O, pH 6.5). This concentration-dilution cycle was 
repeated once. 
The refolding efficiency of the procedure was verified by 18% SDS-PAGE and the concentration of 
the protein solution was measured by the BCA assay (Thermo Scientific, cat. no. 23227). 
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4.8 Titration of neurohormones with OmpA and its derivatives 
An adequate amount of 15N-labeled neurohormone was dissolved in NMR buffer (3% DHPC, 20 
mM sodium phosphate, 100 mM NaCl, 10% D2O, pH 6.5) and increasing quantities of the refolded 
receptor constructs were added to reach a final volume of 250 µl. [15N,1H]-HSQC spectra of these 
samples were measured (for spectroscopic details vide infra) and the peak volumes integrated. 
 
4.9 NMR spectroscopy general 
All spectra were recorded on a Bruker AV-600 or AV-700 spectrometer both equipped with 
cryoprobes.  
Proton chemical shifts were calibrated to the water signal and nitrogen shifts were referenced 
indirectly to liquid NH3
97. Raw data was processed using the Bruker Topspin software versions 2.0 
and 2.1 and transferred to XEASY98 or CARA99 for further analysis. 
All 2D experiments utilized TPPI-States100,101 for quadrature detection in indirect proton 
dimensions, and gradient-selected coherence selection (echo-antiecho)102 in combination with 
sensitivity enhancement schemes102,103 in experiments including detection of amide protons. 
 
4.10 Assignment of NPY, NPY-R33L, NPY-R35L, PYY and PP in DHPC micelles 
The reported assignments for NPY47, PYY32 and PP30 in DPC micelles at pH 4.5 served as the 
starting point for the assignment of the amide resonance of NPY, its two C-terminal Arg-mutants 
R33L and R35L, PYY and PP in DHPC micelles at pH 6.5. All samples consisted of 0.5 mM 15N-
labeled peptide, 3% DHPC, 20 mM sodium phosphate, 100 mM NaCl, 10% D2O, pH 6.5 and 
spectra were acquired at 310 K with a 1 s interscan delay unless stated otherwise. While some 
resonances didn't change much and thus could be adopted, others changed too much to allow for a 
confident assignment without recording further experiments. The adoptable peaks in the [15N,1H]-
HSQC served as starting points for the sequential assignment. Neighboring peaks were then linked 
to these starting points with the help of a [1H,1H]-NOE-relayed [15N,1H]-HSQC104, which was 
acquired with a 300 ms mixing time and 2048 and 256 complex points in the direct and indirect 
dimension, respectively. Water suppression wash achieved through continuous-wave irradiation of 
the water resonance. A 15N-resolved TOCSY105 utilizing a 75 ms DIPSI2 mixing sequence was 
recorded with 2048, 40 and 128 points per increment in the direct and the two indirect (15N, 1H) 
dimensions respectively. Spin systems were identified in this spectra and used to verify the 
assignments gained from the NOE-relayed [15N,1H]-HSQC. 
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4.11 NMR spectroscopy and data analysis of titration of OmpA derivatives with neurohormones 
Spectra were recorded on uniformly 15N-labeled receptor construct at concentrations between 0.25 
and 1 mM in NMR buffer (3% DHPC, 20 mM sodium phosphate at pH 6.5, 100 mM NaCl and 10% 
D2O) and at a temperature of 320 K. Unlabeled ligand was dissolved in a minimal amount of NMR-
buffer and added to the receptor construct sample. [15N,1H]-TROSY106-108 with 1024(1H)*128(15N) 
complex data points was recorded. Spectral widths were 18 ppm and 36 ppm for the 1H and 15N 
dimension, respectively. The carrier positions were placed at 4.71 ppm (1H) and 119.5 ppm (15N). 
32 scans were recorded per increment. 
 
4.12 Assignment of Y1L3 
All spectra for the assignment of Y1L3 were recorded on the AV-700 spectrometer on a 0.5 mM 
sample of uniformly 15N,13C,2H-labeled Y1L3 in 3% DHPC, 20 mM sodium phosphate at pH 6.5, 
100 mM NaCl and 10% D2O and at a temperature of 320 K. 
A [15N,1H]-TROSY106-108 with 1024(1H)*75(15N) complex data points was recorded. Spectral 
widths were 18 ppm and 31 ppm for the 1H and 15N dimensions, respectively. The carrier positions 
were placed at 4.71 ppm (1H) and 119.5 ppm (15N). 
A TROSY-version of the HN(CO)CACB109-111 with 1024(1H)*25(15N)*70(13C) complex data points 
was recorded. Spectral widths were 18 ppm, 31 ppm and 60 ppm for the 1H, 15N and 13C dimension, 
respectively. The carrier positions were placed at 4.71 ppm (1H), 118.7 ppm (15N), 39.0 ppm (13C"/!) 
and 54 ppm (13C"). 16 scans were recorded per increment. 
A TROSY-version of the HNCACB110,111 with 1024(1H)*20(15N)*64(13C) complex data points was 
recorded. Spectral widths were 18 ppm, 31 ppm and 60 ppm for the 1H, 15N and 13C dimension, 
respectively. The carrier positions were placed at 4.71 ppm (1H), 118.7 ppm (15N) and 39 ppm 
(13C). 32 scans were recorded per increment. 
A proton-detected version of the steady-state 15N{1H} heteronuclear Overhauser effect sequence 
was used for measurement of the heteronuclear NOE112. Therein, the buildup of the NOE was 
achieved through a pulse train of 120 degree proton pulses separated by 5 ms over a period of 3 
seconds. 
 
4.13 Calculation of mismatch score 
The extracellular loop domain of a GPCR is composed of six anchor points for the loops (i.e. the 
terminal amino acids of the TM helices, which serve as membrane anchors to the extracellular 
loops). The overall topology of these anchor points is defined by 15 unique distances. Likewise, the 
topology of the eight anchor points of the four extracellular loops of OmpA is defined by 28 unique 
distances. Theoretically there are 24 different ways of arranging three foreign loop sequences on the 
243  
four acceptor sites of the scaffold. We calculated a "mismatch score" for each of the 24 possible 
arrangements. The following GPCR crystal structures served to calculate a matrix of the average 
distances between the anchor points of the extracellular loops: 1) the original crystal structure of 
bovine rhodopsin82 (pdb code 1F88), 2) the T4 lysozyme fusion of !2-AR bound to the inverse 
agonist carazolol84 (2RH1), 3) the T4 lysozyme fusion of !2-AR bound to the inverse agonist 
timolol80 (3D4S), 4) !2-AR in complex the inverse agonist carazolol and bound to a Fab fragment83 
(2R4R), 5) the !1-AR bound to the antagonist cyanopindolol63 (2VT4), 6) bovine opsin85 (3CAP), 
7) squid rhodopsin81 (2Z73), 8) squid rhodopsin113 (2ZIY), 9) the human A2A adenosine receptor in 
complex with the antagonist ZM241385114 (3EML), and 10) bovine opsin in complex with a 
transducin peptide115 (3DQB). 
The distances between the six involved anchor points for each of the possible 24 arrangements of 
the three Y1-receptor loops on the four acceptor sites of the OmpA scaffold were calculated and 
compared to the distances calculated for an average GPCR. Mismatches were summed up and 
interpreted as mismatch scores. 
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6. Appendix 
 
A - plasmid map covering the region of the expressed TMD-OmpA sequence (bold letters) 
 
NdeI restriction site: 5' c a't a t g 3' 
    3' g t a t'a c 5' 
 
XhoI restriction site:  5' c't c g a g 3' 
    3' g a g c t'c 5' 
 
cgccatatggctccgaaagataacacctggtacactggtgccaaactgggctggtctcag 
 R  H  M  A  P  K  D  N  T  W  Y  T  G  A  K  L  G  W  S  Q  
taccatgacactggtttcatcaacaacaatggcccgacccatgaaaaccaactgggcgct 
 Y  H  D  T  G  F  I  N  N  N  G  P  T  H  E  N  Q  L  G  A  
ggtgcttttggtggttaccaggttaacccgtatgttggctttgaaatgggttacgaatgg 
 G  A  F  G  G  Y  Q  V  N  P  Y  V  G  F  E  M  G  Y  E  W  
ttaggtcgtatgccgtacaaaggcagcgttgaaaacggtgcatacaaagctcagggcgtt 
 L  G  R  M  P  Y  K  G  S  V  E  N  G  A  Y  K  A  Q  G  V  
caactgaccgctaaactgggttacccaatcactgacgacctggacatctacactcgtctg 
 Q  L  T  A  K  L  G  Y  P  I  T  D  D  L  D  I  Y  T  R  L  
ggtggcatggtatggcgggccgacactaaatccaacgtatacggtaaaaaccacgacacc 
 G  G  M  V  W  R  A  D  T  K  S  N  V  Y  G  K  N  H  D  T  
ggcgtttctccggtcttcgctggcggtgttgagtacgcgatcactcctgaaatcgctacc 
 G  V  S  P  V  F  A  G  G  V  E  Y  A  I  T  P  E  I  A  T  
cgtctagaataccagtggaccaacaacatcggtgacgcacacaccatcggcactcgtccg 
 R  L  E  Y  Q  W  T  N  N  I  G  D  A  H  T  I  G  T  R  P  
gacaacggcatgctgagcctgggtgtttcctaccgtttcggtcagggcgaagcagcttga 
 D  N  G  M  L  S  L  G  V  S  Y  R  F  G  Q  G  E  A  A  -  
ctcgagcag 
 L  E  Q  
 
 
B - Thermocycling for QuickChange mutagenesis 
 95 °C 3 min 
     --------------- 
 95 °C 30 s 
 55 °C 1 min 
 68 °C 6 min 
 --------------- 
 4 °C  ! 
 
The central block was repeated 18 times for insertions and deletions, 16 times for single amino acid 
changes and 12 times for point mutations. 
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C - Composition of M9 minimal medium 
Amounts are for 1 l medium: 
4 g  KH2PO4 
4 g  K2HPO4 
3.5 g  Na2HPO4 * 2 H2O 
1 g  NaCl 
1 g 15NH4Cl (or 
14NH4Cl if no labeling was required) 
fill up to 960 ml with de-ionized water and autoclave 
To these 960 ml the following were added: 
10 ml MgSO4 1 M (autoclaved) 
25 ml glucose 20% w/v (sterile filtered) 
2 ml trace metal stock solution (autoclaved) 
1 ml thiamineHCl 150 mM (sterile filtered) 
1 ml ampicillin 100 mg/ml 
 
trace metal stock solution (500X): 
FeSO4 * 7 H2O  4 g/l 
CaCl2 * 2 H2O  4 g/l 
AlCl3 * 6 H2O   1 g/l 
MnSO4 * n H2O  1 g/l 
CoCl2 * 6 H2O  0.4 g/l 
ZnSO4 * 7 H2O  0.2 g/l 
CuCl2 * 2 H2O  0.1 g/l 
H3BO3    0.1 g/l 
 
D - 18% SDS-PAGE for assaying the folding state of OmpA and its derivatives 
The stacking gel was prepared as described in Sambrook et al. (Sambrook J et al. 2000. Molecular 
Cloning: A Laboratory Manual (Third Edition)). 
The resolving gel was composed as follows (for 10 ml of resolving gel): 
2.5 ml 1.5 M Tris pH 8 
6 ml 30% acrylamide 
1.3 ml ddH2O 
0.1 ml 10% SDS 
0.1 ml 10% APS 
0.017 ml TEMED 
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E - GPCR structures deposited in the Protein Data Bank as of December 2009 
GPCR Description pdb 
Bovine rhodopsin First crystal structure of rhodopsin 1F88 
Bovine rhodopsin 
Alternative model of ground state rhodopsin deposited under 
pdb code 1GZM 
3C9L 
Bovine rhodopsin 
N2C/D282C mutant 
Alternative model of the N2C/D282C thermostable rhodopsin 
mutant deposited under pdb code 2J4Y 
3C9M 
Bovine rhodopsin Rhodopsin in trigonal crystal form 1GZM 
Bovine rhodopsin 
Study of the role of internal water molecules in the rhodopsin 
crystal structure 
1L9H 
Bovine rhodopsin 
Refinement of rhodopsin crystal structure with focus on the 
retinal conformation 
1U19 
Bovine rhodopsin Refinement of rhodopsin crystal structure 1HZX 
Bovine rhodopsin 
N2C/D282C mutant 
Crystal structure of a thermally stable N2C/D282C rhodopsin 
mutant 
2J4Y 
Bovine rhodopsin 9-
cis form 
Crystal structure of 9-cis rhodopsin and comparison with 11-cis 
rhodopsin and bathorhodopsin 
2PED 
Bovine rhodopsin 
lumirhodopsin 
Crystal structure of lumirhodopsin (=nearly all-trans rhodopsin) 2HPY 
Bovine rhodopsin 
bathorhodospin 
Crystal structure of bathorhodopsin, the first activation 
intermediate 
2G87 
Bovine rhodopsin 
Crystal structure of rhombohedral crystal form of ground-state 
rhodopsin 
2I35 
Bovine rhodopsin 
Crystal structure of trigonal crystal form of ground-state 
rhodopsin 
2I36 
Bovine rhodopsin 
Crystal structure of photoactivated deprotonated intermediate 
of rhodopsin, reminiscent of metarhodopsin II the G-protein 
activating state 
2I37 
Human "2-AR Fab 
complex 
Crystal structure of human "2-AR in complex with a Fab 
fragment; in complex with the inverse agonist carazolol 
2R4R 
Human "2-AR Fab 
complex 
Crystal structure of human "2-AR with an engineered TEV 
cleavage site after residue 24 in the N-terminus in complex 
with a Fab fragment; in complex with the inverse agonist 
carazolol 
2R4S 
Human "2-AR T4L 
fusion 
Crystal structure of human "2-AR carrying the T4 lysozyme 
sequence in its i3 loop; in complex with the inverse agonist 
carazolol 
2RH1 
Human "2-AR T4L 
fusion 
Crystal structure of "2-AR-T4L in complex with the inverse 
agonist timolol revealing the binding sites for two cholesterol 
molecules 
3D4S 
Squid rhodopsin Crystal structure of squid rhodopsin 2Z73 
Human "1-AR 
Crystal structure of human "1-AR thermostabilized through 
point mutations in complex with the antagonist cyanopindolol 
2VT4 
Human A2A-
adenosine receptor 
Crystal structure of the human A2A-adenosine receptor in 
complex with the antagonist ZM241385 
3EML 
Bovine opsin Crystal structure of bovine opsin 3CAP 
BovineOpsin+GaCT 
Crystal structure of bovine opsin in complex with transducin 
peptide 
3DQB 
Squid rhodopsin 
Crystal structure of squid rhodopsin with extended cytoplasmic 
region 
2ZIY 
 
253  
F - Multiple sequence alignments of the four Y-receptors from a number of major mammalian 
species. The intensity of the blue coloring indicates the conservation levels of different residues.  
 
 
 
Above the sequence the predicted TM helices are indicated by gray rods and the intracellular loops 
and N- and C-termini by gray lines. Extracellular loops are represented by red lines. 
254  
G - Snake plot representations of the four human Y-receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
255  
H - Amide proton and nitrogen resonance assignments of pNPY, pPYY, bPP, pNPY-R33L and 
pNPY-R35L in 3% DHPC, 20 mM sodium phosphate, 100 mM NaCl at pH 6.5 and 37 °C. 
pNPY     pNPY     
pNPY-
R33L 
    
pNPY-
R33L 
   
res. no. shift atom  res. no. shift atom  res. no. shift atom  res. no. shift atom 
S 3 8.402 H  Y 27 8.308 H  S 3 8.388 H  Y 27 8.280 H 
  116.774 N    119.048 N    116.675 N    118.757 N 
K 4 8.277 H  I 28 8.580 H  K 4 8.278 H  I 28 8.486 H 
  123.623 N    118.310 N    123.636 N    118.083 N 
D 6 8.238 H  N 29 8.253 H  D 6 8.247 H  N 29 8.243 H 
  118.872 N    120.294 N    118.901 N    120.479 N 
N 7 8.183 H  L 30 7.876 H  N 7 8.201 H  L 30 8.020 H 
  118.644 N    120.021 N    118.666 N    119.991 N 
G 9 8.395 H  I 31 8.043 H  G 9 8.393 H  I 31 8.063 H 
  108.663 N    116.427 N    108.732 N    116.799 N 
E 10 8.102 H  T 32 8.044 H  E 10 8.102 H  T 32 7.999 H 
  120.229 N    112.523 N    120.250 N    114.744 N 
D 11 8.375 H  R 33 7.862 H  D 11 8.376 H  L 33 7.956 H 
  121.116 N    120.687 N    121.154 N    121.527 N 
A 12 8.151 H  Q 34 7.996 H  A 12 8.155 H  Q 34 8.020 H 
  125.048 N    117.723 N    125.071 N    117.096 N 
A 14 8.399 H  R 35 8.092 H  A 14 8.408 H  R 35 7.903 H 
  123.798 N    120.717 N    123.966 N    117.839 N 
E 15 8.464 H  Y 36 7.985 H  E 15 8.489 H  Y 36 7.923 H 
  119.449 N    119.922 N    119.575 N    118.671 N 
D 16 8.188 H       D 16 8.178 H      
  120.729 N         120.809 N      
L 17 8.203 H       L 17 8.198 H      
  121.237 N         121.309 N      
A 18 8.098 H       A 18 8.085 H      
  121.885 N         120.718 N      
R 19 7.984 H       R 19 7.959 H      
  118.812 N         118.259 N      
Y 20 7.988 H       Y 20 7.957 H      
  119.128 N         119.819 N      
Y 21 8.417 H       Y 21 8.377 H      
  118.862 N         118.772 N      
S 22 8.361 H       S 22 8.335 H      
  114.289 N         114.225 N      
A 23 8.003 H       A 23 7.959 H      
  124.509 N         124.024 N      
L 24 8.291 H       L 24 8.226 H      
  118.649 N         118.226 N      
R 25 8.329 H       R 25 8.248 H      
  118.260 N         118.183 N      
H 26 7.978 H       H 26 8.014 H      
  118.339 N         117.740 N      
 
 
256  
pNPY-
R35L 
    
pNPY-
R35L 
    pPYY     pPYY    
res. no. shift atom  res. no. shift atom  res. no. shift atom  res. no. shift atom 
S 3 8.403 H  Y 27 8.051 H  A 3 8.364 H  Y 27 8.560 H 
  116.766 N    117.667 N    124.446 N    119.063 N 
K 4 8.286 H  I 28 8.626 H  K 4 8.264 H  L 28 8.167 H 
  123.661 N    118.689 N    122.200 N    121.131 N 
D 6 8.252 H  N 29 8.296 H  E 6 8.508 H  N 29 8.155 H 
  118.950 N    120.622 N    121.937 N    118.929 N 
N 7 8.196 H  L 30 7.866 H  A 7 8.330 H  L 30 7.823 H 
  118.649 N    120.148 N    126.541 N    119.776 N 
G 9 8.390 H  I 31 8.150 H  G 9 8.326 H  V 31 8.089 H 
  108.685 N    117.721 N    108.002 N    115.932 N 
E 10 8.101 H  T 32 8.334 H  E 10 8.587 H  T 32 7.826 H 
  120.148 N    113.353 N    118.801 N    112.592 N 
D 11 8.374 H  R 33 7.890 H  D 11 8.299 H  R 33 7.855 H 
  121.037 N    120.295 N    118.757 N    120.566 N 
A 12 8.136 H  Q 34 7.792 H  A 12 8.488 H  Q 34 8.004 H 
  125.029 N    117.121 N    124.135 N    117.879 N 
A 14 8.409 H  L 35 7.949 H  S 13 8.246 H  R 35 8.027 H 
  123.813 N    118.158 N    116.150 N    121.235 N 
E 15 8.480 H  Y 36 7.805 H  E 15 8.391 H  Y 36 8.008 H 
  119.360 N    116.520 N    119.362 N    118.961 N 
D 16 8.162 H       E 16 8.528 H      
  120.761 N         121.462 N      
L 17 8.190 H       L 17 7.966 H      
  121.416 N         118.932 N      
A 18 8.089 H       S 18 8.270 H      
  120.744 N         114.011 N      
R 19 7.972 H       R 19 8.596 H      
  118.376 N         117.970 N      
Y 20 7.995 H       Y 20 8.257 H      
  120.218 N         119.318 N      
Y 21 8.448 H       Y 21 8.462 H      
  118.826 N         119.219 N      
S 22 8.357 H       A 22 7.671 H      
  114.281 N         123.147 N      
A 23 8.000 H       S 23 8.586 H      
  124.781 N         118.145 N      
L 24 8.340 H       L 24 8.305 H      
  118.778 N         120.673 N      
R 25 8.318 H       R 25 7.929 H      
  118.699 N         121.958 N      
H 26 8.344 H       H 26 8.057 H      
  118.076 N         121.404 N      
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bPP     bPP    
res. no. shift atom  res. no. shift atom 
L 3 8.309 H  Y 27 8.144 H 
  122.211 N    120.298 N 
E 4 8.163 H  I 28 8.480 H 
  122.805 N    118.261 N 
E 6 8.454 H  N 29 8.153 H 
  121.947 N    118.971 N 
Y 7 8.448 H  M 30 7.825 H 
  125.215 N    118.446 N 
G 9 8.405 H  L 31 7.694 H 
  111.365 N    119.042 N 
D 10 8.272 H  T 32 7.591 H 
  117.062 N    107.722 N 
N 11 8.242 H  R 33 7.630 H 
  118.943 N    123.168 N 
A 12 7.563 H  R 35 8.195 H 
  122.855 N    120.231 N 
T 13 8.267 H  Y 36 7.923 H 
  113.118 N    120.205 N 
E 15 8.645 H      
  118.242 N      
Q 16 7.871 H      
  120.371 N      
M 17 8.379 H      
  118.890 N      
A 18 8.190 H      
  122.007 N      
Q 19 7.845 H      
  119.403 N      
Y 20 8.067 H      
  120.298 N      
A 21 8.378 H      
  120.761 N      
A 22 7.813 H      
  119.650 N      
E 23 8.165 H      
  119.897 N      
L 24 8.591 H      
  121.440 N      
R 25 8.108 H      
  118.230 N      
R 26 7.698 H      
  118.230 N      
 
 
 
I - Primers used in the Quick Change mutagenesis reactions 
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